U.S. patent application number 11/731950 was filed with the patent office on 2007-12-06 for indazole compounds.
Invention is credited to Lily K. Abbott, Maria A. Argiriadi, Claude E. Barberis, David W. Borhani, Andrew Burchat, David J. Calderwood, Kevin P. Cusack, Richard W. Dixon, Anna M. Ericsson, Kristine E. Frank, Thomas D. Gordon, Biqin Li, Kelly D. Mullen, Robert V. Talanian, Lu Wang, Neil Wishart, Xiaoyun Wu, Xiaolei Zhang.
Application Number | 20070282101 11/731950 |
Document ID | / |
Family ID | 38581581 |
Filed Date | 2007-12-06 |
United States Patent
Application |
20070282101 |
Kind Code |
A1 |
Ericsson; Anna M. ; et
al. |
December 6, 2007 |
Indazole compounds
Abstract
Novel compounds of Formula (I) or pharmaceutically acceptable
salts, prodrugs and biologically active metabolites thereof of
Formula (I) ##STR1## wherein the substituents are as defined
herein, which are useful as therapeutic agents.
Inventors: |
Ericsson; Anna M.;
(Shrewsbury, MA) ; Burchat; Andrew; (Shrewsbury,
MA) ; Frank; Kristine E.; (Worcester, MA) ;
Calderwood; David J.; (Framingham, MA) ; Abbott; Lily
K.; (Brighton, MA) ; Argiriadi; Maria A.;
(Wayland, MA) ; Borhani; David W.; (Worcester,
MA) ; Cusack; Kevin P.; (Holden, MA) ; Dixon;
Richard W.; (Jefferson, MA) ; Gordon; Thomas D.;
(Medway, MA) ; Mullen; Kelly D.; (Charlton,
MA) ; Talanian; Robert V.; (Harvard, MA) ; Wu;
Xiaoyun; (Westborough, MA) ; Zhang; Xiaolei;
(Ashland, MA) ; Wang; Lu; (Northborough, MA)
; Li; Biqin; (Northborough, MA) ; Barberis; Claude
E.; (Hillsborough, NJ) ; Wishart; Neil;
(Jefferson, MA) |
Correspondence
Address: |
ABBOTT BIORESEARCH
100 RESEARCH DRIVE
WORCESTER
MA
01605-4314
US
|
Family ID: |
38581581 |
Appl. No.: |
11/731950 |
Filed: |
April 2, 2007 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
60788553 |
Mar 31, 2006 |
|
|
|
Current U.S.
Class: |
544/119 ;
544/371; 544/405; 546/121; 546/199; 546/275.7; 548/126; 548/159;
548/204; 548/236; 548/262.8; 548/311.7; 548/362.5; 549/424 |
Current CPC
Class: |
C07D 487/04 20130101;
C07D 403/14 20130101; A61P 43/00 20180101; A61P 37/02 20180101;
C07D 409/14 20130101; A61P 35/00 20180101; C07D 403/12 20130101;
C07D 409/04 20130101 |
Class at
Publication: |
544/119 ;
544/371; 544/405; 546/121; 546/199; 546/275.7; 548/126; 548/159;
548/204; 548/236; 548/262.8; 548/311.7; 548/362.5; 549/424 |
International
Class: |
C07D 409/14 20060101
C07D409/14; C07D 409/04 20060101 C07D409/04; C07D 413/14 20060101
C07D413/14 |
Claims
1. A compound of Formula (I) ##STR926## wherein R.sup.1 is selected
from the group consisting of H, benzyl substituted with OCH.sub.3,
optionally substituted (C.sub.1-C.sub.3)alkyl, pyrimidine
substituted with NH.sub.2 and amino(C.sub.1-C.sub.3)alkyl; R.sup.3
is selected from the group consisting of H, halogen, NH.sub.2, OH,
COOH, --C(O)--NH--CH.sub.2--C(O)--OCH.sub.3, --NH--CH.sub.2-phenyl,
--C(O)-pyridinyl, --NH--C(O)-cyclobutyl and --NH--C(O)-phenyl
wherein phenyl is optionally substituted with either
N(CH.sub.3).sub.2 or OCH.sub.3; or R.sup.3 is selected from the
optionally substituted group consisting of (C.sub.1-C.sub.6)alkyl,
benzo[b]thienyl, 2,3-dihydrobenzofuranyl, indolyl, isoquinolinyl,
morpholinyl, naphthyl, phenyl, piperazinyl, pyrazolyl, pyridinyl,
pyrimidinyl, pyrrolyl, quinolinyl and thienyl; wherein the
substituent is selected from one or more CH.sub.3, NH.sub.2, Cl, F,
dimethylamino, OH, CH.sub.2OH, --C(O)NH.sub.2, COOH, CF.sub.3,
isopropyl, OCF.sub.3, OCH.sub.3, --O--CH.sub.2-phenyl, CN,
OCH.sub.2CH.sub.3, --NH--C(O)-cyclobutyl, --NH--C(O)-phenyl,
NH--C(O)--CH.sub.3, NHC(O)CH.sub.3, N(CH.sub.3).sub.2,
S(O).sub.2CH.sub.3 and C(O)NH-phenyl; or R.sup.3 is
--C(O)--NY.sup.100--(C(Y.sup.100).sub.2).sub.x--R.sup.a wherein x
is 0, 1, 2 or 3; y.sup.100 is independently H or
(C.sub.1-C.sub.3)alkyl; and R.sup.a is --C(O)--CH.sub.3 or is
selected from the optionally substituted group
(C.sub.1-C.sub.3)alkyl, amino, aminoalkyl, benzimidazolyl,
benzo[b]thienyl, benzotriazolyl, biphenyl,
1,3-dihydrobenzimidazolyl, 1,3-dihydrobenzimidazolyl-2-one,
imidazolyl, indolyl, naphthyl, phenyl, pyrazolyl, pyridinyl,
pyrimidinyl, tetrahydropyranyl and thiazolyl; or R.sup.3 is A-B
wherein A is connected to the indazole and A is selected from the
group consisting of --C.ident.C, --C.ident.C-phenyl, indazolyl,
phenyl, pyridinyl and thienyl; B is selected from the group
consisting of benzyloxy, morpholinyl, phenyl, thienyl, t-butyl,
--NH--C(O)-cyclobutyl and --NH--C(O)-phenyl; R.sup.4 is H or
NH.sub.2; R.sup.5 is selected from the group consisting of H,
NH.sub.2, NO.sub.2, halo; or R.sup.5 is selected from the
optionally substituted group consisting of benzimidazolyl,
3,4-dihydrobenzo[1,4]thiazinyl, benzyloxyphenyl,
furo[3,2-c]pyridine, indazolyl, indolyl, isoquinolinyl, phenyl,
piperidinyl, pyrazolo[3,4-d]pyrimidine, pyrazinyl, pyrazolyl,
pyridinyl, pyrrolo[2,3-b]pyridinyl, pyrrolo[2,3-c]pyridinyl,
pyrrolo[2,3-d]pyridinyl, pyrimidinyl, pyrrolo[3,2-d]pyridine,
pyrrolo[2,3-d]pyrimidinyl, pyridinyl, pyrrolyl, quinolinyl,
quinazolinyl, thienyl, thieno[2,3-c]pyridinyl,
thieno[2,3-d]pyrimidine, thieno[3,2-c]pyridine, 7-azaindolinyl and
7-azaindolyl; or R.sup.5 is --C(O)--R.sup.b; wherein R.sup.b is
selected from the group consisting of OH, (C.sub.1-C.sub.3)alkoxy,
phenyl, optionally substituted piperidinyl, optionally substituted
pyridinyl and optionally substituted pyrrolidinyl; or R.sup.b is
D-E wherein D is attached to the C(O) and D is selected from the
group consisting of piperidinyl and pyrrolidinyl; E is selected
from the group consisting of pyridinyl and pyrimidinylaminemethyl;
R.sup.5 is --C(O)--NH--(CH.sub.2).sub.a--R.sup.c; wherein a is 0,
1, 2 or 3; R.sup.c is --CONH.sub.2 or R.sup.c is selected from the
optionally substituted group consisting of benzimidazolyl,
benzothiazolyl, benzo[b]thiophenyl, dimethylamino, fluorene,
imidazolyl, indanyl, indazolyl, isoxazolyl, oxazolyl, phenyl,
piperidinyl, pyrazolyl, pyridinyl, quinazolinyl, thiadiazolyl and
1,2,4-triazolyl; or R.sup.c is J.sup.100-J.sup.200 wherein
J.sup.100 is attached to (CH.sub.2).sub.x and J.sup.100 is selected
from the optionally substituted group consisting of isoxazolyl,
piperazinyl, pyrazolyl pyridinyl, and phenyl; and J.sup.200 is
selected from the group consisting of benzimidazolyl, benzoxazolyl,
cyclohexyl, furanyl, imidazo[1,2-a]pyridinyl, indolyl, isoxazolyl,
--NH--C(O)-phenyl, phenoxy and optionally substituted phenyl;
R.sup.5 is --NH--C(O)--(CH.sub.2).sub.n--R.sup.d; wherein n is 0 to
3; R.sup.d is --C(CH.sub.3).sub.2--CH.sub.2--C(O)--CH.sub.3; or
R.sup.d is selected from the optionally substituted group of
(C.sub.1-C.sub.2)alkoxy, alkylamino, benzimidazolyl,
benzo[1,3]dioxazolyl, benzo[1,2,5]oxadiazolyl, benzotriazolyl,
benzo[b]thienyl, benzofuranyl, benzyloxy, cyclopropyl, cyclohexyl,
chromenyl, dimethylamino, furanyl, hexahydropyrimidinyl,
imidazolyl, imidazo[2,1-b]thiazolyl, imidazo[2,1-b]thiazolyl,
imidazolidinyl, indolyl, isoxazolyl, morpholinyl, phenyl,
piperazinyl, piperidinyl, pyrazinyl, pyrazolyl,
pyrazolo[1,5-a]pyrimidinyl, pyridazinyl, pyridinyl, pyrimidinyl,
pyrrolidinyl, pyrrolyl, quinolinyl, quinoxalinyl,
tetrahydrobenzofuranyl, tetrahydrofuranyl, thiazolyl,
thieno[2,3-d]pyrimidinyl, thienyl,
2,3-dihydrothiazolo[3,2-a]pyrimidine, --S-pyrimidinyl, --O-phenyl,
--O--Si(CH.sub.3).sub.2--C(CH.sub.3).sub.3,
--NH--S(O).sub.2-phenyl, --NH--C(O)--NH.sub.2,
1,2,3,4-tetrahydronaphthyridinyl or N(CH.sub.3).sub.2; or R.sup.d
is M-Q wherein M is attached to the (CH.sub.2).sub.n and M is
selected from the group consisting of optionally substituted
methylene, cyclopropylidene, optionally substituted isoxazolyl,
phenyl, pyrazolyl, --NH--C(O) and optionally substituted
1,3,5-triazinyl; Q is selected from the group consisting of
furanyl, morpholinyl, phenyl, phenylamine and optionally
substituted 1,3,4-thiadiazolyl; R.sup.5 is
--NH--CH.sub.2--C(Y.sup.200).sub.2--R.sup.e wherein Y.sup.200 is
independently H or (C.sub.1-C.sub.3)alkyl and R.sup.e is selected
from the optionally substituted group of (C.sub.1-C.sub.6)alkoxy,
imidazolyl, phenyl, piperidinyl, pyrrolidinyl and
1,2,3,4-tetrahydro[1,8]naphthyridine; or R.sup.5 is
--NH--C(O)--N(R.sup.f).sub.2 wherein R.sup.f is independently H or
optionally substituted (C.sub.1-C.sub.3)alkyl; or R.sup.5 is
--NH--(C(O)).sub.m--NY.sup.300--(CH.sub.2).sub.p--R.sup.g; wherein
m is 0, 1 or 2; Y.sup.300 is H or optionally substituted
(C.sub.1-C.sub.3)alkyl; p is 1 or 2; and R.sup.g is selected from
the optionally substituted group of amino, (C.sub.1-C.sub.2)alkoxy,
benzo[1,3]dioxazolyl, benzothiazolyl, benzo[1,4]oxazinyl,
benzo[1,2,5]thiadiazolyl, imidazol[1,2-a]pyridinyl, imidazolyl,
isoxazolyl, morpholinyl, oxazolyl, phenyl, piperidinyl, pyrazinyl,
pyrazolyl, pyridinyl, pyrrolyl, tetrahydropyranyl, thiazolyl and
triazolyl; or R.sup.g is W--X wherein W is attached to the
(CH.sub.2).sub.p and W is thiazolyl and X is thienyl; R.sup.5 is
--NH--S(O).sub.2R.sup.h wherein R.sup.h is selected from the group
of optionally substituted benzo[1,2,5]oxodiazolyl,
benzo[1,2,5]thiadiazolyl, imidazolyl, isoxazolyl, oxazolyl,
benzo[1,4]oxazinyl, pyrazolyl, phenyl, quinolinyl, thiazolyl,
thienyl and thienyl; or R.sup.h is T-U wherein T is attached to the
S(O).sub.2 and T is phenyl or thienyl; U is selected from the group
consisting of pyridinyl, optionally substituted thiazolyl and
--NH-pyrimidinyl wherein the pyrimidinyl can be optionally
substituted; or R.sup.5 is --N(Y.sup.400)--R.sup.i wherein
Y.sup.400 is H or Y.sup.400 is selected from the optionally
substituted group consisting of (C.sub.1-C.sub.3)alkyl,
amino(C.sub.1-C.sub.3)alkyl and pyridinylmethyl; and R.sup.i is
selected from the optionally substituted group of
(C.sub.1-C.sub.3)alkyl, 6-azaindolyl cyclobutenyl, phenyl, purinyl,
pyrazinyl, pyrazolo[1,5-a]pyrimidine, pyridazinyl, pyridinyl,
pyrimidinyl, pyrrolo[2,3-c]pyridinyl, pyrrolo[2,3-b]pyrimidinyl,
pyrrolo[3,2-d]pyrimidinyl, pyrrolo[3,4-b]pyrimidinyl,
pyrrolo[2,3-d]pyrimidinyl, quinazolinyl, thieno[3,2-d]pyrimidinyl,
thieno[3,2-b]pyridinyl, and triazinyl; or R.sup.i is V--W wherein V
is attached to the nitrogen and V is a bond or is selected from the
optionally substituted group consisting of isoquinolinyl,
pyridinyl, pyrimidinyl and pyrrolo[3,2-d]pyrimidinyl; W is selected
from the optionally substituted group consisting of
(C.sub.1-C.sub.3)alkyl, alkoxyalkyl, cyclopentyl, morpholinyl,
phenyl, pyrimidinyl, pyrrolidinyl, thieno[3,2-b]pyridinyl,
--NH-phenyl, --NH--CH.sub.2--CH.sub.2--N(CH.sub.3).sub.2,
--NH--NH.sub.2, NH--C(O)--CH.sub.3, CH.sub.2-phenyl,
NH--C(O)-furanyl, S-isopropyl, S-naphthyl, S-phenyl and
S--CH.sub.2--CH.sub.2--NH.sub.2; or R.sup.5 is Z.sup.100-Z.sup.200
wherein Z.sup.100 is attached to the indazole and Z.sup.100 is
selected from the group consisting of butyl, ethyl, indazolyl,
optionally substituted phenyl, optionally substituted pyridinyl,
optionally substituted pyrimidinyl, pyrrolo[3,2-d]pyrimidinyl and
optionally substituted thienyl; Z.sup.200 is selected from the
group consisting of --C(O)--NH--CH.sub.2CH.sub.2--NH.sub.2,
NH.sub.2, --NH--C(O)-thienyl, --NH--C(O)--CH(CH.sub.3).sub.2,
--NH--C(O)--CH.sub.3, --NH--C(O)C(CH.sub.3).sub.3,
--NH--C(O)--NH-furanyl, --NH--C(O)--NH-phenyl, benzo[b]thienyl,
morpholinylethyl, phenyl, piperazinyl, piperidinyl, pyrazolyl and
tetrazolyl; or R.sup.5 is --NH--C(O)--Y.sup.500--C(O)--R.sup.k;
wherein Y.sup.500 is optionally substituted (C.sub.1-C.sub.3)alkyl;
and R.sup.k is H or R.sup.k is selected from the optionally
substituted group consisting of phenyl, phenylamino and thienyl; or
R.sup.5 is --NH--C(O)--(CH.sub.2).sub.y--NH-T-R.sup.m; wherein y is
1 or 2; T is C(O) or S(O).sub.2; and R.sup.m is selected from the
group consisting of furanyl, phenyl and thienyl; R.sup.6 is H or
R.sup.6 is selected from the optionally substituted group
consisting of (C.sub.1)alkoxy, (C.sub.1-C.sub.3)alkyl,
benzo[b]thienyl, --NH-pyrimidinyl,
--NH--S(O).sub.2-phenyl-NH-pyrimidinyl, --NH--C(O)-benzo[b]thienyl,
pyrrolo[2,3-b]pyrimidinyl and pyridinyl; and R.sup.7 is selected
from the group consisting of H, halo, NH.sub.2, or R.sup.7 is
selected from optionally substituted group consisting of
(C.sub.2-C.sub.5)alkenyl, (C.sub.2-C.sub.5)alkynyl, aminoalkynyl,
benzofuranyl, benzothiazolyl, benzo[b]thienyl, furanyl, indolyl,
isoquinolinyl, naphthyl, phenyl, phenylalkyl,
phenyl(C.sub.2-C.sub.5)alkenyl, phenyl(C.sub.2-C.sub.5)alkynyl,
pyridinyl, pyrimidinyl, pyrrolyl, quinolinyl, quinoxalinyl,
thieno[2,3-b]pyridinyl, thienyl, --NH--S(O).sub.2--CH.sub.3,
--NH--C(O)--CH.sub.3, --NH--C(O)-phenyl,
--C(O)--NH--CH.sub.2-phenyl and --C(O)--NH-phenyl; or R.sup.7 is
Y-Z wherein Y is attached to the indazole; and Y is benzo[b]thienyl
or thienyl; and Z is selected from the group consisting of phenyl,
thienyl, CH.sub.2NHCH.sub.2CH.sub.2-morpholinyl and substituted
piperazinyl; or R.sup.7 is --C(O)--NH--(CH.sub.2).sub.r-phenyl
wherein r is 0 or 1 and the phenyl is optionally substituted;
provided that the compound is not ##STR927## wherein R.sup.3 is
selected from the group consisting of H, OH and COOH; R.sup.5 is H
or NO.sub.2; R.sup.7 is H or NH.sub.2 R.sup.100 is OCH.sub.3 and
R.sup.200 is H or --C(O)--OCH.sub.3; provided that the compound is
not ##STR928## wherein R.sup.3 is NH.sub.2 or phenyl; and R.sup.5
is H or NO.sub.2; provided that the compound is not ##STR929##
wherein R.sup.1 is H, methyl or propyl; R.sup.7 is H, F or methyl;
and R is H, methyl, OH, NH, or OCH.sub.3; provided that the
compound is not ##STR930## wherein R.sup.3 is selected from the
group consisting of I, Br, COOH, NH.sub.2, thienyl, pyridinyl,
pyrrolyl, --C(O)--NH--CH--(CH.sub.2OH).sub.2,
--C(O)--NH--CH.sub.2--X.sup.100, ##STR931## wherein X.sup.100 is
pyridinyl or phenyl optionally substituted with methyl; provided
that the compound is not ##STR932## wherein R.sup.3 is morpholinyl
or 4-methylpiperazinyl; R.sup.c is H, Cl or NO.sub.2; R.sup.6 is H
or Cl and R.sup.7 is H, Cl or NO.sub.2; provided that the compound
is not ##STR933## wherein R.sup.6 is H, methyl or OCH.sub.3;
R.sup.6 is H or OCH.sub.3; L.sup.100 is H or isopropyl; and
X.sup.200 is phenyl or 4-chlorophenyl; provided that the compound
is not ##STR934## wherein R.sup.1 is H or CH.sub.3 and X.sup.300 is
benzyl, phenyl, 2-aminophenyl or 2-hydroxyphenyl; and provided that
the compound is not ##STR935## wherein R.sup.1 is H, CH.sub.2OH,
methyl, phenyl or 4-methoxybenzyl; R.sup.3 is H, I, pyridinyl or
##STR936## and R.sup.5 is H, Br, F, C(OH),
--C(O)--OCH.sub.2CH.sub.3 or --NH--C(O)--NH-benzyl.
2. The compound of claim 1 wherein R.sup.1 is H or pyrimidinyl
substituted with NH.sub.2; R.sup.3 is selected from the group
consisting of H, CH.sub.3, OH, Cl, benzo[b]thienyl,
2,3-dihydrobenzofuranyl, indolyl, naphthyl, phenyl, pyrazolyl,
pyridinyl, pyrimidinyl, pyrrolyl, quinolinyl, thienyl,
--NH--C(O)-cyclobutyl and --NH--C(O)-phenyl; wherein the indolyl is
optionally substituted with CH.sub.3; the naphthyl is optionally
substituted with OCH.sub.3 or OH; and the phenyl optionally
substituted with one or more substituents selected from the group
consisting of CH.sub.3, NH.sub.2, Cl, F, N(CH.sub.3).sub.2, OH,
CH.sub.2OH, C(O)NH.sub.2, COOH, CF.sub.3, OCF.sub.3, OCH.sub.3, CN,
OCH.sub.2CH.sub.3, NHC(O)CH.sub.3, --S(O).sub.2CH.sub.3 and
--C(O)--NH-pheny; or R.sup.3 is
--C(O)--NY.sup.100--(C(Y.sup.100).sub.2).sub.x--R.sup.a wherein x
is 0 or 1; Y.sup.100 is H; R.sup.a is selected from the optionally
substituted group consisting of benzo[b]thienyl, benzimidazolyl,
1,3-dihydrobenzimidazolyl-2-one, benzotriazolyl, biphenyl,
1,3-dihydrobenzimidazolyl, indolyl, naphthyl and phenyl; wherein
the naphthyl is substituted with OH or OCH.sub.3; the phenyl is
optionally substituted with one or more Cl, F, OH, CH.sub.2OH,
CH.sub.2CH.sub.2OH, COOH, C(O)NH.sub.2, N(CH.sub.3).sub.2 or
methyl; or R.sup.3 is A-B wherein A is selected from the group
consisting of --C.ident.C, --C.ident.C-phenyl, phenyl and thienyl;
and B is selected from the group consisting of benzyloxy, phenyl,
thienyl, --NH--C(O)-cyclobutyl and --NH--C(O)-phenyl; R.sup.4 is H;
R.sup.5 is pyridinyl substituted with C(O)H, CH.sub.2OH,
SCH.sub.2CH.sub.2NH.sub.2 or NH.sub.2; or R.sup.5 is selected from
the group consisting of ##STR937## wherein E is selected from the
group consisting of H, OH, CH.sub.3, --CH.sub.2CH.sub.2NH.sub.2,
CH.sub.2CH.sub.2CH.sub.2OH, CH.sub.2CH.sub.2OCH.sub.3,
CH.sub.2CH.sub.2CH.sub.2NH.sub.2, CH.sub.2C(O)OH,
CH.sub.2CH.sub.2C(O)OH, CH.sub.2CH.sub.2C(O)NH.sub.2,
CH.sub.2CH.sub.2C(O)OCH.sub.3, CH.sub.2CH.sub.2CH.sub.2OCH.sub.3,
NHCH.sub.2CH.sub.2CH.sub.3, CH.sub.2CH.sub.2C(O)NH(CH.sub.3),
CH.sub.2CH.sub.2C(O)N(CH.sub.3).sub.2,
C(O)NHCH.sub.2CH.sub.2NH(CH.sub.3), NHCH.sub.2CH.sub.2OCH.sub.3,
NHCH.sub.2CH.sub.2OH, NHCH.sub.2CH.sub.2N(CH.sub.3).sub.2,
isopropyl, CH.sub.2C(O)NH.sub.2, CH.sub.2CH(CH.sub.3)C(O)OH,
CH.sub.2CH.sub.2CH.sub.2C(O)OH, CH.sub.2CH(CH.sub.3)C(O)OCH.sub.3,
CH.sub.2CH.sub.2CH.sub.2CH.sub.2NH.sub.2,
CH.sub.2CH.sub.2CH.sub.2C(O)NH.sub.2, N(CH.sub.3).sub.2,
morpholinylethyl, piperidinylethyl, ##STR938## and
4-methylpiperazinylcyclohexyl; E.sup.300 is H or
CH.sub.2CH.sub.2OCH.sub.3; G is selected from the group consisting
of H, Cl, NH.sub.2, CH.sub.2CH.sub.2C(O)NHCH.sub.2CH.sub.2NH.sub.2,
C(O)NH.sub.2, C(O)NHCH.sub.2CH.sub.2NH.sub.2,
C(O)NHCH.sub.2CH.sub.2N(CH.sub.3).sub.2, CH.sub.2CH.sub.2NH.sub.2,
CH.sub.2CH.sub.2CH.sub.2NH.sub.2, CH.sub.2CH.sub.2C(O)OH,
CH.sub.2CH.sub.2C(O)NH.sub.2, NHCH.sub.2CH.sub.2N(CH.sub.3).sub.2,
NHCH.sub.2CH.sub.2-pyridinyl and NHCH.sub.2CH.sub.2NH.sub.2, or
R.sup.5 is --C(O)--NH--(CH.sub.2).sub.a--R.sup.c wherein a is 0
R.sup.c is benzimidazolyl or fluorene substituted with oxo; or
R.sup.c is J.sup.100-J.sup.200 wherein J.sup.100 is selected from
the group consisting of pyrazolyl, pyridinyl, piperazinyl and
phenyl; wherein the phenyl is optionally substituted with one or
more substituents selected from the group consisting of F, OH and
OCH.sub.3; the piperazinyl is substituted with methyl; and
J.sup.200 is selected from the group consisting of benzoxazolyl,
benzimidazolyl, furanyl, imidazo[1,2-a]pyridinyl and
1,8a-dihydroimidazo[1,2-a]pyridinyl; or R.sup.5 is
--NH--C(O)--(CH.sub.2).sub.n--R.sup.d wherein n is 0, 1 or 2; and
R.sup.d is benzimidazolyl, benzo[b]thienyl, imidazolyl, phenyl or
pyrazolo[1,5-a]pyrimidinyl; wherein the phenyl is substituted with
NO.sub.2; R.sup.5 is
--NH--(C(O)).sub.m--NY.sup.300--(CH.sub.2).sub.p--R.sup.g wherein m
is 2; Y.sup.300 is H; p is 1; and R.sup.g is benzo[1,3]dioxazolyl;
or R.sup.5 is --N(Y.sup.400)--R.sup.i wherein Y.sup.400 is selected
from H, CH.sub.2CH.sub.2CH.sub.2OH, CH.sub.2CH.sub.2NH.sub.2 or
pyridinylmethyl; R.sup.i is V--W wherein V is a bond or
pyrimidinyl; and W is pyrimidinyl substituted with NH.sub.2 or
pyrrolidinyl substituted with OH; or R.sup.5 is Z.sup.100-Z.sup.200
wherein Z.sup.100 is thienyl or pyridinyl substituted with CH.sub.3
and Z.sup.200 is thienyl or NH--C(O)-furanyl; R.sup.6 is selected
from the group consisting of H, pyrrolo[2,3-b]pyrimidinyl and
##STR939## and R.sup.7 is selected from the optionally substituted
group consisting of H, Br, Cl, I, benzofuranyl, benzo[b]thienyl,
furanyl, indolyl, naphthyl, phenyl, pyridinyl, pyrrolyl,
quinolinyl,quinoxalinyl, thieno[2,3-b]pyridinyl, thienyl,
--CH.dbd.CH-phenyl, --C.ident.C-phenyl, --C(O)--NH--CH.sub.2-phenyl
and --C(O)--NH-phenyl wherein the naphthyl is optionally
substituted with OH or OCH.sub.3; the benzo[b]thienyl is optionally
substituted with OH, CH.sub.3, OCH.sub.3, N(CH.sub.3).sub.2, OH,
CH.sub.2.dbd.CHNHCH.sub.3, CH.sub.2NH.sub.2,
CH.sub.2CH.sub.2NH.sub.2 or
CH.sub.2NHCH.sub.2CH.sub.2N(CH.sub.3).sub.2; the indolyl is
substituted with C(O)N(CH(CH.sub.3).sub.2).sub.2, CH.sub.2OH,
CH.sub.2C(O)NH.sub.2, COOH C(O)NH.sub.2, N(CH.sub.3).sub.2 or
S(O).sub.2CH.sub.3; and the phenyl is optionally substituted with
one or more substituents selected from the group consisting of Cl,
F, CH.sub.3, CH.sub.2OH, CN, --C(O)NH.sub.2, OH, OCH.sub.3,
N(CH.sub.3).sub.2, NH--C(O)CH.sub.3, --NH--S(O).sub.2--CH.sub.3;
the thienyl is substituted with CH.sub.2OH; or R.sup.7 is Y-Z
wherein Y is benzo[b]thienyl or thienyl; and Z is selected from the
optionally substituted group consisting of CH.dbd.CHNHCH.sub.3,
NHCH.sub.3, CH.sub.2NH.sub.2, CH.sub.2CH.sub.2NH.sub.2,
CH.sub.2NHCH.sub.3, CH.sub.2NHCH.sub.2CH.sub.2N(CH.sub.3).sub.2,
N(CH.sub.3).sub.2, CH.sub.2NHCH.sub.2CH.sub.2-morpholinyl,
benzo[b]thienyl, morpholinylmethyl, piperazinylmethylphenyl and
thienyl; or R.sup.7 is --C(O)--NH--(CH.sub.2).sub.r-phenyl wherein
r is 0 or 1; the phenyl is optionally substituted with
NH.sub.2.
3. The compound of claim 2 wherein R.sup.1 is H or pyrimidinyl
substituted with NH.sub.2; R.sup.3 is selected from the group
consisting of H, CH.sub.3, OH, Cl, benzo[b]thienyl,
2,3-dihydrobenzofuranyl, indolyl, naphthyl, phenyl, pyrazolyl,
pyridinyl, pyrimidinyl, pyrrolyl, quinolinyl, thienyl,
--NH--C(O)-cyclobutyl and --NH--C(O)-phenyl; wherein the indolyl is
optionally substituted with CH.sub.3; the naphthyl is optionally
substituted with OH; and the phenyl optionally substituted with one
or more substituents selected from the group consisting of OH, F,
CH.sub.3, CF.sub.3, CN, --C(O)NH.sub.2, NH.sub.2, NHC(O)CH.sub.3,
OCH.sub.3, OCF.sub.3, OCH.sub.2CH.sub.3, N(CH.sub.3).sub.2,
--C(O)--NH-phenyl and --S(O).sub.2CH.sub.3; or R.sup.3 is
--C(O)--NY.sup.100--(C(Y.sup.100).sub.2).sub.x--R.sup.a wherein
Y.sup.100 is H; x is 0; R.sup.a is selected from the optionally
substituted group consisting of benzimidazolyl,
1,3-dihydrobenzimidazolyl-2-one, benzotriazolyl, biphenyl, indolyl,
naphthyl and phenyl; wherein the naphthyl is substituted with OH or
OCH.sub.3; the phenyl is optionally substituted with one or more
Cl, F, OH, CH.sub.2OH, CH.sub.2CH.sub.2OH, C(O)NH.sub.2,
N(CH.sub.3).sub.2 or methyl; or R.sup.3 is A-B wherein A is
selected from the group consisting of phenyl and thienyl; and B is
selected from the group consisting of benzyloxy, phenyl, thienyl,
--NH--C(O)-cyclobutyl and --NH--C(O)-phenyl; R.sup.5 is pyridinyl
substituted with NH.sub.2; or R.sup.5 is selected from the group
consisting of ##STR940## wherein E is selected from the group
consisting of H, CH.sub.3, CH.sub.2C(O)OH,
CH.sub.2CH.sub.2CH.sub.2OH, CH.sub.2CH.sub.2CH.sub.2NH.sub.2,
CH.sub.2CH.sub.2C(O)OH, CH.sub.2CH.sub.2C(O)NH.sub.2,
CH.sub.2CH.sub.2C(O)OCH.sub.3, CH.sub.2CH.sub.2CH.sub.2OCH.sub.3,
NHCH.sub.2CH.sub.2CH.sub.3, CH.sub.2CH.sub.2C(O)NH(CH.sub.3),
NHCH.sub.2CH.sub.2OCH.sub.3, NHCH.sub.2CH.sub.2OH, isopropyl,
CH.sub.2C(O)NH.sub.2, CH.sub.2CH(CH.sub.3)C(O)OH, morpholinylethyl,
piperidinylethyl, CH.sub.2CH.sub.2CH.sub.2C(O)OH,
CH.sub.2CH(CH.sub.3)C(O)OCH.sub.3, CH.sub.2CH.sub.2NH.sub.2,
CH.sub.2CH.sub.2CH.sub.2CH.sub.2NH.sub.2,
CH.sub.2CH.sub.2CH.sub.2C(O)NH.sub.2,
CH.sub.2CH.sub.2C(O)N(CH.sub.3).sub.2, and N(CH.sub.3).sub.2; and G
is selected from the group consisting of H, NH.sub.2, Cl,
CH.sub.2CH.sub.2C(O)NHCH.sub.2CH.sub.2NH.sub.2,
C(O)NHCH.sub.2CH.sub.2NH.sub.2,
C(O)NHCH.sub.2CH.sub.2N(CH.sub.3).sub.2,
NHCH.sub.2CH.sub.2N(CH.sub.3).sub.2, NHCH.sub.2CH.sub.2NH.sub.2,
CH.sub.2CH.sub.2NH.sub.2, CH.sub.2CH.sub.2CH.sub.2NH.sub.2,
CH.sub.2CH.sub.2C(O)OH, CH.sub.2CH.sub.2C(O)NH.sub.2 and
NHCH.sub.2CH.sub.2-pyridinyl; R.sup.5 is
--C(O)--NH--(CH.sub.2).sub.a--R.sup.c wherein a is 0; R.sup.c is
J.sup.100-J.sup.200 wherein J.sup.100 is pyrazolyl or phenyl
wherein the phenyl is optionally substituted with OCH.sub.3; and
J.sup.200 is benzoxazolyl, benzimidazolyl, furanyl,
imidazo[1,2-a]pyridinyl or 1,8a-dihydroimidazo[1,2-a]pyridinyl; or
R.sup.5 is --NH--C(O)--(CH.sub.2).sub.n--R.sup.d wherein n is 0, 1
or 2; and R.sup.d is selected from the group consisting of
benzimidazolyl, benzo[b]thieny, imidazolyl and
pyrazolo[1,5-a]pyrimidinyl; R.sup.5 is --N(Y.sup.400)--R.sup.i
wherein Y.sup.400 is selected from H, CH.sub.2CH.sub.2CH.sub.2OH,
CH.sub.2CH.sub.2NH.sub.2or pyridinylmethyl; R.sup.i is V--W wherein
V is a bond or pyrimidinyl and W is pyrimidinyl substituted with
NH.sub.2 or pyrrolidinyl substituted with OH; R.sup.5 is
Z.sup.100-Z.sup.200 wherein Z.sup.100 is thienyl; Z.sup.200 is
thienyl; R.sup.6 is H or ##STR941## and R.sup.7 is selected from
the optionally substituted group consisting of H, benzofuranyl,
benzo[b]thienyl, furanyl, indolyl, naphthyl, quinolinyl, phenyl,
pyrrolyl, quinoxalinyl, thienyl, thieno[2,3-b]pyridinyl,
--CH.dbd.CH-phenyl, --C.ident.C-phenyl, --C(O)--NH--CH.sub.2-phenyl
and --C(O)--NH-phenyl wherein the benzo[b]thienyl is optionally
substituted with OH, CH.sub.3, OCH.sub.3, N(CH.sub.3).sub.2,
CH.sub.2.dbd.CHNHCH.sub.3, CH.sub.2NH.sub.2,
CH.sub.2CH.sub.2NH.sub.2 or
CH.sub.2NHCH.sub.2CH.sub.2N(CH.sub.3).sub.2; the indolyl is
substituted with methyl, CN, C(O)H,
CH.sub.2CH.sub.2CH.sub.2NH.sub.2,
CH.sub.2NHCH.sub.2CH.dbd.CH.sub.2, C(O)CH.sub.3, C(O)OCH.sub.3,
OCH.sub.3, C(O)N(CH(CH.sub.3).sub.2).sub.2, CH.sub.2OH,
CH.sub.2C(O)NH.sub.2, C(O)NH.sub.2,
CH.sub.2NHCH.sub.2CH.sub.2N(CH.sub.3).sub.2 or piperidinylmethyl;
and the phenyl is optionally substituted with one or more
substituents selected from the group consisting of Cl, F, CH.sub.3,
CH.sub.2OH, CN, --C(O)NH.sub.2, OH, OCH.sub.3, N(CH.sub.3).sub.2
and --NH--S(O).sub.2--CH.sub.3; or R.sup.7 is Y-Z wherein Y is
benzo[b]thienyl or thienyl; and Z is selected from the optionally
substituted group consisting of CH.dbd.CHNHCH.sub.3, NHCH.sub.3,
CH.sub.2NH.sub.2, CH.sub.2CH.sub.2NH.sub.2, CH.sub.2NHCH.sub.3,
CH.sub.2NHCH.sub.2CH.sub.2N(CH.sub.3).sub.2, N(CH.sub.3).sub.2,
CH.sub.2NHCH.sub.2CH.sub.2-morpholinyl, benzo[b]thienyl,
morpholinylmethyl and piperazinylmethyl; wherein the piperazinyl is
optionally substituted with methyl.
4. The compound of claim 3 wherein R.sup.1 and R.sup.4 are H;
R.sup.3 is selected from the optionally substituted group
consisting of H, OH, 2,3-dihydrobenzofuranyl, naphthyl, pyrazolyl
and pyrrolyl; wherein R.sup.3 is
--C(O)--NY.sup.100--(C(Y.sup.100).sub.2).sub.x--R.sup.a wherein
Y.sup.100 is H; x is 0; R.sup.a is selected from the optionally
substituted group consisting of naphthyl and phenyl; wherein the
naphthyl is optionally substituted with OH; the phenyl is
optionally substituted with OH; or R.sup.3 is selected from the
group consisting of --NH--C(O)-cyclobutyl and --NH--C(O)-phenyl;
R.sup.3 is A-B wherein A is selected from the group consisting of
phenyl and thienyl; and B is selected from the group consisting of
benzyloxy, phenyl and thienyl; R.sup.5 is selected from the group
consisting of ##STR942## wherein E is selected from the group
consisting of H, CH.sub.2C(O)NH.sub.2,
CH.sub.2CH(CH.sub.3)C(O)OCH.sub.3, CH.sub.2CH.sub.2CH.sub.2OH,
CH.sub.2CH.sub.2C(O)OCH.sub.3, CH.sub.2CH.sub.2CH.sub.2OCH.sub.3,
CH.sub.2CH.sub.2NH.sub.2, CH.sub.2CH.sub.2CH.sub.2NH.sub.2,
CH.sub.2CH.sub.2C(O)OH, CH.sub.2CH.sub.2C(O)NH.sub.2,
CH.sub.2CH.sub.2CH.sub.2CH.sub.2NH.sub.2,
CH.sub.2CH.sub.2CH.sub.2OCH.sub.3, CH.sub.2CH.sub.2CH.sub.2C(O)OH,
CH.sub.2CH.sub.2CH.sub.2C(O)NH.sub.2, CH.sub.2CH(CH.sub.3)C(O)OH,
CH.sub.2CH.sub.2C(O)NH(CH.sub.3),
CH.sub.2CH.sub.2C(O)N(CH.sub.3).sub.2, N(CH.sub.3).sub.2,
isopropyl, morpholinylethyl and piperidinylethyl; and G is H,
NH.sub.2 or NHCH.sub.2CH.sub.2-pyridinyl or R.sup.5 is
--C(O)--NH--(CH.sub.2).sub.a--R.sup.c wherein a is 0 R.sup.c is
J.sup.100-J.sup.200 wherein J.sup.100 is phenyl optionally
substituted with OCH.sub.3 and J.sup.200 is imidazo[1,2-a]pyridinyl
or 1,8a-dihydroimidazo[1,2-a]pyridinyl; or R.sup.5 is
--NH--C(O)--(CH.sub.2).sub.n--R.sup.d wherein n is 2 and R.sup.d is
imidazolyl; or R.sup.5 is Z.sup.100-Z.sup.200 wherein Z.sup.100 is
thienyl; Z.sup.200 is thienyl; R.sup.6 is H or ##STR943## and
R.sup.7 is selected from the optionally substituted group
consisting of H, benzofuranyl, benzo[b]thienyl, indolyl, naphthyl,
quinolinyl, CH.dbd.CH-phenyl, --C.ident.C-phenyl,
--C(O)--NH--CH.sub.2-phenyl and --C(O)--NH-phenyl wherein the
benzo[b]thienyl is optionally substituted with OH, CH.sub.3,
OCH.sub.3, N(CH.sub.3).sub.2, CH.sub.2.dbd.CH.sub.2NHCH.sub.3,
CH.sub.2NH.sub.2, CH.sub.2CH.sub.2NH.sub.2,
CH.sub.2NHCH.sub.2CH.sub.2N(CH.sub.3).sub.2, piperidinylmethyl or
CH.sub.2NHCH.sub.2N(CH.sub.3).sub.2; and the indolyl is optionally
substituted with methyl, CN, C(O)H,
CH.sub.2CH.sub.2CH.sub.2NH.sub.2,
CH.sub.2NHCH.sub.2CH.dbd.CH.sub.2, C(O)CH.sub.3, C(O)OCH.sub.3, or
OCH.sub.3; methyl, CN, C(O)H, CH.sub.2CH.sub.2CH.sub.2NH.sub.2,
CH.sub.2NHCH.sub.2CH.dbd.CH.sub.2, C(O)CH.sub.3, C(O)OCH.sub.3, or
OCH.sub.3 the phenyl is optionally substituted with one or more
substituents selected from the group consisting of OH and
OCH.sub.3; or R.sup.7 is Y-Z wherein Y is benzo[b]thienyl or
thienyl; and Z is selected from the group consisting of
CH.dbd.CHNHCH.sub.3, NHCH.sub.3, CH.sub.2NH.sub.2,
CH.sub.2CH.sub.2NH.sub.2, CH.sub.2NHCH.sub.3,
CH.sub.2NHCH.sub.2CH.sub.2N(CH.sub.3).sub.2, N(CH.sub.3).sub.2,
CH.sub.2NHCH.sub.2CH.sub.2-morpholinyl, benzo[b]thienyl,
morpholinylmethyl and piperazinylmethyl; wherein the piperazinyl is
optionally substituted with methyl.
5. The compound of claim 4 wherein R.sup.1 and R.sup.4 are H;
R.sup.3 is selected from the group consisting of H, OH,
2,3-dihydrobenzofuranyl, pyrrolyl and optionally substituted
napthyl; or R.sup.3 is
--C(O)--NY.sup.100--(C(Y.sup.100).sub.2).sub.x--R.sup.a wherein
Y.sup.100 is H; x is 0; and R.sup.a is phenyl substituted with OH;
R.sup.5 is ##STR944## wherein E is selected from the group
consisting of H, CH.sub.2C(O)NH.sub.2, CH.sub.2CH.sub.2NH.sub.2,
CH.sub.2CH.sub.2CH.sub.2NH.sub.2,
CH.sub.2CH.sub.2CH.sub.2CH.sub.2NH.sub.2,
CH.sub.2CH.sub.2CH.sub.2OCH.sub.3, CH.sub.2CH.sub.2CH.sub.2OH,
CH.sub.2CH.sub.2C(O)OH, CH.sub.2CH.sub.2CH.sub.2C(O)OH,
CH.sub.2CH.sub.2C(O)NH.sub.2, CH.sub.2CH.sub.2CH.sub.2C(O)NH.sub.2,
CH.sub.2CH(CH.sub.3)C(O)OCH.sub.3 CH.sub.2CH(CH.sub.3)C(O)OH,
CH.sub.2CH.sub.2C(O)OCH.sub.3, CH.sub.2CH.sub.2C(O)NH(CH.sub.3),
CH.sub.2CH.sub.2C(O)N(CH.sub.3).sub.2, N(CH.sub.3).sub.2,
isopropyl, morpholinylethyl and piperidinylethyl; and G is H,
NH.sub.2 or NHCH.sub.2CH.sub.2-pyridinyl or R.sup.5 is
--C(O)--NH--(CH.sub.2).sub.a--R.sup.c wherein a is 0; and R.sup.c
is J.sup.100-J.sup.200 wherein J.sup.100 is phenyl and J.sup.200 is
1,8a-dihydroimidazo[1,2a]pyridinyl; or R.sup.5 is
--NH--C(O)--(CH.sub.2).sub.n--R.sup.d wherein n is 2 and R.sup.d is
imidazolyl; or R.sup.5 is Z.sup.100-Z.sup.200 wherein Z.sup.100 is
thienyl and Z.sup.200 is thienyl; R.sup.6 is H or ##STR945## and
R.sup.7 is selected from the optionally substituted group
consisting of H, --CH.dbd.CH-phenyl, --C.ident.C-phenyl,
benzofuranyl, benzo[b]thienyl, indolyl, quinolinyl, naphthyl,
--C(O)--NH--CH.sub.2-phenyl and --C(O)--NH-phenyl; wherein the
naphthyl is optionally substituted with OH, C(O)H or OCH.sub.3; the
benzo[b]thienyl optionally substituted with OH, CH.sub.3,
OCH.sub.3, CH.sub.2.dbd.CH.sub.3--NHCH.sub.3, CH.sub.2NH.sub.2,
CH.sub.2CH.sub.2NH.sub.2,
CH.sub.2NHCH.sub.2CH.sub.2N(CH.sub.3).sub.2, N(CH.sub.3).sub.2 or
piperidinylmethyl; the indolyl is optionally substituted with
methyl, CN, C(O)H, CH.sub.2CH.sub.2CH.sub.2NH.sub.2,
CH.sub.2NHCH.sub.2CH.dbd.CH.sub.2, C(O)CH.sub.3, C(O)OCH.sub.3, or
OCH.sub.3; the phenyl is optionally substituted with OH or
OCH.sub.3; or R.sup.7 is Y-Z wherein Y is benzo[b]thienyl; and Z is
selected from the group consisting of
CH.sub.2NHCH.sub.2CH.sub.2-morpholinyl, morpholinylmethyl and
piperazinylmethyl wherein the piperazinyl is optionally substituted
with methyl.
6. The compound of claim 5 wherein R.sup.1, R.sup.3, R.sup.4 and
R.sup.6 are H; R.sup.5 is ##STR946## wherein E is selected from the
group consisting of H, --CH.sub.2CH.sub.2NH.sub.2,
CH.sub.2CH.sub.2CH.sub.2NH.sub.2, CH.sub.2CH.sub.2CH.sub.2OH,
CH.sub.2CH.sub.2C(O)OH and CH.sub.2CH.sub.2C(O)NH.sub.2; and
R.sup.7 is selected from the group consisting of benzo[b]thienyl,
indolyl, --C(O)--NH--CH.sub.2-phenyl and --C(O)--NH-phenyl wherein
the benzo[b]thienyl is optionally substituted by piperidinylmethyl;
the indolyl is optionally substituted by CN, methyl or C(O)H.
7. The compound of claim 6 wherein R.sup.1, R.sup.3, R.sup.4 and
R.sup.6 are H; R.sup.5 is ##STR947## wherein E is H; and R.sup.7 is
--C(O)--NH--CH.sub.2-phenyl or --C(O)--NH-phenyl.
8. The compound of claim 6 wherein R.sup.1, R.sup.3, R.sup.4 and
R.sup.6 are H; R.sup.5 is ##STR948## wherein E is selected from the
group consisting of H, --CH.sub.2CH.sub.2NH.sub.2,
CH.sub.2CH.sub.2CH.sub.2NH.sub.2, CH.sub.2CH.sub.2CH.sub.2OH,
CH.sub.2CH.sub.2C(O)OH and CH.sub.2CH.sub.2C(O)NH.sub.2; and
R.sup.7 is benzo[b]thienyl or indolyl wherein the benzo[b]thienyl
is optionally substituted by piperidinylmethyl; the indolyl is
optionally substituted by CN, methyl or C(O)H;
9. The compound of claim 8 wherein R.sup.1, R.sup.3, R.sup.4 and
R.sup.6 are H; R.sup.5 is ##STR949## wherein E is selected from the
group consisting of --CH.sub.2CH.sub.2NH.sub.2,
CH.sub.2CH.sub.2CH.sub.2NH.sub.2, CH.sub.2CH.sub.2CH.sub.2OH,
CH.sub.2CH.sub.2C(O)OH and CH.sub.2CH.sub.2C(O)NH.sub.2; and
R.sup.7 is benzo[b]thienyl.
Description
BACKGROUND OF THE INVENTION
[0001] Protein phosphorylation, at specific amino acid residues, is
important for the regulation of many cellular processes including
cell cycle progression and division, signal transduction, and
apoptosis. The phosphorylation is usually a transfer reaction of
the terminal phosphate group from ATP to the protein substrate. The
specific structure in the target substrate to which the phosphate
is transferred is a tyrosine, serine or threonine residue. Since
these amino acid residues are the target structures for the
phosphoryl transfer, and since most kinases target either tyrosine
or both serine and threonine, these protein kinase enzymes are
commonly referred to as tyrosine kinases or serine/threonine (S/T)
kinases. The phosphorylation reactions, and counteracting
phosphatase reactions, on the tyrosine, serine and threonine
residues are involved in many cellular processes that underlie
responses to diverse intracellular signals, regulation of cellular
functions, and activation or deactivation of cellular processes. A
cascade of protein kinases often function in intracellular signal
transduction. Protein kinases can be found integrated into the
plasma membrane, as cytoplasmic enzymes or localized in the
nucleus, often as components of enzyme complexes. In many
instances, these protein kinases are an essential element of enzyme
and structural protein complexes that determine where and when a
cellular process occurs within a cell. Given the importance and
diversity of protein kinase function, it is not surprising that
phosphorylation events are required in cellular processes
associated with many diseases such as cancer, diabetes,
inflammation, and hypertension.
[0002] The identification of effective small molecules that
specifically inhibit protein kinases involved in abnormal or
inappropriate cell proliferation, signaling, differentiation,
protein production, or metabolism is therefore desirable. The
identification of methods and compounds that specifically inhibit
the function of kinases that are involved in immune modulation or
proliferative disorders is particularly desirable.
[0003] The present invention provides novel compounds that inhibit
one or more receptor, or non-receptor, tyrosine or S/T kinase.
SUMMARY OF THE INVENTION
[0004] The present invention provides a compound of Formula (I)
##STR2## wherein [0005] R.sup.1 is selected from the group
consisting of H, benzyl substituted with OCH.sub.3, optionally
substituted (C.sub.1-C.sub.3)alkyl, pyrimidine substituted with
NH.sub.2 and amino(C.sub.1-C.sub.3)alkyl; [0006] R.sup.3 is
selected from the group consisting of H, halogen, NH.sub.2, OH,
COOH, --C(O)--NH--CH.sub.2--C(O)--OCH.sub.3, --NH--CH.sub.2-phenyl,
--C(O)-pyridinyl, --NH--C(O)-cyclobutyl and --NH--C(O)-phenyl
wherein phenyl is optionally substituted with either
N(CH.sub.3).sub.2 or OCH.sub.3; or [0007] R.sup.3 is selected from
the optionally substituted group consisting of
(C.sub.1-C.sub.6)alkyl, benzo[b]thienyl, 2,3-dihydrobenzofuranyl,
indolyl, isoquinolinyl, morpholinyl, naphthyl, phenyl, piperazinyl,
pyrazolyl, pyridinyl, pyrimidinyl, pyrrolyl, quinolinyl and
thienyl; [0008] wherein the substituent is selected from one or
more CH.sub.3, NH.sub.2, Cl, F, dimethylamino, OH, CH.sub.2OH,
--C(O)NH.sub.2, COOH, CF.sub.3, isopropyl, OCF.sub.3, OCH.sub.3,
--O--CH.sub.2-phenyl, CN, OCH.sub.2CH.sub.3, --NH--C(O)-cyclobutyl,
--NH--C(O)-phenyl, NH--C(O)--CH.sub.3, NHC(O)CH.sub.3,
N(CH.sub.3).sub.2, S(O).sub.2CH.sub.3 and C(O)NH-phenyl; or [0009]
R.sup.3 is --C(O)--NY.sup.100--(C(Y.sup.100).sub.2).sub.x--R.sup.a
wherein [0010] x is 0, 1, 2 or 3; [0011] Y.sup.100 is independently
H or (C.sub.1-C.sub.3)alkyl; and [0012] R.sup.a is --C(O)--CH.sub.3
or is selected from the optionally substituted group
(C.sub.1-C.sub.3)alkyl, amino, aminoalkyl, benzimidazolyl,
benzo[b]thienyl, benzotriazolyl, biphenyl,
1,3-dihydrobenzimidazolyl, 1,3-dihydrobenzimidazolyl-2-one,
imidazolyl, indolyl, naphthyl, phenyl, pyrazolyl, pyridinyl,
pyrimidinyl, tetrahydropyranyl and thiazolyl; or [0013] R.sup.3 is
A-B wherein A is connected to the indazole and [0014] A is selected
from the group consisting of --C.ident.C, --C.ident.C-phenyl,
indazolyl, phenyl, pyridinyl and thienyl; [0015] B is selected from
the group consisting of benzyloxy, morpholinyl, phenyl, thienyl,
t-butyl, --NH--C(O)-cyclobutyl and --NH--C(O)-phenyl; [0016]
R.sup.4 is H or NH.sub.2; [0017] R.sup.5 is selected from the group
consisting of H, NH.sub.2, NO.sub.2, halo; or [0018] R.sup.5 is
selected from the optionally substituted group consisting of
benzimidazolyl, 3,4-dihydrobenzo[1,4]thiazinyl, benzyloxyphenyl,
furo[3,2-c]pyridine, indazolyl, indolyl, isoquinolinyl, phenyl,
pyrazolo[3,4-d]pyrimidine, pyrazinyl, pyrazolyl, pyridinyl,
pyrrolo[2,3-b]pyridinyl, pyrrolo[2,3-c]pyridinyl,
pyrrolo[2,3-d]pyridinyl, pyrimidinyl, pyrrolo[3,2-d]pyridine,
pyrrolo[2,3-d]pyrimidinyl, pyridinyl, pyrrolyl, quinolinyl,
quinazolinyl, thienyl, thieno[2,3-c]pyridinyl,
thieno[2,3-d]pyrimidine, thieno[3,2-c]pyridine, 7-azaindolinyl and
7-azaindolyl; or [0019] R.sup.5 is --C(O)--R.sup.b; wherein [0020]
R.sup.b is selected from the group consisting of OH,
(C.sub.1-C.sub.3)alkoxy, phenyl, optionally substituted
piperidinyl, optionally substituted pyridinyl and optionally
substituted pyrrolidinyl; or [0021] R.sup.b is D-E wherein D is
attached to the C(O) and [0022] D is selected from the group
consisting of piperidinyl and pyrrolidinyl; [0023] E is selected
from the group consisting of pyridinyl and pyrimidinylaminemethyl;
[0024] R.sup.5 is --C(O)--NH--(CH.sub.2).sub.a--R.sup.c; wherein
[0025] a is 0, 1, 2 or 3; [0026] R.sup.c is --CONH.sub.2 or [0027]
R.sup.c is selected from the optionally substituted group
consisting of benzimidazolyl, benzothiazolyl, benzo[b]thiophenyl,
dimethylamino, fluorene, imidazolyl, indanyl, indazolyl,
isoxazolyl, oxazolyl, phenyl, piperidinyl, pyrazolyl, pyridinyl,
quinazolinyl, thiadiazolyl and 1,2,4-triazolyl; or [0028] R.sup.c
is J.sup.100-J.sup.200 wherein J.sup.100 is attached to
(CH.sub.2).sub.x and [0029] J.sup.100 is selected from the
optionally substituted group consisting of isoxazolyl, piperazinyl,
pyrazolyl pyridinyl, and phenyl; and [0030] J.sup.200 is selected
from the group consisting of benzimidazolyl, benzoxazolyl,
cyclohexyl, furanyl, imnidazo[1,2-a]pyridinyl, indolyl, isoxazolyl,
--NH--C(O)-phenyl, phenoxy and optionally substituted phenyl;
[0031] R.sup.5 is --NH--C(O)--(CH.sub.2).sub.n--R.sup.d; wherein
[0032] n is 0 to 3; [0033] R.sup.d is
--C(CH.sub.3).sub.2--CH.sub.2--C(O)--CH.sub.3; or [0034] R.sup.d is
selected from the optionally substituted group of
(C.sub.1-C.sub.2)alkoxy, alkylamino, benzimidazolyl,
benzo[1,3]dioxazolyl, benzo[1,2,5]oxadiazolyl, benzotriazolyl,
benzo[b]thienyl, benzofuranyl, benzyloxy, cyclopropyl, cyclohexyl,
chromenyl, dimethylamino, furanyl, hexahydropyrimidinyl,
imidazolyl, imidazo[2,1-b]thiazolyl, imidazo[2,1-b]thiazolyl,
imidazolidinyl, indolyl, isoxazolyl, morpholinyl, phenyl,
piperazinyl, piperidinyl, pyrazinyl, pyrazolyl,
pyrazolo[1,5-a]pyrimidinyl, pyridazinyl, pyridinyl, pyrimidinyl,
pyrrolidinyl, pyrrolyl, quinolinyl, quinoxalinyl,
tetrahydrobenzofuranyl, tetrahydrofuranyl, thiazolyl,
thieno[2,3-d]pyrimidinyl, thienyl,
2,3-dihydrothiazolo[3,2-a]pyrimidine, --S-pyrimidinyl, --O-phenyl,
--O--Si(CH.sub.3).sub.2--C(CH.sub.3).sub.3,
--NH--S(O).sub.2-phenyl, --NH--C(O)--NH.sub.2,
1,2,3,4-tetrahydronaphthyridinyl or N(CH.sub.3).sub.2; or [0035]
R.sup.d is M-Q wherein M is attached to the (CH.sub.2).sub.n and
[0036] M is selected from the group consisting of optionally
substituted methylene, cyclopropylidene, optionally substituted
isoxazolyl, phenyl, pyrazolyl, --NH--C(O) and optionally
substituted 1,3,5-triazinyl; [0037] Q is selected from the group
consisting of furanyl, morpholinyl, phenyl, phenylamine and
optionally substituted 1,3,4-thiadiazolyl; [0038] R.sup.5 is
--NH--CH.sub.2--C(Y.sup.200).sub.2--R.sup.e wherein Y.sup.200 is
independently H or (C.sub.1-C.sub.3)alkyl and R.sup.e is selected
from the optionally substituted group of (C.sub.1-C.sub.6)alkoxy,
imidazolyl, phenyl, piperidinyl, pyrrolidinyl and
1,2,3,4-tetrahydro[1,8]naphthyridine; or [0039] R.sup.5 is
--NH--C(O)--N(R.sup.f).sub.2 wherein R.sup.f is independently H or
optionally substituted (C.sub.1-C.sub.3)alkyl; or [0040] R.sup.5 is
--NH--(C(O)).sub.m--NY.sup.300--(CH.sub.2).sub.p--R.sup.g; wherein
[0041] m is 0, 1 or 2; [0042] Y.sup.300 is H or optionally
substituted (C.sub.1-C.sub.3)alkyl; [0043] p is 1 or 2; and [0044]
R.sup.g is selected from the optionally substituted group of amino,
(C.sub.1-C.sub.2)alkoxy, benzo[1,3]dioxazolyl, benzothiazolyl,
benzo[1,4]oxazinyl, benzo[1,2,5]thiadiazolyl,
imidazol[1,2-a]pyridinyl, imidazolyl, isoxazolyl, morpholinyl,
oxazolyl, phenyl, piperidinyl, pyrazinyl, pyrazolyl, pyridinyl,
pyrrolyl, tetrahydropyranyl, thiazolyl and triazolyl; or [0045]
R.sup.g is W--X wherein W is attached to the (CH.sub.2).sub.p and W
is thiazolyl and X is thienyl; [0046] R.sup.5 is
--NH--S(O).sub.2R.sup.h wherein R.sup.h is selected from the group
of optionally substituted benzo[1,2,5]oxodiazolyl,
benzo[1,2,5]thiadiazolyl, imidazolyl, isoxazolyl, oxazolyl,
benzo[1,4]oxazinyl, pyrazolyl, phenyl, quinolinyl, thiazolyl,
thienyl and thienyl; or [0047] R.sup.h is T-U wherein T is attached
to the S(O).sub.2 and [0048] T is phenyl or thienyl; [0049] U is
selected from the group consisting of pyridinyl, optionally
substituted thiazolyl and --NH-pyrimidinyl wherein the pyrimidinyl
can be optionally substituted; or [0050] R.sup.5 is
--N(Y.sup.400)--R.sup.i wherein [0051] Y.sup.400 is H or Y.sup.400
is selected from the optionally substituted group consisting of
(C.sub.1-C.sub.3)alkyl, amino(C.sub.1-C.sub.3)alkyl and
pyridinylmethyl; and [0052] R.sup.i is selected from the optionally
substituted group of (C.sub.1-C.sub.3)alkyl, 6-azaindolyl
cyclobutenyl, phenyl, purinyl, pyrazinyl,
pyrazolo[1,5-a]pyrimidine, pyridazinyl, pyridinyl, pyrimidinyl,
pyrrolo[2,3-c]pyridinyl, pyrrolo[2,3-b]pyrimidinyl,
pyrrolo[3,2-d]pyrimidinyl, pyrrolo[3,4-b]pyrimidinyl,
pyrrolo[2,3-d]pyrimnidinyl, quinazolinyl, thieno[3,2-d]pyrimidinyl,
thieno[3,2-b]pyridinyl, and triazinyl; or [0053] R.sup.i is V--W
wherein V is attached to the nitrogen and [0054] V is a bond or is
selected from the optionally substituted group consisting of
isoquinolinyl, pyridinyl, pyrimidinyl and
pyrrolo[3,2-d]pyrimidinyl; [0055] W is selected from the optionally
substituted group consisting of (C.sub.1-C.sub.3)alkyl,
alkoxyalkyl, cyclopentyl, morpholinyl, phenyl, pyrimidinyl,
pyrrolidinyl, thieno[3,2-b]pyridinyl, --NH-phenyl,
--NH--CH.sub.2--CH.sub.2--N(CH.sub.3).sub.2, --NH--NH.sub.2,
NH--C(O)--CH.sub.3, CH.sub.2-phenyl, NH--C(O)-furanyl, S-isopropyl,
S-naphthyl, S-phenyl and S--CH.sub.2--CH.sub.2--NH.sub.2; or [0056]
R.sup.5 is Z.sup.100-Z.sup.200 wherein Z.sup.100 is attached to the
indazole and [0057] Z.sup.100 is selected from the group consisting
of butyl, ethyl, indazolyl, optionally substituted phenyl,
optionally substituted pyridinyl, optionally substituted
pyrimidinyl, pyrrolo[3,2-d]pyrimidinyl and optionally substituted
thienyl; [0058] Z.sup.200 is selected from the group consisting of
--C(O)--NH--CH.sub.2CH.sub.2--NH.sub.2, NH.sub.2,
--NH--C(O)-thienyl, --NH--C(O)--CH(CH.sub.3).sub.2,
--NH--C(O)--CH.sub.3, --NH--C(O)C(CH.sub.3).sub.3,
--NH--C(O)--NH-furanyl, --NH--C(O)--NH-phenyl, benzo[b]thienyl,
morpholinylethyl, phenyl, piperazinyl, piperidinyl, pyrazolyl and
tetrazolyl; or [0059] R.sup.5 is
--NH--C(O)--Y.sup.500--C(O)--R.sup.k; wherein [0060] Y.sup.500 is
optionally substituted (C.sub.1-C.sub.3)alkyl; and [0061] R.sup.k
is H or R.sup.k is selected from the optionally substituted group
consisting of phenyl, phenylamino and thienyl; or [0062] R.sup.5 is
--NH--C(O)--(CH.sub.2).sub.y--NH-T-R.sup.m; wherein [0063] y is 1
or 2; [0064] T is C(O) or S(O).sub.2; and [0065] R.sup.m is
selected from the group consisting of furanyl, phenyl and thienyl;
[0066] R.sup.6 is H or R.sup.6 is selected from the optionally
substituted group consisting of (C.sub.1)alkoxy,
(C.sub.1-C.sub.3)alkyl, benzo[b]thienyl, --NH-pyrimidinyl,
--NH--S(O).sub.2-phenyl-NH-pyrimidinyl, --NH--C(O)-benzo[b]thienyl,
pyrrolo[2,3-b]pyrimidinyl and pyridinyl; and [0067] R.sup.7 is
selected from the group consisting of H, halo, NH.sub.2, or R.sup.7
is selected from optionally substituted group consisting of
(C.sub.2-C.sub.5)alkenyl, (C.sub.2-C.sub.5)alkynyl, aminoalkynyl,
benzofuranyl, benzothiazolyl, benzo[b]thienyl, furanyl, indolyl,
isoquinolinyl, naphthyl, phenyl, phenylalkyl,
phenyl(C.sub.2-C.sub.5)alkenyl, phenyl(C.sub.2-C.sub.5)alkynyl,
piperidinyl, pyridinyl, pyrimidinyl, pyrrolyl, quinolinyl,
quinoxalinyl, thieno[2,3-b]pyridinyl, thienyl,
--NH--S(O).sub.2--CH.sub.3, --NH--C(O)--CH.sub.3,
--NH--C(O)-phenyl, --C(O)--NH--CH.sub.2-phenyl and
--C(O)--NH-phenyl; or [0068] R.sup.7 is Y-Z wherein Y is attached
to the indazole; and [0069] Y is benzo[b]thienyl or thienyl; and
[0070] Z is selected from the group consisting of phenyl, thienyl,
CH.sub.2NHCH.sub.2CH.sub.2-morpholinyl and substituted piperazinyl;
or [0071] R.sup.7 is --C(O)--NH--(CH.sub.2).sub.r-phenyl wherein r
is 0 or 1 and the phenyl is optionally substituted; provided that
the compound is not ##STR3## wherein [0072] R.sup.3is selected from
the group consisting of H, OH and COOH; [0073] R.sup.5is H or
NO.sub.2; [0074] R.sup.7is H or NH.sub.2 [0075] R.sup.100 is
OCH.sub.3 and [0076] R.sup.200 is H or --C(O)--OCH.sub.3; provided
that the compound is not ##STR4## wherein [0077] R.sup.3is NH.sub.2
or phenyl; and [0078] R.sup.5is H or NO.sub.2; provided that the
compound is not ##STR5## wherein [0079] R.sup.1 is H, methyl or
propyl; [0080] R.sup.7 is H, F or methyl; and [0081] R is H,
methyl, OH, NH, or OCH.sub.3; provided that the compound is not
##STR6## [0082] wherein R.sup.3 is selected from the group
consisting of I, Br, COOH, NH.sub.2, thienyl, pyridinyl, pyrrolyl,
--C(O)--NH--CH--(CH.sub.2OH).sub.2,
--C(O)--NH--CH.sub.2--X.sup.100, ##STR7## [0083] wherein X.sup.100
is pyridinyl or phenyl optionally substituted with methyl; provided
that the compound is not ##STR8## wherein [0084] R.sup.3 is
morpholinyl or 4-methylpiperazinyl; [0085] R.sup.c is H, Cl or
NO.sub.2; [0086] R.sup.6 is H or Cl and [0087] R.sup.7 is H, Cl or
NO.sub.2; provided that the compound is not ##STR9## wherein [0088]
R.sup.6 is H, methyl or OCH.sub.3; [0089] R.sup.6 is H or
OCH.sub.3; [0090] L.sup.100 is H or isopropyl; and [0091] X.sup.200
is phenyl or 4-chlorophenyl; provided that the compound is not
##STR10## wherein [0092] R.sup.1 is H or CH.sub.3 and X.sup.300 is
benzyl, phenyl, 2-aminophenyl or 2-hydroxyphenyl; and provided that
the compound is not ##STR11## wherein [0093] R.sup.1 is H,
CH.sub.2OH, methyl, phenyl or 4-methoxybenzyl; [0094] R.sup.3 is H,
I, pyridinyl or ##STR12## [0095] and [0096] R.sup.5 is H, Br, F,
C(OH), --C(O)--OCH.sub.2CH.sub.3 or --NH--C(O)--NH-benzyl.
[0097] In a second embodiment, the invention provides compounds or
pharmaceutically acceptable salts thereof according to any of the
foregoing inventions wherein [0098] R.sup.1 is H or pyrimidinyl
substituted with NH.sub.2; [0099] R.sup.3 is selected from the
group consisting of H, CH.sub.3, OH, Cl, benzo[b]thienyl,
2,3-dihydrobenzofuranyl, indolyl, naphthyl, phenyl, pyrazolyl,
pyridinyl, pyrimidinyl, pyrrolyl, quinolinyl, thienyl,
--NH--C(O)-cyclobutyl and --NH--C(O)-phenyl; wherein [0100] the
indolyl is optionally substituted with CH.sub.3; [0101] the
naphthyl is optionally substituted with OCH.sub.3 or OH; and [0102]
the phenyl optionally substituted with one or more substituents
selected from the group consisting of CH.sub.3, NH.sub.2, Cl, F,
N(CH.sub.3).sub.2, OH, CH.sub.2OH, C(O)NH.sub.2, COOH, CF.sub.3,
OCF.sub.3, OCH.sub.3, CN, OCH.sub.2CH.sub.3, NHC(O)CH.sub.3,
--S(O).sub.2CH.sub.3 and --C(O)--NH-pheny; or [0103] R.sup.3 is
--C(O)--NY.sup.100--(C(Y.sup.100).sub.2).sub.x--R.sup.a wherein
[0104] x is 0 or 1; [0105] Y.sup.100 is H; [0106] R.sup.a is
selected from the optionally substituted group consisting of
benzo[b]thienyl, benzimidazolyl, 1,3-dihydrobenzimidazolyl-2-one,
benzotriazolyl, biphenyl, 1,3-dihydrobenzimidazolyl, indolyl,
naphthyl and phenyl; wherein [0107] the naphthyl is substituted
with OH or OCH.sub.3; [0108] the phenyl is optionally substituted
with one or more Cl, F, OH, CH.sub.2OH, CH.sub.2CH.sub.2OH, COOH,
C(O)NH.sub.2, N(CH.sub.3).sub.2 or methyl; or [0109] R.sup.3 is A-B
wherein [0110] A is selected from the group consisting of
--C.ident.C, --C.ident.C-phenyl, phenyl and thienyl; and [0111] B
is selected from the group consisting of benzyloxy, phenyl,
thienyl, --NH--C(O)-cyclobutyl and --NH--C(O)-phenyl; [0112]
R.sup.4 is H; [0113] R.sup.5 is pyridinyl substituted with C(O)H,
CH.sub.2OH, SCH.sub.2CH.sub.2NH.sub.2 or NH.sub.2; or [0114]
R.sup.5 is selected from the group consisting of ##STR13## [0115]
wherein [0116] E is selected from the group consisting of H, OH,
CH.sub.3, --CH.sub.2CH.sub.2NH.sub.2, CH.sub.2CH.sub.2CH.sub.2OH,
CH.sub.2CH.sub.2OCH.sub.3, CH.sub.2CH.sub.2CH.sub.2NH.sub.2,
CH.sub.2C(O)OH, CH.sub.2CH.sub.2C(O)OH,
CH.sub.2CH.sub.2C(O)NH.sub.2, CH.sub.2CH.sub.2C(O)OCH.sub.3,
CH.sub.2CH.sub.2CH.sub.2OCH.sub.3, NHCH.sub.2CH.sub.2CH.sub.3,
CH.sub.2CH.sub.2C(O)NH(CH.sub.3),
CH.sub.2CH.sub.2C(O)N(CH.sub.3).sub.2,
C(O)NHCH.sub.2CH.sub.2NH(CH.sub.3), NHCH.sub.2CH.sub.2OCH.sub.3,
NHCH.sub.2CH.sub.2OH, NHCH.sub.2CH.sub.2N(CH.sub.3).sub.2,
isopropyl, CH.sub.2C(O)NH.sub.2, CH.sub.2CH(CH.sub.3)C(O)OH,
CH.sub.2CH.sub.2CH.sub.2C(O)OH, CH.sub.2CH(CH.sub.3)C(O)OCH.sub.3,
CH.sub.2CH.sub.2CH.sub.2CH.sub.2NH.sub.2,
CH.sub.2CH.sub.2CH.sub.2C(O)NH.sub.2, N(CH.sub.3).sub.2,
morpholinylethyl, piperidinylethyl, ##STR14## [0117] and
4-methylpiperazinylcyclohexyl; [0118] E.sup.300 is H or
CH.sub.2CH.sub.2OCH.sub.3; [0119] G is selected from the group
consisting of H, Cl, NH.sub.2,
CH.sub.2CH.sub.2C(O)NHCH.sub.2CH.sub.2NH.sub.2, C(O)NH.sub.2,
C(O)NHCH.sub.2CH.sub.2NH.sub.2,
C(O)NHCH.sub.2CH.sub.2N(CH.sub.3).sub.2, CH.sub.2CH.sub.2NH.sub.2,
CH.sub.2CH.sub.2CH.sub.2NH.sub.2, CH.sub.2CH.sub.2C(O)OH,
CH.sub.2CH.sub.2C(O)NH.sub.2, NHCH.sub.2CH.sub.2N(CH.sub.3).sub.2,
NHCH.sub.2CH.sub.2-pyridinyl and NHCH.sub.2CH.sub.2NH.sub.2; or
[0120] R.sup.5 is --C(O)--NH--(CH.sub.2).sub.a--R.sup.c wherein
[0121] a is 0 [0122] R.sup.c is benzimidazolyl or fluorene
substituted with oxo; or [0123] R.sup.c is J.sup.100-J.sup.200
wherein [0124] J.sup.100 is selected from the group consisting of
pyrazolyl, pyridinyl, piperazinyl and phenyl; wherein [0125] the
phenyl is optionally substituted with one or more substituents
selected from the group consisting of F, OH and OCH.sub.3; [0126]
the piperazinyl is substituted with methyl; and [0127] J.sup.200 is
selected from the group consisting of benzoxazolyl, benzimidazolyl,
furanyl, imidazo[1,2-a]pyridinyl and
1,8a-dihydroimidazo[1,2-a]pyridinyl; or [0128] R.sup.5 is
--NH--C(O)--(CH.sub.2).sub.n--R.sup.d wherein [0129] n is 0, 1 or
2; and [0130] R.sup.d is benzimidazolyl, benzo[b]thienyl,
imidazolyl, phenyl or pyrazolo[1,5-a]pyrimidinyl; wherein [0131]
the phenyl is substituted with NO.sub.2; [0132] R.sup.5 is
--NH--(C(O)).sub.m--NY.sup.300--(CH.sub.2).sub.p--R.sup.g wherein
[0133] m is 2; [0134] Y.sup.300 is H; [0135] p is 1; and [0136]
R.sup.g is benzo[1,3]dioxazolyl; or [0137] R.sup.5 is
--N(Y.sup.400)--R.sup.i wherein [0138] Y.sup.400 is selected from
H, CH.sub.2CH.sub.2CH.sub.2OH, CH.sub.2CH.sub.2NH.sub.2 or
pyridinylmethyl; [0139] R.sup.i is V--W wherein [0140] V is a bond
or pyrimidinyl; and [0141] W is pyrimidinyl substituted with
NH.sub.2 or pyrrolidinyl substituted with OH; or [0142] R.sup.5 is
Z.sup.100-Z.sup.200 wherein [0143] Z.sup.100 is thienyl or
pyridinyl substituted with CH.sub.3 and Z.sup.200 is thienyl or
NH--C(O)-furanyl; [0144] R.sup.6 is selected from the group
consisting of H, pyrrolo[2,3-b]pyrimidinyl and ##STR15## [0145] and
[0146] R.sup.7 is selected from the optionally substituted group
consisting of H, Br, Cl, I, benzofuranyl, benzo[b]thienyl, furanyl,
indolyl, naphthyl, phenyl, pyridinyl, pyrrolyl,
quinolinyl,quinoxalinyl, thieno[2,3-b]pyridinyl, thienyl,
--CH.dbd.CH-phenyl, --C.ident.C-phenyl, --C(O)--NH--CH.sub.2-phenyl
and --C(O)--NH-phenyl wherein [0147] the naphthyl is optionally
substituted with OH or OCH.sub.3; [0148] the benzo[b]thienyl is
optionally substituted with OH, CH.sub.3, OCH.sub.3,
N(CH.sub.3).sub.2, OH, CH.sub.2.dbd.CHNHCH.sub.3, CH.sub.2NH.sub.2,
CH.sub.2CH.sub.2NH.sub.2 or
CH.sub.2NHCH.sub.2CH.sub.2N(CH.sub.3).sub.2; [0149] the indolyl is
substituted with C(O)N(CH(CH.sub.3).sub.2).sub.2, CH.sub.2OH,
CH.sub.2C(O)NH.sub.2, COOH, C(O)NH.sub.2, N(CH.sub.3).sub.2 or
S(O).sub.2CH.sub.3; and [0150] the phenyl is optionally substituted
with one or more substituents selected from the group consisting of
Cl, F, CH.sub.3, CH.sub.2OH, CN, --C(O)NH.sub.2, OH, OCH.sub.3,
N(CH.sub.3).sub.2, NH--C(O)CH.sub.3, --NH--S(O).sub.2--CH.sub.3;
[0151] the thienyl is substituted with CH.sub.2OH; or [0152]
R.sup.7 is Y-Z wherein [0153] Y is benzo[b]thienyl or thienyl; and
[0154] Z is selected from the optionally substituted group
consisting of CH.dbd.CHNHCH.sub.3, NHCH.sub.3, CH.sub.2NH.sub.2,
CH.sub.2CH.sub.2NH.sub.2, CH.sub.2NHCH.sub.3,
CH.sub.2NHCH.sub.2CH.sub.2N(CH.sub.3).sub.2, N(CH.sub.3).sub.2,
CH.sub.2NHCH.sub.2CH.sub.2-morpholinyl, benzo[b]thienyl,
morpholinylmethyl, piperazinylmethylphenyl and thienyl; or [0155]
R.sup.7 is --C(O)--NH--(CH.sub.2).sub.r-phenyl wherein [0156] r is
0 or 1; [0157] the phenyl is optionally substituted with
NH.sub.2.
[0158] In a third embodiment, the invention provides compounds or
pharmaceutically acceptable salts thereof according to any of the
foregoing inventions wherein R.sup.1 is H or pyrimidinyl
substituted with NH.sub.2; [0159] R.sup.3 is selected from the
group consisting of H, CH.sub.3, OH, Cl, benzo[b]thienyl,
2,3-dihydrobenzofuranyl, indolyl, naphthyl, phenyl, pyrazolyl,
pyridinyl, pyrimidinyl, pyrrolyl, quinolinyl, thienyl,
--NH--C(O)-cyclobutyl and --NH--C(O)-phenyl; wherein [0160] the
indolyl is optionally substituted with CH.sub.3; [0161] the
naphthyl is optionally substituted with OH; and [0162] the phenyl
optionally substituted with one or more substituents selected from
the group consisting of OH, F, CH.sub.3, CF.sub.3, CN,
--C(O)NH.sub.2, NH.sub.2, NHC(O)CH.sub.3, OCH.sub.3, OCF.sub.3,
OCH.sub.2CH.sub.3, N(CH.sub.3).sub.2, --C(O)--NH-phenyl and
--S(O).sub.2CH.sub.3; or [0163] R.sup.3 is
--C(O)--NY.sup.100--(C(Y.sup.100).sub.2).sub.x--R.sup.a wherein
[0164] Y.sup.100 is H; [0165] x is 0; [0166] R.sup.a is selected
from the optionally substituted group consisting of benzimidazolyl,
1,3-dihydrobenzimidazolyl-2-one, benzotriazolyl, biphenyl, indolyl,
naphthyl and phenyl; wherein [0167] the naphthyl is substituted
with OH or OCH.sub.3; [0168] the phenyl is optionally substituted
with one or more Cl, F, OH, CH.sub.2OH, CH.sub.2CH.sub.2OH,
C(O)NH.sub.2, N(CH.sub.3).sub.2 or methyl; or [0169] R.sup.3 is A-B
wherein [0170] A is selected from the group consisting of phenyl
and thienyl; and [0171] B is selected from the group consisting of
benzyloxy, phenyl, thienyl, --NH--C(O)-cyclobutyl and
--NH--C(O)-phenyl; [0172] R.sup.5 is pyridinyl substituted with
NH.sub.2; or [0173] R.sup.5 is selected from the group consisting
of ##STR16## [0174] wherein [0175] E is selected from the group
consisting of H, CH.sub.3, CH.sub.2C(O)OH,
CH.sub.2CH.sub.2CH.sub.2OH, CH.sub.2CH.sub.2CH.sub.2NH.sub.2,
CH.sub.2CH.sub.2C(O)OH, CH.sub.2CH.sub.2C(O)NH.sub.2,
CH.sub.2CH.sub.2C(O)OCH.sub.3, CH.sub.2CH.sub.2CH.sub.2OCH.sub.3,
NHCH.sub.2CH.sub.2CH.sub.3, CH.sub.2CH.sub.2C(O)NH(CH.sub.3),
NHCH.sub.2CH.sub.2OCH.sub.3, NHCH.sub.2CH.sub.2OH, isopropyl,
CH.sub.2C(O)NH.sub.2, CH.sub.2CH(CH.sub.3)C(O)OH, morpholinylethyl,
piperidinylethyl, CH.sub.2CH.sub.2CH.sub.2C(O)OH,
CH.sub.2CH(CH.sub.3)C(O)OCH.sub.3, CH.sub.2CH.sub.2NH.sub.2,
CH.sub.2CH.sub.2CH.sub.2CH.sub.2NH.sub.2,
CH.sub.2CH.sub.2CH.sub.2C(O)NH.sub.2,
CH.sub.2CH.sub.2C(O)N(CH.sub.3).sub.2, and N(CH.sub.3).sub.2; and
[0176] G is selected from the group consisting of H, NH.sub.2, Cl,
CH.sub.2CH.sub.2C(O)NHCH.sub.2CH.sub.2NH.sub.2,
C(O)NHCH.sub.2CH.sub.2NH.sub.2,
C(O)NHCH.sub.2CH.sub.2N(CH.sub.3).sub.2,
NHCH.sub.2CH.sub.2N(CH.sub.3).sub.2, NHCH.sub.2CH.sub.2NH.sub.2,
CH.sub.2CH.sub.2NH.sub.2, CH.sub.2CH.sub.2CH.sub.2NH.sub.2,
CH.sub.2CH.sub.2C(O)OH, CH.sub.2CH.sub.2C(O)NH.sub.2 and
NHCH.sub.2CH.sub.2-pyridinyl; [0177] R.sup.5 is
--C(O)--NH--(CH.sub.2).sub.a--R.sup.c wherein [0178] a is 0; [0179]
R.sup.c is J.sup.100-J.sup.200 wherein [0180] J.sup.100 is
pyrazolyl or phenyl wherein the phenyl is optionally substituted
with OCH.sub.3; and [0181] J.sup.200 is benzoxazolyl,
benzimidazolyl, furanyl, imidazo[1,2-a]pyridinyl or
1,8a-dihydroimidazo[1,2-a]pyridinyl; or [0182] R.sup.5 is
--NH--C(O)--(CH.sub.2).sub.n--R.sup.d wherein [0183] n is 0, 1 or
2; and [0184] R.sup.d is selected from the group consisting of
benzimidazolyl, benzo[b]thieny, imidazolyl and
pyrazolo[1,5-a]pyrimidinyl; [0185] R.sup.5 is
--N(Y.sup.400)--R.sup.i wherein [0186] Y.sup.400 is selected from
H, CH.sub.2CH.sub.2CH.sub.2OH, CH.sub.2CH.sub.2NH.sub.2 or
pyridinylmethyl; [0187] R.sup.i is V-W wherein [0188] V is a bond
or pyrimidinyl and W is pyrimidinyl substituted with NH.sub.2 or
pyrrolidinyl substituted with OH; [0189] R.sup.5 is
Z.sup.100-Z.sup.200 wherein [0190] Z.sup.100 is thienyl; [0191]
Z.sup.200 is thienyl; [0192] R.sup.6 is H or ##STR17## [0193] and
[0194] R.sup.7 is selected from the optionally substituted group
consisting of H, benzofuranyl, benzo[b]thienyl, furanyl, indolyl,
naphthyl, quinolinyl, phenyl, pyrrolyl, quinoxalinyl, thienyl,
thieno[2,3-b]pyridinyl, --CH.dbd.CH-phenyl, --C.ident.C-phenyl,
--C(O)--NH--CH.sub.2-phenyl and --C(O)--NH-phenyl wherein [0195]
the benzo[b]thienyl is optionally substituted with OH, CH.sub.3,
OCH.sub.3, N(CH.sub.3).sub.2, CH.sub.2.dbd.CHNHCH.sub.3,
CH.sub.2NH.sub.2, CH.sub.2CH.sub.2NH.sub.2 or
CH.sub.2NHCH.sub.2CH.sub.2N(CH.sub.3).sub.2; [0196] the indolyl is
substituted with methyl, CN, C(O)H,
CH.sub.2CH.sub.2CH.sub.2NH.sub.2,
CH.sub.2NHCH.sub.2CH.dbd.CH.sub.2, C(O)CH.sub.3, C(O)OCH.sub.3,
OCH.sub.3, C(O)N(CH(CH.sub.3).sub.2).sub.2, CH.sub.2OH,
CH.sub.2C(O)NH.sub.2, C(O)NH.sub.2,
CH.sub.2NHCH.sub.2CH.sub.2N(CH.sub.3).sub.2 or piperidinylmethyl;
and [0197] the phenyl is optionally substituted with one or more
substituents selected from the group consisting of Cl, F, CH.sub.3,
CH.sub.2OH, CN, --C(O)NH.sub.2, OH, OCH.sub.3, N(CH.sub.3).sub.2
and --NH--S(O).sub.2--CH.sub.3; or [0198] R.sup.7 is Y-Z wherein
[0199] Y is benzo[b]thienyl or thienyl; and [0200] Z is selected
from the optionally substituted group consisting of
CH.dbd.CHNHCH.sub.3, NHCH.sub.3, CH.sub.2NH.sub.2,
CH.sub.2CH.sub.2NH.sub.2, CH.sub.2NHCH.sub.3,
CH.sub.2NHCH.sub.2CH.sub.2N(CH.sub.3).sub.2, N(CH.sub.3).sub.2,
CH.sub.2NHCH.sub.2CH.sub.2-morpholinyl, benzo[b]thienyl,
morpholinylmethyl and piperazinylmethyl; wherein [0201] the
piperazinyl is optionally substituted with methyl.
[0202] In a fourth embodiment, the invention provides compounds or
pharmaceutically acceptable salts thereof according to any of the
foregoing inventions wherein R.sup.1 and R.sup.4 are H; [0203]
R.sup.3 is selected from the optionally substituted group
consisting of H, OH, 2,3-dihydrobenzofuranyl, naphthyl, pyrazolyl
and pyrrolyl; wherein [0204] R.sup.3 is
--C(O)--NY.sup.100--(C(Y.sup.100).sub.2).sub.x--R.sup.a wherein
[0205] Y.sup.100 is H; [0206] x is 0; [0207] R.sup.a is selected
from the optionally substituted group consisting of naphthyl and
phenyl; wherein [0208] the naphthyl is optionally substituted with
OH; [0209] the phenyl is optionally substituted with OH; or [0210]
R.sup.3 is selected from the group consisting of
--NH--C(O)-cyclobutyl and --NH--C(O)-phenyl; [0211] R.sup.3 is A-B
wherein [0212] A is selected from the group consisting of phenyl
and thienyl; and [0213] B is selected from the group consisting of
benzyloxy, phenyl and thienyl; [0214] R.sup.5 is selected from the
group consisting of ##STR18## [0215] wherein [0216] E is selected
from the group consisting of H, CH.sub.2C(O)NH.sub.2,
CH.sub.2CH(CH.sub.3)C(O)OCH.sub.3, CH.sub.2CH.sub.2CH.sub.2OH,
CH.sub.2CH.sub.2C(O)OCH.sub.3, CH.sub.2CH.sub.2CH.sub.2OCH.sub.3,
CH.sub.2CH.sub.2NH.sub.2, CH.sub.2CH.sub.2CH.sub.2NH.sub.2,
CH.sub.2CH.sub.2C(O)OH, CH.sub.2CH.sub.2C(O)NH.sub.2,
CH.sub.2CH.sub.2CH.sub.2CH.sub.2NH.sub.2,
CH.sub.2CH.sub.2CH.sub.2OCH.sub.3, CH.sub.2CH.sub.2CH.sub.2C(O)OH,
CH.sub.2CH.sub.2CH.sub.2C(O)NH.sub.2, CH.sub.2CH(CH.sub.3)C(O)OH,
CH.sub.2CH.sub.2C(O)NH(CH.sub.3),
CH.sub.2CH.sub.2C(O)N(CH.sub.3).sub.2, N(CH.sub.3).sub.2,
isopropyl, morpholinylethyl and piperidinylethyl; and [0217] G is
H, NH.sub.2 or NHCH.sub.2CH.sub.2-pyridinyl or [0218] R.sup.5 is
--C(O)--NH--(CH.sub.2).sub.a--R.sup.c wherein [0219] a is 0 [0220]
R.sup.c is J.sup.100-J.sup.200 wherein [0221] J.sup.100 is phenyl
optionally substituted with OCH.sub.3 and [0222] J.sup.200 is
imidazo[1,2-a]pyridinyl or 1,8a-dihydroimidazo[1,2-a]pyridinyl; or
[0223] R.sup.5 is --NH--C(O)--(CH.sub.2).sub.n--R.sup.d wherein
[0224] n is 2 and R.sup.d is imidazolyl; or [0225] R.sup.5 is
Z.sup.100-Z.sup.200 wherein [0226] Z.sup.100 is thienyl; [0227]
Z.sup.200 is thienyl; [0228] R.sup.6 is H or ##STR19## [0229] and
[0230] R.sup.7 is selected from the optionally substituted group
consisting of H, benzofuranyl, benzo[b]thienyl, indolyl, naphthyl,
quinolinyl, CH.dbd.CH-phenyl, --C.ident.C-phenyl,
--C(O)--NH--CH.sub.2-phenyl and --C(O)--NH-phenyl wherein [0231]
the benzo[b]thienyl is optionally substituted with OH, CH.sub.3,
OCH.sub.3, N(CH.sub.3).sub.2, CH.sub.2.dbd.CH.sub.2NHCH.sub.3,
CH.sub.2NH.sub.2,
CH.sub.2CH.sub.2NH.sub.2,CH.sub.2NHCH.sub.2CH.sub.2N(CH.sub.3).sub.2,
piperidinylmethyl or CH.sub.2NHCH.sub.2N(CH.sub.3).sub.2; and
[0232] the indolyl is optionally substituted with methyl, CN,
C(O)H, CH.sub.2CH.sub.2CH.sub.2NH.sub.2,
CH.sub.2NHCH.sub.2CH.dbd.CH.sub.2, C(O)CH.sub.3, C(O)OCH.sub.3, or
OCH.sub.3; methyl, CN, C(O)H, CH.sub.2CH.sub.2CH.sub.2NH.sub.2,
CH.sub.2NHCH.sub.2CH.dbd.CH.sub.2, C(O)CH.sub.3, C(O)OCH.sub.3, or
OCH.sub.3 [0233] the phenyl is optionally substituted with one or
more substituents selected from the group consisting of OH and
OCH.sub.3; or [0234] R.sup.7 is Y-Z wherein [0235] Y is
benzo[b]thienyl or thienyl; and [0236] Z is selected from the group
consisting of CH.dbd.CHNHCH.sub.3, NHCH.sub.3, CH.sub.2NH.sub.2,
CH.sub.2CH.sub.2NH.sub.2, CH.sub.2NHCH.sub.3,
CH.sub.2NHCH.sub.2CH.sub.2N(CH.sub.3).sub.2, N(CH.sub.3).sub.2,
CH.sub.2NHCH.sub.2CH.sub.2-morpholinyl, benzo[b]thienyl,
morpholinylmethyl and piperazinylmethyl; [0237] wherein the
piperazinyl is optionally substituted with methyl.
[0238] In a fifth embodiment, the invention provides compounds or
pharmaceutically acceptable salts thereof according to any of the
foregoing inventions wherein [0239] R.sup.1 and R.sup.4 are H;
[0240] R.sup.3 is selected from the group consisting of H, OH,
2,3-dihydrobenzofuranyl, pyrrolyl and optionally substituted
napthyl; or [0241] R.sup.3 is
--C(O)--NY.sup.100--(C(Y.sup.100).sub.2).sub.x--R.sup.a wherein
[0242] Y.sup.100 is H; [0243] x is 0; and [0244] R.sup.a is phenyl
substituted with OH; [0245] R.sup.5 is ##STR20## [0246] wherein
[0247] E is selected from the group consisting of H,
CH.sub.2C(O)NH.sub.2, CH.sub.2CH.sub.2NH.sub.2,
CH.sub.2CH.sub.2CH.sub.2NH.sub.2,
CH.sub.2CH.sub.2CH.sub.2CH.sub.2NH.sub.2,
CH.sub.2CH.sub.2CH.sub.2OCH.sub.3, CH.sub.2CH.sub.2CH.sub.2OH,
CH.sub.2CH.sub.2C(O)OH, CH.sub.2CH.sub.2CH.sub.2C(O)OH,
CH.sub.2CH.sub.2C(O)NH.sub.2, CH.sub.2CH.sub.2CH.sub.2C(O)NH.sub.2,
CH.sub.2CH(CH.sub.3)C(O)OCH.sub.3 CH.sub.2CH(CH.sub.3)C(O)OH,
CH.sub.2CH.sub.2C(O)OCH.sub.3, CH.sub.2CH.sub.2C(O)NH(CH.sub.3),
CH.sub.2CH.sub.2C(O)N(CH.sub.3).sub.2, N(CH.sub.3).sub.2,
isopropyl, morpholinylethyl and piperidinylethyl; and [0248] G is
H, NH.sub.2 or NHCH.sub.2CH.sub.2-pyridinyl or [0249] R.sup.5 is
--C(O)--NH--(CH.sub.2).sub.a--R.sup.c wherein [0250] a is 0; and
[0251] R.sup.c is J.sup.100-J.sup.200 wherein [0252] J.sup.100 is
phenyl and J.sup.200 is 1,8a-dihydroimidazo[1,2a]pyridinyl; or
[0253] R.sup.5 is --NH--C(O)--(CH.sub.2).sub.n--R.sup.d wherein
[0254] n is 2 and R.sup.d is imidazolyl; or [0255] R.sup.5 is
Z.sup.100-Z.sup.200 wherein [0256] Z.sup.100 is thienyl and
Z.sup.200 is thienyl; [0257] R.sup.6 is H or ##STR21## [0258] and
[0259] R.sup.7 is selected from the optionally substituted group
consisting of H, --CH.dbd.CH-phenyl, --C.ident.C-phenyl,
benzofuranyl, benzo[b]thienyl, indolyl, quinolinyl, naphthyl,
--C(O)--NH--CH.sub.2-phenyl and --C(O)--NH-phenyl; [0260] wherein
the naphthyl is optionally substituted with OH, C(O)H or OCH.sub.3:
[0261] the benzo[b]thienyl optionally substituted with OH,
CH.sub.3, OCH.sub.3, CH.sub.2.dbd.CH.sub.3--NHCH.sub.3,
CH.sub.2NH.sub.2, CH.sub.2CH.sub.2NH.sub.2,
CH.sub.2NHCH.sub.2CH.sub.2N(CH.sub.3).sub.2, N(CH.sub.3).sub.2 or
piperidinylmethyl; [0262] the indolyl is optionally substituted
with methyl, CN, C(O)H, CH.sub.2CH.sub.2CH.sub.2NH.sub.2,
CH.sub.2NHCH.sub.2CH.dbd.CH.sub.2, C(O)CH.sub.3, C(O)OCH.sub.3, or
OCH.sub.3; [0263] the phenyl is optionally substituted with OH or
OCH.sub.3; or [0264] R.sup.7 is Y-Z wherein [0265] Y is
benzo[b]thienyl; and [0266] Z is selected from the group consisting
of CH.sub.2NHCH.sub.2CH.sub.2-morpholinyl, morpholinylmethyl and
piperazinylmethyl wherein the piperazinyl is optionally substituted
with methyl.
[0267] In a sixth embodiment, the invention provides compounds or
pharmaceutically acceptable salts thereof according to any of the
foregoing inventions wherein R.sup.1, R.sup.3, R.sup.4 and R.sup.6
are H; [0268] R.sup.5 is ##STR22## [0269] wherein [0270] E is
selected from the group consisting of H,
--CH.sub.2CH.sub.2NH.sub.2, CH.sub.2CH.sub.2CH.sub.2NH.sub.2,
CH.sub.2CH.sub.2CH.sub.2OH, CH.sub.2CH.sub.2C(O)OH and
CH.sub.2CH.sub.2C(O)NH.sub.2; and [0271] R.sup.7 is selected from
the group consisting of benzo[b]thienyl, indolyl,
--C(O)--NH--CH.sub.2-phenyl and --C(O)--NH-phenyl wherein [0272]
the benzo[b]theinyl is optionally substituted by piperidinylmethyl;
[0273] the indolyl is optionally substituted by CN, methyl or
C(O)H.
[0274] In a seventh embodiment, the invention provides compounds or
pharmaceutically acceptable salts thereof according to any of the
foregoing inventions wherein R.sup.1, R.sup.3, R.sup.4 and R.sup.6
are H; [0275] R.sup.5 is ##STR23## [0276] wherein [0277] E is H;
and [0278] R.sup.7 is --C(O)--NH--CH.sub.2-phenyl or
--C(O)--NH-phenyl.
[0279] In an eighth embodiment, the invention provides compounds or
pharmaceutically acceptable salts thereof according to any of the
foregoing inventions wherein R.sup.1, R.sup.3, R.sup.4 and R.sup.6
are H; [0280] R.sup.5 is ##STR24## [0281] wherein [0282] E is
selected from the group consisting of H,
--CH.sub.2CH.sub.2NH.sub.2, CH.sub.2CH.sub.2CH.sub.2NH.sub.2,
CH.sub.2CH.sub.2CH.sub.2OH, CH.sub.2CH.sub.2C(O)OH and
CH.sub.2CH.sub.2C(O)NH.sub.2; and [0283] R.sup.7 is benzo[b]thienyl
or indolyl wherein [0284] the benzo[b]theinyl is optionally
substituted by piperidinylmethyl; [0285] the indolyl is optionally
substituted by CN, methyl or C(O)H;
[0286] In a ninth embodiment, the invention provides compounds or
pharmaceutically acceptable salts thereof according to any of the
foregoing inventions wherein wherein R.sup.1, R.sup.3, R.sup.4 and
R.sup.6 are H; [0287] R.sup.5 is ##STR25## [0288] wherein [0289] E
is selected from the group consisting of
--CH.sub.2CH.sub.2NH.sub.2, CH.sub.2CH.sub.2CH.sub.2NH.sub.2,
CH.sub.2CH.sub.2CH.sub.2OH, CH.sub.2CH.sub.2C(O)OH and
CH.sub.2CH.sub.2C(O)NH.sub.2; and [0290] R.sup.7 is
benzo[b]thienyl.
DETAILED DESCRIPTION OF THE INVENTION
[0290] Protein Kinases
[0291] Protein kinases are a broad and diverse class, of over 500
enzymes, that include growth factors receptors, signal transduction
intermediates, apoptosis related kinases and cyclin dependent
kinases. Many can function as oncogenes. They are responsible for
the transfer of a phosphate group to specific tyrosine, serine or
threonine amino acid residues, and are broadly classified as
tyrosine and S/T kinases as a result of their substrate
specificity.
Serine/Threonine Kinases
[0292] S/T kinases are a large sub-family of protein kinases that
specifically transfer a phosphate group to a terminal hydroxyl
moiety of specific serine or threonine residues (Hanks et al.,
(1988) Science, 241: 42-52). A number of S/T kinase family members
are involved in inflammatory signaling, tumor growth or cellular
transformation. For example, the mitogen-activated protein kinases
(MAPKs) are S/T kinases that act as intermediates within the
signaling cascades of Toll like receptors (TLRs), such as TLR4,
growth/survival factors, such as EGF, and death receptors, such as
the TNF receptor. Activation of MAPKs, such as extracellular
signal-regulated kinases (ERK1-2), p38.alpha., c-Jun N-terminal
kinase (JNK) or MAPKAP-K2 (MK2) have been shown to transduce
signaling in cells, such as macrophages, resulting in the
production and secretion of pro-inflammatory cytokines, such as
TNF.
[0293] TPL-2 is a S/T kinase which is homologous to a subfamily of
kinases called MAP kinase kinase kinases (MAP3K) in its catalytic
domain (Salmeron, et al., (1996) EMBO J., 15, 817-826) and is
>90% identical to the proto-oncogene product of human COT (Aoki
et al., (1993) J. Biol. Chem., 268, 22723-22732). TPL-2 was
originally identified, in a C-terminally deleted form, as the
product of an oncogene associated with Moloney murine leukemia
virus-induced T cell lymphomas in rats (Patriotis, et al., (1993)
Proc. Natl. Acad. Sci. USA 90, 2251-2255). TPL-2 is also highly
homologous to the kinase NIK, which has been shown to regulate the
inducible degradation of I.kappa.B-.alpha. (Malinin et al., (1997)
Nature, 385, 540-544; WO 97/37016; May and Ghosh, (1998) Immunol.
Today, 19, 80-88). TPL-2 is essential for the activation of a MAP2K
(MEK1-2), which in turn activate a MAPK (extracellular
signal-regulated kinase, ERK1-2) in macrophages stimulated by TLR
agonists, such as lipopolysachharide (LPS). TPL-2 plays a crucial
role in the regulation of LPS-induced TNF, IL-1.beta. and COX-2
induced prostaglandin-E2 production in macrophages (Tsichlis et al,
(2000), Cell, 103, 1071; Tsichlis et al, (2002), EMBO J, 21,
4831-4840). The expression of COT/TPL-2 in various tumors (Tsanisi
et al., (2000), Int J Mol Med, 5, 583) and the defect in TNF
production observed in COT knockout mice (Tsichlis et al, (2000),
Cell, 103, 1071) suggests that inhibition of COT may be a useful
approach in the treatment of cancer, inflammation or other diseases
mediated by pro-inflammatory cytokines.
[0294] MK2 (MAPKAP-K2) is an S/T kinase critically involved in
inflammatory processes. MK2 is a substrate for the MAPK p38 (Stokoe
et al., (1992), EMBO J., 11, 3985-3994; Ben-Levy et al., (1995),
EMBO J., 14, 5920-5930). Activation of MK2 in immune cells results
in an array of cellular responses including cytokine production,
proliferation and activation. Knockout mice defective in MK2
production are healthy and fertile but fail to produce cytokines
such as tumor necrosis factor (TNF) in response to inflammatory
stimuli (Kotlyarov et al., (1999), Nat. Cell Biol, 1, 94-97.). MK2
may alter gene expression by phosphorylation of mRNA-binding
proteins (Winzen et al., (1999), EMBO J., 18, 4969-4980; Lasa et
al., (2000), Mol. Cell. Biol., 20, 4265-4274; Rousseau et al.,
(2002), EMBO J., 21, 6505-6514; Bollig et al., (2003), Biochem.
Biophys. Res. Commun, 301, 665-670; Tran et al., (2003), Mol. Cell.
Biol., 23, 7177-7188.), Chrestensen, C. A. et al. J. Biol. Chem.
2004, 279, 10176-10184 and Stoecklin, G. et al. EMBO J. 2004, 23,
1313-1324) transcription factors (Heidenreich et al., (1999), J.
Biol. Chem., 274, 14434-14443) or other proteins (Stokoe et al,
(1992), FEBS Lett., 313, 307-313; Sutherland et al., (1993), Eur.
J. Biochem., 217, 715-722; Werz et al, (2000), Proc. Natl. Acad.
Sci._USA, 97, 5261-5266). The defect in TNF production in MK2
knockouts suggests that the antiinflammatory effect of p38 MAPK
inhibitors may be largely due to blockade of activation of MK2.
Inhibitors of MK2 may be effective treatments of inflammation or
other diseases mediated by pro-inflammatory cytokines.
[0295] Protein Tyrosine Kinases.
[0296] Protein tyrosine kinases (PTKs) are enzymes that catalyse
the phosphorylation of specific tyrosine residues in cellular
proteins. This post-translational modification of these substrate
proteins, often enzymes themselves, acts as a molecular switch
regulating cell proliferation, activation or differentiation (for
review, see Schlessinger and Ulrich, 1992, Neuron 9:383-391).
Aberrant or excessive PTK activity has been observed in many
disease states including benign and malignant proliferative
disorders as well as diseases resulting from inappropriate
activation of the immune system (e.g. autoimmune disorders),
allograft rejection, and graft vs. host disease. In addition,
endothelial-cell specific receptor PTKs such as KDR and Tie-2
mediate the angiogenic process, and are thus involved in supporting
the progression of cancers and other diseases involving
inappropriate vascularization (e.g., diabetic retinopathy,
choroidal neovascularization due to age-related macular
degeneration, psoriasis, arthritis, retinopathy of prematurity, and
infantile hemangiomas).
[0297] Tyrosine kinases can be of the receptor-type (having
extracellular, transmembrane and intracellular domains) or the
non-receptor type (being wholly intracellular).
[0298] Receptor Tyrosine Kinases (RTKs). The RTKs comprise a large
family of transmembrane receptors with diverse biological
activities. At present, at least nineteen (19) distinct RTK
subfamilies have been identified. The receptor tyrosine kinase
(RTK) family includes receptors that are crucial for the growth and
differentiation of a variety of cell types (Yarden and Ullrich,
Ann. Rev. Biochem. 57:433-478, 1988; Ullrich and Schlessinger, Cell
61:243-254, 1990). The intrinsic function of RTKs is activated upon
ligand binding, which results in phosphorylation of the receptor
and multiple cellular substrates, and subsequently in a variety of
cellular responses (Ullrich & Schlessinger, 1990, Cell
61:203-212). Thus, receptor tyrosine kinase mediated signal
transduction is initiated by extracellular interaction with a
specific growth factor (ligand), typically followed by receptor
dimerization, stimulation of the intrinsic protein tyrosine kinase
activity and receptor trans-phosphorylation. Binding sites are
thereby created for intracellular signal transduction molecules and
lead to the formation of complexes with a spectrum of cytoplasmic
signaling molecules that facilitate the appropriate cellular
response (e.g., cell division, differentiation, metabolic effects,
and changes in the extracellular microenvironment; see Schiessinger
and Ullrich, 1992, Neuron 9:1-20).
[0299] Non-Receptor Tyrosine Kinases. Non-receptor tyrosine kinases
represent a collection of cellular enzymes that lack extracellular
and transmembrane sequences. Over twenty-four individual
non-receptor tyrosine kinases, comprising eleven (11) subfamilies
(Src, Frk, Btk, Csk, Abl, Zap70, Fes/Fps, Fak, Jak, Ack and LIMK)
have been identified. The Src subfamily of non-receptor tyrosine
kinases is comprised of the largest number of PTKs and include Src,
Yes, Fyn, Lyn, Lck, Blk, Hck, Fgr and Yrk. The Src subfamily of
enzymes has been linked to oncogenesis and immune responses. A more
detailed discussion of non-receptor tyrosine kinases is provided in
Bohlen, 1993, Oncogene 8:2025-2031, which is incorporated herein by
reference.
[0300] Many of the kinases, whether a receptor or non-receptor
tyrosine kinase or a S/T kinase have been found to be involved in
cellular signaling pathways involved in numerous pathogenic
conditions, including immunomodulation, inflammation, or
proliferative disorders such as cancer.
[0301] In a related aspect the invention provides a method for
inhibiting COT in a human subject suffering from a disorder in
which COT activity is detrimental, comprising administering to the
human subject a compound of Formula (I) such that COT activity in
the human subject is inhibited and treatment is achieved.
[0302] In another related aspect the invention provides a method
for inhibiting MK2 in a human subject suffering from a disorder in
which MK2 activity is detrimental, comprising administering to the
human subject a compound of Formula (I) such that MK2 activity in
the human subject is inhibited and treatment is achieved.
[0303] A compound of formula (I) or a salt thereof or
pharmaceutical compositions containing a therapeutically effective
amount thereof is useful in the treatment of a disorder selected
from the group comprising rheumatoid arthritis, osteoarthritis,
juvenile chronic arthritis, Lyme arthritis, psoriatic arthritis,
reactive arthritis, and septic arthritis, spondyloarthropathy,
systemic lupus erythematosus, Crohn's disease, ulcerative colitis,
inflammatory bowel disease, insulin dependent diabetes mellitus,
thyroiditis, asthma, allergic diseases, psoriasis, dermatitis
scleroderma, graft versus host disease, organ transplant rejection
(including but not limited to bone marrow and solid organ
rejection), acute or chronic immune disease associated with organ
transplantation, sarcoidosis, atherosclerosis, disseminated
intravascular coagulation, Kawasaki's disease, Grave's disease,
nephrotic syndrome, chronic fatigue syndrome, Wegener's
granulomatosis, Henoch-Schoenlein purpurea, microscopic vasculitis
of the kidneys, chronic active hepatitis, uveitis, septic shock,
toxic shock syndrome, sepsis syndrome, cachexia, infectious
diseases, parasitic diseases, acquired immunodeficiency syndrome,
acute transverse myelitis, Huntington's chorea, Parkinson's
disease, Alzheimer's disease, stroke, primary biliary cirrhosis,
hemolytic anemia, malignancies, heart failure, myocardial
infarction, Addison's disease, sporadic, polyglandular deficiency
type I and polyglandular deficiency type II, Schmidt's syndrome,
adult (acute) respiratory distress syndrome, alopecia, alopecia
areata, seronegative arthopathy, arthropathy, Reiter's disease,
psoriatic arthropathy, ulcerative colitic arthropathy, enteropathic
synovitis, chlamydia, yersinia and salmonella associated
arthropathy, atheromatous disease/arteriosclerosis, atopic allergy,
autoimmune bullous disease, pemphigus vulgaris, pemphigus
foliaceus, pemphigoid, linear IgA disease, autoimmune haemolytic
anaemia, Coombs positive haemolytic anaemia, acquired pernicious
anaemia, juvenile pernicious anaemia, myalgic encephalitis/Royal
Free Disease, chronic mucocutaneous candidiasis, giant cell
arteritis, primary sclerosing hepatitis, cryptogenic autoimmune
hepatitis, Acquired Immunodeficiency Disease Syndrome, Acquired
Immunodeficiency Related Diseases, Hepatitis B, Hepatitis C, common
varied immunodeficiency (common variable hypogammaglobulinaemia),
dilated cardiomyopathy, female infertility, ovarian failure,
premature ovarian failure, fibrotic lung disease, chronic wound
healing, cryptogenic fibrosing alveolitis, post-inflammatory
interstitial lung disease, interstitial pneumonitis, connective
tissue disease associated interstitial lung disease, mixed
connective tissue disease associated lung disease, systemic
sclerosis associated interstitial lung disease, rheumatoid
arthritis associated interstitial lung disease, systemic lupus
erythematosus associated lung disease, dermatomyositis/polymyositis
associated lung disease, Sjogren's disease associated lung disease,
ankylosing spondylitis associated lung disease, vasculitic diffuse
lung disease, haemosiderosis associated lung disease, drug-induced
interstitial lung disease, radiation fibrosis, bronchiolitis
obliterans, chronic eosinophilic pneumonia, lymphocytic
infiltrative lung disease, postinfectious interstitial lung
disease, gouty arthritis, autoimmune hepatitis, type-1 autoimmune
hepatitis (classical autoimmune or lupoid hepatitis), type-2
autoimmune hepatitis (anti-LKM antibody hepatitis), autoimmune
mediated hypoglycaemia, type B insulin resistance with acanthosis
nigricans, hypoparathyroidism, acute immune disease associated with
organ transplantation, chronic immune disease associated with organ
transplantation, osteoarthrosis, primary sclerosing cholangitis,
psoriasis type 1, psoriasis type 2, idiopathic leucopaenia,
autoimmune neutropaenia, renal disease NOS, glomerulonephritides,
microscopic vasulitis of the kidneys, Lyme disease, discoid lupus
erythematosus, male infertility idiopathic or NOS, sperm
autoimmunity, multiple sclerosis (all subtypes), sympathetic
ophthalmia, pulmonary hypertension secondary to connective tissue
disease, Goodpasture's syndrome, pulmonary manifestation of
polyarteritis nodosa, acute rheumatic fever, rheumatoid
spondylitis, Still's disease, systemic sclerosis, Sjogren's
syndrome, Takayasu's disease/arteritis, autoimmune
thrombocytopaenia, idiopathic thrombocytopaenia, autoimmune thyroid
disease, hyperthyroidism, goitrous autoimmune hypothyroidism
(Hashimoto's disease), atrophic autoimmune hypothyroidism, primary
myxoedema, phacogenic uveitis, primary vasculitis, vitiligo, acute
liver disease, chronic liver diseases, alcoholic cirrhosis,
alcohol-induced liver injury, choleosatatis, idiosyncratic liver
disease, Drug-Induced hepatitis, Non-alcoholic Steatohepatitis,
allergy and asthma, group B streptococci (GBS) infection, mental
disorders (e.g., depression and schizophrenia), Th2 Type and Th1
Type mediated diseases, and cancers such as lung, breast, stomach,
bladder, colon, pancreas, ovarian, prostate and rectal cancer and
hematopoietic malignancies (leukemia and lymphoma), and
hematopoietic malignancies (leukemia and lymphoma), and diseases
involving inappropriate vascularization for example diabetic
retinopathy, retinopathy of prematurity, choroidal
neovascularization due to age-related macular degeneration, and
infantile hemangiomas in human beings. In addition, such compounds
may be useful in the treatment of disorders such as edema, ascites,
effusions, and exudates, including for example macular edema,
cerebral edema, acute lung injury, adult respiratory distress
syndrome (ARDS), proliferative disorders such as restenosis,
fibrotic disorders such as hepatic cirrhosis and atherosclerosis,
mesangial cell proliferative disorders such as glomerulonephritis,
diabetic nephropathy, malignant nephrosclerosis, thrombotic
microangiopathy syndromes, and glomerulopathies, myocardial
angiogenesis, coronary and cerebral collaterals, ischemic limb
angiogenesis, ischemia/reperfusion injury, peptic ulcer
Helicobacter related diseases, virally-induced angiogenic
disorders, Crow-Fukase syndrome (POEMS), preeclampsia,
menometrorrhagia, cat scratch fever, rubeosis, neovascular glaucoma
and retinopathies such as those associated with diabetic
retinopathy, retinopathy of prematurity, or age-related macular
degeneration. In addition, these compounds can be used as active
agents against solid tumors, malignant ascites, von Hippel Lindau
disease, hematopoietic cancers and hyperproliferative disorders
such as thyroid hyperplasia (especially Grave's disease), and cysts
(such as hypervascularity of ovarian stroma characteristic of
polycystic ovarian syndrome (Stein-Leventhal syndrome) and
polycystic kidney disease since such diseases require a
proliferation of blood vessel cells for growth and/or
metastasis.
[0304] Compounds of formula (I) of the invention can be used alone
or in combination with another therapeutic agent to treat such
diseases. It should be understood that the compounds of the
invention can be used alone or in combination with an additional
agent, e.g., a therapeutic agent, said additional agent being
selected by the skilled artisan for its intended purpose. For
example, the additional agent can be a therapeutic agent
art-recognized as being useful to treat the disease or condition
being treated by the compound of the present invention. The
additional agent also can be an agent that imparts a beneficial
attribute to the therapeutic composition e.g., an agent which
effects the viscosity of the composition.
[0305] It should further be understood that the combinations that
are to be included within this invention are those combinations
useful for their intended purpose. The agents set forth below are
illustrative for purposes and not intended to be limited. The
combinations, which are part of this invention, can be the
compounds of the present invention and at least one additional
agent selected from the lists below. The combination can also
include more than one additional agent, e.g., two or three
additional agents if the combination is such that the formed
composition can perform its intended function.
[0306] Preferred combinations are non-steroidal anti-inflammatory
drug(s) also referred to as NSAIDS which include drugs like
ibuprofen. Other preferred combinations are corticosteroids
including prednisolone; the well known side-effects of steroid use
can be reduced or even eliminated by tapering the steroid dose
required when treating patients in combination with the anti-IL-18
antibodies of this invention. Non-limiting examples of therapeutic
agents for rheumatoid arthritis with which a compound of formula
(I) of the invention can be combined include the following:
cytokine suppressive anti-inflammatory drug(s) (CSAIDs); antibodies
to or antagonists of other human cytokines or growth factors, for
example, TNF, LT, IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8,
IL-12, IL-15, IL-16, IL-21, IL-23, interferons, EMAP-II, GM-CSF,
FGF, and PDGF. Antibodies of the invention, or antigen binding
portions thereof, can be combined with antibodies to cell surface
molecules such as CD2, CD3, CD4, CD8, CD25, CD28, CD30, CD40, CD45,
CD69, CD80 (B7.1), CD86 (B7.2), CD90, CTLA or their ligands
including CD154 (gp39 or CD40L).
[0307] Preferred combinations of therapeutic agents may interfere
at different points in the autoimmune and subsequent inflammatory
cascade; preferred examples include TNF antagonists like chimeric,
humanized or human TNF antibodies, D2E7 (HUMIRA.TM.), (PCT
Publication No. WO 97/29131), CA2 (REMICADE.TM.), CDP 571, and
soluble p55 or p75 TNF receptors, derivatives, thereof, (p75TNFR1gG
(ENBREL.TM.) or p55TNFR1gG (Lenercept), and also TNF.alpha.
converting enzyme (TACE) inhibitors; similarly IL-1 inhibitors
(Interleukin-1-converting enzyme inhibitors, IL-1RA etc.) may be
effective for the same reason. Other preferred combinations include
Interleukin 11. Yet another preferred combination are other key
players of the autoimmune response which may act parallel to,
dependent on or in concert with IL-18 function; especially
preferred are IL-12 antagonists including IL-12 antibodies or
soluble IL-12 receptors, or IL-12 binding proteins. It has been
shown that IL-12 and IL-18 have overlapping but distinct functions
and a combination of antagonists to both may be most effective. Yet
another preferred combination are non-depleting anti-CD4
inhibitors. Yet other preferred combinations include antagonists of
the co-stimulatory pathway CD80 (B7.1) or CD86 (B7.2) including
antibodies, soluble receptors or antagonistic ligands.
[0308] A compound of formula (I) of the invention may also be
combined with agents, such as methotrexate, 6-MP, azathioprine
sulphasalazine, mesalazine, olsalazine
chloroquinine/hydroxychloroquine, pencillamine, aurothiomalate
(intramuscular and oral), azathioprine, cochicine, corticosteroids
(oral, inhaled and local injection), beta-2 adrenoreceptor agonists
(salbutamol, terbutaline, salmeteral), xanthines (theophylline,
aminophylline), cromoglycate, nedocromil, ketotifen, ipratropium
and oxitropium, cyclosporin, FK506, rapamycin, mycophenolate
mofetil, leflunomide, NSAIDs, for example, ibuprofen,
corticosteroids such as prednisolone, phosphodiesterase inhibitors,
adensosine agonists, antithrombotic agents, complement inhibitors,
adrenergic agents, agents which interfere with signalling by
proinflammatory cytokines such as TNF.alpha. or IL-1 (e.g. IRAK
family, NIK, IKK family, p38 or other MAP kinase inhibitors),
IL-1.beta. converting enzyme inhibitors, TNTF.alpha. converting
enzyme (TACE) inhibitors, T-cell signalling inhibitors such as
kinase inhibitors, metalloproteinase inhibitors, sulfasalazine,
azathioprine, 6-mercaptopurines, angiotensin converting enzyme
inhibitors, soluble cytokine receptors and derivatives thereof
(e.g. soluble p55 or p75 TNF receptors and the derivatives
p75TNFRIgG (Enbrel.TM. and p55TNFRIgG (Lenercept)), sIL-1RI,
sIL-1RII, sIL-6R), antiinflammatory cytokines (e.g. IL-4, IL-10,
IL-11, IL-13 and TGF.beta.), celecoxib, folic acid,
hydroxychloroquine sulfate, rofecoxib, etanercept, infliximab,
naproxen, valdecoxib, sulfasalazine, methylprednisolone, meloxicam,
methylprednisolone acetate, gold sodium thiomalate, aspirin,
triamcinolone acetonide, propoxyphene napsylate/apap, folate,
nabumetone, diclofenac, piroxicam, etodolac, diclofenac sodium,
oxaprozin, oxycodone HCl, hydrocodone bitartrate/apap, diclofenac
sodiun/misoprostol, fentanyl, anakinra, human recombinant, tramadol
HCl, salsalate, sulindac, cyanocobalamin/fa/pyridoxine,
acetaminophen, alendronate sodium, prednisolone, morphine sulfate,
lidocaine hydrochloride, indomethacin, glucosamine
sulf/chondroitin, amitriptyline HCl, sulfadiazine, oxycodone
HCl/acetaminophen, olopatadine HCl, misoprostol, naproxen sodium,
omeprazole, cyclophosphamide, rituximab, IL-1 TRAP, MRA, CTLA4-IG,
IL-18 BP, anti-IL-12, Anti-IL15, BIRB-796, SCIO-469, VX-702,
AMG-548, VX-740, Roflumilast, IC-485, CDC-801, and Mesopram.
Preferred combinations include methotrexate or leflunomide and in
moderate or severe rheumatoid arthritis cases, cyclosporine and
anti-TNF antibodies as noted above.
[0309] Non-limiting examples of therapeutic agents for inflammatory
bowel disease with which a compound of formula (I) of the invention
can be combined include the following: budenoside; epidermal growth
factor; corticosteroids; cyclosporin, sulfasalazine;
aminosalicylates; 6-mercaptopurine; azathioprine; metronidazole;
lipoxygenase inhibitors; mesalamine; olsalazine; balsalazide;
antioxidants; thromboxane inhibitors; IL-1 receptor antagonists;
anti-IL-1.beta. monoclonal antibodies; anti-IL-6 monoclonal
antibodies; growth factors; elastase inhibitors;
pyridinyl-imidazole compounds; antibodies to or antagonists of
other human cytokines or growth factors, for example, TNF, LT,
IL-1, IL-2, IL-6, IL-7, IL-8, IL-12, IL-15, IL-16, EMAP-II, GM-CSF,
FGF, and PDGF; cell surface molecules such as CD2, CD3, CD4, CD8,
CD25, CD28, CD30, CD40, CD45, CD69, CD90 or their ligands;
methotrexate; cyclosporine; FK506; rapamycin; mycophenolate
mofetil; leflunomide; NSAIDs, for example, ibuprofen;
corticosteroids such as prednisolone; phosphodiesterase inhibitors;
adenosine agonists; antithrombotic agents; complement inhibitors;
adrenergic agents; agents which interfere with signalling by
proinflammatory cytokines such as TNF.alpha. or IL-1 (e.g. IRAK,
NIK, IKK, p38 or MAP kinase inhibitors); IL-1.beta. converting
enzyme inhibitors; TNF.alpha. converting enzyme inhibitors; T-cell
signalling inhibitors such as kinase inhibitors; metalloproteinase
inhibitors; sulfasalazine; azathioprine; 6-mercaptopurines;
angiotensin converting enzyme inhibitors; soluble cytokine
receptors and derivatives thereof (e.g. soluble p55 or p75 TNF
receptors, sIL-1RI, sIL-1RII, sIL-6R) and antiinflammatory
cytokines (e.g. IL-4, IL-10, IL-11, IL-13 and TGF.beta.). Preferred
examples of therapeutic agents for Crohn's disease in which a
compound of formula (I) can be combined include the following: TNF
antagonists, for example, anti-TNF antibodies, D2E7 (PCT
Publication No. WO 97/29131; HUMIRA.TM.), CA2 (REMICADE.TM.), CDP
571, TNFR-Ig constructs, (p75TNFRIgG (ENBREL.TM.) and p55TNFRIgG
(LENERCEPT.TM.)) inhibitors and PDE4 inhibitors. A compound of
formula (I) can be combined with corticosteroids, for example,
budenoside and dexamethasone; sulfasalazine, 5-aminosalicylic acid;
olsalazine; and agents which interfere with synthesis or action of
proinflammatory cytokines such as UL-1, for example, IL-1.beta.
converting enzyme inhibitors and IL-1ra; T cell signaling
inhibitors, for example, tyrosine kinase inhibitors
6-mercaptopurines; IL-11; mesalamine; prednisone; azathioprine;
mercaptopurine; infliximab; methylprednisolone sodium succinate;
diphenoxylate/atrop sulfate; loperamide hydrochloride;
methotrexate; omeprazole; folate; ciprofloxacin/dextrose-water;
hydrocodone bitartrate/apap; tetracycline hydrochloride;
fluocinonide; metronidazole; thimerosal/boric acid;
cholestyramine/sucrose; ciprofloxacin hydrochloride; hyoscyamine
sulfate; meperidine hydrochloride; midazolam hydrochloride;
oxycodone HCl/acetaminophen; promethazine hydrochloride; sodium
phosphate; sulfamethoxazole/trimethoprim; celecoxib; polycarbophil;
propoxyphene napsylate; hydrocortisone; multivitamins; balsalazide
disodium; codeine phosphate/apap; colesevelam HCl; cyanocobalamin;
folic acid; levofloxacin; methylprednisolone; natalizumab and
interferon-gamma.
[0310] Non-limiting examples of therapeutic agents for multiple
sclerosis with which a compound of formula (I) can be combined
include the following: corticosteroids; prednisolone;
methylprednisolone; azathioprine; cyclophosphamide; cyclosporine;
methotrexate; 4-aminopyridine; tizanidine; interferon-.beta.1a
(AVONEX; Biogen); interferon-.beta.1b (BETASERON; Chiron/Berlex);
interferon (.alpha.-n3) (Interferon Sciences/Fujimoto),
interferon-.alpha. (Alfa Wassermann/J&J), interferon
.beta.1A-IF (Serono/Inhale Therapeutics), Peginterferon .alpha. 2b
(Enzon/Schering-Plough), Copolymer 1 (Cop-1; COPAXONE; Teva
Pharmaceutical Industries, Inc.); hyperbaric oxygen; intravenous
immunoglobulin; clabribine; antibodies to or antagonists of other
human cytokines or growth factors and their receptors, for example,
TNF, LT, IL-1, IL-2, IL-6, IL-7, IL-8, IL-12, IL-23, IL-15, IL-16,
EMAP-II, GM-CSF, FGF, and PDGF. A compound of formula (I) can be
combined with antibodies to cell surface molecules such as CD2,
CD3, CD4, CD8, CD19, CD20, CD25, CD28, CD30, CD40, CD45, CD69,
CD80, CD86, CD90 or their ligands. A compound of formula (I) may
also be combined with agents, such as methotrexate, cyclosporine,
FK506, rapamycin, mycophenolate mofetil, leflunomide, NSAIDs, for
example, ibuprofen, corticosteroids such as prednisolone,
phosphodiesterase inhibitors, adensosine agonists, antithrombotic
agents, complement inhibitors, adrenergic agents, agents which
interfere with signalling by proinflammatory cytokines such as
TNF.alpha. or IL-1 (e.g. IRAK, NIK, IKK, p38 or MAP kinase
inhibitors), IL-1.beta. converting enzyme inhibitors, TACE
inhibitors, T-cell signaling inhibitors such as kinase inhibitors,
metalloproteinase inhibitors, sulfasalazine, azathioprine,
6-mercaptopurines, angiotensin converting enzyme inhibitors,
soluble cytokine receptors and derivatives thereof (e.g. soluble
p55 or p75 TNF receptors, sIL-1RI, sIL-1RII, sIL-6R) and
antiinflammatory cytokines (e.g. IL-4, IL-10, IL-13 and
TGF.beta.).
[0311] Preferred examples of therapeutic agents for multiple
sclerosis in which a compound of formula (I) can be combined to
include interferon-.beta. for example, IFN.beta.1a and IFN.beta.1b;
copaxone, corticosteroids, caspase inhibitors, for example
inhibitors of caspase-1, IL-1 inhibitors, TNF inhibitors, and
antibodies to CD40 ligand and CD80.
[0312] A compound of formula (I) may also be combined with agents,
such as alemtuzumab, dronabinol, Unimed, daclizumab, mitoxantrone,
xaliproden hydrochloride, fampridine, glatiramer acetate,
natalizumab, sinnabidol, a-immunokine NNSO3, ABR-215062,
AnergiX.MS, chemokine receptor antagonists, BBR-2778, calagualine,
CPI-1189, LEM (liposome encapsulated mitoxantrone), THC.CBD
(cannabinoid agonist) MBP-8298, mesopram (PDE4 inhibitor), MNA-715,
anti-IL-6 receptor antibody, neurovax, pirfenidone allotrap 1258
(RDP-1258), sTNF-R1, talampanel, teriflunomide, TGF-beta2,
tiplimotide, VLA-4 antagonists (for example, TR-14035, VLA4
Ultrahaler, Antegran-ELAN/Biogen), interferon gamma antagonists,
IL4 agonists.
[0313] Non-limiting examples of therapeutic agents for Angina with
which a compound of formula (I) of the invention can be combined
include the following: aspirin, nitroglycerin, isosorbide
mononitrate, metoprolol succinate, atenolol, metoprolol tartrate,
amlodipine besylate, diltiazem hydrochloride, isosorbide dinitrate,
clopidogrel bisulfate, nifedipine, atorvastatin calcium, potassium
chloride, furosemide, simvastatin, verapamil HCl, digoxin,
propranolol hydrochloride, carvedilol, lisinopril, spironolactone,
hydrochlorothiazide, enalapril maleate, nadolol, ramipril,
enoxaparin sodium, heparin sodium, valsartan, sotalol
hydrochloride, fenofibrate, ezetimibe, bumetanide, losartan
potassium, lisinopril/hydrochlorothiazide, felodipine, captopril,
bisoprolol fumarate.
[0314] Non-limiting examples of therapeutic agents for Ankylosing
Spondylitis with which a compound of formula (I) can be combined
include the following: ibuprofen, diclofenac and misoprostol,
naproxen, meloxicam, indomethacin, diclofenac, celecoxib,
rofecoxib, Sulfasalazine, Methotrexate, azathioprine, minocyclin,
prednisone, etanercept, infliximab.
[0315] Non-limiting examples of therapeutic agents for Asthma with
which a compound of formula (I) can be combined include the
following: albuterol, salmeterol/fluticasone, montelukast sodium,
fluticasone propionate, budesonide, prednisone, salmeterol
xinafoate, levalbuterol HCl, albuterol sulfate/ipratropium,
prednisolone sodium phosphate, triamcinolone acetonide,
beclomethasone dipropionate, ipratropium bromide, azithromycin,
pirbuterol acetate, prednisolone, theophylline anhydrous,
methylprednisolone sodium succinate, clarithromycin, zafirlukast,
formoterol fumarate, influenza virus vaccine, methylprednisolone,
amoxicillin trihydrate, flunisolide, allergy injection, cromolyn
sodium, fexofenadine hydrochloride, flunisolide/menthol,
amoxicillin/clavulanate, levofloxacin, inhaler assist device,
guaifenesin, dexamethasone sodium phosphate, moxifloxacin HCl,
doxycycline hyclate, guaifenesin/d-methorphan,
p-ephedrine/cod/chlorphenir, gatifloxacin, cetirizine
hydrochloride, mometasone furoate, salmeterol xinafoate,
benzonatate, cephalexin, pe/hydrocodone/chlorphenir, cetirizine
HCl/pseudoephed, phenylephrine/cod/promethazine,
codeine/promethazine, cefprozil, dexamethasone,
guaifenesin/pseudoephedrine, chlorpheniramine/hydrocodone,
nedocromil sodium, terbutaline sulfate, epinephrine,
methylprednisolone, metaproterenol sulfate.
[0316] Non-limiting examples of therapeutic agents for COPD with
which a compound of formula (I) can be combined include the
following: albuterol sulfate/ipratropium, ipratropium bromide,
salmeterol/fluticasone, albuterol, salmeterol xinafoate,
fluticasone propionate, prednisone, theophylline anhydrous,
methylprednisolone sodium succinate, montelukast sodium,
budesonide, formoterol fumarate, triamcinolone acetonide,
levofloxacin, guaifenesin, azithromycin, beclomethasone
dipropionate, levalbuterol HCl, flunisolide, ceftriaxone sodium,
amoxicillin trihydrate, gatifloxacin, zafirlukast,
amoxicillin/clavulanate, flunisolide/menthol,
chlorpheniramine/hydrocodone, metaproterenol sulfate,
methylprednisolone, mometasone furoate,
p-ephedrine/cod/chlorphenir, pirbuterol acetate,
p-ephedrine/loratadine, terbutaline sulfate, tiotropium bromide,
(R,R)-formoterol, TgAAT, Cilomilast, Roflumilast.
[0317] Non-limiting examples of therapeutic agents for HCV with
which a compound of formula (I) can be combined include the
following: Interferon-alpha-2a, Interferon-alpha-2b,
Interferon-alpha con1, Interferon-alpha-n1, Pegylated
interferon-alpha-2a, Pegylated interferon-alpha-2b, ribavirin,
Peginterferon alfa-2b+ribavirin, Ursodeoxycholic Acid, Glycyrrhizic
Acid, Thymalfasin, Maxamine, VX-497 and any compounds that are used
to treat HCV through intervention with the following targets: HCV
polymerase, HCV protease, HCV helicase, HCV IRES (internal ribosome
entry site).
[0318] Non-limiting examples of therapeutic agents for Idiopathic
Pulmonary Fibrosis with which a compound of formula (I) can be
combined include the following: prednisone, azathioprine,
albuterol, colchicine, albuterol sulfate, digoxin, gamma
interferon, methylprednisolone sod succ, lorazepam, furosemide,
lisinopril, nitroglycerin, spironolactorie, cyclophosphamide,
ipratropium bromide, actinomycin d, alteplase, fluticasone
propionate, levofloxacin, metaproterenol sulfate, morphine sulfate,
oxycodone HCl, potassium chloride, triamcinolone acetonide,
tacrolimus anhydrous, calcium, interferon-alpha, methotrexate,
mycophenolate mofetil, Interferon-gamma-1.beta..
[0319] Non-limiting examples of therapeutic agents for Myocardial
Infarction with which a compound of formula (I) can be combined
include the following: aspirin, nitroglycerin, metoprolol tartrate,
enoxaparin sodium, heparin sodium, clopidogrel bisulfate,
carvedilol, atenolol, morphine sulfate, metoprolol succinate,
warfarin sodium, lisinopril, isosorbide mononitrate, digoxin,
furosemide, simvastatin, ramipril, tenecteplase, enalapril maleate,
torsemide, retavase, losartan potassium, quinapril HCl/mag carb,
bumetanide, alteplase, enalaprilat, amiodarone hydrochloride,
tirofiban HCl m-hydrate, diltiazem hydrochloride, captopril,
irbesartan, valsartan, propranolol hydrochloride, fosinopril
sodium, lidocaine hydrochloride, eptifibatide, cefazolin sodium,
atropine sulfate, aminocaproic acid, spironolactone, interferon,
sotalol hydrochloride, potassium chloride, docusate sodium,
dobutamine HCl, alprazolam, pravastatin sodium, atorvastatin
calcium, midazolam hydrochloride, meperidine hydrochloride,
isosorbide dinitrate, epinephrine, dopamine hydrochloride,
bivalirudin, rosuvastatin, ezetimibe/simvastatin, avasimibe,
cariporide.
[0320] Non-limiting examples of therapeutic agents for Psoriasis
with which a compound of formula (I) can be combined include the
following: calcipotriene, clobetasol propionate, triamcinolone
acetonide, halobetasol propionate, tazarotene, methotrexate,
fluocinonide, betamethasone diprop augmented, fluocinolone
acetonide, acitretin, tar shampoo, betamethasone valerate,
mometasone furoate, ketoconazole, pramoxine/fluocinolone,
hydrocortisone valerate, flurandrenolide, urea, betamethasone,
clobetasol propionate/emoll, fluticasone propionate, azithromycin,
hydrocortisone, moisturizing formula, folic acid, desonide,
pimecrolimus, coal tar, diflorasone diacetate, etanercept folate,
lactic acid, methoxsalen, hc/bismuth subgal/znox/resor,
methylprednisolone acetate, prednisone, sunscreen, halcinonide,
salicylic acid, anthralin, clocortolone pivalate, coal extract,
coal tar/salicylic acid, coal tar/salicylic acid/sulfur,
desoximetasone, diazepam, emollient, fluocinonide/emollient,
mineral oil/castor oil/na lact, mineral oil/peanut oil,
petroleum/isopropyl myristate, psoralen, salicylic acid,
soap/tribromsalan, thimerosal/boric acid, celecoxib, infliximab,
cyclosporine, alefacept, efalizumab, tacrolimus, pimecrolimus,
PUVA, WVB, sulfasalazine.
[0321] Non-limiting examples of therapeutic agents for Psoriatic
Arthritis with which a compound of formula (I) can be combined
include the following: methotrexate, etanercept, rofecoxib,
celecoxib, folic acid, sulfasalazine, naproxen, leflunomide,
methylprednisolone acetate, indomethacin, hydroxychloroquine
sulfate, prednisone, sulindac, betamethasone diprop augmented,
infliximab, methotrexate, folate, triamcinolone acetonide,
diclofenac, dimethylsulfoxide, piroxicam, diclofenac sodium,
ketoprofen, meloxicam, methylprednisolone, nabumetone, tolmetin
sodium, calcipotriene, cyclosporine, diclofenac sodium/misoprostol,
fluocinonide, glucosamine sulfate, gold sodium thiomalate,
hydrocodone bitartrate/apap, ibuprofen, risedronate sodium,
sulfadiazine, thioguanine, valdecoxib, alefacept, efalizumab.
[0322] Non-limiting examples of therapeutic agents for Restenosis
with which a compound of formula (I) can be combined include the
following: sirolimus, paclitaxel, everolimus, tacrolimus, ABT-578,
acetaminophen.
[0323] Non-limiting examples of therapeutic agents for Sciatica
with which a compound of formula (I) can be combined include the
following: hydrocodone bitartrate/apap, rofecoxib, cyclobenzaprine
HCl, methylprednisolone, naproxen, ibuprofen, oxycodone
HCl/acetaminophen, celecoxib, valdecoxib, methylprednisolone
acetate, prednisone, codeine phosphate/apap, tramadol
HCl/acetaminophen, metaxalone, meloxicam, methocarbamol, lidocaine
hydrochloride, diclofenac sodium, gabapentin, dexamethasone,
carisoprodol, ketorolac tromethamine, indomethacin, acetaminophen,
diazepam, nabumetone, oxycodone HCl, tizanidine HCl, diclofenac
sodium/misoprostol, propoxyphene napsylate/apap,
asa/oxycod/oxycodone ter, ibuprofen/hydrocodone bit, tramadol HCl,
etodolac, propoxyphene HCl, amitriptyline HCl, carisoprodol/codeine
phos/asa, morphine sulfate, multivitamins, naproxen sodium,
orphenadrine citrate, temazepam.
[0324] Preferred examples of therapeutic agents for SLE (Lupus) in
which a compound of formula (I) include the following: NSAIDS, for
example, diclofenac, naproxen, ibuprofen, piroxicam, indomethacin;
COX2 inhibitors, for example, Celecoxib, rofecoxib, valdecoxib;
anti-malarials, for example, hydroxychloroquine; Steroids, for
example, prednisone, prednisolone, budenoside, dexamethasone;
Cytotoxics, for example, azathioprine, cyclophosphamide,
mycophenolate mofetil, methotrexate; inhibitors of PDE4 or purine
synthesis inhibitor, for example Cellcept. A compound of formula
(I) may also be combined with agents such as sulfasalazine,
5-aminosalicylic acid, olsalazine, Imuran and agents which
interfere with synthesis, production or action of proinflammatory
cytokines such as IL-1, for example, caspase inhibitors like
IL-1.beta. converting enzyme inhibitors and IL-1ra. A compound of
formula (I) may also be used with T cell signaling inhibitors, for
example, tyrosine kinase inhibitors; or molecules that target T
cell activation molecules, for example, CTLA4-IgG or anti-B7 family
antibodies, anti-PD-1 family antibodies. A compound of formula (I)
can be combined with UL-11 or anti-cytokine antibodies, for
example, fonotolizumab (anti-IFNg antibody), or anti-receptor
receptor antibodies, for example, anti-IL-6 receptor antibody and
antibodies to B-cell surface molecules. A compound of formula (I)
may also be used with LJP 394 (abetimus), agents that deplete or
inactivate B-cells, for example, Rituximab (anti-CD20 antibody),
lymphostat-B (anti-BlyS antibody), TNF antagonists, for example,
anti-TNF antibodies, D2E7 (PCT Publication No. WO 97/29131;
HUMIRA.TM.), CA2 (REMICADE.TM.), CDP 571, TNFR-Ig constructs,
(p75TNFRIgG (ENBREL.TM.) and p55TNFRIgG (LENERCEP.TM.)).
[0325] In this invention, the following definitions are
applicable:
[0326] A "therapeutically effective amount" is an amount of a
compound of Formula I or a combination of two or more such
compounds, which inhibits, totally or partially, the progression of
the condition or alleviates, at least partially, one or more
symptoms of the condition. A therapeutically effective amount can
also be an amount which is prophylactically effective. The amount
which is therapeutically effective will depend upon the patient's
size and gender, the condition to be treated, the severity of the
condition and the result sought. For a given patient, a
therapeutically effective amount can be determined by methods known
to those of skill in the art.
[0327] "Physiologically acceptable salts" refers to those salts
which retain the biological effectiveness and properties of the
free bases and which are obtained by reaction with inorganic acids,
for example, hydrochloric acid, hydrobromic acid, sulfuric acid,
nitric acid, and phosphoric acid or organic acids such as sulfonic
acid, carboxylic acid, organic phosphoric acid, methanesulfonic
acid, ethanesulfonic acid, p-toluenesulfonic acid, citric acid,
fumaric acid, maleic acid, succinic acid, benzoic acid, salicylic
acid, lactic acid, tartaric acid (e.g. (+) or (-)-tartaric acid or
mixtures thereof), amino acids (e.g. (+) or (-)-amino acids or
mixtures thereof), and the like. These salts can be prepared by
methods known to those skilled in the art.
[0328] Certain compounds of formula I which have acidic
substituents may exist as salts with pharmaceutically acceptable
bases. The present invention includes such salts. Examples of such
salts include sodium salts, potassium salts, lysine salts and
arginine salts. These salts may be prepared by methods known to
those skilled in the art.
[0329] Certain compounds of formula I and their salts may exist in
more than one crystal form and the present invention includes each
crystal form and mixtures thereof.
[0330] Certain compounds of formula I and their salts may also
exist in the form of solvates, for example hydrates, and the
present invention includes each solvate and mixtures thereof.
[0331] Certain compounds of formula I may contain one or more
chiral centers, and exist in different optically active forms. When
compounds of formula I contain one chiral center, the compounds
exist in two enantiomeric forms and the present invention includes
both enantiomers and mixtures of enantiomers, such as racemic
mixtures. The enantiomers may be resolved by methods known to those
skilled in the art, for example by formation of diastereoisomeric
salts which may be separated, for example, by crystallization;
formation of diastereoisomeric derivatives or complexes which may
be separated, for example, by crystallization, gas-liquid or liquid
chromatography; selective reaction of one enantiomer with an
enantiomer-specific reagent, for example enzymatic esterification;
or gas-liquid or liquid chromatography in a chiral environment, for
example on a chiral support for example silica with a bound chiral
ligand or in the presence of a chiral solvent. It will be
appreciated that where the desired enantiomer is converted into
another chemical entity by one of the separation procedures
described above, a further step is required to liberate the desired
enantiomeric form. Alternatively, specific enantiomers may be
synthesized by asymmetric synthesis using optically active
reagents, substrates, catalysts or solvents, or by converting one
enantiomer into the other by asymmetric transformation.
[0332] When a compound of formula I contains more than one chiral
center it may exist in diastereoisomeric forms. The
diastereoisomeric pairs may be separated by methods known to those
skilled in the art, for example chromatography or crystallization
and the individual enantiomers within each pair may be separated as
described above. The present invention includes each
diastereoisomer of compounds of formula I and mixtures thereof.
[0333] Certain compounds of formula I may exist in different
tautomeric forms or as different geometric isomers, and the present
invention includes each tautomer and/or geometric isomer of
compounds of formula I and mixtures thereof.
[0334] Certain compounds of formula I may exist in different stable
conformational forms which may be separable. Torsional asymmetry
due to restricted rotation about an asymmetric single bond, for
example because of steric hindrance or ring strain, may permit
separation of different conformers. The present invention includes
each conformational isomer of compounds of formula I and mixtures
thereof.
[0335] Certain compounds of formula I may exist in zwitterionic
form and the present invention includes each zwitterionic form of
compounds of formula I and mixtures thereof.
[0336] As used herein the term "pro-drug" refers to an agent which
is converted into the parent drug in vivo by some physiological
chemical process (e.g., a prodrug on being brought to the
physiological pH is converted to the desired drug form). Pro-drugs
are often useful because, in some situations, they may be easier to
administer than the parent drug. They may, for instance, be
bioavailable by oral administration whereas the parent drug is not.
The prodrug may also have improved solubility in pharmacological
compositions over the parent drug. An example, without limitation,
of a pro-drug would be a compound of the present invention wherein
it is administered as an ester (the "pro-drug") to facilitate
transmittal across a cell membrane where water solubility is not
beneficial, but then it is metabolically hydrolyzed to the
carboxylic acid once inside the cell where water solubility is
beneficial
[0337] Pro-drugs have many useful properties. For example, a
pro-drug may be more water soluble than the ultimate drug, thereby
facilitating intravenous administration of the drug. A pro-drug may
also have a higher level of oral bioavailability than the ultimate
drug. After administration, the prodrug is enzymatically or
chemically cleaved to deliver the ultimate drug in the blood or
tissue.
[0338] Exemplary pro-drugs upon cleavage release the corresponding
free acid, and such hydrolyzable ester-forming residues of the
compounds of this invention include but are not limited to
carboxylic acid substituents (e.g., --(CH.sub.2)C(O)H or a moiety
that contains a carboxylic acid) wherein the free hydrogen is
replaced by (C.sub.1-C.sub.4)alkyl,
(C.sub.2-C.sub.12)alkanoyloxymethyl,
(C.sub.4-C.sub.9)1-(alkanoyloxy)ethyl,
1-methyl-1-(alkanoyloxy)-ethyl having from 5 to 10 carbon atoms,
alkoxycarbonyloxymethyl having from 3 to 6 carbon atoms,
1-(alkoxycarbonyloxy)ethyl having from 4 to 7 carbon atoms,
1-methyl-1-(alkoxycarbonyloxy)ethyl having from 5 to 8 carbon
atoms, N-(alkoxycarbonyl)aminomethyl having from 3 to 9 carbon
atoms, 1-(N-(alkoxycarbonyl)amino)ethyl having from 4 to 10 carbon
atoms, 3-phthalidyl, 4-crotonolactonyl, gamma-butyrolacton-4-yl,
di-N,N-(C.sub.1-C.sub.2)alkylamino(C.sub.2-C.sub.3)alkyl (such as
.beta.-dimethylaminoethyl), carbamoyl-(C.sub.1-C.sub.2)alkyl,
N,N-di(C.sub.1-C.sub.2)-alkylcarbamoyl-(C.sub.1-C.sub.2)alkyl and
piperidino-, pyrrolidino- or morpholino(C.sub.2-C.sub.3)alkyl.
[0339] Other exemplary pro-drugs release an alcohol of Formula I
wherein the free hydrogen of the hydroxyl substituent (e.g.,
R.sup.1 contains hydroxyl) is replaced by
(C.sub.1-C.sub.6)alkanoyloxymethyl,
1-((C.sub.1-C.sub.6)alkanoyloxy)ethyl,
1-methyl-1-((C.sub.1-C.sub.6)alkanoyloxy)ethyl,
(C.sub.1-C.sub.6)alkoxycarbonyloxymethyl,
N-(C.sub.1-C.sub.6)alkoxycarbonylamino-methyl, succinoyl,
(C.sub.1-C.sub.6)alkanoyl, .alpha.-amino(C.sub.1-C.sub.4)alkanoyl,
arylactyl and .alpha.-aminoacyl, or
.alpha.-aminoacyl-.alpha.-aminoacyl wherein said .alpha.-aminoacyl
moieties are independently any of the naturally occurring L-amino
acids found in proteins, P(O)(OH).sub.2,
--P(O)(O(C.sub.1-C.sub.6)alkyl).sub.2 or glycosyl (the radical
resulting from detachment of the hydroxyl of the hemiacetal of a
carbohydrate).
[0340] Heteroaromatic groups, as used herein, include heteroaryl
ring systems (e.g., for purposes of exemplification, which should
not be construed as limiting the scope of this invention: thienyl,
pyridyl, pyrazole, isoxazolyl, thiadiazolyl, oxadiazolyl,
indazolyl, furans, pyrroles, imidazoles, pyrazoles, triazoles,
pyrimidines, pyrazines, thiazoles, isothiazoles, oxazolyl or
tetrazoles) and heteroaryl ring systems in which a carbocyclic
aromatic ring, carbocyclic non-aromatic ring or heteroaryl ring is
fused to one or more other heteroaryl rings (e.g., for purposes of
exemplification, which should not be construed as limiting the
scope of this invention: benzo(b)thienyl, benzimidazolyl,
benzoxazolyl, benzothiazolyl, benzothiadiazolyl, benzoxadiazolyl,
indole, tetrahydroindole, azaindole, indazole, quinoline,
imidazopyridine, quinazoline purine, pyrrolo[2,3-d]pyrimidine,
pyrazolo[3,4-d]pyrimidine) and their N-oxides. Substituted
heteroaryl groups are preferably substituted with one or more
substituents each independently selected from the group consisting
of halogen, hydroxy, alkyl, alkoxy, alkyl-O--C(O)--, alkoxyalkyl, a
heterocycloalkyl group, optionally substituted phenyl, nitro,
amino, mono-substituted amino or di-substituted amino.
[0341] The term "heterocyclic" or "heterocyclyl", as used herein,
include aromatic and non-aromatic, ring systems, including, but not
limited to, monocyclic, bicyclic and tricyclic rings, which can be
completely saturated or which can contain one or more units of
unsaturation and have 3 to 12 atoms including at least one
heteroatom, such as nitrogen, oxygen, or sulfur. For purposes of
exemplification, which should not be construed as limiting the
scope of this invention: azaindole, azetidinyls furans, imidazoles,
imidazopyridine, indole, isoxazoles, isothiazoles, oxadiazoles,
oxazoles, piperazines, piperidines, pyrans, pyrazines, pyrazoles,
pyridines, pyrimidines, pyrroles, pyrrolidines, quinolines,
quinazolines, triazoles, thiazoles, tetrahydroindole, tetrazoles,
thiadiazoles, thienyls, thiomorpholinos or triazles.
[0342] When the term "substituted heterocyclic" (or heterocyclyl)
is used, what is meant is that the heterocyclic group is
substituted with one or more substituents that can be made by one
of ordinary skill in the art and results in a molecule that is a
kinase inhibitor. For purposes of exemplification, which should not
be construed as limiting the scope of this invention, preferred
substituents for the heterocyclyls of this invention are each
independently selected from the optionally substituted group
consisting of alkenyl, alkoxy, alkoxyalkoxy, alkoxyalkyl,
alkoxycarbonyl, alkoxycarbonylheterocycloalkoxy, alkyl,
alkylcarbonyl, alkylester, alkyl-O--C(O)--, alkyl-heterocyclyl,
alkyl-cycloalkyl, alkyl-nitrile, alkynyl, amido groups, amino,
aminoalkyl, aminocarbonyl, carbonitrile, carbonylalkoxy,
carboxamido, CF.sub.3, CN, --C(O)OH, --C(O)H,
--C(O)--)(CH.sub.3).sub.3, --OH, --C(O)O-alkyl, --C(O)O-cycloalkyl,
--C(O)O-heterocyclyl, --C(O)-alkyl, --C(O)-cycloalkyl,
--C(O)-heterocyclyl, cycloalkyl, dialkylaminoalkoxy,
dialkylaminocarbonylalkoxy, dialkylaminocarbonyl, halogen,
heterocyclyl, a heterocycloalkyl group, heterocyclyloxy, hydroxy,
hydroxyalkyl, nitro, NO.sub.2, OCF.sub.3, oxo, phenyl,
--SO.sub.2CH.sub.3, --SO.sub.2CR.sub.3, tetrazolyl, thienylalkoxy,
trifluoromethylcarbonylamino, trifluoromethylsulfonamido,
heterocyclylalkoxy, heterocyclyl-S(O).sub.p, cycloalkyl-S(O).sub.p,
alkyl-S--, heterocyclyl-S, heterocycloalkyl, cycloalkylalkyl,
heterocycolthio, cycloalkylthio, -Z.sub.105-C(O)N(R).sub.2,
-Z.sup.105-N(R)--C(O)-Z.sup.300,
-Z.sup.105-N(R)--S(O).sub.2-Z.sup.200,
-Z.sup.105-N(R)--C(O)--N(R)-Z.sup.200, --N(R) --C(O)R, --N(R)--C(O)
OR, OR--C(O)-heterocyclyl-OR, R.sub.c and --CH.sub.2OR.sub.c;
where R.sub.c for each occurrence is independently hydrogen,
optionally substituted alkyl, optionally substituted aryl,
--(C.sub.1-C.sub.6)--NR.sub.dR.sub.e,
-E-(CH.sub.2).sub.t--NR.sub.dR.sub.e, -E-(CH.sub.2).sub.t--O-alkyl,
-E-(CH.sub.2).sub.t--S-alkyl, or -E-(CH.sub.2).sub.t--OH
[0343] wherein t is an integer from about 1 to about 6; [0344]
Z.sup.105 for each occurrence is independently a covalent bond,
alkyl, alkenyl or alkynyl; and [0345] Z.sup.200 for each occurrence
is independently selected from an optionally substituted group
selected from the group consisting of alkyl, alkenyl, alkynyl,
phenyl, alkyl-phenyl, alkenyl-phenyl or alkynyl-phenyl; [0346] E is
a direct bond, O, S, S(O), S(O).sub.2, or NR.sub.f, wherein R.sub.f
is H or alkyl and R.sub.d and R.sub.e are independently H, alkyl,
alkanoyl or SO.sub.2-alkyl; or R.sub.d, R.sub.e and the nitrogen
atom to which they are attached together form a five- or
six-membered heterocyclic ring.
[0347] An "heterocycloalkyl" group, as used herein, is a
heterocyclic group that is linked to a compound by an aliphatic
group having from one to about eight carbon atoms. For example, a
preferred heterocycloalkyl group is an imidazolylethyl group.
[0348] As used herein, "aliphatic" or "an aliphatic group" or
notations such as "(C.sub.0-C.sub.8)" include straight chained or
branched hydrocarbons which are completely saturated or which
contain one or more units of unsaturation, and, thus, includes
alkyl, alkenyl, alkynyl and hydrocarbons comprising a mixture of
single, double and triple bonds. When the group is a C.sub.0 it
means that the moiety is not present or in other words, it is a
bond. As used herein, "alkyl" means C.sub.1-C.sub.8 and includes
straight chained or branched hydrocarbons which are completely
saturated. Preferred alkyls are methyl, ethyl, propyl, butyl,
pentyl, hexyl and isomers thereof. As used herein, "alkenyl" and
"alkynyl" means C.sub.2-C.sub.8 and includes straight chained or
branched hydrocarbons which contain one or more units of
unsaturation, one or more double bonds for alkenyl and one or more
triple bonds for alkynyl.
[0349] As used herein, aromatic groups (or aryl groups) include
aromatic carbocyclic ring systems (e.g. phenyl and
cyclopentyldienyl) and fused polycyclic aromatic ring systems (e.g.
naphthyl, biphenylenyl and 1,2,3,4-tetrahydronaphthyl).
[0350] As used herein, cycloalkyl means C.sub.3-C.sub.12 monocyclic
or multicyclic (e.g., bicyclic, tricyclic, etc.) hydrocarbons which
is completely saturated or has one or more unsaturated bonds but
does not amount to an aromatic group. Preferred examples of a
cycloalkyl group are cyclopropyl, cyclobutyl, cyclopentyl,
cyclopentenyl, cyclohexyl and cyclohexenyl.
[0351] As used herein, amido group means --NHC(.dbd.O)--.
[0352] As used herein, acyloxy groups are --OC(O)R.
[0353] As used herein, many moieties or substituents are termed as
being either "substituted" or "optionally substituted". When a
moiety is modified by one of these terms, it denotes that any
portion of the moiety that is known to one skilled in the art as
being available for substitution can be substituted, which includes
one or more substituents, where if more than one substituent then
each substituent is independently selected. Such means for
substitution are well-known in the art and/or taught by the instant
disclosure. For purposes of exemplification, which should not be
construed as limiting the scope of this invention, some examples of
groups that are substituents are: alkenyl groups, alkoxy group
(which itself can be substituted, such as
--O--C.sub.1-C.sub.6-alkyl-OR,
--O--C.sub.1-C.sub.6-alkyl-N(R).sub.2, and OCF.sub.3),
alkoxyalkoxy, alkoxycarbonyl, alkoxycarbonylpiperidinylalkoxy,
alkyl groups (which itself can also be substituted, such as
--C.sub.1-C.sub.6-alkyl-OR, --C.sub.1-C.sub.6-alkyl-N(R).sub.2, and
--CF.sub.3), alkylamino, alkylcarbonyl, alkylester, alkylnitrile,
alkylsulfonyl, amino, aminoalkoxy, CF.sub.3, COH, COOH, CN,
cycloalkyl, dialkylamino, dialkylaminoalkoxy, dialkylaminocarbonyl,
dialkylaminocarbonylalkoxy, dialkylaminosulfonyl, esters
(--C(O)--OR, where R is groups such as alkyl, heterocycloalkyl
(which can be substituted), heterocyclyl, etc., which can be
substituted), halogen or halo group (F, Cl, Br, I), hydroxy,
morpholinoalkoxy, morpholinoalkyl, nitro, oxo, OCF.sub.3,
optionally substituted phenyl, S(O).sub.2CH.sub.3,
S(O).sub.2CF.sub.3, and sulfonyl, N-alkylamino or N,N-dialkylamino
(in which the alkyl groups can also be substituted).
Effective Dosage
[0354] Pharmaceutical compositions suitable for use in the present
invention include compositions wherein the active ingredients are
contained in an effective amount to achieve its intended purpose.
More specifically, a therapeutically effective amount means an
amount effective to prevent development of or to alleviate the
existing symptoms of the subject being treated. Determination of
the effective amounts is well within the capability of those
skilled in the art.
[0355] For any compound used in a method of the present invention,
the therapeutically effective dose can be estimated initially from
cellular assays. For example, a dose can be formulated in cellular
and animal models to achieve a circulating concentration range that
includes the IC.sub.50 as determined in cellular assays (i.e., the
concentration of the test compound which achieves a half-maximal
inhibition of a given protein kinase activity). In some cases it is
appropriate to determine the IC.sub.50 in the presence of 3 to 5%
serum albumin since such a determination approximates the binding
effects of plasma protein on the compound. Such information can be
used to more accurately determine useful doses in humans. Further,
the most preferred compounds for systemic administration
effectively inhibit protein kinase signaling in intact cells at
levels that are safely achievable in plasma.
[0356] A therapeutically effective dose refers to that amount of a
compound of Formula I or a combination of two or more such
compounds, which inhibits, totally or partially, the progression of
a condition or alleviates, at least partially, one or more symptoms
of the condition. A therapeutically effective amount can also be an
amount which is prophylactically effective. Toxicity and
therapeutic efficacy of such compounds can be determined by
standard pharmaceutical procedures in cell cultures or experimental
animals, e.g., for determining the maximum tolerated dose (MTD) and
the ED.sub.50 (effective dose for 50% maximal response). The dose
ratio between toxic and therapeutic effects is the therapeutic
index and it can be expressed as the ratio between MTD and
ED.sub.50. Compounds which exhibit high therapeutic indices are
preferred. The data obtained from these cell culture assays and
animal studies can be used in formulating a range of dosage for use
in humans. The dosage of such compounds lies preferably within a
range of circulating concentrations that include the ED.sub.50 with
little or no toxicity. The dosage may vary within this range
depending upon the dosage form employed and the route of
administration utilized. A therapeutically effective amount can
also be an amount which is prophylactically effective. The amount
which is therapeutically effective will depend upon the patient's
size and gender, the condition to be treated, the severity of the
condition and the result sought. For a given patient, a
therapeutically effective amount can be determined by methods known
to those of skill in the art. The exact formulation, route of
administration and dosage can be chosen by the individual physician
in view of the patient's condition. (See e.g. Fingl et al., 1975,
in "The Pharmacological Basis of Therapeutics", Ch. 1 p1). In the
treatment of crises, the administration of an acute bolus or an
infusion approaching the MTD may be required to obtain a rapid
response.
[0357] Dosage amount and interval may be adjusted individually to
provide plasma levels of the active moiety which are sufficient to
maintain the kinase modulating effects, or minimal effective
concentration (MEC). The MEC will vary for each compound but can be
estimated from in vitro data; e.g. the concentration necessary to
achieve 50-90% inhibition of protein kinase using the assays
described herein. Dosages necessary to achieve the MEC will depend
on individual characteristics and route of administration. However,
HPLC assays or bioassays can be used to determine plasma
concentrations.
[0358] Dosage intervals can also be determined using the MEC value.
Compounds should be administered using a regimen which maintains
plasma levels above the MEC for 10-90% of the time, preferably
between 30-90% and most preferably between 50-90% until the desired
amelioration of symptoms is achieved. In cases of local
administration or selective uptake, the effective local
concentration of the drug may not be related to plasma
concentration.
[0359] The amount of composition administered will, of course, be
dependent on the subject being treated, on the subject's weight,
the severity of the affliction, the manner of administration and
the judgment of the prescribing physician.
Packaging
[0360] The compositions may, if desired, be presented in a pack or
dispenser device which may contain one or more unit dosage forms
containing the active ingredient. The pack may for example comprise
metal or plastic foil, such as a blister pack. The pack or
dispenser device may be accompanied by instructions for
administration. Compositions comprising a compound of the invention
formulated in a compatible pharmaceutical carrier may also be
prepared, placed in an appropriate container, and labeled for
treatment of an indicated condition.
[0361] In some formulations it may be beneficial to use the
compounds of the present invention in the form of particles of very
small size, for example as obtained by fluid energy milling.
[0362] The use of compounds of the present invention in the
manufacture of pharmaceutical compositions is illustrated by the
following description. In this description the term "active
compound" denotes any compound of the invention but particularly
any compound which is the final product of one of the preceding
Examples.
a) Capsules
[0363] In the preparation of capsules, 10 parts by weight of active
compound and 240 parts by weight of lactose can be de-aggregated
and blended. The mixture can be filled into hard gelatin capsules,
each capsule containing a unit dose or part of a unit dose of
active compound.
b) Tablets
[0364] Tablets can be prepared, for example, from the following
ingredients. TABLE-US-00001 Parts by weight Active compound 10
Lactose 190 Maize starch 22 Polyvinylpyrrolidone 10 Magnesium
stearate 3
[0365] The active compound, the lactose and some of the starch can
be de-aggregated, blended and the resulting mixture can be
granulated with a solution of the polyvinyl-pyrrolidone in ethanol.
The dry granulate can be blended with the magnesium stearate and
the rest of the starch. The mixture is then compressed in a
tabletting machine to give tablets each containing a unit dose or a
part of a unit dose of active compound.
c) Enteric Coated Tablets
[0366] Tablets can be prepared by the method described in (b)
above. The tablets can be enteric coated in a conventional manner
using a solution of 20% cellulose acetate phthalate and 3% diethyl
phthalate in ethanol:dichloromethane (1:1).
d) Suppositories
[0367] In the preparation of suppositories, for example, 100 parts
by weight of active compound can be incorporated in 1300 parts by
weight of triglyceride suppository base and the mixture formed into
suppositories each containing a therapeutically effective amount of
active ingredient.
[0368] In the compositions of the present invention the active
compound may, if desired, be associated with other compatible
pharmacologically active ingredients. For example, the compounds of
this invention can be administered in combination with another
therapeutic agent that is known to treat a disease or condition
described herein. For example, with one or more additional
pharmaceutical agents that inhibit or prevent the production of
VEGF or angiopoietins, attenuate intracellular responses to VEGF or
angiopoietins, block intracellular signal transduction, inhibit
vascular hyperpermeability, reduce inflammation, or inhibit or
prevent the formation of edema or neovascularization. The compounds
of the invention can be administered prior to, subsequent to or
simultaneously with the additional pharmaceutical agent, whichever
course of administration is appropriate. The additional
pharmaceutical agents include, but are not limited to any of the
agents, for examples, described in pages 20-28. The compounds of
the invention and the additional pharmaceutical agents act either
additively or synergistically. Thus, the administration of such a
combination of substances that inhibit angiogenesis, vascular
hyperpermeability and/or inhibit the formation of edema can provide
greater relief from the deletrious effects of a hyperproliferative
disorder, angiogenesis, vascular hyperpermeability or edema than
the administration of either substance alone. In the treatment of
malignant disorders combinations with antiproliferative or
cytotoxic chemotherapies or radiation are included in the scope of
the present invention.
[0369] The present invention also comprises the use of a compound
of formula I as a medicament.
[0370] A further aspect of the present invention provides the use
of a compound of formula I or a salt thereof in the manufacture of
a medicament for treating vascular hyperpermeability,
angiogenesis-dependent disorders, proliferative diseases and/or
disorders of the immune system in mammals, particularly human
beings.
[0371] The present invention also provides a method of treating
vascular hyperpermeability, inappropriate neovascularization,
proliferative diseases and/or disorders of the immune system which
comprises the administration of a therapeutically effective amount
of a compound of formula I to a mammal, particularly a human being,
in need thereof.
[0372] The contents of all references, patents and published patent
applications, in their entirety, cited throughout this application
are incorporated herein by reference.
Assays for Screening Compounds of Formula (I)
Enzyme Assays
[0373] The in vitro potency of compounds in inhibiting one or more
of the protein kinases discussed herein or described in the art may
be determined by the procedures detailed below.
[0374] The potency of compounds can be determined by the amount of
inhibition of the phosphorylation of an exogenous substrate (e.g.,
a synthetic peptide (Z. Songyang et al., Nature. 373:536-539) by a
test compound relative to control.
Homogenous time-resolved fluorescence (HTRF) in vitro kinase assay
(see Mathis, G., HTRF(R) Technology. J Biomol Screen, 1999. 4(6):
p. 309-314, the contents of which are incorporated in its entirety
herein by reference):
[0375] Purified enzymes (available from commercial sources) were
mixed with different amounts of N-biotinylated substrates or
GST-tagged substrates (see table) at varying concentrations of
inhibitor in different reaction buffers (40 .mu.L final volume, see
table). The kinase reaction was initiated by addition of ATP
(0.01-0.1 mM final conc.) in a black 96-half-well plate (Perkin
Elmer). After 50-60 minutes incubation at room temperature, the
reaction was quenched by addition of EDTA (final conc. 100 mM) and
developed by addition of revelation reagents (final approximate
concentrations: 30 mM HEPES, pH7.0, 0.06% BSA, 0.006% Tween-20,
0.24 M KF, varying amounts of donor europium labeled antibodies and
acceptor streptavidin labeled allophycocyanin (SAXL) or anti-GST-XL
which are specific to the enzyme reactions. (see table).
[0376] The developed reaction was incubated in the dark either at
room temperature for 10 min, or at 4.degree. C. overnight (see
table), then read in a time-resolved fluorescence detector
(Discovery, Perkin Elmer or Rubystar, BMG) at 620 nm and 665 nm
simultaneously. A 337 nm nitrogen laser was used for excitation.
The ratio between the signal of 620 nm and 665 nm was used to
calculate the IC.sub.50.
[0377] Specific detailed reaction conditions for the various
enzymes are included below: TABLE-US-00002 Enzyme Substrate ATP
DMSO Reaction Assay Conc. Conc. Conc. Conc. Time Detection Enzyme
Construct/Mw Substrate Buffer (ng/well) (.mu.M) (mM) (%) (min)
condition Comments Akt1 NA/56 kD Biotin- Akt 0.12 4 0.1 5 50 13.6
ng/well Develop Bad- Buffer Anti-P-BAD-Eu; at 4.degree. C. peptide
0.17 .mu.g/well overnight SAXL B-Raf Flag-B-Raf GST- COT 30 0.15
0.1 5 60 14 ng/well Develop (446-766)/ Unactive Buffer
Anti-P-MEK-Eu; at 4.degree. C. 37.3 kD MEK1 0.75 .mu.g/well
overnight (UBI) anti-GST-XL Casine Human Biotin- CKII 60 0.5 0.1 5
60 13.6 ng/well Develop Kinase II recombinant/ I.kappa.B.alpha.-
buffer Anti-P- at 4.degree. C. (Calbio- 130 kDa peptide
I.kappa.B.alpha.-Eu; overnight chem) 0.34 .mu.g/well SAXL CDK2/
C-His Biotin- MK2 1.335 0.1 0.1 5 60 15 ng/well Develop Cyclin
CDK2; N-GST MBP buffer Anti-P-MBP-Eu; at 4.degree. C. A (UBI)
Cyclin protein 0.34 .mu.g/well overnight A/110 kD (UBI) SAXL CHK1
CHK1(1-289)- Biotin- PKA 0.6 4 0.1 5 60 1.8 ng/well Develop
His6/33.8 kD cdc25- buffer Anti-P-14-3-3 at RT 10 peptide binding
motif-Eu; min 0.11 .mu.g/well CR130-100 COT Flag-COT30- Biotin- COT
25 0.5 0.1 5 60 8.6 ng/well Develop 397/45 kD MEK- Buffer
Anti-P-MEK-Eu; at 4.degree. C. peptide 0.34 ng/well overnight SAXL
Erk2 GST-Erk2/ Biotin- COT 1 0.05 0.1 5 60 15 ng/well Develop (UBI)
68 kD MBP Buffer Anti-P-MBP-Eu; at 4.degree. C. protein 0.34
.mu.g/well overnight (UBI) SAXL IKK1 His-IKK1/ Biotin- COT 60 0.5
0.1 5 50 13.6 ng/well Develop 80 kD I.kappa.B.alpha.- Buffer
Anti-P- at 4.degree. C. peptide I.kappa.B.alpha.-Eu; overnight 0.34
.mu.g/well SAXL IKK2 His-IKK2/ Biotin- COT 60 0.5 0.1 5 50 13.6
ng/well Develop 80 kD I.kappa.B.alpha.- Buffer Anti-P- at 4.degree.
C. peptide I.kappa.B.alpha.-Eu; overnight 0.34 ng/well SAXL JNK1
His-JNK1/ Biotin- MK2 40 2 0.1 5 60 15 ng/well Develop (UBI) 45 kD
MBP buffer Anti-P-MBP-Eu; at 4.degree. C. protein 0.34 .mu.g/well
overnight (UBI) SAXL MAPKAP GST-MK2 Biotin- MK2 1.5 I 0.01 5 60 1.8
ng/well Develop K2 (36-400)/68 cdc25- buffer Anti-P-14-3-3 at RT 10
kD peptide binding motif-Eu; min 0.11 .mu.g/well CR130-100 MAPKAP
GST-MK3 Biotin- MK2 3 1 0.1 5 60 1.8 ng/well Develop K3 (35-382)/
cdc25- buffer Anti-P-14-3-3 at RT 10 66.9 KD peptide binding
motif-Eu; min 0.11 .mu.g/well CR130-100 MEK1 GST-MEK1- unactive COT
3 0.1 0.1 5 60 15 ng/well Develop (UBI) His6/71 kDa Erk2 Buffer
Anti-P-Erk-Eu; at 4.degree. C. (UBI) 0.39 .mu.g/well overnight
Anti-GST-XL MEKK3 Flag-MEKK3 Unactive COT 85 40 ng/well 0.1 5 50 15
ng/well Develop (2-627)/ MEK1 Buffer MEK1 Anti-P-MBP-Eu; at
4.degree. C. 73 kDa Unactive 250 ng/well 0.34 .mu.g/well overnight
Erk2 Erk2 SAXL Biotin-MBP 0.06 uM protein (all Biotin-MBP from UBI)
NIK/ Flag-NIK; Biotin- COT 8.5 0.5 0.1 5 60 13.6 ng/well Develop
p100 HA-p100/ I.kappa.B.alpha.- Buffer Anti-P- at 4.degree. C.
203.3 kD peptide I.kappa.B.alpha.-Eu; overnight 0.34 .mu.g/well
SAXL p38- GST- Biotin- COT 1.5 0.1 0.1 5 60 15 ng/well Develop
alpha p38.alpha./ MBP Buffer Anti-P-MBP-Eu; at 4.degree. C. (UBI)
64 kD protein 0.34 .mu.g/well overnight (UBI) SAXL PKA Catalytic
Biotin- PKA 1.6 1 0.1 5 60 13.6 ng/well Develop (Invi- subunit,
Bad- buffer Anti-P-BAD-Eu; at 4.degree. C. trogen) human peptide
0.17 .mu.g/well overnight recombinant/ SAXL 43 kDa PKC-
His-PKC.alpha./ Biotin- PKC 0.4 2 0.1 5 60 1.8 ng/well Develop
alpha 78 kD cdc25- buffer Anti-P-14-3-3 at RT 10 (UBI) peptide
binding motif-Eu; min 0.11 .mu.g/well CR130-100 PKC-
His-PKC.delta./ Biotin- PKC 1.5 1 0.1 5 60 1.8 ng/well Develop
delta 77.5 kD cdc25- buffer Anti-P-14-3-3 at RT 10 (UBI) peptide
binding motif-Eu; min 0.11 .mu.g/well CR130-100 PRAK His-PRAK/
Biotin- MK2 40 1 0.1 5 60 29.2 ng/well Develop (UBI) 54 kD MBP
buffer Anti-P-MBP-Eu; at 4.degree. C. protein 0.67 .mu.g/well
overnight (UBI) SAXL Raf-1 Full length Unactive COT 0.1 7.5 0.1 5
60 15 ng/well Develop (UBI) human MEK1 Buffer U/well ng/well
Anti-P-MBP-Eu; at 4.degree. C. recombinant Unactive MEK1 0.34
.mu.g/well overnight Raf-1/74 kD Erk2 60 ng/well SAXL Biotin- Erk2
MBP 0.12 .mu.M protein Biotin- (all from MBP UBI) SGK1 His-SGK1
Biotin- MK2 0.3 4 0.1 5 60 13.6 ng/well Develop (UBI) (1-60a.a.
Bad- buffer Anti-P-BAD-Eu; at 4.degree. C. deleted, peptide 0.17
.mu.g/well overnight S422D) SAXL cTAK1 Full Biotin- COT 30.5 4 0.1
5 60 1.8 ng/well Develop (UBI) length/ cdc25- Buffer Anti-P-14-3-3
at RT 10 90 kDa peptide binding motif-Eu; min 0.11 .mu.g/well
CR130-100
Reaction Buffers: COT Buffer: [0378] 50 mM Tris-HCl, pH7.5; 10 mM
MgCl.sub.2; 1 mM EGTA; 2 mM DTT; 0.01% Brij; 5 mM
Beta-phosphoglycerol MK2 Buffer: [0379] 20 mM MOPS, pH7.2; 10 mM
MgCl.sub.2; 5 mM EGTA; 5 mM Beta-phosphoglycerol; 1 mM
Na.sub.3VO.sub.4; 0.01% Triton-X-100; 1 mM DTT Akt Buffer: [0380]
20 mM HEPES, pH7.5; 10 mM MgCl.sub.2; 0.01% Triton X-100; 1 mM DTT
CKII Buffer: [0381] 20 mM Tris, pH7.5; 10 mM MgCl.sub.2; 10 mM KCl;
0.01% Tfiton-X-100; 1 mM DTT; 0.5 mM Na.sub.3VO.sub.4 PKA Buffer:
[0382] 25 mM HEPES, pH7.4; 10 mM MgCl.sub.2; 0.01% Triton-X-100;
0.5 mM DTT; 0.1 mM Na.sub.3VO.sub.4 PKC Buffer: [0383] 20 mM MOPS,
pH7.2; 10 mM MgCl.sub.2; 5 mM EGTA; 1.2 mM DTT; 0.01% Triton-X-100;
10 mM Beta-phosphoglycerol; 1.2 mM N.sub.a3VO.sub.4; 0.1 mg/mL
phosphatidylserine; 0.01 mg/mL diacylglycerol; 0.5 mM CaCl.sub.2
Substrates: [0384] Biotin-I.kappa.B.alpha.-peptide:
Biotin-Ahx-LDDRHDSGLDSMKDC-amide [0385] Biotin-Bad-peptide:
Biotin-EELSPFRGRSRSAPPNLWAAQR-amide [0386]
Biotin-CKII-substrate-peptide: Biotin-Ahx-RRADDSDDDDD-amide [0387]
Biotin-cdc25-peptide: Biotin-Ahx-AKVSRSGLYRSPSMPENLNRPR [0388]
Biotin-MEK-peptide: biotin-AGAGSGQLIDSMANSFVGTR [0389] Biotin-MBP
protein, GST-unactive MEK1, unactive Erk2 were all purchased from
UBI Detection Reagents: [0390] Anti-P-MBP was purchased from UBI,
labeled by Cis-Bio International [0391] Anti-P-MEK, Anti-P-BAD,
Anti-P-I.kappa.B.alpha., Anti-P-Erk were all purchased from
Cell-Signaling, and labeled by Cis-Bio International [0392]
Anti-P-14-3-3 Binding Motif was purchased from Cell-Signaling,
labeled by Perkin Elmer [0393] SAXL was purchased from Prozyme
[0394] CR130-100 was purchased from Perkin Elmer [0395] Anti-GST-XL
was purchased from Cis-Bio International Cellular Assays HSP27
Cellular Assay in THP-1 Cells
[0396] THP-1 cells were serum starved (0.5% FBS) for about 24 hours
and seeded to 96 well plates at a density of 2.times.10.sup.5
cells/well in 100 ul of low serum media. Test compounds were
solubilized in DMSO and added to cells over the range of 25 uM-8 nM
(final DMSO conc 0.5%). Compounds were pre-incubated for about 30
mins. before the addition of lug/ml LPS. Cells were stimulated for
about 45 mins., washed and lysed in 100 ul of Biorad cell lysis
buffer. Level of HSP27 phosphorylation was measured via Bio-Plex
phosphoprotein assay utilizing pHSP27 Beadmates from Upstate.
LPS Induced TNF in THP-1 Cells
[0397] Thp-1 cells were serum starved (0.5% FBS) for about 24 hours
and seeded to 96 well plates at a density of 2.times.10.sup.5
cells/well in 100 ul of low serum media. Test compounds were
solubilized in DMSO and added to cells over the range of 25 uM-8 nM
(final DMSO conc 0.5%). Compounds were pre-incubated for 30 mins
before the addition of 1 ug/ml LPS. Cells were stimulated for about
3 hrs. Supernatent media was removed and TNF release was quantified
by ELISA. Cellular toxicity was determined by the addition of MTT
to the remaining cells.
L PS Induced TNF in Peripheral Blood Mononuclear Cell (PBMC) Assay
Protocol:
[0398] Prepare PBMC's from leukopak's by Ficoll separation. Adjust
the cell density to 1.times.10.sup.7 cells/ml in media.
[0399] Media used is RPMI Medium 1640 (Gibco BRL, Grand Island,
N.Y., Catalog Number 31800)+2% human AB sera (Sigma Chemical
Company, St. Louis, Mo., Catalog Number S7148, heat inactivated)
with 100 U/ml penicillin (Gibco BRL, Catalog Number 15140), 2 mM
L-glutamine (Gibco BRL, Catalog Number 25030), 1.times.MEM
Non-Essential Amino Acids (Gibco BRL, Catalog Number 11140), and 10
mM pH 7.3 Hepes. Media is filtered through a 0.2-micron filter
unit.
[0400] To the wells of 96 well plate(s) appfy: 100 uL/well
inhibitors (at 2.times. concentrations) in 1% Dimethyl Sulphoxide,
99% media+100 uL/well PBMC's (1E6 cells/well.)
[0401] Pre-incubate cells and inhibitors (test compounds) in
37.degree. C. CO.sub.2 incubator for about 30 minutes.
[0402] Apply 10 ng/ml Lipopolysaccharide Escherichia coli
(Calbiochem, La Jolla, Calif., Catalog Number 437625) and incubate
plate(s) overnight (about 16 hours) in a 37.degree. C. CO.sub.2
incubator to stimulate cytokine production.
[0403] Harvest supernates for cytokine analysis: Spin plate(s) in a
centrifuge at 180 g for about 10 minutes with no brake to pellet
cells (we used a Beckman GPKR centrifuge and spin at 1,000 rpm.)
Remove 100 uL/well supernate for cytokine analysis.
[0404] For hTNF ELISA, use R&D Systems Catalog Number DTA50
kits and dilute samples about 1/20.
[0405] After supernates are harvested, cells are used for MTT Assay
to assess compound toxicity.
PBMC MTT Assay to Assess Cellular Toxicity:
[0406] MTT is converted into a colored product when it is cleaved
by the mitochondrial reductase system, which is present in
metabolically active cells. The MTT Assay can be used as a measure
of cellular viability.
[0407] Follow the LPS induced TNF Peripheral Blood Mononuclear Cell
(PBMC) Assay Protocol and harvest supernates for cytokine analysis.
Use the remaining PBMC's in 96-well plates for the MTT Assay.
[0408] To cells (in about 1.times.10.sup.6 cells/100 uL/well) apply
50 .mu.L/well MTT (2.5 mg/mi in
D-PBS,3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl-tetrazolium
bromide, Sigma Chemical Company, Catalog Number M-2128) and
incubate for 4 hours in a 37.degree. C. CO.sub.2 incubator.
[0409] Apply 50 .mu.L/well of 20% Sodium Dodecyl Sulfate
(Natriumlauryl-sulfat, BioRad, Hercules, Calif., Catalog Number
161-0301) and incubate in a 37.degree. C. CO.sub.2 incubator
overnight. Read the absorbance at 570 nM-630 nM in an ELISA plate
reader. The percent viability of cells is then calculated. Toxicity
from putative inhibitor(s) is determined by comparison to a control
without inhibitor. This is the 100% viable control (1%
DMSO/media+cells+MTT+SDS.) OD570/630 of sample/OD570/630 of 100%
viable control X 100=% viability of sample.
LPS Induced TNF in PECs
[0410] Collect PEC's (peritoneal exudated cells) by washing the
peritoneal cavity of B6 mice injected 4 days prior with 2ml of 3%
thioglycollate IP.
[0411] Wash cells with D-PBS and plate
2.5.times.10.sup.5/0.25ml/well in 96 well plates in 10% FBS RPMI
media supplemented with Penicillin-Streptomycin and 2 mM
L-Glutamine. Grow cells overnight in 37.degree. C. CO, incubator.
Pre-incubate cells and inhibitors in 1%DMSO/media 0.5% FBS for
about 30 minutes. Apply Lipopolysaccharide Escherichia coli (1
.mu.g/ml, Calbiochem, La Jolla, Calif., Catalog Number 437625) and
stimulate cells 2 hours in 37.degree. C. CO.sub.2 incubator.
[0412] Harvest supernates for cytokine analysis: [0413] Spin
plate(s) in a centrifuge at 180 g for about 10 minutes with no
brake to pellet cells. [0414] Remove 50 .mu.L/well supernate for
cytokine analysis.
[0415] To measure mTNFcytokine levels, use R & D Systems
Catalog Number MTA00 ELISA kits. Calculate TNFIC.sub.50.
LPS Induced TNF and IL-1.beta. in Differentiated Human Peripheral
Blood Mononuclear Cells (PBMC)
[0416] PBMCs are prepared from leukopaks and stored frozen in vials
in liquid nitrogen freezer.
[0417] Thaw PBMCs and plate in 48 well plates at 2.times.10.sup.6
cells per well in 400 .mu.l media (RPMI+2% Hu ab
serum+Penicillin/Streptomycin+L-glutamine+non-essential amino
acids+Hepes+50 ng/ml Recombinant Human MCSF). Incubate 24 h at
37.degree. C. 5% CO.sub.2. Wash cells 3.times. with media (no
MCSF). In separate 48 well plate, dilute compounds in Media+2% Hu
ab serum. For compounds at 10 mM add 10 .mu.l of the compound to
990 .mu.l media then do 1:5 serial dilutions in Media+1% DMSO 200
.mu.l+800 .mu.l media.
[0418] Remove media from cells and add 250 .mu.l of compound
dilutions in duplicate wells of 48 well plates of cells. To
negative and positive control wells, add 250 .mu.l media+1% DMSO.
Incubate for about 30 minutes 37.degree. C. 5% CO.sub.2. Stimulate
cells with 10 ng/ml LPS for 3 h 30' at 37.degree. C. 5% CO.sub.2.
LPS stock 500 .mu.g/ml: dilute stock 1:5000 in media then add 25
.mu.l to each well except negative controls which get media alone.
Incubate for about 3 hours 30 minutes at 37.degree. C. 5%
CO.sub.2.
[0419] Add Nigericin (Sigma Cat. # N-7143 FW=747):
[0420] (Nigericin Final concentration=20 .mu.M: dissolve 2.7 mg in
805 .mu.l ethanol. Dilute this 1:8 in media 250 .mu.l to 1.75 ml.
Add 10 .mu.l/well of 48 well plates.) Incubate 30 minutes
37.degree. C. 5% CO.sub.2. After 30 minutes, remove supernatant to
96 well plates and assay human IL-1.beta. and human TNF.alpha.
using R & D Systems ELISA Kits.
[0421] Compounds of formula I may have therapeutic utility in the
treatment of diseases involving both identified, including those
not mentioned herein, and as yet unidentified protein tyrosine
kinases which are inhibited by compounds of formula I. All
compounds exemplified herein significantly inhibit either COT or
MK2 at concentrations of 50 micromolar or below.
In Vivo Models
In Vivo Inhibition of LPS-Induced Cytokines
[0422] Mice are injected i.v. with LPS (from Escherichia coli
Serotype 0111:B4, Sigma #L-4130), dissolved in saline. In order to
monitor TNF-.alpha. production, 0.1 mpk LPS is given and to measure
IFN-.gamma., IL-1.beta., IL-18, IL-6, and L-12, Smpk LPS is given.
The mice are then cardiac bled for serum at the appropriate time
points listed below. The animals are bled at 90 minutes for
TNF-.alpha. or at 4 hours for IFN-.gamma., IL-1.beta., IL-18, IL-6,
IL-12, then the serum cytokine levels are measured by ELISA. In
compound efficacy studies, the compound is dosed either p.o. or
i.p. one hour prior to the LPS injection and the levels of target
cytokines are measured and compared with those obtained for the
control group in order to calculate ED.sub.50 levels.
[0423] Compounds can also be tested in animal models of human
disease. These are exemplified by experimental auto-immune
encephalomyelitis (EAE) and collagen-induced arthritis (CIA). EAE
models which mimic aspects of human multiple sclerosis have been
described in both rats and mice (reviewed FASEB J. 5:2560-2566,
1991; murine model: Lab. Invest. 4(3):278, 1981; rodent model: J.
Immunol 146(4):1163-8, 1991). Briefly, mice or rats are immunized
with an emulsion of myelin basic protein (MBP), or neurogenic
peptide derivatives thereof, and CFA. Acute disease can be induced
with the addition of bacterial toxins such as bordetella pertussis.
Relapsing/remitting disease is induced by adoptive transfer of
T-cells from MBP/peptide immunized animals.
[0424] CIA may be induced in DBA/1 mice by immunization with type
II collagen (J. Immunol: 142(7):2237-2243). Mice will develop signs
of arthritis as early as ten days following antigen challenge and
may be scored for as long as ninety days after immunization. In
both the EAE and CIA models, a compound may be administered either
prophylactically or at the time of disease onset. Efficacious drugs
should reduce severity and/or incidence.
[0425] Certain compounds of this invention which inhibit one or
more angiogenic receptor PTK, and/or a protein kinase such as Ick
involved in mediating inflammatory responses can reduce the
severity and incidence of arthritis in these models.
[0426] The teachings of all references, including journal articles,
patents and published patent applications, are incorporated herein
by reference in their entirety.
[0427] The following examples are for illustrative purposes and are
not to be construed as limiting the scope of the present
invention.
Abbreviations
[0428] ACN Acetonitrile [0429] Racemic-BINAP
(.+-.)-2,2'-Bis(diphenylphosphino)-1,1'-binaphthalene [0430]
(R)-BINAP (R)-(+)-2,2'-Bis(diphenylphosphino)-1,1'-binaphthalene
[0431] (S)-BINAP
(S)-(-)-2,2'-Bis(diphenylphosphino)-1,1'-binaphthalene [0432] Boc
tert-Butoxycarbonyl [0433] t-BuOH tert-Butyl alcohol [0434] t-BuOK
Potassium tert-butoxide [0435] Cbz Benzyloxycarbonyl [0436] DCC
N,N'-Dicyclohexylcarbodiimide [0437] DCM Dichloromethane [0438] DIC
N,N'-Diisopropylcarbodiimide [0439] DIEA N,N-Diisopropylethylamine
[0440] DMA N,N-Dimethylacetamide [0441] DME 1,2-Dimethoxyethane
[0442] DMF N,N-Dimethylformamide [0443] DMFDMA
N,N-Dimethylformamide dimethyl acetal [0444] DMSO Dimethyl
sulfoxide [0445] DPPF 1,1'-Bis(diphenylphosphino)ferrocene [0446]
EDC 1-(3-Dimethylaminopropyl)-3-ethylcarbodiimide [0447] Et.sub.2O
Diethyl ether [0448] Et.sub.3N Triethylamine [0449] EtOAc Ethyl
acetate [0450] HATU
O-(7-Azabenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium
hexafluorophosaphate [0451] HBTU
O-Benzotriazol-1-yl-N,N,N',N'-tetramethyluronium
hexafluorophosaphate [0452] HOAc Acetic acid [0453] HOAT
1-Hydroxy-7-azabenzotriazole [0454] HOBT 1-Hydroxybenzotriazole
[0455] HPLC High Performance Liquid Chromatography [0456] KOAc
Potassium acetate [0457] LDA Lithium diisopropylamide [0458]
MP-carbonate Polymer bound tetraalkylammonium carbonate [0459] PMB
p-Methoxybenzyl [0460] PPh.sub.3 Triphenylphosphine [0461] PPTS
Pyridinium p-toluenesulfonate [0462] i-PrOH 2-Propanol [0463] RP
Reverse Phase [0464] R.sub.t Retention time [0465] SEM
2-(Trimethylsilyl)ethoxymethyl [0466] SEM-Cl
2-(Trimethylsilyl)ethoxymethyl chloride [0467] Si-DCT Silica bound
dichlorotriazine [0468] TBAF tetra-n-Butylammonium fluoride [0469]
TBDMS tert-Butyldimethylsilane [0470] TFA Trifluoroacetic acid
[0471] TFFH Fluoro-N,N,N',N'-tetramethylformamidinium
hexafluorophosphate [0472] THF Tetrahydrofuran [0473] TMS
Trimethylsilyl [0474] XANTPHOS
9,9-Dimethyl-4,5-bis(diphenylphosphino)xanthene Synthetic
Details
[0475] Analytical data is defined either within the general
procedures or in the tables of examples. Unless otherwise stated,
all .sup.1H or .sup.13C NMR data were collected on a Varian Mercury
Plus 400 MHz; chemical shifts are quoted in parts per million
(ppm). High performance liquid chromatography (HPLC) analytical
data are either detailed within the experimental or referenced to
the table of HPLC conditions, using the lower case method letter,
in Table 1. TABLE-US-00003 TABLE 1 List of HPLC methods Method HPLC
Conditions a LC/MS (30% to 95% acetonitrile/0.01M aqueous ammonium
acetate over 4.5 min at 0.8 mL/min; UV .lamda. = 190-400 nm;
Genesis C18, 3 .mu.m, 30 .times. 4.6 mm column; ESI +ve/-ve) b
RP-HPLC (5% to 85% acetonitrile/0.05M aqueous ammonium acetate,
buffered to pH 4.5, over 20 min at 1 mL/min; UV .lamda. = 254 nm;
Hypersil C18, 100 .ANG., 5 .mu.m, 250 .times. 4.6 mm column) c
LC/MS (5% to 100% acetonitrile/5 mM ammonium acetate over 5 min at
2.0 ml/min; UV .lamda. = 250-380 nm; Genesis C18,4 .mu.m, 33
.times. 4.6 mm column; ESI +ve/-ve) d LC/MS (5% to 100%
acetonitrile/5 mM ammonium acetate over 5 min at 2.0 ml/min; UV
.lamda. = 250-380 nm; Pecosphere C18, 3 .mu.m, 33 .times. 4.6 mm
column; ESI +ve/-ve) e LC/MS (30% to 95% acetonitrile/0.01M aqueous
ammonium acetate over 2.0 min; 95% acetonitrile/0.01M aqueous
ammonium acetate for 1.5 min at 1.0 mL/min; UV .lamda. = 210-360
nm; Genesis C8, 4 .mu.m, 30 .times. 4.6 mm column; ESI +ve/-ve) f
LC/MS (10% to 40% acetonitrile/0.01M aqueous ammonium acetate over
4.0 min; 40% to 95% acetonitrile/0.01M aqueous ammonium acetate
over 2.0 min; 95% acetonitrile/ 0.01M aqueous ammonium acetate for
1.0 min at 1.0 mL/min; UV .lamda. = 210-360 nm; Genesis C8, 4
.mu.m, 30 .times. 4.6 mm column; ESI +ve/-ve) g LC/MS (5% to 95%
acetonitrile/0.01M aqueous ammonium acetate over 2.0 min; 95%
acetonitrile/0.01M aqueous ammonium acetate for 1.5 min at 1.4
mL/min; UV .lamda. = 210-360 nm; Genesis C8, 4 .mu.m, 30 .times.
4.6 mm column; ESI +ve/-ve) h LC/MS (30% to 95% acetonitrile/0.01M
aqueous ammonium acetate over 2.0 min; 95% acetonitrile/0.01M
aqueous ammonium acetate for 3.5 min at 1.0 mL/min; UV .lamda. =
190-400 nm; Genesis C8, 4 .mu.m, 30 .times. 4.6 mm column; ESI
+ve/-ve) i LC/MS (5% to 35% acetonitrile/0.01M aqueous ammonium
acetate over 4.0 min; 35%-95% acetonitrile/0.01M aqueous ammonium
acetate over 2 min; 95% acetonitrile/ 0.01 M aqueous ammonium
acetate for 1.0 min at 1.0 mL/min; UV .lamda. = 190-400 nm; Genesis
C8, 4 .mu.m, 30 .times. 4.6 mm column; ESI +ve/-ve) J RP-HPLC (5%
to 100% acetonitrile/0.05M aqueous ammonium acetate, buffered to pH
4.5, over 10 min at 1 mL/min; UV .lamda. = 254 nm; Hypersil C18,
100 .ANG., 5 .mu.m, 250 .times. 4.6 mm column) k LC/MS (5% to 95%
acetonitrile/5 mM aqueous ammonium acetate over 3.0 min; 95% to
100% acetonitrile/5 mM aqueous ammonium acetate over 0.7 min; 100%
to 5% acetonitrile/5 mM aqueous ammonium acetate over 0.1 min; 5%
acetonitrile/5 mM aqueous ammonium acetate for 0.2 min at 2.0
ml/min; .lamda. = 250-380 nm; Pecosphere C18, 3 .mu.m, 33 .times.
4.6 mm column; ESI +ve/-ve) l LC/MS (5% acetonitrile/0.01M aqueous
ammonium acetate for 0.25 min; 5-95% acetonitrile/0.01M aqueous
ammonium acetate over 2.5 min; 95% acetonitrile/0.01M aqueous
ammonium acetate for 0.85 min; 95-5% acetonitrile/ 0.01M aqueous
ammonium acetate over 0.15 min; 5% acetonitrile/0.01M aqueous
ammonium acetate for 0.25 min at 1.0 mL/min; UV .lamda. = 210-360
nm; Genesis C8, 4 .mu.m, 30 .times. 4.6 mm column ESI +ve/-ve) m
LC/MS (10% to 100% acetonitrile/0.1% aqueous trifluoro- acetic acid
over 3 min; hold at 100% acetonitrile for 1 min at 1.5 mL/min;
ELSD; UV .lamda. = 254 nm; Phenomenex Luna C8(2), 5 .mu.m, 100
.ANG., 30 .times. 2.0 mm column; APCI +ve) .sup.1MS data from flow
injection ESI + experiment not the LC-MS method (ion not detected
in LC-MS run)
GENERAL PROCEDURES AND EXAMPLES
[0476] The general synthetic schemes that were utilized to
construct the majority of compounds disclosed in this application
are described below in (Schemes 1-25). ##STR26## ##STR27##
##STR28## ##STR29## ##STR30## ##STR31## ##STR32## ##STR33##
##STR34## ##STR35## ##STR36## ##STR37## ##STR38## ##STR39##
##STR40## ##STR41## ##STR42## ##STR43## ##STR44## ##STR45##
##STR46## ##STR47## ##STR48## ##STR49## ##STR50## List of General
Procedures [0477] General Procedure A: Formation of a urea from an
amine [0478] General Procedure B: Formation of an amide from a
carboxylic acid and amine [0479] General Procedure C: Formation of
an amide from a carboxylic acid and amine using Si-DCT [0480]
General Procedure D: Protection of an indazole with a
trimethyl-silanylethoxymethyl group [0481] General Procedure E:
Conversion of a bromide to a boronic acid or boronate [0482]
General Procedure F: Suzuki coupling of a boronate or boronic acid
with an aryl halide substrate [0483] General Procedure G:
Deprotection of a trimethylsilanylethoxymethyl (SEM) protected
indazole [0484] General Procedure H: Acid cleavage of a
TBDMS-protecting group [0485] General Procedure I: Deprotection of
a benzyl ether [0486] General Procedure J: Reduction of an aldehyde
to an alcohol [0487] General Procedure K: Nucleophilic substitution
of an aryl sulfone [0488] General Procedure L: Reduction of a
nitroaromatic compound to an aniline [0489] General Procedure M:
Amide formation from an ester [0490] General Procedure N:
Nucleophilic substitution of an aromatic halide with amine [0491]
General Procedure O: Reductive Alkylation of an Amine with an
Aldehyde or a Ketone [0492] General Procedure P: Deprotection of a
methyl-protected alcohol using boron tribromide [0493] General
Procedure Q: Acid catalyzed cleavage of esters, amidines, and
carbamates [0494] General Procedure R: Base-promoted amine
alkylation [0495] General Procedure S: Formation of a sulfonamide
from an amine [0496] General Procedure T: Mitsunobu coupling [0497]
General Procedure U: Sonogashira coupling of an aryl halide with an
acetylene [0498] General Procedure V: Hydrolysis of ester to a
carboxylic acid [0499] General Procedure W: Amide formation from an
acid chloride and an amine [0500] General Procedure X: Indazole
formation using hydrazine [0501] General Procedure Y: Pd mediated
coupling of an aryl halide with an amine followed by acid
deprotection [0502] General Procedure Z: Acid cleavage of a
THP-protecting group [0503] General Procedure AA: Deprotection of a
Cbz-protected amino group
[0504] The general procedure letter codes constitute a synthetic
route to the final product. A worked example of how the route is
determined is given below using the synthesis of Example #G.19 as a
non-limiting illustration. Example #G.19 was prepared from
2-(3-{2-(dimethylamino-methyleneamino)-7-[7-benzo[b]thiophen-2-yl-1-(2-tr-
imethylsilanyl-ethoxymethyl)-1H-indazol-5-5-yl]-pyrrolo[3,2-d]pyrimidin-5--
yl}-propan-1-oxy)tetrahydropyran using general procedure G, as
represented in the following synthetic scheme: ##STR51##
[0505] The precursor to Example #G.19,
2-(3-{2-(dimethylamino-methyleneamino)-7-[7-benzo[b]thiophen-2-yl-1-(2-tr-
imethylsilanyl-ethoxymethyl)-1H-indazol-5-yl]-pyrrolo[3,2-d]pyrimidin-5-yl-
}-propan-1-oxy)tetrahydropyran was prepared via the noted reaction
sequence: Preparation #23, E, F (using Preparation #4), R (using
2-(3-bromo-propan-1-oxy)tetrahydropyran, which translates into the
following synthetic scheme: ##STR52##
[0506] The general synthetic methods used in each General Procedure
follow, and include an illustration of a compound that was
synthesized using the designated General Procedure. None of the
specific conditions and reagents noted in the following are to be
construed as limiting the scope of the instant invention and are
provided for illustrative purposes only. General Procedure A:
Formation of a Urea from an Amine ##STR53##
[0507] To a mixture of thiocarbamic acid methyl ester in an organic
solvent (for example, methylene chloride or ethanol, preferably
ethanol) is added an amine (2 to 4 equivalents, preferably 3
equivalents). The reaction mixture is stirred at about
40-70.degree. C. (preferably about 50.degree. C.) for about 3-24
hours (preferably, about 5-10 hours). The solvent is removed under
reduced pressure to afford the crude product. The crude product can
be further purified by crystallization or chromatography.
Illustration of General Procedure A
Example #11
1-(7-Benzo[b]thiophen-2-yl-1H-indazol-5-yl)-3-(2-pyridin-2-yl-ethyl)-urea
[0508] ##STR54##
[0509] A mixture of
7-benzo[b]thiophen-2-yl-1H-indazole-5-yl-thiocarbamic acid methyl
ester (Preparation #14, 25.0 mg, 0.074 mmol) and
2-pyridin-2-yl-ethylamine (23 mg, 0.185 mmol) in 20 ethanol (2 mL)
was stirred at about 50.degree. C. for about 8 hours. The solvent
was removed under reduced pressure and the product was purified by
crystallization in ethanol to give
1-(7-benzo[b]thiophen-2-yl-1H-indazol-5-yl)-3-(2-pyridin-2-yl-ethyl)-urea
(12 mg, 39% yield); RP HPLC (Table 1, Method e) R.sub.t=1.82 min;
MS m/z: (M-H).sup.- 412. TABLE-US-00004 TABLE A Examples
synthesized using general procedure A from Preparation #14
##STR55## Amine Product Example # HPLC R.sub.t(min)(Method) m/z
4-Nitroaniline ##STR56## A.1 2.21(a) 558 (M - H).sup.-
2-Piperidin-1-yl- ethylamine ##STR57## A.2 1.96(a) 4.20 (M +
H).sup.+ 2-(1H-Imidazol-4- yl)-ethylamine ##STR58## A.3 1.63(a) 403
(M + H).sup.+ 2-Methoxy- ethylamine ##STR59## A.4 1.75(a) 367 (M +
H).sup.+ N,N-Dimethyl- ethane-1,2-diamine ##STR60## A.5 1.75(a) 380
(M + H).sup.+ Tetrahydro-pyran- 4-ylamine ##STR61## A.6 1.70(a) 391
(M - H).sup.- 2-Pyridin-3-yl- ethylamine ##STR62## A.7 1.60(a) 414
(M + H).sup.+ 3-Amino-propan-1- ol ##STR63## A.8 1.50(a) 367 (M +
H).sup.+ 2-Amino-propane- 1,3-diol ##STR64## A.9 1.32(a) 383 (M +
H).sup.+ Pyridin-2-yl- methylamine ##STR65## A.10 1.75(a) 400 (M +
H).sup.+ Pyridin-3-yl- methylamine ##STR66## A.11 1.71(a) 400 (M +
H).sup.+ 3-Amino-propionic acid ##STR67## A.12 0.65(a) 381 (M +
H).sup.+ 2-Amino-ethanol ##STR68## A.13 1.42(a) 383 (M + H).sup.+
1-Methoxy-but-2- ylamine ##STR69## A.14 1.93(a) 393 (M - H).sup.-
(5-Methyl-pyrazin- 2-yl)-methylamine ##STR70## A.15 1.71(a) 415 (M
+ H).sup.+ 2-(1-Methyl-1H- pyrrol-2-yl)- ethylamine ##STR71## A.16
2.05(a) 416 (M + H).sup.+ 2-Pyridin-4-yl- ethylamine ##STR72## 1.17
1.62(a) 412 (M - H).sup.- (1,3,5-Trimethyl- 1H-pyrazol-4-yl)-
methylamine ##STR73## A.18 1.61(a) 429 (M - H).sup.- 3-Amino-
propionamide ##STR74## A.19 1.36(a) 380 (M + H).sup.+
(6-Chloro-pyridin- 3-yl)-methylamine ##STR75## A.20 1.92(a) 434 (M
+ H).sup.+ 1-Pyridin-3-yl- ethylamine ##STR76## A.21 1.70(a) 412 (M
- H).sup.- 1-Methyl-piperidin- 4-ylamine ##STR77## A.22 1.78(a) 404
(M - H).sup.- 2-Piperazin-1-yl- ethanol ##STR78## A.23 1.42(a) 422
(M + H).sup.+ Bis-(2-methoxy- ethyl)-amine ##STR79## A.24 2.09(a)
425 (M + H).sup.+ 1-Methyl piperazine ##STR80## A.25 1.62(a) 392 (M
+ H).sup.+ [2-(Thiophen-2-yl)- thiazol-4-yl]- methylamine ##STR81##
A.26 2.09(a) 488 (M + H).sup.+ Benzothiazol-2-yl- methylamine
##STR82## A.27 2.00(a) 456 (M + H).sup.+ Oxazol-2-yl- methylamine
##STR83## A.28 1.65(a) 388 (M - H).sup.- Imidazo[1,2-
.alpha.]pyridin-2-yl- methylamine ##STR84## A.29 1.69(a) 437 (M -
H).sup.- Benzo[2,1,3]thiadia- zol-5-yl- methylamine ##STR85## A.30
1.98(a) 455 (M - H).sup.- 5-Aminomethyl- 2H-[1,2,4]triazol-3-
ylamine ##STR86## A.31 1.19(a) 403 (M - H).sup.- 5-(2-Amino-ethyl)-
2H-[1,2,4]triazol-3- ylamine ##STR87## A.32 1.22(a) 419 (M +
H).sup.+ Morpholine ##STR88## A.33 1.79(a) 379 (M + H).sup.+
2-Methylamino- ethanol ##STR89## A.34 1.50(a) 367 (M + H).sup.+
N,N,N'-Trimethyl- ethane-1,2-diamine ##STR90## A.35 1.32(a) 394 (M
+ H).sup.+ N,N,N'-Trimethyl- propane-1,3- diamine ##STR91## A.36
1.37(a) 408 (M + H).sup.+ 3-Methylamino- propane-1,2-diol ##STR92##
A.37 1.38(a) 397 (M + H).sup.+ Piperidin-4-yl- methanol ##STR93##
A.38 1.57(a) 407 (M + H).sup.+ Piperazine ##STR94## A.39 1.14(a)
378 (M + H).sup.+ (2-Methoxy-ethyl)- methyl-amine ##STR95## A.40
1.92(a) 381 (M + H).sup.+ Piperidin-4-ol ##STR96## A.41 1.51(a) 393
(M + H).sup.+ (S)-1-Pyrrolidin-2- yl-methanol ##STR97## A.42
1.71(a) 393 (M + H).sup.+ (R)-1-Pyrrolidin-2- yl-methanol ##STR98##
A.43 1.71(a) 393 (M + H).sup.+ Bis-(2- ethanol)amine ##STR99## A.44
1.46(a) 397 (M + H).sup.+ Ammonia ##STR100## A.45 1.42(a) 309 (M +
H).sup.+ Methylamine ##STR101## A.46 1.67(a) 323 (M + H).sup.+
Dimethylamine ##STR102## A.47 1.78(a) 335 (M - H).sup.- Pyrid-4-yl
methylamine ##STR103## A.48 1.67(a) 400.0(M + H).sup.+398.0(M -
H).sup.- 4-(2-Aminoethyl) morpholine ##STR104## A.49 1.57(a)
422.0(M + H).sup.+419.5(M - H).sup.-
General Procedure B: Formation of an Amide from Carboxylic Acid and
Amine ##STR105##
[0510] To a mixture of a carboxylic acid (1-2.5 equivalents,
preferably 1-1.5 equivalents) and an amine (1-2.5 equivalents,
preferably 1-1.5 equivalents) in an organic solvent (for example,
THF, EtOAc, Et.sub.2O, or DMF, preferably DMF) is added the
coupling reagent (for example, DCC, DIC, EDC, HBTU, HATU or TFFH,
preferably HBTU) (1-5 equivalents, preferably 1.2 equivalents),
with or without a coupling additive (for example, HOBT or HOAT,
preferably HOBT) (0.1-5 equivalents, preferably 0.2 equivalents)
and,optionally, DIEA (0.1-25 equivalents, preferably 3
equivalents). The reaction mixture is stirred at about
20-70.degree. C. (preferably about 50.degree. C) for about 5-40
hours (preferably about 35 hours) and then cooled to ambient
temperature. The reaction mixture can be purified in three
different ways: 1). The reaction mixture is treated with
MP-carbonate (3-10 equivalents, preferably 5 equivalents) with or
without methanol. After about 4-48 hours (preferably about 14
hours), the reaction solution is separated from the resin by
filtration and concentrated under reduced pressure to afford the
crude product that can be further purified by crystallization or
chromatography. If the product precipitates prior to filtration of
the resin, the suspension containing the product is separated from
the resin via pipette and filtered to afford the crude product that
can be further purified by crystallization or chromatography. 2).
The reaction mixture is partitioned between water and an organic
solvent (for example, CH.sub.2Cl.sub.2, EtOAc or Et.sub.2O,
preferably CH.sub.2Cl.sub.2). The organic layer is separated and
the aqueous layer is further extracted with organic solvent. The
combined organic extracts are dried over a desiccant and evaporated
under reduced pressure to afford the product that can be further
purified by crystallization or chromatography. 3). The reaction
mixture is directly concentrated under reduced pressure and the
residue is purified by crystallization or chromatography.
Illustration of General Procedure B
Example #12
N-Benzyl
5-(5-Amino-1H-pyrrolo[2,3-c]pyridin-3-yl)-1H-indazole-7-carboxami-
de acetate
[0511] ##STR106##
[0512] A solution of
5-(5-amino-1H-pyrrolo[2,3-c]pyridin-3-yl)-1H-indazole-7-carboxylic
acid hydrochloride (Preparation #13, 32.9 mg, 0.10 mmol) and
benzylamine (24.0 .mu.L, 0.22 mmol) in DMF (1.0 mL) were treated
with o-(7-azabenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium
hexafluorophosphate (38.0 mg, 0.10 mmol) at ambient temperature and
the reaction was stirred for about 1 hour. The reaction was
concentrated under reduced pressure and the residue was purified by
preparative HPLC (Waters Symmetry C8 column (25.times.100 mm, 7
.mu.m particle size) using a gradient of 10%-100% CH.sub.3CN/0.1%
aqueous TFA over 8 min (10 min run time) at a flow rate of 40
mL/min). Product fractions were combined and concentrated to remove
organic solvents and then lyophilized to yield N-benzyl
5-(5-amino-1H-pyrrolo[2,3-c]pyridin-3-yl)-1H-indazole-7-carboxam-
ide acetate (10 mg, 23%) as an off-white powder; RP-HPLC (Table 1,
Method e) R.sub.t 1.94 min; m/z: (M-H).sup.-381. TABLE-US-00005
TABLE B.1 Examples were prepared using general procedure B
##STR107## Acid Amine Product Ex # HPLC R.sub.t(min)(Method) m/z
Preparation #13 Aniline ##STR108## B.1.1 1.97(e) 367 (M - H).sup.-
Preparation #11c, V Aniline ##STR109## B.1.2 1.63(e) 314 and 316 (M
+ H.sup.+)
[0513] TABLE-US-00006 TABLE B.2 Examples prepared using general
procedure B from Example #F.8.1 ##STR110## HPLC Acid Product
Example # Rt(min)(Method) m/z 1H-Benzimidazole- 5-carboxylic acid
##STR111## B.2.1 1.69(e) 409.9 (M + H).sup.+ Imidazo[2,1-
b]thiazole-6- carboxylic acid ##STR112## B.2.2 2.02(e) 415.9 (M +
H).sup.+ 1H-Pyrazole-4- carboxylic acid ##STR113## B.2.3 1.60(e)
359.9 (M + H).sup.+ 1H-Indazole-3- carboxylic acid ##STR114## B.2.4
2.14(e) 409.9 (M + H).sup.+ [(2R)-3,6- Dioxopiperazin-2- yl]acetic
acid ##STR115## B.2.5 1.26(e) 419.9 (M + H).sup.+ 3-Methyl-5-(4-
methyl-1,2,3- thiadiazol-5- yl)isoxazole-4- carboxylic acid
##STR116## B.2.6 2.21(e) 470.5 (M - H).sup.- N-(Aminocarbonyl)
glycine ##STR117## B.2.7 1.33(e) 365.9 (M + H).sup.+ 3-Amino-1-
carboxymethyl- pyridin-2-one trifluoroacetate ##STR118## B.2.8
1.61(e) 415.9 (M + H).sup.+ 3-Aminopyrazine- 2-carboxylic acid
##STR119## B.2.9 2.24(e) 384.5 (M - H).sup.- 6-Aminonicotinic acid
##STR120## B.2.10 1.70(e) 385.9 (M + H).sup.+ 2-Hydroxy cinchoninic
acid ##STR121## B.2.11 1.84(e) 437.1 (M + H).sup.+ 1H-Benzimidazol-
2-ylacetic acid ##STR122## B.2.12 1.87(e) 388.0 (M + H).sup.+
2-(Acetylamino)- 1,3-thiazole-4- carboxylic acid ##STR123## B.2.13
1.84(e) 433.8 (M + H).sup.+ 2-Aminonicotinic acid ##STR124## B.2.14
1.99(e) 385.9 (M + H).sup.+ 3- Aminoisonicotinic acid ##STR125##
B.2.15 1.85(e) 386.0 (M + H).sup.+ 4-(Methylamino)-6-
morpholin-4-yl- 1,3,5-triazine-2- carboxylic acid ##STR126## B.2.16
2.00(e) 486.9 (M + H).sup.+ 3-[(4R)-2,5- Dioxoimidazolidin-
4-yl]propanoic acid ##STR127## B.2.17 1.45(e) 417.9 (M - H).sup.-
2,6- Dihydroxypyrimi- dine-4-carboxylic acid-lithium monohydrate
##STR128## B.2.18 1.34(e) 401.6 (M - H).sup.- 3-(1H-Imidazol-2-
yl)propanoic acid ##STR129## B.2.19 1.34(e) 388.0 (M + H).sup.+
3-(5,6,7,8- Tetrahydro-1,8- naphthyridin-2- yl)propanoic acid
##STR130## B.2.20 1.73(e) 454.0 (M + H).sup.+ 4- Aminopyrimidine-
5-carboxylic acid ##STR131## B.2.21 1.76(e) 387.3 (M + H).sup.+
5-Methyl-4-oxo- 3,4-dihydro- thieno[2,3- d]pyrimidine-6- carboxylic
acid ##STR132## B.2.22 1.78(e) 458.3 (M + H).sup.+ 7-Amino-2-
methylpyrazolo[1,5-a]py- rimidine-6- carboxylic acid ##STR133##
B.2.23 2.00(e) 440.3 (M + H).sup.+ 2,1,3- Benzoxadiazole-5-
carboxylic acid ##STR134## B.2.24 2.27(e) 406.3 (M + H).sup.+
1H-Imidazole-2- carboxylic acid ##STR135## B.2.25 1.82(e) 360.2 (M
+ H).sup.+ 1H-Benzimidazole- 2-carboxylic acid ##STR136## B.2.26
2.19(e) 410.2 (M + H).sup.+ 2,7- Dimethylpyrazolo[1,5-.alpha.]py-
rimidine-6- carboxylic acid ##STR137## B.2.27 1.95(e) 439.4 (M +
H).sup.+ 5-Oxo-2,3-dihydro- 5H-[1,3]thia- zolo[3,2-.alpha.]py-
rimidine-6- carboxylic acid ##STR138## B.2.28 1.97(e) 446.2 (M +
H).sup.+ 3-Hydroxy quinoxaline-2- carboxylic acid ##STR139## B.2.29
1.85(e) 438.3 (M + H).sup.+ 5-Aminonicotinic acid ##STR140## B.2.30
1.60(g) 386.2 (M + H).sup.+ 6-Oxo-1,4,5,6- tetrahydro-
pyridazine-3- carboxylic acid ##STR141## B.2.31 1.63(g) 390.2 (M +
H).sup.+ 2- (Acetylamino)isoni- cotinic acid ##STR142## B.2.32
1.68(g) 428.3 (M + H).sup.+ (3R)-5- Oxopyrrolidine-3-car- boxylic
acid ##STR143## B.2.33 1.49(g) 377.2 (M + H).sup.+ (4R)-2,6-
Dioxohexahydropy- rimidine-4- carboxylic acid ##STR144## B.2.34
1.48(g) 406.3 (M + H).sup.+ 1H-Imidazole-4- carboxylic acid
##STR145## B.2.35 1.58(g) 360.2 (M + H).sup.+ 1H-1,2,3-
Benzotriazole-5- carboxylic acid ##STR146## B.2.36 1.66(g) 411.2 (M
+ H).sup.+ 1H-Pyrazole-3- carboxylic acid ##STR147## B.2.37 1.68(g)
360.2 (M + H).sup.+ 1-Methyl-1H- benzimidazole-2- carboxylic acid
##STR148## B.2.38 2.24(g) 424.3 (M + H).sup.+ Sodium
benzothiazole-2- carboxylate ##STR149## B.2.39 2.35(g) 427.2 (M +
H).sup.+
[0514] TABLE-US-00007 TABLE B.3 Examples prepared using general
procedure C from Preparation #7. ##STR150## Amine Precursor Product
Example # R.sub.t/min(Method) m/z(ESI+) N-(2-amino-phenyl)-
acetamide ##STR151## B.3.1 1.44(e) 426.9 (M + H).sup.+
3-methoxymethyl- pyrrolidine ##STR152## B.3.2 1.52(e) 391.9 (M +
H).sup.+ 5-amino-piperidin-2- one ##STR153## B.3.3 1.43(e) 391 (M +
H).sup.+ Piperidin-4-ylmethyl- pyrimidin-2-yl- amine ##STR154##
B.3.4 1.83(e) 469.0 (M + H).sup.+ 3-Imidazol-1-yl- propylamine
##STR155## B.3.5 1.71(e) 401 (M + H).sup.+ Piperidin-4-yl- methanol
##STR156## B.3.6 1.13(e) 391.9 (M + H).sup.+ 1-Methyl-1H-
benzoimidazol-4- ylamine ##STR157## B.3.7 2.13(e) 423.9 (M +
H).sup.+ 2-Pyrrolidin-3-yl- pyridine ##STR158## B.3.8 1.88(e) 424.9
(M + H).sup.+ 5-Methylsulfanyl-1H- [1,2,4]triazol- 3-ylamine
##STR159## B.3.9 1.72(e) 404.6 (M + H).sup.+ 5-Benzooxazol-2-yl-2-
methoxy-phenyl amine ##STR160## B.3.10 2.13(e) 517.0 (M + H).sup.+
N-(6-Amino- benzothiazol-2-yl)- acetamide ##STR161## B.3.11 1.45(e)
483.9 (M + H).sup.+ 1H-Indazol-6-ylamine ##STR162## B.3.12 1.47(e)
408.0 (M - H).sup.- 1H-Indazol-5-ylamine ##STR163## B.3.13 1.37(e)
407.6 (M - H).sup.- 1H-Benzoimidazol-5- ylamine ##STR164## B.3.14
1.23(e) 409.9 (M + H).sup.+ Quinazolin-4-ylamine ##STR165## B.3.15
2.35(e) 420.2 (M - H).sup.- 4-(4-Fluoro-phenyl)-5-
methyl-2H-pyrazol-3- ylamine ##STR166## B.3.16 2.48(e) 466.3 (M -
H).sup.- 5-Methyl-1H- [1,2,4]triazol-3- ylamine ##STR167## B.3.17
2.02(e) 375.1 (M + H).sup.+ 4-Cyclohexyl- phenylamine ##STR168##
B.3.18 2.71(e) 450.4 (M - H).sup.- 2-Amino-4-hydroxy- benzamide
##STR169## B.3.19 1.85(e) 427.2 (M - H).sup.- C-Oxazol-2-yl-
methylamine ##STR170## B.3.20 1.62(e) 373.2 (M - H).sup.-
[1,3,4]Thiadiazol-2- ylamine ##STR171## B.3.21 1.79(e) 376.1 (M -
H).sup.- 4-Methyl-thiazol-2- ylamine ##STR172## B.3.22 2.11(e)
391.1 (M + H).sup.+ 5-Furan-2-yl-1H- pyrazol-3-ylamine ##STR173##
B.3.23 2.21(e) 424.2 (M - H).sup.- 2-(1H-Indol-2-yl)- phenylamine
##STR174## B.3.24 2.35(e) 483.2 (M - H).sup.- Biphenyl-2-ylamine
##STR175## B.3.25 2.35(e) 444.3 (M - H).sup.- 4-(1H-Imidazo[1,2-
a]pyridin-2-yl)- phenylamine ##STR176## B.3.26 1.97(e) 486.3 (M +
H).sup.+ 5-Amino-1,3-dihydro- benzoimidazol-2-one ##STR177## B.3.27
1.49(e) 424.2 (M - H).sup.- 2-Methyl- benzothiazol-5- ylamine
##STR178## B.3.28 2.09(e) 439.3 (M - H).sup.- 5-Aminomethyl-2H-
[1,2,4]triazol-3- yllamine ##STR179## B.3.29 1.20(e) 388.2 (M -
H).sup.- 2-Amino-fluoren-9- one ##STR180## B.3.30 2.36(e) 470.3 (M
- H).sup.- N-(3-Amino-phenyl)- benzamide ##STR181## B.3.31 2.10(e)
487.3 (M - H).sup.- C-(5-Methyl-3-phenyl- isoxazol-4-yl)-
methylamine ##STR182## B.3.32 2.08(e) 2.08 (M - H).sup.-
Indan-5-ylamine ##STR183## B.3.33 2.37(e) 408.3 (M - H).sup.-
2-(4-Phenoxy-phenyl)- ethylamine ##STR184## B.3.34 2.38(e) 488.3 (M
- H).sup.- 4-Amino-4-methyl- pentan-2-one ##STR185## B.3.35 1.94(e)
390.2 (M - H).sup.- 5-(2-Amino-ethyl)-2H- [1,2,4]triazol- 3-ylamine
##STR186## B.3.36 1.21(e) 403.2 (M - H).sup.- Benzo[b]thiophen-5-
ylamine ##STR187## B.3.37 2.26(e) 424.3 (M - H).sup.-
3-Amino-4-methoxy- benzamide ##STR188## B.3.38 1.69(e) 443.3 (M +
H).sup.+ 2-Methoxy- phenylamine ##STR189## B.3.39 2.34(e) 400.2 (M
+ H).sup.+ 4-Methoxy-biphenyl- 3-ylamine ##STR190## B.3.40 2.69(e)
476.3 (M + H).sup.+ N-(3-Amino-4- methoxy-phenyl)- acetamide
##STR191## B.3.41 1.86(e) 457.3 (M + H).sup.+ 2,5-Dimethoxy-
phenylamine ##STR192## B.3.42 2.39(e) 430.3 (M + H).sup.+
3-Methoxy- phenylamine ##STR193## B.3.43 2.24(e) 400.3 (M +
H).sup.+ 4-Methoxy- phenylamine ##STR194## B.3.44 2.17(e) 400.3 (M
+ H).sup.+ 3-(1H-Benzoimidazol- 2-yl)-phenylamine ##STR195## B.3.45
2.11(e) 486.3 (M + H).sup.+ 3-Amino-benzamidine ##STR196## B.3.46
1.95(e) 412.3 (M + H).sup.+ 3-Amino-benzoic acid methyl ester
##STR197## B.3.47 2.29(e) 458.3 (M + H).sup.+ 3-(1H-Tetrazol-5-yl)-
phenylamine ##STR198## B.3.48 1.56(e) 438.3 (M + H).sup.+
2-Amino-phenol ##STR199## B.3.49 2.16(e) 386.2 (M + H).sup.+
3-Amino-4-hydroxy- benzoic acid methyl ester ##STR200## B.3.50
2.13(e) 444.2 (M + H).sup.+ 3-Benzooxazol-2-yl- phenylamine
##STR201## B.3.51 2.54(e) 484.7 (M - H).sup.- Phenylamine
##STR202## B.3.52 2.27(e) 370.2 (M + H).sup.+ 5-Amino-2-phenyl-
2,4-dihydro-pyrazol-3- one ##STR203## B.3.53 1.77(e) 450.5 (M -
H).sup.- 4-Amino-N-[5-methyl- 3H-[1,3,4]oxadiazol- (2E)-ylidene]-
benzenesulfonamide ##STR204## B.3.54 1.51(e) 529.0 (M - H).sup.-
5-Trifluoromethyl- [1,3,4]thiadiazol- 2-ylamine ##STR205## B.3.55
2.42(e) 443.8 (M - H).sup.- N-(3-Amino-phenyl)- acetamide
##STR206## B.3.56 1.86(e) 427.3 (M + H).sup.+ 6-Morpholin-4-yl-
pyridin-3-ylamine ##STR207## B.3.57 1.92(e) 456.3 (M + H).sup.+
2-Amino-5,6-dihydro- 4H-benzothiazol-7-one ##STR208## B.3.58
2.12(e) 445.3 (M + H).sup.+ N-(4-Amino-2,5- dimethoxy-phenyl)-ben-
zamide ##STR209## B.3.59 2.46(e) 547.0 (M + H).sup.+
4-Morpholin-4-yl- phenylamine ##STR210## B.3.60 2.06(e) 455.4 (M +
H).sup.+ 4-(6-Methyl- benzothiazol-2-yl)- phenylamine ##STR211##
B.3.61 2.77(e) 515.5 (M - H).sup.- 4-Benzooxazol-2-yl- phenylamine
##STR212## B.3.62 2.56(e) 487.2 (M + H).sup.+ 4-(1H-Benzoimidazol-
2-yl)-phenylamine ##STR213## B.3.63 2.0(e) 483.8 (M - H)-
5-(1H-Benzoimidazol- 2-yl)-2-methoxy- phenylamine (Labotest)
##STR214## B.3.64 2.1(e) 516.2 (M + H)+ Glycinamide ##STR215##
B.3.65 1.37(e) 351.2 (M + H).sup.+ 4-Amino-N-(3,4-
dimethyl-isoxazol-5- yl)- benzenesulfonamide ##STR216## B.3.66
2.04(e) 542.3 (M - H).sup.- 4-Amino-N-thiazol-2-
yl-benzenesulfonamide ##STR217## B.3.67 1.85(e) 530.4 (M - H).sup.-
6-(4-Methyl-piperazine- 1-yl)-pyridin-3- ylamine ##STR218## B.3.68
1.35(e) 467.5 (M - H).sup.- 4-Amino-N-(5-methyl- isoxazol-3-yl)-
benzenesulfonamide ##STR219## B.3.69 2.08(e) 527.9 (M + H).sup.+
5-Amino-pyridine-2- sulfonic acid isopropylamide ##STR220## B.3.70
2.62(e) 489.1 (M + H).sup.+ 6-(Propane-1- sulfonyl)-1H-
benzoimidazol-2- ylamine ##STR221## B.3.71 2.07(e) 514.6 (M -
H).sup.- 4-Amino-N-(4,6- dimethyl-pyrimidin-2- yl)-
benzenesulfonamide ##STR222## B.3.72 1.94(e) 553.5 (M - H).sup.-
4-Amino-N-(2,6- dimethyl-pyrimidin-4- yl)- benzenesulfonamide
##STR223## B.3.73 1.59(e) 553.5 (M - H).sup.- N-(4-Amino-2-
methoxy-phenyl)-2- methoxy-benzamide ##STR224## B.3.74 2.38(e)
547.2 (M - H).sup.- 5-tert-Butyl- [1,3,4]thiadiazol-2-yl amine
##STR225## B.3.75 2.34(e) 432.2 (M - H).sup.- 3-Amino-benzamide
##STR226## B.3.76 1.75(e) 411.2 (M - H).sup.- 2-(1H-Imidazol-4-yl)-
ethylamine ##STR227## B.3.77 1.54(e) 388.0 (M + H).sup.+
Pyridin-2-yl- methylamine ##STR228## B.3.78 1.80(e) 384.0 (M +
H).sup.+ Dimethyl-(R)- pyrrolidin-3-yl-amine ##STR229## B.3.79
1.89(e) 389.0 (M - H).sup.- Piperidine-3- carboxamide ##STR230##
B.3.80 1.44(e) 404.9 (M + H).sup.+
[0515] TABLE-US-00008 TABLE B.4 Examples prepared using general
procedure C from Example #N.2.8 ##STR231## Amine Precursor Product
Example # R.sub.t/min(Method) m/z(ESI+) Phenylamine ##STR232##
B.4.1 192(e) 346 (M + H).sup.+ Amino-acetic acid methyl ester
##STR233## B.4.2 2.63(e) 341 (M + H).sup.+ Benzylamine ##STR234##
B.4.3 1.48(e) 360 (M + H).sup.+ Tetrahydro-pyran- 4-ylamine
##STR235## B.4.4 0.72(e) 354 (M + H).sup.+ N,N,N'-Trimethyl-
propane-1,3- diamine ##STR236## B.4.5 0.63(e) 369.7 (M + H).sup.+
2-Amino-ethanol ##STR237## B.4.6 0.53(e) 314 (M + H).sup.+
4-Fluoro- benzylamine ##STR238## B.4.7 1.57(e) 378 (M + H).sup.+
N,N-Dimethyl- benzene-1,4- diamine ##STR239## B.4.8 1.58(e) 389 (M
+ H).sup.+ 4-Methoxy- benzylamine ##STR240## B.4.9 1.52(e) 390 (M +
H).sup.+ C- Benzo[b]thiophen- 3-yl-methylamine ##STR241## B.4.10
1.78(e) 416 (M + H).sup.+ 4-Fluoro- phenylamine ##STR242## B.4.11
1.65(e) 364 (M + H).sup.+ 3-Amino-propan-1- ol ##STR243## B.4.12
0.57(e) 328 (M + H).sup.+ 4-Amino-phenol ##STR244## B.4.13 0.95(e)
362 (M + H).sup.+ 4-Chloro- phenylamine ##STR245## B.4.14 1.82(e)
380 (M + H).sup.+ p-Tolylamine ##STR246## B.4.15 1.72(e) 360 (M +
H).sup.+ (4-Amino-phenyl)- methanol ##STR247## B.4.16 0.80(e) 375
(M + H).sup.+ 1H-Benzoimidazol- 5-ylamine ##STR248## B.4.17 0.72(e)
385.7 (M + H).sup.+ Biphenyl-4-ylamine ##STR249## B.4.18 2.03(e)
422 (M + H).sup.+ Naphthalen-2- ylamine ##STR250## B.4.19 1.87(e)
396 (M + H).sup.+ 4-Methoxy- naphthalen-2- ylamine ##STR251##
B.4.20 1.98(e) 426 (M + H).sup.+ m-Tolylamine ##STR252## B.4.21
1.70(e) 360.4 (M + H).sup.+ 1H-Benzotriazol-5- ylamine ##STR253##
B.4.22 0.75(e) 387 (M + H).sup.+ 1H-Indol-6-ylamine ##STR254##
B.4.23 1.42(e) 385 (M + H).sup.+ 3-Amino-phenol ##STR255## B.4.24
1.23(e) 362 (M + H).sup.+ 5-Amino-1,3- dihydro- benzoimidazol-2-
one ##STR256## B.4.25 0.67(e) 402 (M + H).sup.+ 2-(4-Amino-
phenyl)-ethanol ##STR257## B.4.26 1.15(e) 389.9 (M + H).sup.+
4-Amino-2-fluoro- phenol ##STR258## B.4.27 1.22(e) 380 (M +
H).sup.+ 2-Amino-phenol ##STR259## B.4.28 1.52(e) 362 (M +
H).sup.+
General Procedure C: Formation of an Amide from Carboxylic Acid and
Amine Using Si-DCT ##STR260##
[0516] In a 20 mL vial, a solution of N-methylmorpholine (2-5
equivalents, preferably 4 equivalents) in an organic solvent (for
example, THF, CH.sub.2Cl.sub.2, CH.sub.3CN, or
CH.sub.3CN/CH.sub.2Cl.sub.2 1:1) is added to Si-dichlorotriazine
(Si-DCT) (2-4 equivalents, preferably 3 equivalents). A solution of
the carboxylic acid (1.1-2.5 equivalents, preferably 1.25
equivalents) in an organic solvent (for example, THF,
CH.sub.2Cl.sub.2, CH.sub.3CN, or 1:1 CH.sub.3CN/CH.sub.2Cl.sub.2,
preferably 1:1 CH.sub.3CN/CH.sub.2Cl.sub.2) is added and mixed for
about 1 min. A solution of the amine (1 equivalent) in an organic
solvent (for example, THF, CH.sub.2Cl.sub.2, CH.sub.3CN, or 1:1
CH.sub.3CN/CH.sub.2Cl.sub.2, preferably 1:1
CH.sub.3CN/CH.sub.2Cl.sub.2) is then added. The reaction is shaken
at about 10-60.degree. C., preferably about ambient temperature,
for about 10-24 hours, preferably about 16 hours. The crude
reaction solution is mixed with DMF, eluted through a Si-carbonate
(1 g, 6 mL) cartridge with additional organic solvent (for example,
MeOH), and concentrated in vacuo. The crude product can then be
further purified by crystallization or chromatography.
Illustration of General Procedure C.
Example #13
Furan-2-carboxylic acid
(7-benzo[b]thiophen-2-yl-1H-indazol-5-yl)-amide
[0517] ##STR261##
[0518] In a 20 mL vial, a solution of N-methylmorpholine (0.060 g,
0.60 mmol) in MeCN/CH.sub.2Cl.sub.2 (1:1, 0.688 mL) was added to
Si-dichlorotriazine (SiliCycle, Inc; 0.60 mmol/g, 0.74 g, 0.44
mmol). Then, a solution of 2-furoic acid (0.021 g, 0.19 mmol) in
MeCN (0.925 mL) was added and mixed for about 1 min., prior to the
addition of a solution of
7-benzo[b]thiophen-2-yl-1H-indazol-5-ylamine (Example #F.8.1, 0.039
g, 0.15 mmol) in MeCN/CH.sub.2Cl.sub.2 (1:1, 0.688 mL). The
reaction mixture was shaken at ambient temperature for about 16
hours. The crude reaction solution was mixed with DMF (5 mL) to aid
in solubility, eluted through a Si-carbonate (SiliCycle, Inc; 1 g,
6 mL) cartridge using MeOH (approx 3 mL), and concentrated in
vacuo. The crude product was then purified by preparative HPLC
(Waters Symmetry C8 column (25.times.100 mm, 7 .mu.m particle size)
using a gradient of 10%-100% CH.sub.3CN/0.1% aqueous TFA over 8 min
(10 min run time) at a flow rate of 40 mL/min) to
affordffuran-2-carboxylic acid
(7-benzo[b]thiophen-2-yl-1H-indazol-5-yl)-amide (0.0025 g, 4.7%);
RP-HPLC (Table 1, Method 1) R.sub.t 2.51 min; m/z: (M+H).sup.+360.
TABLE-US-00009 TABLE C.1 Examples prepared using general procedure
C using Example #F.8.1 ##STR262## HPLC R.sub.t Acid Product Example
# min(Method) m/z Tetrahydro-3-furoic acid ##STR263## C.1.1 2.31(l)
364 (M + H).sup.+ 2-Methoxy phenylacetic acid ##STR264## C.1.2
2.65(l) 414 (M + H).sup.+ 3-Methoxy phenylacetic acid ##STR265##
C.1.3 2.62(l) 414 (M + H).sup.+ 4-Methoxy phenylacetic acid
##STR266## C.1.4 2.61(l) 414 (M + H).sup.+ 3- (Trifluoromethoxy)
phenylacetic acid ##STR267## C.1.5 2.85(l) 468 (M + H).sup.+ 3,4-
(Methylenedioxy)phenyl- acetic acid ##STR268## C.1.6 2.59(l) 428 (M
+ H).sup.+ 3-Ethoxypropionic acid ##STR269## C.1.7 2.43(l) 366 (M +
H).sup.+ L-Pyroglutamic acid ##STR270## C.1.8 2.07(l) 377 (M +
H).sup.+ D-Pyroglutamic acid ##STR271## C.1.9 2.07(l) 377 (M +
H).sup.+ 1-(Aminocarbonyl)- 1-cyclopropane carboxylic acid
##STR272## C.1.10 2.24(l) 377 (M + H).sup.+ Benzyloxyacetic acid
##STR273## C.1.11 2.72(l) 414 (M + H).sup.+ 4- Methoxycyclohexane
carboxylic acid ##STR274## C.1.12 2.53(l) 406 (M + H).sup.+
1-Phenyl-1- cyclopropane carboxylic acid ##STR275## C.1.13 2.85(l)
410 (M + H).sup.+ (S)-(+)-2- Phenylbutyric acid ##STR276## C.1.14
2.83(l) 412 (M + H).sup.+ 4-Phenylbutyric acid ##STR277## C.1.15
2.78(l) 412 (M + H).sup.+ N-(2-Furoyl)glycine ##STR278## C.1.16
2.63(l) 376 (M + H).sup.+ 4-(2- Thienyl)butyric aid ##STR279##
C.1.17 2.75(l) 418 (M + H).sup.+ 1-Acetylpiperidine- 4-carboxylic
acid ##STR280## C.1.18 2.21(l) 419 (M + H).sup.+ N-(N,N-Di-propyl)-
L-alanine ##STR281## C.1.19 2.92(l) 421 (M + H).sup.+
3-Benzoylpropionic acid ##STR282## C.1.20 2.62(l) 426 (M + H).sup.+
Hippuric acid ##STR283## C.1.21 1.86(m) 427.1.sup.1(M + H).sup.+
3-(3- Methoxyphenyl) propionic acid ##STR284## C.1.22 2.30(l) 360
(M + H).sup.+ 3- Methoxyphenoxyacetic acid ##STR285## C.1.23
2.69(l) 430 (M + H).sup.+ 4-Oxo-4-(2- thienyl)butyric acid
##STR286## C.1.24 2.56(l) 432 (M + H).sup.+ 2-(4-
Methylpyrimidin-2- ylthio)acetic acid ##STR287## C.1.25 2.48(l) 432
(M + H).sup.+ Glutaranilic acid ##STR288## C.1.26 2.48(l) 455 (M +
H).sup.+ 4-Methylsulfonyl phenylacetic acid ##STR289## C.1.27
2.40(l) 462 (M + H).sup.+ N-p-Tosylglycine ##STR290## C.1.28
2.52(l) 477 (M + H).sup.+ 4-Acetyl benzoic acid ##STR291## C.1.29
2.56(l) 412 (M + H).sup.+ 4-(Methylthio) benzoic acid ##STR292##
C.1.30 2.74(l) 416 (M + H).sup.+ 3-Fluoro-4- methoxy benzoic acid
##STR293## C.1.31 2.67(l) 418 (M + H).sup.+ 2-Acetamido benzoic
acid ##STR294## C.1.32 2.55(l) 425 (M - H).sup.- 3-Acetamido
benzoic acid ##STR295## C.1.33 2.35(l) 427 (M + H).sup.+
4-Diethylamino benzoic acid ##STR296## C.1.34 2.85(l) 441 (M +
H).sup.+ N-Phenylanthranilic acid ##STR297## C.1.35 3.02(l) 461 (M
+ H).sup.+ 3-Furoic acid ##STR298## C.1.36 2.52(l) 360 (M +
H).sup.+ Thiophene-2- carboxylic acid ##STR299## C.1.37 2.63(l) 374
(M + H).sup.+ 3-Methyl-2- thiophene carboxylic acid ##STR300##
C.1.38 2.70(l) 390 (M + H).sup.+ Pyrrole-2- carboxylic acid
##STR301## C.1.39 2.49(l) 359 (M + H).sup.+ Thiazole-4- carboxylic
acid ##STR302## C.1.40 2.53(l) 377 (M + H).sup.+ Thiazole-5-
carboxylic acid ##STR303## C.1.41 2.43(l) 375 (M - H).sup.-
1H-Pyrazole-5- carboxylic acid ##STR304## C.1.42 2.30(l) 360 (M +
H).sup.+ Isoxazole-5- carboxylic acid ##STR305## C.1.43 2.46(l) 361
(M + H).sup.+ 3,5-Dimethyl isoxazole-4- carboxylic acid ##STR306##
C.1.44 2.51(l) 389 (M + H).sup.+ 5-Methyl-3- phenylisoxazole-4-
carboxylic acid ##STR307## C.1.45 2.72(l) 451 (M + H).sup.+
Picolinic acid ##STR308## C.1.46 2.68(l) 371 (M + H).sup.+
2-Hydroxynicotinic acid ##STR309## C.1.47 1.73(m) 387.5.sup.1(M +
H).sup.+ 6-Hydroxynicotinic acid ##STR310## C.1.48 2.12(l) 387 (M +
H).sup.+ 2-Pyridylacetic acid ##STR311## C.1.49 2.37(l) 385 (M +
H).sup.+ 3-Pyridylacetic acid ##STR312## C.1.50 2.32(l) 385 (M +
H).sup.+ Pyrimidine-4- carboxylic acid ##STR313## C.1.51 1.88(m)
372.0 (M + H).sup.+ 2-Methylpyrazine- 5-carboxylic acid ##STR314##
C.1.52 2.58(l) 386 (M + H).sup.+ Indole-3-carboxylic acid
##STR315## C.1.53 2.05(m) 409.1 (M + H).sup.+ 5-Methyl-1-
phenylpyrazole-4- carboxylic acid ##STR316## C.1.54 2.68(l) 450 (M
+ H).sup.+ 4-Oxo-4,5,6,7- tetrahydrobenzo[b]fur- an-3-carboxylic
acid ##STR317## C.1.55 2.76(l) 428 (M + H).sup.+ 6-Chloro-2H-1-
benzopyran-3- carboxylic acid ##STR318## C.1.56 2.93(l) 458 (M +
H).sup.+ 3-(Dimethylamino) propanoic acid ##STR319## C.1.57 2.05(l)
365 (M + H).sup.+ 1-Pyrrolidine propanoic acid ##STR320## C.1.58
2.12(l) 391 (M + H).sup.+ 1-Piperidine propionic acid ##STR321##
C.1.59 2.18(l) 405 (M + H).sup.+ 4-Morpholinoacetic acid ##STR322##
C.1.60 2.34(l) 393 (M + H).sup.+ 5-(5-Amino-1H- pyrrolo[2,3-
c]pyridin-3-yl)-1H- indazole-7- carboxylic acid ##STR323## C.1.61
1.894(k) 373 (M + H).sup.+ 5-(5-Amino-1H- pyrrolo[2,3-
c]pyridin-3-yl)-1H- indazole-7- carboxylic acid ##STR324## C.1.62
1.628(k) 384 (M + H).sup.+ 5-(5-Amino-1H- pyrrolo[2,3-
c]pyridin-3-yl)-1H- indazole-7- carboxylic acid ##STR325## C.1.63
1.536(k) 384 (M + H).sup.+ 5-(5-Amino-1H- pyrrolo[2,3-
c]pyridin-3-yl)-1H- indazole-7- carboxylic acid ##STR326## C.1.64
1.487(k) 384 (M + H).sup.+ 5-(5-Amino-1H- pyrrolo[2,3-
c]pyridin-3-yl)-1H- indazole-7- carboxylic acid ##STR327## C.1.65
1.301(k) 364 (M + H).sup.+ 5-(5-Amino-1H- pyrrolo[2,3-
c]pyridin-3-yl)-1H- indazole-7- carboxylic acid ##STR328## C.1.66
1.442(k) 390 (M + H).sup.+ 5-(5-Amino-1H- pyrrolo[2,3-
c]pyridin-3-yl)-1H- indazole-7- carboxylic acid ##STR329## C.1.67
1.461(k) 404 (M + H).sup.+ 5-(5-Amino-1H- pyrrolo[2,3-
c]pyridin-3-yl)-1H- indazole-7- carboxylic acid ##STR330## C.1.68
2.093(k) 387 (M + H).sup.+ 5-(5-Amino-1H- pyrrolo[2,3-
c]pyridin-3-yl)-1H- indazole-7- carboxylic acid ##STR331## C.1.69
2.201(k) 436 (M + H).sup.+ 5-(5-Amino-1H- pyrrolo[2,3-
c]pyridin-3-yl)-1H- indazole-7- carboxylic acid ##STR332## C.1.70
1.624(k) 377 (M + H).sup.+ 5-(5-Amino-1H- pyrrolo[2,3-
c]pyridin-3-yl)-1H- indazole-7- carboxylic acid ##STR333## C.1.71
1.628(k) 377 (M + H).sup.+ 5-(5-Amino-1H- pyrrolo[2,3-
c]pyridin-3-yl)-1H- indazole-7- carboxylic acid ##STR334## C.1.72
1.819(k) 347 (M + H).sup.+ 5-(5-Amino-1H- pyrrolo[2,3-
c]pyridin-3-yl)-1H- indazole-7- carboxylic acid ##STR335## C.1.73
2.007(k) 361 (M + H).sup.+ 5-(5-Amino-1H- pyrrolo[2,3-
c]pyridin-3-yl)-1H- indazole-7- carboxylic acid ##STR336## C.1.74
2.436(k) 389 (M + H).sup.+ 5-(5-Amino-1H- pyrrolo[2,3-
c]pyridin-3-yl)-1H- indazole-7- carboxylic acid ##STR337## C.1.75
1.652(k) 361 (M + H).sup.+ 5-(5-Amino-1H- pyrrolo[2,3-
c]pyridin-3-yl)-1H- indazole-7- carboxylic acid ##STR338## C.1.76
1.391(k) 363 (M + H).sup.+ 5-(5-Amino-1H- pyrrolo[2,3-
c]pyridin-3-yl)-1H- indazole-7- carboxylic acid ##STR339## C.1.77
2.101(k) 383 (M + H).sup.+ 5-(5-Amino-1H- pyrrolo[2,3-
c]pyridin-3-yl)-1H- indazole-7- carboxylic acid ##STR340## C.1.78
2.021(k) 383 (M + H).sup.+ 5-(5-Amino-1H- pyrrolo[2,3-
c]pyridin-3-yl)-1H- indazole-7- carboxylic acid ##STR341## C.1.79
2.328(k) 399 (M + H).sup.+ 5-(5-Amino-1H- pyrrolo[2,3-
c]pyridin-3-yl)-1H- indazole-7- carboxylic acid ##STR342## C.1.80
2.129(k) 399 (M + H).sup.+ 5-(5-Amino-1H- pyrrolo[2,3-
c]pyridin-3-yl)-1H- indazole-7- carboxylic acid ##STR343## C.1.81
2.555(k) 403 (M + H).sup.+ 5-(5-Amino-1H- pyrrolo[2,3-
c]pyridin-3-yl)-1H- indazole-7- carboxylic acid ##STR344## C.1.82
2.563(k) 403 (M + H).sup.+ 5-(5-Amino-1H- pyrrolo[2,3-
c]pyridin-3-yl)-1H- indazole-7- carboxylic acid ##STR345## C.1.83
2.845(k) 461 (M + H).sup.+ 5-(5-Amino-1H- pyrrolo[2,3-
c]pyridin-3-yl)-1H- indazole-7- carboxylic acid ##STR346## C.1.84
2.179(k) 412 (M + H).sup.+ 5-(5-Amino-1H- pyrrolo[2,3-
c]pyridin-3-yl)-1H- indazole-7- carboxylic acid ##STR347## C.1.85
2.142(k) 413 (M + H).sup.+
5-(5-Amino-1H- pyrrolo[2,3- c]pyridin-3-yl)-1H- indazole-7-
carboxylic acid ##STR348## C.1.86 2.096(k) 413 (M + H).sup.+
5-(5-Amino-1H- pyrrolo[2,3- c]pyridin-3-yl)-1H- indazole-7-
carboxylic acid ##STR349## C.1.87 2.107(k) 413 (M + H).sup.+
5-(5-Amino-1H- pyrrolo[2,3- c]pyridin-3-yl)-1H- indazole-7-
carboxylic acid ##STR350## C.1.88 2.338(k) 417 (M + H).sup.+
5-(5-Amino-1H- pyrrolo[2,3- c]pyridin-3-yl)-1H- indazole-7-
carboxylic acid ##STR351## C.1.89 2.37(k) 417 (M + H).sup.+
5-(5-Amino-1H- pyrrolo[2,3- c]pyridin-3-yl)-1H- indazole-7-
carboxylic acid ##STR352## C.1.90 2.31(k) 417 (M + H).sup.+
5-(5-Amino-1H- pyrrolo[2,3- c]pyridin-3-yl)-1H- indazole-7-
carboxylic acid ##STR353## C.1.91 2.446(k) 451 (M + H).sup.+
5-(5-Amino-1H- pyrrolo[2,3- c]pyridin-3-yl)-1H- indazole-7-
carboxylic acid ##STR354## C.1.92 1.74(k) 413 (M + H).sup.+
5-(5-Amino-1H- pyrrolo[2,3- c]pyridin-3-yl)-1H- indazole-7-
carboxylic acid ##STR355## C.1.93 2.232(k) 427 (M + H).sup.+
5-(5-Amino-1H- pyrrolo[2,3- c]pyridin-3-yl)-1H- indazole-7-
carboxylic acid ##STR356## C.1.94 2.161(k) 417 (M + H).sup.+
5-(5-Amino-1H- pyrrolo[2,3- c]pyridin-3-yl)-1H- indazole-7-
carboxylic acid ##STR357## C.1.95 1.349(k) 406 (M + H).sup.+
5-(5-Amino-1H- pyrrolo[2,3- c]pyridin-3-yl)-1H- indazole-7-
carboxylic acid ##STR358## C.1.96 2.26(k) 399 (M + H).sup.+
5-(5-Amino-1H- pyrrolo[2,3- c]pyridin-3-yl)-1H- indazole-7-
carboxylic acid ##STR359## C.1.97 1.994(k) 389 (M + H).sup.+
5-(5-Amino-1H- pyrrolo[2,3- c]pyridin-3-yl)-1H- indazole-7-
carboxylic acid ##STR360## C.1.98 2.074 389 (M + H).sup.+
5-(5-Amino-1H- pyrrolo[2,3- c]pyridin-3-yl)-1H- indazole-7-
carboxylic acid ##STR361## C.1.99 2.99(e) 426 (M + H).sup.+
5-(5-Amino-1H- pyrrolo[2,3- c]pyridin-3-yl)-1H- indazole-7-
carboxylic acid ##STR362## C.1.100 3.09(e) 468 (M + H).sup.+
5-(5-Amino-1H- pyrrolo[2,3- c]pyridin-3-yl)-1H- indazole-7-
carboxylic acid ##STR363## C.1.101 3.28(e) 452 (M + H).sup.+
5-(5-Amino-1H- pyrrolo[2,3- c]pyridin-3-yl)-1H- indazole-7-
carboxylic acid ##STR364## C.1.102 3.22(e) 481 (M + H).sup.+
5-(5-Amino-1H- pyrrolo[2,3- c]pyridin-3-yl)-1H- indazole-7-
carboxylic acid ##STR365## C.1.103 0.96(e) 381 5-(5-Amino-1H-
pyrrolo[2,3- c]pyridin-3-yl)-1H- indazole-7- carboxylic acid
##STR366## C.1.104 1.09(e) 395.2 5-(5-Amino-1H- pyrrolo[2,3-
c]pyridin-3-yl)-1H- indazole-7- carboxylic acid ##STR367## C.1.105
0.77(e) 396.2 5-(5-Amino-1H- pyrrolo[2,3- c]pyridin-3-yl)-1H-
indazole-7- carboxylic acid ##STR368## C.1.106 0.85(e) 399.2
5-(5-Amino-1H- pyrrolo[2,3- c]pyridin-3-yl)-1H- indazole-7-
carboxylic acid ##STR369## C.1.107 1.17(e) 408.2 5-(5-Amino-1H-
pyrrolo[2,3- c]pyridin-3-yl)-1H- indazole-7- carboxylic acid
##STR370## C.1.108 1.29(e) 466 5-(5-Amino-1H- pyrrolo[2,3-
c]pyridin-3-yl)-1H- indazole-7- carboxylic acid ##STR371## C.1.109
0.78(e) 462.1 5-(5-Amino-1H- pyrrolo[2,3- c]pyridin-3-yl)-1H-
indazole-7- carboxylic acid ##STR372## C.1.110 1.30(e) 467.1
5-(5-Amino-1H- pyrrolo[2,3- c]pyridin-3-yl)-1H- indazole-7-
carboxylic acid ##STR373## C.1.111 1.29(e) 426 5-(5-Amino-1H-
pyrrolo[2,3- c]pyridin-3-yl)-1H- indazole-7- carboxylic acid
##STR374## C.1.112 0.45(e) 398.1 5-(5-Amino-1H- pyrrolo[2,3-
c]pyridin-3-yl)-1H- indazole-7- carboxylic acid ##STR375## C.1.113
0.61(e) 467.2 5-(5-Amino-1H- pyrrolo[2,3- c]pyridin-3-yl)-1H-
indazole-7- carboxylic acid ##STR376## C.1.114 1.19(e) 397.3
5-(2-Amino-5H- pyrrolo[3,2- d]pyrimidin-7-yl)- 1H-indazole-7-
carboxylic acid ##STR377## C.1.115 1.33(e) 382 5-(2-Amino-5H-
pyrrolo[3,2- d]pyrimidin-7-yl)- 1H-indazole-7- carboxylic acid
##STR378## C.1.116 1.30(e) 370.1 5-(5-Amino-1H- pyrrolo[2,3-
c]pyridin-3-yl)-1H- indazole-7- carboxylic acid ##STR379## C.1.117
1.15(e) 408.2
General Procedure D: Protection of an Indazole with a
trimethyl-silanylethoxymethyl Group ##STR380##
[0519] A mixture of an indazole (1 equivalent) and a base (for
example, Na.sub.2CO.sub.3, NaOH, Cs.sub.2CO.sub.3 or t-BuOK,
preferably Na.sub.2CO.sub.3) (1-10 equivalents, preferably 1-2
equivalents) and SEMCl (1-2 equivalents, preferably 1.2
equivalents) in a solvent (for example, DME or CH.sub.2Cl.sub.2,
preferably CH.sub.2Cl.sub.2) mixed with either water or in an
anhydrous solvent, (for example, DMF or DMA, preferably DMF) is
stirred at about 10-40.degree. C. (preferably about 20-25.degree.
C.) for about 0.5-24 hours (preferably about 1-2 hours) under an
inert atmosphere. Saturated aqueous NH.sub.4Cl is added and the
solvents are removed under reduced pressure. The residue is
dissolved in an organic solvent (CH.sub.2Cl.sub.2 or EtOAc,
preferably EtOAc) and washed with water. The organic layer is dried
over a desiccant (for example, magnesium sulfate or sodium sulfate,
preferably magnesium sulfate) and further purified by
crystallization or chromatography.
Illustration of General Procedure D:
Preparation #23.
7-Benzo[b]thiophen-2-yl-5-bromo-1-(2-trimethylsilanyl-ethoxymethyl)-1H-in-
dazole, and,
[0520] Preparation #24.
7-Benzo[b]thiophen-2-yl-5-bromo-2-(2-trimethylsilanyl-ethoxymethyl)-2H-in-
dazole ##STR381##
[0521] To a mixture of 7-benzo[b]thiophen-2-yl-5-bromo-1H-indazole
(Preparation #26, 38.0 g, 0.116 mol) in DMF (570 mL) at about
5.degree. C. was added t-BuOK (15.5 g, 0.139 mmol). The mixture was
stirred for about 30 minutes then SEM-Cl (23.2 g, 0.139 mmol) was
added over the course of about 5 minutes while maintaining the
temperature between about 0-5.degree. C. After warming to ambient
temperature and stirring the solution for about 30 minutes the
solution was treated with saturated aqueous NH.sub.4Cl
(approximately 5 mL). The solvents were removed under reduced
pressure and the residue was partitioned between EtOAc:water (1:1,
700 mL). The organic layer was further washed with water (150 mL)
and brine (150 mL), dried over anhydrous MgSO.sub.4, filtered and
concentrated to give an oil that solidified upon standing. Heptane
(500 mL) was added and the mixture was heated to about 100.degree.
C. to dissolve all of the solids. The mixture was cooled to ambient
temperature and the resulting solids were collected by filtration
to afford
7-benzo[b]thiophen-2-yl-5-bromo-2-(2-trimethylsilanyl-ethoxymethyl)-2H-in-
dazole (33 g, 62%); (DMSO-d.sub.6, 400 MHz) .delta. 8.73 (s, 1H),
8.61 (s, 1H), 8.11 (d, 1H), 8.04 (m, 1H), 7.95 (m, 1H), 7.79 (d,
1H), 7.45 (m, 2H), 5.89 (s, 2H), 3.79 (m, 2H), 0.96 (m, 2H), 0.00
(s, 9H); RP-HPLC (Table 1, Method e) R.sub.t 3.63 min; m/z:
(M+H).sup.+. 461. The filtrate was concentrated and purified by
flash chromatography over silica gel using heptane/EtOAc (9:1) as
an eluent to give
7-benzo[b]thiophen-2-yl-5-bromo-1-(2-trimethylsilanyl-ethoxymethyl)-1H-in-
dazole 7.8 g (15%) as an oil which solidified upon standing;
(DMSO-d.sub.6, 400 MHz) .delta. 8.50 (s, 1H), 8.40 (s, 1H), 8.26
(m, 1H), 8.12 (m, 1H), 7.89 (s, 1H), 7.80 (d, 1H), 7.67 (m, 2H),
5.64 (s, 2H), 3.34 (m, 2H), 0.81 (m, 2H), 0.00 (s, 9H); RP-HPLC
(Table 1, Method e) R.sub.t 3.63 min; m/z: (M+H).sup.+. 461.
General Procedure E: Conversion of an Aryl Halide to a Boronic Acid
or Boronate ##STR382##
[0522] To a mixture of a boronating reagent (bis(pinacolato)diboron
or pinacolatoborane, preferably bis(pinacolato)diboron)(1-1.5
equivalents, preferably 1.3 equivalents), an aryl halide (for
example, an aryl bromide or an aryl iodide, preferably an aryl
iodide) (0.5-3 equivalents, preferably 1 equivalent), a palladium
catalyst (for example tris(benzylideneacetone)dipalladium (0),
tetrakis(triphenylphosphine)palladium(0),
bis(acetato)triphenylphosphinepalladium(II) (.about.5% Pd)
polymer-bound FibreCat.TM. or
[1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II),
complex with dichloromethane) (preferably dichloro
[1,1'-bis(diphenylphosphino)ferrocene]-palladium (II)
dichloromethane adduct) (0.03-0.15 equivalent, preferably 0.10
equivalents) and a base (for example, NaOAc or KOAc, preferably
KOAc) (1.5-3.0 equivalents, preferably 2.5 equivalents) is added an
organic solvent (for example, DMF, dioxane, or THF, preferably
DMF). The mixture is heated at about 50-100.degree. C. (preferably
about 80.degree. C.) for about 1-24 hours (preferably about 15
hours) under an inert atmosphere. The mixture is allowed to cool to
ambient temperature, and the solvent is removed under reduced
pressure. The residue can then be further purified by
chromatography or crystallization.
Illustration of General Procedure E.
[0523] Preparation #25:
7-Benzo[b]thiophen-2-yl-5-(4,4,5,5-tetramethyl-[1,3,2]dioxa
borolan-2-yl)-1H -indazole ##STR383##
[0524] A mixture of 7-benzo[b]thiophen-2-yl-5-bromo-1H-indazole
(Preparation #26, 5.0 g, 15.2 mmol), bis(pinacolato)diboron (5.78,
22.8 mmol), KOAc (3.72 g, 38 mmol) and
[1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II),
complex with dichloromethane (1:1) (0.99 g, 1.22 mmol) in DMF (125
mL) was heated at about 100.degree. C. under an atmosphere of
nitrogen for about 18 hours. The dark reaction solution was cooled
to ambient temperature, diluted with CH.sub.2Cl.sub.2 (25 mL) then
washed with water (2.times.20 mL). The reaction mixture was cooled,
concentrated under reduced pressure, triturated with
CH.sub.2Cl.sub.2 (175 mL), filtered and the filtrate concentrated
under reduced pressure. The resulting material was purified by
flash chromatography over silica gel using CH.sub.2Cl.sub.2/EtOAc
(97:3) as the eluent and the material was triturated with heptane
(25 mL) to give
7-benzo[b]thiophen-2-yl-5-(4,4,5,5-tetramethyl-[1,3,2]dioxaborola-
n-2-yl)-1H-indazole as a white solid (2.23 g, 39%); (DMSO-d.sub.6,
400 MHz) .delta.13.5 (s, 1H), 8.31 (s, 1H), 8.22 (s, 1H), 8.06 (s,
1H), 8.02 (d, 1H), 7.89 (d, 1H), 7.83 (s, 1H), 7.43 (m, 2H), 1.35
(s, 12H); RP-HPLC (Table 1, Method e) R.sub.t 2.77 min; m/z
(M-H).sup.- 374.5. General Procedure F: Suzuki Coupling of a
Boronate or Boronic acid with an Aryl Halide Substrate
##STR384##
[0525] To a mixture of a boronate ester or a boronic acid (1-5
equivalents, preferably 2 equivalents), an aryl halide (for
example, an aryl bromide, aryl chloride or an aryl iodide,
preferably an aryl iodide) (0.7-3 equivalents, preferably 1
equivalent) and an inorganic base (for example, KF,
Na.sub.2CO.sub.3 or Cs.sub.2CO.sub.3, preferably Cs.sub.2CO.sub.3)
(2-16 equivalents, preferably 2.5 equivalents) in a degassed
organic solvent (for example THF, DME, DMF, 1,4-dioxane, DME/water
or toluene, preferably DMF or DME/water) is added a palladium
catalyst (for example tris(benzylideneacetone)dipalladium (0),
tetrakis(triphenylphosphine)palladium(0),
bis(acetato)triphenylphosphinepalladium(II) (.about.5% Pd)
polymer-bound FibreCat.TM. or
[1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II),
complex with dichloromethane, preferably
tetrakis(triphenylphosphine)palladium(0)) (0.01-0.10 equivalents,
preferably 0.05 equivalents). If necessary,
tributylphosphinetetraflouroborate (0.01 to 0.20 equivalents,
preferably 0.05 equivalents) is also added. The reaction mixture is
heated at about 40-150.degree. C. (preferably about 80.degree. C.)
for about 2-24 hours (preferably about 18 hours) or at about
100-200.degree. C. (preferably 150.degree. C.) for about 5-60
minutes (preferably about 15 minutes) in a microwave under an inert
atmosphere. The reaction mixture is allowed to cool to ambient
temperature. Subsequently, the solvents are removed under reduced
pressure and the residue is suspended in a mixture of EtOAc and
water; the mixture is stirred for 30 minutes and the resulting
solid is collected by filtration; the product can be further
purified by chromatography or crystallization. Alternatively, the
cooled reaction mixture is diluted with water or an aqueous basic
solution (such as saturated aqueous NaHCO.sub.3) and extracted (1-5
times, preferably 3 times) with a suitable solvent (such as EtOAc
or CH.sub.2Cl.sub.2) then the combined organic extracts are dried
(for example, over Na.sub.2SO.sub.4 or MgSO.sub.4), decanted or
filtered, and concentrated under reduced pressure to afford the
product that can be further purified by chromatography or
crystallization. If a tert-butoxycarbonyl (Boc) protected amine is
used, then the material is subsequently suspended in a mixture of
methanol/6 N HCl and heated to about 65.degree. C. for about one
hour then cooled, concentrated and purified by chromatography or
crystallization.
Illustrations of General Procedure F.
Example #13a
7-Benzo[b]thiophen-2-yl-5-bromo-1H-indazole
[0526] ##STR385##
[0527] A mixture of 5-bromo-7-iodo-1H-indazole (Preparation #22a,
30.0 g, 92.9 mmol) and thianapthene-2-boronic acid (21.5 g, 120.7
mmol), DME (480 mL), water (48 mL), Na.sub.2CO.sub.3 (29.5 g, 279
mmol) and tetrakis triphenylphosphine palladium (0) (8.6 g, 7.43
mmol) was heated at about 90.degree. C. in an oil bath under an
atmosphere of nitrogen for about 15 hours. The solvent was removed
under reduced pressure and the residue was suspended in a mixture
of ethyl acetate (600 mL) and water (300 mL). The mixture was
stirred for about 30 minutes and the resulting solid was collected
by filtration and dried to yield
7-Benzo[b]thiophen-2-yl-5-bromo-1H-indazole (21.4 g, 70%);
(DMSO-d.sub.6, 400 MHz) .delta. 13.63 (s, 1H), 8.24 (s, 1H),
8.05-8.09 (m, 3H), 7.92 (d, 1H), 7.65 (s, 1H), 7.16 (m, 2H);
RP-HPLC (Table 1, Method e) R.sub.t=2.69 min; m/z: (M-H).sup.-
328.4.
Example #13c
N-Phenyl-5-pyridin-3-yl-1H-indazole-7-carboxamide
[0528] ##STR386##
[0529] A mixture of N-phenyl-5-bromo-1H-indazole-7-carboxamide
(Example #B.1.2, 0.05 g, 0.16 mmol) and pyridine-3-yl-boronic acid
(0.11 g, 0.8 mmol), 1,2-dimethoxyethane (1.3 mL), water (0.7 mL),
Cs.sub.2CO.sub.3 (0.16 g, 0.48 mmol) and
[1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II),
complex with dichloromethane (0.013 g, 0.016 mmol) was heated at
about 150.degree. C. in the microwave under an atmosphere of
nitrogen for about 15 minutes. The crude product was filtered and
the solvent was removed under reduced pressure. The residue was
dissolved in DMSO then purified by reverse phase HPLC (Waters
Symmetry C8 column (25.times.100 mm, 7 .mu.m particle size) using a
gradient of 10%-100% CH.sub.3CN/0.1% aqueous TFA over 8 min (10 min
run time) at a flow rate of 40 mL/min) to yield
N-phenyl-5-pyridin-3-yl-1H-indazole-7-carboxamide (0.014 g, 6%);
(DMSO-d.sub.6, 400 MHz) .delta. 13.4 (bs, 1H), 10.5 (bs, 1H), 9.12
(d, 1H), 8.62 (d, 1H), 8.48 (s, 1H), 8.34 (s, 1H), 8.28 (m, 2H),
7.84 (d, 2H), 7.56 (m, 1H), 7.42 (m, 2H), 7.16 (m, 2H); RP-HPLC
(Table 1, Method e) R.sub.t=1.81 min; m/z: (M+H).sup.+ 315.3.
TABLE-US-00010 TABLE F.1 Examples prepared using general procedure
F from Preparation #25 ##STR387## Aryl Halide Product Example #
HPLC R.sub.t(min)(method) m/z 2-Chloro-4-iodo- pyridine ##STR388##
F.1.1 2.63(e) 359.5 (M - H).sup.- 5-Bromo- nicotinonitrile
##STR389## F.1.2 2.28(e) 350.8 (M - H).sup.- 5-Bromo- nicotinamide
##STR390## F.1.3 1.70(e) 368.7 (M - H).sup.- (5-Bromo-pyridin-2-
yl)-methanol ##STR391## F.1.4 1.93(e) 355.8 (M - H).sup.-
1-(5-Bromo-pyridin- 2-yl)-ethanone ##STR392## F.1.5 2.44(e) 368.1
(M - H).sup.- 5-Bromo-nicotinic acid hydrazide ##STR393## F.1.6
1.55(e) 384.0 (M - H).sup.- 5-Bromo-pyridine-2- carbonitrile
##STR394## F.1.7 2.39(e) 351.1 (M - H).sup.- 5-Bromo-pyridine-2-
carboxylic acid ##STR395## F.1.8 1.55(e) 369.9 (M - H).sup.-
5-Bromo-pyridine-3- carboxaldehyde ##STR396## F.1.9 2.26(e) 354.2
(M - H).sup.- (3-Bromo-phenyl)- urea ##STR397## F.1.10 1.94(e)
382.7 (M - H).sup.- 3-Bromo-thieno[3,2- c]pyridin-4-yl amine
##STR398## F.1.11 2.49(e) 399.0 (M - H).sup.- 3-Bromo-furo[3,2-
c]pyridin-4-ylamine ##STR399## F.1.12 2.39(e) 383.0 (M - H).sup.-
Cis-{3-iodo-1-[4-(4- methyl-piperazin-1-yl)- cyclohexyl]-1H-
pyrazolo[3,4-d]py- rimidin-4-ylamine} ##STR400## F.1.13 1.79(e)
564.1 (M + H).sup.+ 3-Iodo-pyridin-4- ylamine ##STR401## F.1.14
1.88(e) 343.0 (M + H).sup.+ 3-Iodo-pyridin-2- ylamine ##STR402##
F.1.15 2.30(e) 343.0 (M + H).sup.+ 4-(3-Iodo-pyridin-2-
yl)-morpholine ##STR403## F.1.16 2.41(e) 412.9 (M + H).sup.+
3-Iodo-1-methyl-1H- pyrazolo[3,4- d]pyrimidin-4- ylamine ##STR404##
F.1.17 1.96(e) 398.0 (M + H).sup.+ 3-Iodo-2-isopropoxy- pyridine
##STR405## F.1.18 2.79(e) 383.7 (M + H).sup.+ 3-Iodo-2-methoxy-
pyridine ##STR406## F.1.19 2.56(e) 357.9 (M + H).sup.+
[2-(6-Iodo-pyridin-2- ylamino)-ethyl]- carbamic acid tert- butyl
ester ##STR407## F.1.20 2.10(e) 386.0 (M + H).sup.+
[2-(6-Iodo-pyridin-2- yloxy)-ethyl]- carbamic acid tert- butyl
ester ##STR408## F.1.21 2.02(e) 387.0 (M + H).sup.+ Thiophene-2-
carboxylic acid(5- bromo-4,6-dimethyl- pyrimidin-2-yl)- amide
##STR409## F.1.22 2.02(e) 481.9 (M + H).sup.+ N-(5-Bromo-3-
methyl-pyridin-2-yl)- acetamide ##STR410## F.1.23 1.83(e) 399.0 (M
+ H).sup.+ N-(2-Bromo-pyridin- 3-yl)-acetamide ##STR411## F.1.24
1.70(e) 385.0 (M + H).sup.+ 5-Iodo-6-methyl- pyrimidin-4-ylamine
##STR412## F.1.25 2.16(e) 358.0 (M + H).sup.+ N-(5-Iodo-6-methyl-
pyridin-2-yl)-2,2- dimethyl- propionamide ##STR413## F.1.26 2.42(e)
441.0 (M + H).sup.+ 5-Bromo-4-methyl- pyridin-2-ylamine ##STR414##
F.1.27 2.14(e) 354.6 (M - H).sup.- 3-Bromo-5-(1H-
tetrazol-5-yl)-pyridine ##STR415## F.1.28 1.30(e) 441.0 (M +
H).sup.+ 2-Bromo-pyridin-3- ylamine ##STR416## F.1.29 1.92(e) 342.9
(M + H).sup.+ 4-Bromo-6- trifluoromethyl-1H- benzoimidazole
##STR417## F.1.30 2.39(e) 432.4 (M - H).sup.- 1-(5-Bromo-2-chloro-
pyridin-3-yl)-3- phenyl-urea ##STR418## F.131 2.56(e) 493.9 (M -
H).sup.- 3-Iodo-indazole-1- carboxylic acid tert- butyl ester
##STR419## F.1.32 2.27(e) 364.6 (M - H).sup.- 2-Cyclopropyl
methoxy-3-iodo- pyridine ##STR420## F.1.33 2.81(e) 396.0 (M -
H).sup.- 6'-Bromo-3,4,5,6- tetrahydro-2H- [1,2']bipyriidnyl-3'-
ylamine ##STR421## F.1.34 2.84(e) 426 (M + H).sup.+
4-Bromo-quinolin-3- ylamine ##STR422## F.1.35 2.44(e) 393 (M +
H).sup.+ 4-(3-Iodo-pyridin-2- yl)-piperazine-1- carboxylic acid
tert- butyl ester ##STR423## F.1.36 2.29(e) 412 (M + H).sup.+
6-Bromo-pyridin-2- ylamine ##STR424## F.1.37 2.19(e) 341 (M +
H).sup.+ 3-(5-Bromo-thiophen- 2-yl)-1H-pyrazole ##STR425## F.1.38
2.42(e) 399 (M + H).sup.+ 3-Bromo-5-methyl- pyridin-2-ylamine
##STR426## F.1.39 2.50(e) 357 (M + H).sup.+ 7-Bromo-4H-
benzo[1,4]thiazin-3- one ##STR427## F.1.40 2.30(e) 412 (M -
H).sup.- [2-(3-Iodo-pyridin-2- ylsulfanyl)-ethyl]- carbamic acid
tert- butyl ester ##STR428## F.1.41 2.30(e) 401 (M - H).sup.-
5-Bromo-pyrazin- 2-yl amine ##STR429## F.1.42 1.98(e) 342 (M -
H).sup.- 5-Bromo-2-methoxy- nicotinic acid methyl ester ##STR430##
F.1.43 1.21(e) 400 (M - H).sup.- 3-Fluoro-4-iodo- pyridine
##STR431## F.1.44 2.78(e) 344 (M - H).sup.- 3-Fluoro-2-iodo-
pyridine ##STR432## F.1.45 2.48(e) 344 (M - H).sup.-
2-Chloro-5-iodo- pyridine ##STR433## F.1.46 2.53(e) 360 (M -
H).sup.- N-(5-iodo-3-methyl- pyridin-2-yl) thiophene-2- carboxamide
##STR434## F.1.47 2.2(e) 466.8 (M + H).sup.+ N-(5-Iodo-6-methyl-
pyridin-2-yl)- isobutyramide ##STR435## F.1.48 2.3(e) 427.0 (M +
H).sup.+ 4-Bromo-1H-indazole ##STR436## F.1.49 2.4(e) 364.5 (M -
H).sup.- 1-Bromo-4-(4- fluorophenyl)- isoquinolin-3-yl amine
##STR437## F.1.50 2.9(e) 486.9 (M + H).sup.+ N-(5-Iodo-3-methyl-
pyridin-2-yl)-furan-2- carboxamide ##STR438## F.1.51 2.1(e) 450.9
(M + H).sup.+ N-(5-Iodo-pyridin-2- yl)-acetamide ##STR439## F.1.52
2.1(e) 383.2 (M - H).sup.- 4-Bromo-quinoline-2- carboxamide
##STR440## F.1.53 2.5(e) 420.9 (M + H).sup.+ 5-Bromo-1H-
pyrrolo[2,3- b]pyridine ##STR441## F.1.54 2.5(e) 365.0 (M -
H).sup.- 5-Iodo-3-methyl- pyridin-2-ylamine ##STR442## F.1.55
2.4(e) 354.6 (M - H).sup.- 5-Bromo-1H-indazole ##STR443## F.1.56
2.3(e) 364.6 (M - H).sup.- 6-Iodo-1H- quinazolin-4-one ##STR444##
F.1.57 2.1(e) 392.6 (M - H).sup.-
[0530] TABLE-US-00011 TABLE F.2 Examples prepared using general
procedure F from Example #N.2.2 ##STR445## Boronates/ HPLC R.sub.t
Boronic Example (min) m/z Acids Product # (method) (ESI+)
4-Hydroxyphenyl boronic acid ##STR446## F.2.1 1.1 (e) 317.6 (M -
H).sup.- 2-Hydroxyphenyl boronic acid ##STR447## F.2.2 1.7 (e)
317.6 (M - H).sup.- 3-Hydroxyphenyl boronic acid ##STR448## F.2.3
1.1 (e) 317.4 (M - H).sup.- 4-Hydroxymethyl phenyl boronic acid
##STR449## F.2.4 0.98 (e) 333.2 (M + H).sup.+ 6-Methoxy-2-
naphthalene boronic acid ##STR450## F.2.5 1.87 (e) 383.8 (M +
H).sup.+ Benzamide-3- boronic acid ##STR451## F.2.6 0.93 (e) 346.1
(M + H).sup.+ Benzamide 4- boronic acid ##STR452## F.2.7 0.67 (e)
346.8 (M + H).sup.+ 3-(Trifluoromethyl) phenylboronic acid
##STR453## F.2.8 1.93 (e) 369.6 (M - H).sup.- 3-(Isopropyl)
phenylboronic acid ##STR454## F.2.9 1.97 (e) 343.8 (M - H).sup.-
3-(Trifluoro methoxy) phenylboronic acid ##STR455## F.2.10 2.02 (e)
385.4 (M - H).sup.- 3-(Methoxy) phenylboronic acid ##STR456##
F.2.11 1.58 (e) 331.6 (M - H).sup.- 3-(Benzyloxy) phenylboronic
acid ##STR457## F.2.12 2.05 (e) 409.2 (M + H).sup.+ 3-Biphenyl
boronic acid ##STR458## F.2.13 2.02 (e) 377.6 (M - H).sup.-
3-Cyanophenyl boronic acid ##STR459## F.2.14 1.52 (e) 328.1 (M +
H).sup.+ 3-Ethoxyphenyl boronic acid ##STR460## F.2.15 1.82 (e)
347.3 (M + H).sup.+ 3-Aminophenyl boronic acid ##STR461## F.2.16
0.93 (e) 318.7 (M + H).sup.+ 3,5-Dimethylphenyl boronic acid
##STR462## F.2.17 1.75 (e) 331.0 (M + H).sup.+ 3-Methyl-4-
methoxyphenyl boronic acid ##STR463## F.2.18 1.55 (e) 347.0 (M +
H).sup.+ 3-(Hydroxymethyl) phenyl boronic acid ##STR464## F.2.19
0.93 (e) 333.3 (M + H).sup.+ 3,4-Dimethylphenyl boronic acid
##STR465## F.2.20 1.65 (e) 331.0 (M + H).sup.+ 3,4- Dimethoxyphenyl
boronic acid ##STR466## F.2.21 1.30 (e) 362.0 (M + H).sup.+
3-Methyl-4-fluoro phenyl boronic acid ##STR467## F.2.22 1.24 (e)
335.3 (M + H).sup.+ Thianaphthene-2- boronic acid ##STR468## F.2.23
1.59 (e) 359.3 (M + H).sup.+ 5-(Dimethylamino)- 1-benzothiophen-2-
yl boronic acid ##STR469## F.2.24 1.67 (e) 402.3 (M + H).sup.+
5-Methoxy-1- benzothiophen-2-yl boronic acid ##STR470## F.2.25 1.15
(e) 346.2 (M + H).sup.+ 4-Carboxyphenyl boronic acid ##STR471##
F.2.26 0.5 (e) 345.5 (M - H).sup.-
[0531] TABLE-US-00012 TABLE F.3 Examples prepared using general
procedure F using 6-bromo-1H-indazole ##STR472## Example R.sub.t
(min) m/z Boronic Acid Product # (method) (ESI+) Benzothiophene-2-
boronic acid ##STR473## F.3.1 2.34 (e) 248.8 (M - H).sup.-
2-Methoxy-5- pyridineboronic acid ##STR474## F.3.2 1.70 (e) 224.1
(M - H).sup.-
[0532] TABLE-US-00013 TABLE F.4 Examples prepared using general
procedure F using 5-(2-aminopyrimidin-4-
yl)amino-3-chloro-7-iodo-1H-indazole ##STR475##
5-(2-Aminopyrimidin-4-yl)amino-3-chloro-7-iodo-1H-indazole was
prepared from 3- Chloro-5-nitro-1H-indazole (J. Med. Chem., 46(26);
2003; 5663-5673, via halogenation conditions used in the synthesis
of Preparation #22a, and general procedure N (using 2-amino-4-
chloro-pyrimidine)). Example R.sub.t (min) m/z Boronic Acid Product
# (method) (ESI+) Benzothiophene-2- boronic acid ##STR476## F.4.1
1.89 (e) 393.2 (M + H).sup.+ 3-Quinoline boronic acid ##STR477##
F.4.2 1.42 (e) 388.3 (M + H).sup.+
[0533] TABLE-US-00014 TABLE F.5 Examples prepared using general
procedure F from Example #N.2.7 ##STR478## HPLC R.sub.t Example
(min) m/z Boronate Product # (method) (ESI+) 4,4,5,5-Tetramethyl-
2-vinyl-[1,3,2]dioxaborolane ##STR479## F.5.1 0.93 (e) 250.9 (M -
H).sup.- Indole-6-boronic acid ##STR480## F.5.2 1.38 (e) 342.3 (M +
H).sup.+ 2-[5-(4,4,5,5- Tetramethyl-[1,3,2]dioxaborolan-2-yl)-
indol-1-yl]-acetamide (5-(4,4,5,5-
Tetramethyl-[1,3,2]dioxaborolan-2-yl)- indole, R) ##STR481## F.5.3
1.18 (e) 399.3 (M + H).sup.+ 5-Formylbenzo[b]thiophene-2-boronic
acid pinacol ##STR482## F.5.4 1.41 (e) 387.3 (M + H).sup.+
3-Pyridylboronic acid ##STR483## F.5.5 1.10 (e) 304.3 (M + H).sup.+
N,N-dimethyl-1-[5- (4,4,5,5-tetramethyl- 1,3,2-dioxaborolan-2-
yl)-1H-indol-3- yl]methanamine (Preparation #22b) ##STR484## F.5.6
1.43 (e) 399.0 (M + H).sup.+ Thieno[2,3-b]pyridin- 2-ylboronic acid
(Preparation #22c) ##STR485## F.5.7 1.25 (e) 360.3 (M + H).sup.+
2-[6-(4,4,5,5- Tetramethyl-1,3,2- dioxaborolan-2-yl)- 1H-indol-1-
yl]acetamide (6- (4,4,5,5-Tetramethyl- 1,3,2-dioxaborolan-2-
yl)-1H-indole, R) ##STR486## F.5.8 1.19 (e) 399.4 (M + H).sup.+
Indole-2-boronic-1,4- dicarboxylic acid 1- tert-butyl ester 4-
methyl ester (Preparation #21) ##STR487## F.5.9 1.2 (e) 400.3 (M +
H).sup.+ 4-Diisopropyl carbamoyl-indole-2- boronic-1-carboxylic
acid 1-tert-butyl ester (Preparation #22) ##STR488## F.5.10 1.5 (e)
467 (M - H).sup.- Indole-2-boronic-1,7- dicarboxylic acid 1-
tert-butyl ester 7- methyl ester (Preparation #20) ##STR489##
F.5.11 1.4 (e) 400.3 (M + H).sup.+ 5-Cyano-indole-2-
boronic-1-carboxylic acid 1-tert-butyl ester ##STR490## F.5.12 1.0
(e) 367.4 (M + H).sup.+ 2-[(E)-4-(4,4,5,5- Tetramethyl-[1,3,
2]dioxaborolan-2-yl)- but-3-enyloxy]- tetrahydro-pyran ##STR491##
F.5.13 1.47 (e) 381.2 (M + H).sup.+ 2-((E)-2- Trimethylsilanyl-
vinyl)- [1,3,2]dioxaborolane ##STR492## F.5.14 1.95 (e) 325.1 (M +
H).sup.+ 5-Boronic acid- quinoline ##STR493## F.5.15 0.95 (e) 354.1
(M + H).sup.+ Thiophen-2-yl- boronic acid ##STR494## F.5.16 1.15
(e) 309.0 (M + H).sup.+ 5-Boronic acid- pyrimidine ##STR495##
F.5.17 0.98 (e) 304.9 (M + H).sup.+ 8-Boronic acid- quinoline
##STR496## F.5.18 1.17 (e) 354.1 (M + H).sup.+ 6-Boronic acid-
naphthalen-2-ol ##STR497## F.5.19 1.43 (e) 369.1 (M + H).sup.+
6-Methoxy- naphthalen-2-yl- boronic acid ##STR498## F.5.20 1.80 (e)
383.1 (M + H).sup.+ 5-Boronic acid- isoquinoline ##STR499## F.5.21
1.25 (e) 354.1 (M + H).sup.+ Furan-2-yl-boronic acid ##STR500##
F.5.22 0.75 (e) 302.9 (M + H).sup.+ (5-Boronic acid-
thiophen-2-yl)- methanol ##STR501## F.5.23 0.68 (e) 339.1 (M +
H).sup.+ 5-Phenyl-thiophen-2- yl-boronic acid ##STR502## F.5.24
1.92 (e) 385.1 (M + H).sup.+ 6-Boronic acid- quinoxaline ##STR503##
F.5.25 0.97 (e) 355.1 (M + H).sup.+ 6-Boronic acid- quinoline
##STR504## F.5.26 1.23 (e) 354.1 (M + H).sup.+
2-[2,2']Bithiophenyl- 5-yl-4,4,5,5- tetramethyl-
[1,3,2]dioxaborolane ##STR505## F.5.27 2.00 (e) 391.1 (M + H).sup.+
5-Methyl- benzo[b]thiophen-2- yl-boronic acid ##STR506## F.5.28
1.94 (e) 373.1 (M + H).sup.+ (E)-2-(3-Methoxy- phenyl)-vinyl-
boronic acid ##STR507## F.5.29 1.77 (e) 359.1 (M + H).sup.+
(E)-2-(4-Methoxy- phenyl)-vinyl- boronic acid ##STR508## F.5.30
1.76 (e) 359.1 (M + H).sup.+ 4-Boronic acid- pyridine ##STR509##
F.5.31 0.79 (e) 304.0 (M + H).sup.+ 2-Boronic acid-1H- indole
##STR510## F.5.32 1.21 (e) 342.0 (M + H).sup.+ (3-Boronic acid-
phenyl)-methanol ##STR511## F.5.33 0.56 (e) 333.3 (M + H).sup.+
N-(3-Boronic acid- phenyl)- methanesul- fonamide ##STR512## F.5.34
0.63 (e) 396.3 (M + H).sup.+ [3-(4,4,5,5- Tetramethyl-
[1,3,2]dioxaborolan- 2-yl)-phenyl]- acetonitrile ##STR513## F.5.35
0.84 (e) 342.3 (M + H).sup.+ 3-Boronic acid- benzylamine ##STR514##
F.5.36 0.38 (e) 332.3 (M + H).sup.+ 3-Boronic acid- benzylamine
##STR515## F.5.37 0.63 (e) 381.3 (M + H).sup.+ 3-(4,4,5,5-
Tetramethyl- [1,3,2]dioxaborolan- 2-yl)-benzonitrile ##STR516##
F.5.38 0.87 (e) 328.3 (M + H).sup.+ 2-Boronic acid-6-
methyl-1H-indole ##STR517## F.5.39 1.46 (e) 356.6 (M + H).sup.+
2-Boronic acid-5- methoxy-1H-indole ##STR518## F.5.40 1.18 (e)
372.3 (M + H).sup.+ 2-Boronic acid-5- methyl-1H-indole ##STR519##
F.5.41 1.45 (e) 356.3 (M + H).sup.+
[0534] TABLE-US-00015 TABLE F.6 Examples prepared using general
procedure F using 3-iodo-5-(2-
aminopyrimidin-4-yl)amino-1H-indazole ##STR520##
3-Iodo-5-(2-aminopyrimidin-4-yl)amino-1H-indazole was prepared from
Preparation #28 via general procedure N using
2-amino-4-chloropyrimdine. HPLC R.sub.t Example (min) Boronate
Product # (method) m/z 4-Methylphenyl boronic acid ##STR521## F.6.1
5.80 (a) 317 (M + H).sup.+ 4-[5-(4,4,5,5- Tetramethyl-
[1,3,2]dioxaborolan-2- yl)-pyridin-2-yl]- morpholine ##STR522##
F.6.2 4.40 (a) 389 (M + H).sup.+ 4-(4,4,5,5- Tetramethyl- 1,3,2-
dioxaborolan-2- yl)-1H-pyrazole ##STR523## F.6.3 0.60 (a) 293 (M +
H).sup.+ 4-(4,4,5,5- Tetramethyl- 1,3,2- dioxaborolan-2- yl)aniline
##STR524## F.6.4 0.80 (a) 318 (M + H).sup.+ 2-Methylphenyl boronic
acid ##STR525## F.6.5 1.70 (a) 317 (M + H).sup.+ Phenylboronic acid
##STR526## F.6.6 1.70 (a) 303 (M + H).sup.+ 3-Fluorophenyl boronic
acid ##STR527## F.6.7 1.90 (a) 321 (M + H).sup.+ 2-Fluorophenyl
boronic acid ##STR528## F.6.8 1.60 (a) 321 (M + H).sup.+
4-Fluorophenyl boronic acid ##STR529## F.6.9 1.80 (a) 321 (M +
H).sup.+ Pyridin-3-yl boronic acid ##STR530## F.6.10 0.80 (a) 304
(M + H).sup.+ Thiophen-3-yl boronic acid ##STR531## F.6.11 1.50 (a)
309 (M + H).sup.+ Indol-5-yl boronic acid ##STR532## F.6.12 1.40
(a) 342 (M + H).sup.+ 1-(Tert- butoxycarbonyl)- 1H-pyrrol-2-yl
boronic acid ##STR533## F.6.13 1.10 (a) 292 (M + H).sup.+
4-(Methane sulfonyl)phenyl boronic acid ##STR534## F.6.14 1.20 (a)
381 (M + H).sup.+ Pyrimidin-5-yl boronic acid ##STR535## F.6.15
1.80 (a) 347 (M + H).sup.+ 3-Methylphenyl boronic acid ##STR536##
F.6.16 2.00 (a) 317 (M + H).sup.+ 3-(N,N- Dimethylamino)
phenylboronic acid ##STR537## F.6.17 1.90 (a) 346 (M + H).sup.+
4-Fluoro-3- methylphenyl boronic acid ##STR538## F.6.18 2.00 (a)
335 (M + H).sup.+ 3,4- Difluorophenyl boronic acid ##STR539##
F.6.19 2.10 (a) 339 (M + H).sup.+ 2-Methoxy-5- methylphenyl boronic
acid ##STR540## F.6.20 1.80 (a) 347 (M + H).sup.+ 1-Naphthalene
boronic acid ##STR541## F.6.21 2.10 (a) 353 (M + H).sup.+
3-Quinoline boronic acid ##STR542## F.6.22 1.40 (a) 354 (M +
H).sup.+ 2,3-Dihydro-1- benzofuran-5-yl boronic acid ##STR543##
F.6.23 1.70 (a) 345 (M + H).sup.+ 4-Isoquinoline boronic acid
##STR544## F.6.24 1.40 (a) 354 (M + H).sup.+ Benzo[b]thiophene-
2-boronic acid ##STR545## F.6.25 2.40 (a) 359 (M + H).sup.+
2-Naphthalene boronic acid ##STR546## F.6.26 2.30 (a) 353 (M +
H).sup.+ 2,2'-Bithiophene- 5-boronic acid ##STR547## F.6.27 2.60
(a) 390 (M + H).sup.+
[0535] TABLE-US-00016 TABLE F.7 Examples prepared using general
procedure F from 3-iodo-5-(6-
aminopyrrolo[2,3-d]pyrimidin-4-yl)amino-1H-indazole (prepared from
Preparation #28 using general procedure N starting with 6-amino-
4-chloropyrrolo[2,3-d]pyrimidine.) ##STR548## R.sub.t (min)
Boronate Product Ex # (method) m/z Benzo[b]thiophene-2- boronic
acid ##STR549## F.7.1 2.40 (a) 398 (M + H).sup.+
[0536] TABLE-US-00017 TABLE F.8 Examples prepared using general
procedure F from Preparation #6 ##STR550## Boronic Example R.sub.t
(min) m/z Acid Product # (method) (ESI+) Benzothiophene-2- boronic
acid ##STR551## F.8.1 1.82 (e) 266.0 (M + H).sup.+
[0537] TABLE-US-00018 TABLE F.9 Examples prepared using general
procedure F from Example #2 ##STR552## Boronic Example R.sub.t
(min) m/z Acid Product # (method) (ESI+) Phenylboronic acid
##STR553## F.9.1 1.85 (e) 343.1 (M + H).sup.+
[0538] TABLE-US-00019 TABLE F.10 Examples prepared using general
procedure F from 7-(1H-inden-2-yl)-5-
(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-1-(2-trimethylsilanyl-
ethoxymethyl)-1H-indazole (Preparation #23 then E) ##STR554##
Example R.sub.t (min) Aryl Halide Product # (method) m/z
7-Benzo[b]thiophen- 2-yl-5-bromo-1- (2-trimethylsilanyl-
ethoxymethyl)-1H- indazole (Preparation #23) ##STR555## F.10.1 4.9
(h) 759 (M + H).sup.+
[0539] TABLE-US-00020 TABLE F.11 Examples prepared using general
procedure F from Example #N.2.2 ##STR556## m/z or .sup.1H NMR
Boronate/boronic Example R.sub.t/min (d.sub.6 DMSO, acid Precursor
Product # (method) 400 MHz) Thiophen-3-yl- boronic acid ##STR557##
F.11.1 1.13 (e) 309.3 (M + H).sup.+ Naphthalen-2-yl- boronic acid
##STR558## F.11.2 1.59 (e) 351.3 (M + H).sup.+ p-Tolyl- boronic
acid ##STR559## F.11.3 1.36 (e) 317 (M + H).sup.+ Phenyl-boronic
acid ##STR560## F.11.4 1.18 (e) 303 (M + H).sup.+ 5-Boronic
acid-1H- indole ##STR561## F.11.5 0.84 (e) 342.3 (M + H).sup.+
Benzofuran-2-yl- boronic acid ##STR562## F.11.6 1.52 (e) 343.3 (M +
H).sup.+ 4-Chloro-phenyl- boronic acid ##STR563## F.11.7 1.58 (e)
337.2 (M + H).sup.+ 3-Boronic acid- quinoline ##STR564## F.11.8
1.09 (e) 354 (M + H).sup.+ 4-Phenol- boronic acid ##STR565## F.11.9
0.73 (e) 319.3 (M + H).sup.+ N-(4-boronic acid- phenyl)-acetamide
##STR566## F.11.10 0.67 (e) 360 (M + H).sup.+ Furan-3-yl- boronic
acid ##STR567## F.11.11 1.12 (e) 293.2 (M + H).sup.+ 2-Boronic
acid- 1H-pyrrole ##STR568## F.11.12 0.85 (e) 292 (M + H).sup.+
3-Methoxy-phenyl- boronic acid ##STR569## F.11.13 1.47 (e) 333.2 (M
+ H).sup.+ (4-Boronic acid- phenyl)-dimethyl- amine ##STR570##
F.11.14 1.53 (e) 346 (M + H).sup.+ (3-Boronic acid-
phenyl)-dimethyl- amine ##STR571## F.11.15 1.57 (e) 346 (M +
H).sup.+ 3-Boronic acid- benzamide ##STR572## F.11.16 0.65 (e) 346
(M + H).sup.+ (E)-Styryl- boronic acid ##STR573## F.11.17 1.50 (e)
329.2 (M + H).sup.+ 4-Fluoro-3-methyl- phenyl-boronic acid
##STR574## F.11.18 1.67 (e) 335.2 (M + H).sup.+
[0540] TABLE-US-00021 TABLE F.12 Examples prepared using general
procedure F from Example X.1.2 ##STR575## Halide Precursor Product
Example # R.sub.t/min(method) m/z(ESI+) 3-Hydroxybenzenebo- ronic
acid ##STR576## F.12.1 1.07(e) 226.3 (M + H).sup.+ Biphenyl-2-ol-5-
(4,4,5,5- tetramethyl-1,3,2- dioxaborolan-2-yl) (E) ##STR577##
F.12.2 1.59(e) 302.3 (M + H).sup.+ 1H-indazole-5- (4,4,5,5-
tetramethyl-1,3,2- dioxaborolan-2-yl) (E) ##STR578## F.12.3 1.03(e)
250.3 (M + H).sup.+ 5-indolylboronic acid ##STR579## F.12.4 1.38(e)
249.3 (M + H).sup.+ 2-chloro- phenylamine-4- (4,4,5,5-
tetramethyl-1,3,2- dioxaborolan-2-yl) (E) ##STR580## F.12.5 1.40(e)
259.2 (M + H).sup.+ 2- Benzo[b]thiophen- 2-yl-4-(4,4,5,5-
tetramethyl-1,3,2- dioxaborolan-2-yl) phenol (E) ##STR581## F.12.6
1.84(e) 358.3 (M + H).sup.+ 1H-indazol-3- ylamine-5-(4,4,5,5-
tetramethyl-1,3,2- dioxaborolan-2-yl) (E) ##STR582## F.12.7 0.64(e)
265.3 (M + H).sup.+ 4- hydroxybenzenebor- onic acid ##STR583##
F.12.8 0.97(e) 226.2 (M + H).sup.+ 2-chloro-4-(4,4,5,5-
tetramethyl-1,3,2- dioxaborolan-2-yl) phenol (E) ##STR584## F.12.9
1.30(e) 260.2 (M + H).sup.+ 4-Benzyloxy-3- chloro-phenyl- boronic
acid ##STR585## F.12.10 2.08(e) 350.2 (M + H).sup.+ 2-
Benzo[b]thiophen- 2-yl-boronic acid* ##STR586## F.12.11 1.93(e)
266.3 (M + H).sup.+ 5-(4,4,5,5- Tetramethyl- [1,3,2]dioxa
borolan-2-yl)- indazole-1- carboxylic acid tert-butyl ester*
##STR587## F.12.12 1.01(e) 250.3 (M + H).sup.+ Pyridine-4-yl-
boronic acid* ##STR588## F.12.13 0.82(e) 211 (M + H).sup.+
Pyridine-3-yl- boronic acid ##STR589## F.12.14 1.03(e) 211 (M +
H).sup.+ Pyridine-3-yl- boronic acid** ##STR590## F.12.15 0.90(e)
211 (M + H).sup.+ *Reacted with 3-Amino-4-bromo-indazole **Reacted
with 3-Amino-6-bromo-indazole
[0541] TABLE-US-00022 TABLE F.13 Examples prepared using general
procedure F from Example #B.1.2 ##STR591## m/z or .sup.1H
NMR(d.sub.6 DMSO, Boronic acid Product Example #
R.sub.t/min(method) 400 MHz) Pyridine-3-yl- boronic acid ##STR592##
F.13.1 1.81(e) 313.2 (M + H).sup.+ Benzonitrile-3- yl-boronic acid
##STR593## F.13.2 2.08(e) 337.3 (M - H).sup.- Benzonitrile-2-
yl-boronic acid ##STR594## F.13.3 1.98(e) 337.2 (M - H).sup.-
Benzamide-2-yl- boronic acid ##STR595## F.13.4 1.49(e) 357.1 (M +
H).sup.+ Benzamide-3-yl- boronic acid ##STR596## F.13.5 1.51(e) 355
(M + H).sup.+ 5-(boronic acid- 2-yl)- isoquinoline ##STR597##
F.13.6 1.86(e) 363.2 (M + H).sup.+ 4-(boronic acid- 2-yl)-benzoic
acid methyl ester ##STR598## F.13.7 2.31(e) 370 (M + H).sup.+
[0542] TABLE-US-00023 TABLE F.14 Examples prepared using General
Procedure F from Preparation #56 ##STR599## m/z or .sup.1H
NMR(d.sub.6 DMSO, Halide Product Example # R.sub.t/min(method) 400
MHz) 4-Iodo-pyridine ##STR600## F.14.1 2.18(e) 261 (M + H).sup.+
2-Bromo- pyridine ##STR601## F.14.2 2.53(e) 261 (M + H).sup.+
3-Benzyloxy-5- bromo-pyridine ##STR602## F.14.3 2.98(e) 367 (M +
H).sup.+
[0543] TABLE-US-00024 TABLE F.15 Examples prepared using general
procedure F using 5-(Dimethylamino-
methyleneamino)-3-iodo-pyrrolo[2,3-c]pyridine-1-carboxylic acid
tert-butyl ester followed by deprotection (outlined in Procedure
#5, step 1) ##STR603##
5-(Dimethylamino-methyleneamino)-3-iodo-pyrrolo[2,3-c]pyridine-1-carboxyli-
c acid tert- butyl ester was prepared according to Preparation #4
via Preparation 10a and 10b using 4-
Methyl-5-nitro-pyridin-2-ylamine. Boronate Product Example #
R.sub.t/min(method) m/z 2-Chloro-4- (4,4,5,5- tetramethyl-
[1,3,2]dioxaboro- lan-2-yl)-phenol ##STR604## F.15.1 1.16(e) 260.2
(M + H).sup.+ 2-(3- Benzo[b]thiophen- 2-yl-4- methoxy-
phenyl)-4,4,5,5- tetramethyl- [1,3,2]dioxaboro- lane ##STR605##
F.15.2 1.89(e) 358.3 (M + H).sup.+ 4-Boronic acid- N-cyclopropyl-
benzamide ##STR606## F.15.3 0.61(e) 293.2 (M + H).sup.+ 3-boronic
acid- benzamide ##STR607## F.15.4 0.46(e) 253 (M + H).sup.+
Indole-6-boronic acid ##STR608## F.15.5 1.14(e) 249.2 (M + H).sup.+
4-boronic acid- benzoic acid ##STR609## F.15.6 0.44(e) 254.2 (M +
H).sup.+ 4-Boronic acid- N-methyl- benzenesulfona- mide ##STR610##
F.15.7 0.69(e) 303.2 (M + H).sup.+ 4-Boronic acid- benzenesulfona-
mide ##STR611## F.15.8 0.56(e) 289.2 (M + H).sup.+ 4-Boronic acid-
benzylamine ##STR612## F.15.9 1.44(e) 239.2 (M + H).sup.+ 3-boronic
acid- N,N-dimethyl- benzamide ##STR613## F.15.10 0.60(e) 281.2 (M +
H).sup.+ 4-boronic acid- N,N-dimethyl- benzamide ##STR614## F.15.11
0.56(e) 281.2 (M + H).sup.+ 3-boronic acid- benzamide ##STR615##
F.15.12 0.48(e) 253.2 (M + H).sup.+
General Procedure G: Deprotection of a SEM-Protected Indazole
##STR616##
[0544] A mixture of a SEM protected indazole in a solvent (for
example MeOH, EtOH, i-PrOH, CH.sub.2Cl.sub.2 or dioxane, preferably
MeOH) is treated with an excess amount of a mineral acid (for
example HCl, HF or TFA, preferably HCl) and then stirred at about
25-85.degree. C. (preferably about 65.degree. C.) for about 1-24
hours (preferably about 1 hour). The solvent is evaporated and the
product isolated and further purified by crystallization or
chromatography.
Illustration of General Procedure G:
Example #14
5-(7-Benzo[b]thiophen-2-yl-1H-indazol-5-yl)-pyrimidin-2-ylamine
[0545] ##STR617##
[0546] A mixture of 6N HCl (1 mL) and
5-[7-benzo[b]thiophen-2-yl-2-(2-trimethylsilanyl-ethoxymethyl)-2H-indazol-
-5-yl]-pyrimidin-2-ylamine (0.063 g, 0.133 mmol) (prepared from
7-Benzo[b]thiophen-2-yl-5-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)--
2-(2-trimethylsilanyl-ethoxymethyl)-2H-indazole (Preparation #23,
E) and 5-iodo-pyrimidin-2-ylamine according to general procedure F)
in MeOH (2 mL) was heated to about 65.degree. C. for about 1 hour.
The solvents were removed under reduced pressure and the residue
treated with NaHCO.sub.3 (4 mL) and EtOAc (2 mL). The insoluble
product was collected by filtration then dried to give
5-(7-benzo[b]thiophen-2-yl-1H-indazol-5-yl)-pyrimidin-2-ylamine (27
mg, 60%) as an off white solid; (DMSO-d.sub.6, 400 MHz)
.delta.13.56 (bs, 1H), 8.66 (s, 2H), 8.29 (s, 1H), 8.15 (s, 1H),
8.04 (m, 2H), 7.93 (m, 1H), 7.79 (d, 1H), 7.43 (m, 2H), 7.76 (bs,
2H); RP-HPLC (Table 1, Method e) R.sub.t=2.03 MS m/z: (M-H).sup.-
341.7. TABLE-US-00025 TABLE G Examples prepared using general
procedure G ##STR618## Precursor Product Example # HPLC
R.sub.t(min)(method) m/z Preparation #5 ##STR619## G.1 1.68(e)
383.0 (M + H).sup.+ {3-[7-(7- Benzo[b]thiophen-2- yl-1-(2-
trimethylsilanyl- ethoxymethyl)-1H- indazol-5-yl)-2-
(dimethylamino- methyleneamino)- pyrrolo[3,2- d]pyrimidin-5-yl]-
propyl}-carbamic acid tert-butyl ester (Preparation #5, R (using
tert-butyl #3- bromopropyl carbamate) ##STR620## G.2 1.29(e) 440.3
(M + H).sup.+ {2-[7-(7- Benzo[b]thiophen-2- yl-1-(2-
trimethylsilanyl- ethoxymethyl)-1H- indazol-5-yl)-2-
(dimethylamino- methyleneamino)- pyrrolo[3,2- d]pyrimidin-5-yl]-
ethyl}-carbamic acid tert-butyl ester (Preparation #5, R (using
#tert-butyl 2- bromoethyl carbamate)) ##STR621## G.3 1.30(e) 426.3
(M + H).sup.+ {2-Amino-7-[7- benzo[b]thiophen-2- yl-1-(2-
trimethylsilanylethoxy methyl)-1H-indazol-5- yl]-pyrrolo[3,2-
d]pyrimidin-5-yl}- acetic acid (Preparation #5, R (using methyl 2-
bromoacetate), V) ##STR622## G.4 0.97(e) 441.3 (M + H).sup.+
2-{2-Amino-7-[7- benzo[b]thiophen-2- yl-1-(2-
trimethylsilanylethoxy methyl)-1H-indazol-5- yl]-pyrrolo[3,2-
d]pyrimidin-5- yl}propionic acid (Preparation #5, R (using
tert-butyl 2- bromopropionoate), #Q, V) ##STR623## G.5 1.02(e)
455.2 (M + H).sup.+ 7-[7- Benzo[b]thiophen-2- yl-1-(2-
trimethylsilanyl- ethoxymethyl)-1H- indazol-5-yl]-5-
cyclopentyl-5H- pyrrolo[3,2-d]pyrimidin-2- ylamine (Preparation
#5a, T (using cyclopentanol) ##STR624## G.6 2.15(e) 451.3 (M +
H).sup.+ 7-[7- Benzo[b]thiophen-2- yl-1-(2- trimethylsilanyl-
ethoxymethyl)-1H- indazol-5-yl]-5- isopropyl-5H- pyrrolo[3,
2-d]pyrimidin-2- ylamine (Preparation #5a, T (isopropanol))
##STR625## G.7 1.96(e) 425.3 (M + H).sup.+ 3-{2-Amino-7-[7-
benzo[b]thiophen-2- yl-1-(2- trimethylsilanyl- ethoxymethyl)-1H-
indazol-5-yl]- pyrrolo[3,2- d]pyrimidin-5-yl}- propionic acid
(Preparation #5, R (3- bromo ethyl propionate), #V) ##STR626## G.8
1.16(e) 453.1 (M + H).sup.+ 7-[7- Benzo[b]thiophen-2- yl-1-(2-
trimethylsilanyl- ethoxymethyl)-1H- indazol-5-yl]-5-(2-
morpholin-4-yl-ethyl)- 5H-pyrrolo[3,2- d]pyrimidin-2-ylamine N,N-
dimethylformamidine (Preparation #5, R (using #1-(2-
bromoethyl)morpholine) ##STR627## G.9 1.85(e) 494.2 (M - H).sup.+
3-{2-Amino-7-[7- benzo[b]thiophen-2- yl-1-(2-
trimethylsilanylethoxy methyl)-1H-indazol-5- yl]-pyrrolo[3,2-
d]pyrimidin-5- yl}propionamide (Preparation #5, R (using methyl 3-
bromopropionate, M) ##STR628## G.10 1.46(e) 454.3 (M + H).sup.+
4-{2-[7-[7- Benzo[b]thiophen-2- yl-1-(2- trimethylsilanyl-
ethoxymethyl)-1H- indazol-5-yl]-2- (dimethylamino- methyleneamino)-
pyrrolo[3,2- d]pyrimidin-5-yl]- ethyl}-piperidine-1- carboxylic
acid tert- butyl ester (Preparation #5, R (using #4-(2-bromo-
ethyl)-piperidine-1- carboxylic acid tert- butyl ester) ##STR629##
G.11 1.58(e) 494.3 (M + H).sup.+ N-Methyl-3-{5-amino- 3-[7-
benzo[b]thiophen-2- yl-1-(2- trimethylsilanylethoxy meth-
yl)-1H-indazol-5-yl]- pyrrolo[3,2- d]pyrimidin-1-yl}- propionamide
(Preparation #5, R (3- bromo #ethyl propionate), M) ##STR630## G.12
1.56(e) 468.4 (M + H).sup.+ 3-{2-(Dimethylamino- methyleneamino)-7-
[7-benzo[b]thiophen- 2- yl-1-(2- trimethylsilanyl-
ethoxymethyl)-1H- indazol-5-yl]- pyrrolo[3,2-d]pyrimidin-5-yl}-
propionic acid methyl ester (Preparation #5, R (using 3-bromo
#methyl propionate)) ##STR631## G.13 1.87(e) 469.0 (M + H).sup.+
3-{2-Amino-7-[7- benzo[b]thiophen-2- yl-1-(2- trimethylsilanyl-
ethoxymeth- yl)-1H-indazol-5-yl]-
pyrrolo[3,2-d]pyrimidin-5-yl}-N,N- dimethyl propionamide
(Preparation #5, R (3- bromo methyl propionate), M) ##STR632## G.14
1.73(e) 482.3 (M + H).sup.+ 7-[7- Benzo[b]thiophen-2- yl-1-(2-
trimethylsilanyl- ethoxymethyl)-1H- indazol-5-yl]-5-(2-
piperidin-3-yl-ethyl)- 5H-pyrrolo[3,2- d]pyrimidin-2-yl-N,N-
dimethylamino- methyleneamine (Preparation #5, R (using 3-(2-bromo-
ethyl)-piperidine-1- carboxylic acid #tert- butyl ester) ##STR633##
G.15 1.58(e) 494.0 (M + H).sup.+ 3-{2-Amino-7-[7-
benzo[b]thiophen-2- yl-1-(2- trimethylsilanyl- ethoxymeth-
yl)-1H-indaozl-5-yl]- pyrrolo[3,2-d]pyrimidin-5-yl}-N-(2-
amino-ethyl)- propionamide (Preparation #5, R (3- bromo methyl
propionate), M) ##STR634## G.16 1.31(e) 497.0 (M + H).sup.+
{3-[7-(7- Benzo[b]thiophen-2- yl-1-(2- trimethylsilanyl-
ethoxymethyl)-1H- indazol-5-yl)-2- (dimethylamino- methyleneamino)-
pyrrolo[3,2- d]pyrimidin-5-yl]- butyl}-carbamic acid tert-butyl
ester (Preparation #5, R (using tert-butyl #4- bromo-butyl
carbamate) ##STR635## G.17 1.40(e) 454.1 (M + H).sup.+ 7-[7-
Benzo[b]thiophen-2- yl-1-(2- trimethylsilanyl- ethoxymethyl)-1H-
indazol-5-yl]-5-(3- methoxy-propyl)-5H- pyrrolo[3,2-
d]pyrimidin-2-yl-N,N- dimethylamino- methyleneamine (Preparation
#5, R (using #1-bromo-3- methoxypropane)) ##STR636## G.18 2.24(e)
455.0 (M + H).sup.+ 2-(3-{2- (Dimethylamino- methyleneamino)-7-
[7-benzo[b]thiophen- 2-yl-1-(2- trimethylsilanyl- ethoxymethyl)-1H-
indazol-5-yl]- pyrrolo[3,2-d]pyrimidin-5-yl}- propan-1-
oxy)tetrahydropyran (Preparation #5, R (using #2-(3-bromo-
propan-1-oxy) tetrahydropyran)) ##STR637## G.19 1.64(e) 441.3 (M +
H).sup.+ 2-{2-Amino-7-[7- benzo[b]thiophen-2-yl-1-(2-
trimethylsilanyl- ethoxymeth- yl)-1H-indazol-5-yl]-
pyrrolo[3,2-d]pyrimidin-5-yl}- acetamide (Preparation #5, R (using
2-bromo methyl acetate), M) ##STR638## G.20 1.49(e) 440.0 (M +
H).sup.+ 4-{2-Amino-7-[7- benzo[b]thiophen-2- yl-1-(2-
trimethylsilanyl- ethoxymeth- yl)-1H-indazol-5-yl]- pyrrolo[3,2-
d]pyrimidin-5-yl}- butyric acid (Preparation #5, R (using methyl 4-
bromo-butanoate), V) ##STR639## G.21 1.61(e) 467.0 (M - H).sup.+
4-{2-Amino-7-[7- benzo[b]thiophen-2- yl-1-(2- trimethylsilanyl-
ethoxymeth- yl)-1H-indaozl-5-yl]- pyrrolo[3,2- d]pyrimidin-5-yl}-
butyramide (Preparation #5, R (using methyl 4- bromo-butanoate), M)
##STR640## G.22 1.49(e) 468.2 (M + H).sup.+ 3-{2-Amino-7-[7-
benzo[b]thiophen-2- yl-1-(2- trimethylsilanyl- ethoxymeth-
yl)-1H-indazol-5-yl]- pyrrolo[3,2-d]pyrimidin-5-yl}-2-
methylpropionic acid (Preparation #5, R (methyl 3-bromo 2- methyl
propionoate), V ##STR641## G.23 1.63(e) 469.2 (M + H).sup.+
3-{2-Amino-7-[7- benzo[b]thiophen-2- yl-1-(2- trimethylsilanyl-
ethoxymeth- yl)-1H-indaozl-5-yl]- pyrrolo[3,2-d]pyrimidin-5-yl}-2-
methyl-propionic acid methyl ester (Preparation #5, R (using methyl
3-bromo 2-methyl #propionoate)) ##STR642## G.24 1.96(e) 483.3 (M +
H).sup.+ 2-Amino-7-[7- benzo[b]thiophen-2- yl-1-(2-
trimethylsilanyl- ethoxymethyl)- 1H-indazol-5-yl]- pyrrolo[3,2-
d]pyrimidine-5- carboxylic acid isopropyl ester (Preparation #5, T
(using diisopropyl azodicarboxylate) ##STR643## G.25 2.22(e) 469.1
(M + H).sup.+
General Procedure H: Acid Cleavage of a TBDMS-Protecting Group
##STR644##
[0547] To a mixture of a TBDMS protected substrate in an organic
solvent (for example methanol, ethanol, ispropanol,
CH.sub.2Cl.sub.2, or dioxane, preferably methanol) is added an
excess amount of an acid (5-50 equivalents, preferably 20
equivalents) (for example HCl, or TFA, preferably HCl). The
reaction mixture is then stirred at about 25-85.degree. C.
(preferably about 65.degree. C.) for about 0.5-24 hours (preferably
about 1 hour). The solvent is evaporated and the product is
isolated by crystallization or by chromatography.
Illustration of General Procedure H
Example #30
(3-[(2-Amino-pyrimidin-4-yl)-(7-benzo[b]thiophen-2-yl-1H-indazol-5-yl)-ami-
no]-propan-1-ol
[0548] ##STR645##
[0549] 6N hydrochloric acid (1 mL) was added to a mixture of
N.sup.4-(7-benzo[b]thiophen-2-yl-1H-indazol-5-yl)-N.sup.4-[3-(tert-butyl--
dimethyl-silanyloxy)-propyl]-pyrimidine-2,4-diamine (prepared from
example #F.8.1, via general procedures O then N, 0.179 g, 0.339
mmol) in ethanol (2 mL). The reaction mixture was heated to about
65.degree. C. for about 1 hour then cooled to about ambient
temperature. The solvents were evaporated and the residue was
purified by reverse phase chromatography (Thermo Hypersil-Keystone
250.times.21.2 mm 8.mu. Hypersil.RTM. HS C18 column; 5%
acetonitrile/0.1 M aqueous ammonium acetate-100% acetonitrile over
20 min, 100% acetonitrile hold 5 minutes, 21 mL/min) to afford
(3-[(2-amino-pyrimidin-4-yl)-(7-benzo[b]thiophen-2-yl-1H-indazol-5-yl)-am-
ino]-propan-1-ol (0.022 g, 0.053 mmol) as an off white solid;
RP-HPLC (Table 1, Method e) R.sub.t 1.77 min.; m/z: (M+H).sup.+
417.1. TABLE-US-00026 TABLE H.1 Examples prepared using general
procedure H ##STR646## TBDMS protected alcohol Product Example #
R.sub.t/min(method) m/z(ESI+) N'4'-(7- Benzo[b]thiophen-2-yl-
1H-indazol-5-yl)-N'4'- [2-(tert-butyl-dimethyl- silanyloxy)-ethyl]-
pyrimidine- 2,4-diamine (Example #F.8.1, O then N) ##STR647## H.1.1
1.52(e) 390 (M + H).sup.+
General Procedure I: Deprotection of a Benzyl Ether ##STR648##
[0550] A mixture of a benzyl protected ether (1 equivalent) and a
Pd catalyst (for example, 10 wt. % Pd on carbon or palladium (II)
oxide, preferably 10 wt. % Pd on carbon) (5-10 mol %, preferably 7
mol %) in a degassed organic solvent (for example MeOH or EtOH,
preferably MeOH) is shaken under an atmosphere of hydrogen gas at
about 30-50 psi (preferably 40 psi) at about 10-50.degree. C.
(preferably about 25.degree. C.) for about 2-24 hours (preferably
about 18 hours). The reaction mixture is evacuated, flushed with an
inert gas (for example nitrogen or argon, preferably nitrogen) and
filtered. The solvents are removed under reduced pressure to afford
the product that can be further purified by chromatography or
crystallization.
Illustration of General Procedure I:
Example #15
5-[3-(1H-Pyrrol-2-yl)-1H-indazol-5-yl]-pyridin-3-ol
[0551] ##STR649##
[0552] A mixture of
5-(5-benzyloxy-pyridin-3-yl)-3-(1H-pyrrol-2-yl)-1H-indazole
(Preparation #16c, E and F (using 5-benzyloxy-3-bromopyridine),
0.015 g, 0.4 mmol) in MeOH (5 mL) and 10 wt. % Pd/C (3 mg) was
shaken under an atmosphere of hydrogen (about 40 psi) for about 24
hours. The crude product was filtered and the solvent was removed
under reduced pressure to yield
5-[3-(1H-pyrrol-2-yl)-1H-indazol-5-yl]-pyridin-3-ol (0.088 g, 80%);
RP-HPLC (Table 1, Method e) R.sub.t=1.78 mnin; m/z: (M+H).sup.+
277, (M-H).sup.- 275. General Procedure J: Reduction of an Aldehyde
to an Alcohol ##STR650##
[0553] A mixture of an aldehyde (1-1.2 equivalents, preferably 1
equivalent) and a reducing agent (for example borane,
borane-pyridine, borane-diemethylsulfide, LiBH.sub.4 or NaBH.sub.4,
preferably NaBH.sub.4) (1.0-3.0 equivalents, preferably 2.0
equivalents) in an organic solvent (for example, DMF, dioxane, THF,
MeOH or EtOH, preferably MeOH) is stirred at about 5-65.degree. C.
(preferably about 25.degree. C.) for about 0.5-24 hours (preferably
about 1 hour) under an inert atmosphere. If heated, the mixture is
allowed to cool to ambient temperature, and the solvent is removed
under reduced pressure. The solid residue can then be purified by
chromatography or crystallization.
Illustration of General Procedure J:
Example #16
[3-(7-Benzo[b]thiophen-2-yl-1H-indazol-5-yl)-phenyl]-methanol
[0554] ##STR651##
[0555] A mixture of
3-(7-benzo[b]thiophen-2-yl-1H-indazol-5-yl)-benzaldehyde
(Preparation #25, F (using 3-bromobenzaldehyde), 50 mg, 0.14 mmol),
and NaBH.sub.4 (0.01 g, 0.26 mmol) in MeOH (2 mL) was stirred at
ambient temperature for about 1 hour. The reaction mixture was
concentrated under reduced pressure then the residue was purified
by reverse phase preparative HPLC (Thermo Hypersil-Keystone
250.times.21.2 mm 8.mu. Hypersil.RTM. HS C18 column; 5%
CH.sub.3CN/50 mM aqueous ammonium acetate hold for 5 min; 5-50%
CH.sub.3CN/50 mM aqueous ammonium acetate over 20 min; 50-100%
CH.sub.3CN/50 mM aqueous ammonium acetate over 1 min; hold at 100%
CH.sub.3CN for 5 minutes, 21 mL/min) to yield
[3-(7-benzo[b]thiophen-2-yl-1H-indazol-5-yl)-phenyl]-methanol (6
mg, 12%); (DMSO-d.sub.6, 400 MHz) 8.8 (d, 1H), 8.55 (d, 1H), 8.37
(s, 1H), 8.19 (d, 1H), 8.18 (s, 1H), 8.10 (t, 1H), 8.04 (dd, 1H),
7.93 (dd, 1H), 7.89 (d, 1H, 7.45 (m, 2H), 5.40 (t, 1H), 4.6 (d,
2H); RP-HPLC (Table 1, Method e) R.sub.t=1.85 min; m/z: (M-H).sup.-
355.8. General Procedure K: Nucleophilic Displacement of an Aryl
Sulfone ##STR652##
[0556] An aryl sulfone is treated with a large excess of a
nucleophile (for example an amine or an alcohol, preferably an
amine) (100-500 equivalents, preferably 250 equivalents) in the
absence of an organic solvent. The mixture is stirred for 5-60
hours (preferably about 16 hours) at about 0-100.degree. C.
(preferably about 20.degree. C.). If heated, the mixture is allowed
to cool to ambient temperature, filtered, and the solids are
further purified by crystallization or chromatography if
necessary.
Illustration of General Procedure K
Example #17
(7-Benzo[b]thiophen-2-yl-1H-indazol-5-yl)-(2-hydrazino-pyrimidin-4-yl)-ami-
ne
[0557] ##STR653##
[0558]
(7-Benzo[b]thiophen-2-yl-1H-indazol-5-yl)-(2-methanesulfonyl-pyrim-
idin-4-yl)-amine (Preparation #8, 20 mg, 0.048 mmol) was treated
with hydrazine (0.4 mL, 12.2 mmol) at ambient temperature for about
5 hours. A solid was filtered off and was further purified by
trituration in dichloromethane followed by filtration to yield
(7-benzo[b]thiophen-2-yl-1H-indazol-5-yl)-(2-hydrazino-pyrimidin-4-yl)-am-
ine (4 mg, 23% yield); LC/MS (method f) R.sub.t 6.0 min; m/z
(ESI-): (M-H).sup.+ 371.7. TABLE-US-00027 TABLE K Examples using
general procedure K prepared from (7-benzo[b]thiophen-2-yl-1H-
indazol-5-yl)-(2-methanesulfonyl-pyrimidin-4-yl)-amine (Preparation
#8) ##STR654## m/z Nucleophile Product Example #
R.sub.t(min)(method) (ESI-): (M - H).sup.+
N',N'-Dimethyl-ethane-1,2- diamine ##STR655## K.1.1 1.7(e) 430.1 (M
- H).sup.+ Pyrrolidin-3-ol ##STR656## K.1.2 1.7(e) 429.1 (M -
H).sup.+ 2-Amino-ethanol ##STR657## K.1.3 1.6(e) 403.1 (M -
H).sup.+ 2-Methoxy-ethylamine ##STR658## K.1.4 1.8(e) 417.1 (M -
H).sup.+ 2-Dimethylamino-ethanol ##STR659## K.1.5 1.9(e) 431.1 (M -
H).sup.+ 2-(2-Hydroxy-ethylamino)- ethanol ##STR660## K.1.6 1.6(e)
447.1 (M - H).sup.+
General Procedure L: Reduction of a Nitroaromatic Compound to an
Aniline
[0559] To a solution of a nitroaromatic compound (preferably 1
equivalent) in a solvent (for example, EtOAc, EtOH, HOAc, 9M
NH.sub.4OH, preferably EtOAc) is added a reducing reagent (for
example, hydriodic acid, iron powder, iron sulfate hydrate, tin
chloride dehydrate, or palladium on carbon) (0.2-10 equivalents,
preferably 3 equivalents). The reaction mixture is stirred at about
20-100.degree. C. (preferably about 90.degree. C.) for about 1-20
hours (preferably about 2 hours). A hydrogen atmosphere (about
15-60 psi, preferably about 40 psi) is when a palladium catalyst is
employed. If iron sulfate hydrate is used as the reducing reagent
the mixture is filtered hot and then acidified with HOAc to about
pH=4, then the product is filtered off and rinsed with water. If
tin chloride or iron powder are used the mixture is allowed to cool
to ambient temperature and then diluted with an organic solvent
(for example, EtOAc or CH.sub.2Cl.sub.2, preferably
CH.sub.2Cl.sub.2). If palladium is used as the reducing reagent the
reaction mixture is filtered through celite and rinsed with organic
solvent. If hydriodic acid is used, the organic layer is washed
with saturated aqueous sodium thiosulfate. The organic layer is
then washed with an aqueous base solution (for example,
Na.sub.2CO.sub.3 or NaOH, preferably NaOH). The organic layer is
separated, dried over a desiccant, and concentrated to give the
aniline compound.
Illustration of General Procedure L
[0560] Preparation #28: 3-Iodo-1H-indazol-5-ylamine ##STR661##
[0561] A suspension of 3-iodo-5-nitro-1H-indazole (2.0 g, 6.92
mmol) in stabilized hydroiodic acid (57% wt aqueous solution, 21
mL) was heated at about 90.degree. C. for about 2 hours. The
reaction mixture became homogeneous as the reaction progressed.
After cooling to ambient temperature, the dark purple mixture was
diluted with EtOAc (500 mL) and washed successively with saturated
aqueous sodium thiosulfate (200 mL), saturated aqueous NaHCO.sub.3
(200 mL) and brine (200 mL). The colorless organic layer was dried
over anhydrous magnesium sulfate, and concentrated to dryness to
give 3-iodo-1H-indazol-5-ylamine: .sup.1H NMR (DMSO-d.sub.6, 400
MHz) .delta. 13.03 (s, 1H), 7.26 (d, 1H), 6.85 (m, 1H), 6.44(d,
1H), 5.03 (s, 2H); LC/MS (30% to 95% acetonitrile/0.01M aqueous
ammonium acetate over 4.5 min at 0.8 mL/min; .lamda.=190-700 nm;
Genesis C18, 3 .mu.m, 30.times.4.6 mm column; Electrospray
ionization method observing both +ve and -ve ions) R.sub.t 1.25
min.; m/z: 260 (M+H).sup.+. General Procedure M: Amide Formation
from an Ester ##STR662##
[0562] At room temperature, a mixture of an ester (1.0 equivalent)
and an amine (for example, ammonia, a primary amine or a second
amine) (10-500 equivalents, preferably 20 equivalents) optionally
diluted with an alcoholic solvent (MeOH, EtOH or i-PrOH, preferably
i-PrOH) is heated at about 60-140.degree. C. (preferably about
100.degree. C.) in a sealed vessel with stirring for about 0.5-7
days (preferably about 1 day). The mixture is cooled to ambient
temperature, concentrated and is further purified by chromatography
or crystallization, or used in a subsequent step without further
purification.
Illustration of General Procedure M:
See Example #1.
[0563] General Procedure N: Nucleophilic Substitution of Aromatic
Halide with an Amino Compound ##STR663##
[0564] To a solution of an amine (1.0 equivalent) with or without a
base (Et.sub.3N or DIEA, preferably Et.sub.3N) in an organic
solvent (for example, EtOH, MeOH, or dioxane, preferably EtOH) is
added an aromatic halide (1.0-10 equivalents, preferably 1.0
equivalent). The reaction mixture is heated at about 25-160.degree.
C. (preferably about 80.degree. C.) with stirring for about 20
minutes-4 hours (preferably about 30 minutes) or heated in a
microwave reactor at about 120-180.degree. C. (preferably about
150.degree. C.) for about 5-30 minutes (preferably about 10
minutes). The mixture is allowed to cool to ambient temperature.
Then either the solvent is removed under reduced pressure or the
mixture is filtered to give crude product that is then purified
directly by chromatography or crystallization or submitted to the
following aqueous work up. The crude material is suspended in a
basic solution (for example, NH.sub.4OH in MeOH, saturated aqueous
NaHCO.sub.3 or 2M aqueous Na.sub.2CO.sub.3, preferably saturated
aqueous NaHCO.sub.3) then filtered and washed with an organic
solvent (for example MeOH, EtOAc, or CH.sub.2Cl.sub.2). If needed,
the resulting solid can then be purified by chromatography or
crystallization. If a tert-butoxycarbonyl (Boc) protected diamine
is used then the material is suspended in a mixture of methanol/6 N
hydrochloric acid and heated to about 65.degree. C. for about one
hour then cooled, concentrated and purified by chromatography or
crystallization
Illustration of General Procedure N:
[0565] Preparation #46.
(7-Benzo[b]thiophen-2-yl-1H-indazol-5-yl)-(2-methanesulfonyl-pyrimidin-4--
yl)-amine ##STR664##
[0566] To a mixture of 4-chloro-2-methanesulfonyl-pyrimidine (2.54
g, 13.2 mmol) in DME (20 mL) was added a mixture of
7-benzo[b]thiophen-2-yl-1H-indazol-5-ylamine (Example #F.8.1, 1.95
g, 7.35 mmol) and Et.sub.3N (1.43 mL, 10.3 mmol) in DME (160 mL).
The reaction mixture was stirred at room temperature for about 16
hours then filtered, then filtrate was adsorbed onto alumina. The
mixture was purified by flash column chromatography over alumina
using CH.sub.2Cl.sub.2/MeOH (99:1) as an eluent to yield the
initial crop of product. A second crop was obtained by triturating
the alumina in CH.sub.2Cl.sub.2/MeOH (8:2) and combined with the
first to afford
7-benzo[b]thiophen-2-yl-1H-indazol-5-yl)-(2-methanesulfonyl-pyrimidin-4-y-
l)-amine (1.09 g, 36% yield): LC/MS (method e) R.sub.t 1.8 min; m/z
(ESI-): (M-H).sup.+ 419.9. TABLE-US-00028 TABLE N.1 Examples
prepared using general procedure N from Example #F.8.1 ##STR665##
m/z or .sup.1H NMR Aryl halide Product Ex. # R.sub.t(min)(method)
(d.sub.6 DMSO, 400 MHz) 7-Chloro-1H- pyrrolo[2,3- c]pyridine
##STR666## N.1.1 2.2 min(e) 382.0(M + H).sup.+ 4-Chloro- pyridin-3-
ylamine ##STR667## N.1.2 14 min (b) 1.87(s, 3H), 4.85 (bs, 2H),
6.85(d, 1H), 7.41(m, 3H), 7.44(s, 1H), 7.57(s, 1H), 7.61(m, 1H),
7.88(m, 2H), 8.00(m, 1H), 8.15(m, 2H) 2-Chloro-4,6- dimethoxy-
1,3,5-triazine ##STR668## N.1.3 2.1 min(e) 403.0(M + H).sup.+
2-Amino-6- chloropurine ##STR669## N.1.4 1.6 min(e) 399.0(M +
H).sup.+ 6-Chloro- pyrimidine-2,4- diamine ##STR670## N.1.5 1.5
min(e) 373.9(M + H).sup.+ 4-Chloro- thieno[3,2- c]pyridine
##STR671## N.1.6 2.5 min(e) 398.9(M + H).sup.+ 6-Chloro-
pyridazin-3- ylamine ##STR672## N.1.7 1.7 min(e) 358.9(M + H).sup.+
2-Chloro- pyrimidine-4,5- diamine ##STR673## N.1.8 1.6 min(e)
374.0(M + H).sup.+ 6-Chloro- [1,3,5]triazine- 2,4-diamine
##STR674## N.1.9 1.5 min(e) 373.1(M - H).sup.- 4-Chloro-
thieno[3,2- d]pyrimidine ##STR675## N.1.10 2.2 min(e) 399.8(M +
H).sup.+ 2-Chloro-6,7- dimethoxy- quinazolin-4- ylamine ##STR676##
N.1.11 2.1 min(e) 468.9(M + H).sup.+ 1H- Pyrrolo[2,3-
d]pyrimidin-4- ylamine ##STR677## N.1.12 2.0 min(e) 383.0(M +
H).sup.+ 6-Chloro- nicotinamide ##STR678## N.1.13 2.4 min(e)
7.10(d, 1H), 7.34 (m, 3H), 7.37(s, 1H), 7.91(d, 1H), 7.97(d, 2H),
8.08 (m, 3H), 8.22(bs, 1H), 8.58(s, 1H), 9.19(s, 1H), 13.27(bs, 1H)
2-Acetamido- 4-chloro pyrimidine ##STR679## N.1.14 2.50(e) 353.0 (M
- H).sup.-
[0567] TABLE-US-00029 TABLE N.2 Examples using general procedure N
from 4-chloro-2-aminopyrimidine ##STR680## Amine Product Ex. #
R.sub.t(min)(method) m/z (7- Benzo[b]thiophen- 2-yl-1H-
indazol-5-yl)-(4- imidazo[1,2- .alpha.]pyridin-2-yl- benzyl)-amine
(Example #F.8.1, then O) ##STR681## N.2.1 1.6 min(e) 565.4 (M +
H).sup.+ 3-Iodo-1H- indazol-5-ylamine (FR2836914) ##STR682## N.2.2
0.8(e) 261.2 (M - H).sup.- 5-Amino-1H- indazol-3-ol (FR2836914)
##STR683## N.2.3 0.96(f) 241.2 (M - H).sup.- 5-Amino-7-
benzo[b]thiophen- 2-yl-1H-indazol-3- ol (Preparation #50, N, L)
##STR684## N.2.4 1.26(e) 375.3 (M - H).sup.- N-(5-Amino-3-
chloro-1H- indazol-7-yl)- acetamide(J. Med. Chem., 2003, 46(26),
5663-5673) ##STR685## N.2.5 0.62(e) 318.0 (M + H)+ 3-Iodo-1H-
indazol-5- ylamine (Preparation #28) ##STR686## N.2.6 1.22(a) 352.8
(M + H).sup.+ 7-Bromo-1H- indazol-5- ylamine (Preparation #6)
##STR687## N.2.7 1.13(e) 305.1 (M + H).sup.+ 5-Amino-1H-
indazole-3- carboxylic acid ##STR688## N.2.8 0.40(e) 270.9 (M +
H).sup.+ N-(5-Amino- 1H-indazol-3- yl)-benzamide (W, L) ##STR689##
N.2.9 1.08(e) 346.1 (M + H).sup.+ N-(5-Amino- 1H-indazol-3-
yl)-3-methoxy- benzamide (W, L) ##STR690## N.2.10 0.93(e) 376.4 (M
+ H).sup.+ N-(5-Amino- 1H-indazol-3- yl)-3- dimethylamino-
benzamide (W, L) ##STR691## N.2.11 1.13(e) 389.2 (M + H).sup.+
N'3'-Benzyl- 1H-indazole- 3,5-diamine (O, L) ##STR692## N.2.12
1.61(e) 425.3 (M + H).sup.+ 1H-indazol-4- ylamine (L) ##STR693##
N.2.13 0.48(e) 226.8 (M + H).sup.+ 6-Methoxy-1H- indazol-5- ylamine
(According to Preparation #6) ##STR694## N.2.14 0.40(e) 257.3 (M +
H).sup.+ 7-Chloro-1H- indazol-5- ylamine (According to Preparation
#6) ##STR695## N.2.15 1.58(e) 389 (M + H).sup.+ (7-
Benzo[b]thiophen- 2-yl-1H- indazol-5-yl)- (tetrahydro- pyran-4-
ylmethyl)-amine (Example #F.8.1, O) ##STR696## N.2.16 2.17(e) 457.1
(M + H).sup.+ 3-Chloro-1H- indazol-5- ylamine(J. Med. Chem. (2003),
46(26), 5663-5673) ##STR697## N.2.17 3.03(f) 261.2 (M + H).sup.+
3-Morpholin-4- yl-1H-indazol- 5-ylamine (Pharmazie, 33(6), 377-8,
1978, N, L) ##STR698## N.2.18 2.43(f) 311.9 (M + H).sup.+
N-(5-Amino-3- chloro-1H- indazol-7-yl)- benzamide(J. Med. Chem.,
46(26), 5663- 5673, 2003, W, L) ##STR699## N.2.19 1.47(e) 380.3 (M
+ H).sup.+ (5-Amino-3- chloro-1H- indazol-7-yl)- carbamic acid
tert-butyl ester (J. Med. Chem., 46(26), 5663- 5673, 2003, W, L)
##STR700## N.2.20 0.52(e) 276.0 (M + H).sup.+ N-(5-Amino-3-
chloro-1H- indazol-7-yl)- methanesulfona- mide(J. Med. Chem.,
46(26), 5663-5673, 2003, S, L) ##STR701## N.2.21 2.82(f) 354.2 (M +
H).sup.+
Representative NMR Data of Example #N.2.8
[0568] .sup.1H NMR (DMSO-d.sub.6, 400 MHz); 8.28 (br, 1H), 8.10 (m,
1H), 8.03 (d, 1H), 7.92 (d, 1H), 7.78 (s, 1H), 7.61 (d, 1H), 7.43
(m, 3H), 6.07 (m, 2H), 5.42 (d, 1H), 3.92 (d, 2H), 3.82 (m, 2H),
3.21 (t, 2H), 2.33 (m, 1H), 1.91 (s, 3H), 1.60 (m, 2H), 1.29 (m,
2H). TABLE-US-00030 TABLE N.3 Examples prepared using general
procedure N from Preparation #3 ##STR702## R.sub.t(min) (meth-
Precursor Product Ex # od) m/z 1H-Inda- zol-5- ylamine ##STR703##
N.3.1 3.38(a) 266 (M + H).sup.+
[0569] TABLE-US-00031 TABLE N.4 Examples prepared using general
procedure N from Example #F.8.1 ##STR704## Aryl halide Product Ex #
R.sub.t(min)(method) m/z 2,4,6- Trichloro- [1,3,5]triazine
##STR705## N.4.1 2.35(e) 411(M - H).sup.- 2-Amino-6- chloro-
pyrimidine-4- carboxylic acid methyl ester (J. Org. Chem., 1961,
26, 2755-2763) ##STR706## N.4.2 1.77(e) 417(M + H).sup.+
4,6-Dichloro- pyrimidin-2- ylamine ##STR707## N.4.3 2.02(e) 391(M -
H).sup.- 4-Chloro-6- isopropyl- pyrimidin-2-yl amine ##STR708##
N.4.4 1.72(e) 401.3(M + H).sup.+398.9(M - H).sup.-
[0570] TABLE-US-00032 TABLE N.5 Examples prepared using general
procedure N from Example #N.4.3 ##STR709## Amine Product Ex #
R.sub.t(min)(method) m/z N',N'- Dimethyl- ethane-1,2- diamine
##STR710## N.5.1 1.23(e) 446 (M + H).sup.+ Diethyl-amine ##STR711##
N.5.2 2.21(e) 431 (M + H).sup.+
[0571] TABLE-US-00033 TABLE N.6 Examples prepared using general
procedure N from Example #N.4.1 ##STR712## Precursor Product Ex #
R.sub.t(min)(method) m/z Diethylamine ##STR713## N.6.1 3.23(a)
485(M - H)-
[0572] TABLE-US-00034 TABLE N.7 Examples prepared using general
procedure N from Preparation #22d ##STR714## Amine Product Example
# R.sub.t(min)(method) m/z(ESI+) 1H-Indazol-5- ylamine ##STR715##
N.7.1 1.82(a) 340.9 (M + H).sup.+
[0573] TABLE-US-00035 TABLE N.8 Examples prepared using general
procedure N from Preparation #3 ##STR716## Amine Precursor Product
Example # R.sub.t(min)(method) m/z(ESI+) 7-Benzo[b]thiphen-
2-yl-1H-indazol-5- ylamine (Example #F.8.1) ##STR717## N.8.1
1.80(e) 398.1 (M + H).sup.+
[0574] TABLE-US-00036 TABLE N.9 Examples prepared using general
procedure N from Example N.4.3 ##STR718## Amine Precursor Product
Example # R.sub.t(min)(method) m/z(ESI+) 2-Methoxy- ethylamine
##STR719## N.9.1 1.54(e) 432(M + H).sup.+430(M - H).sup.-
2-Morpholin-4- yl-ethylamine ##STR720## N.9.2 1.03(e) 487(M +
H)+485(M - H).sup.- N*1*,N*1*- Dimethyl- ethane-1,2- diamine
##STR721## N.9.3 1.11(e) 445(M + H).sup.+443(M - H).sup.-
Diethyl-amine ##STR722## N.9.4 1.93(e) 430(M + H).sup.+428(M -
H).sup.- Isopropyl- amine ##STR723## N.9.5 1.69(e) 416(M +
H).sup.+414(M - H).sup.- 2-(1H- Imidazol-4-yl)- ethylamine
##STR724## N.9.6 1.10(e) 468(M - H).sup.+466(M - H).sup.- 2-Amino-
ethanol ##STR725## H.9.7 1.28(e) 418(M + H).sup.+416(M - H).sup.-
3-Amino- propanol ##STR726## N.9.8 1.44(e) 432(M + H).sup.+430(M -
H).sup.- Ethane-1,2- diamine ##STR727## N.9.9 1.31(e) 417(M +
H).sup.+415(M - H).sup.- 2-Pyridin-3-yl- ethylamine ##STR728##
N.9.10 1.53(e) 479(M + H).sup.+477(M - H).sup.- Propyl-amine
##STR729## N.9.11 Phenethylamine ##STR730## N.9.12 1.78(e) 478(M +
H).sup.+476(M - H).sup.-
General Procedure O: Reductive Alkylation of an Amine with an
Aldehyde or a Ketone. ##STR731##
[0575] To a suspension of an amine and an aldehyde or a ketone
(1-10 equivalents, preferably 1-2 equivalents) in an organic
solvent (for example 1,2-dichloroethane, THF, CH.sub.2Cl.sub.2,
DMF, or EtOAc, preferably 1,2-dichloroethane) with or without
acetic acid (1-10 equivalents, preferably 1 equivalent) is added a
reducing agent (for example, sodium triacetoxyborohydride or sodium
cyanoborohydride, preferably sodium triacetoxyborohydride) (1-10
equivalents, preferably about 2 equivalents). Additional acetic
acid (1-10 equivalents, preferably 3 equivalents) is added to
progress the reaction when necessary. The resulting mixture is
allowed to stir at room temperature for 2-112 hours (preferably 24
hours). The reaction mixture is purified in one of two ways: 1).
The reaction solution is treated with an aqueous solution of an
appropriate base (for example NaOH, NaHCO.sub.3, or
Na.sub.2CO.sub.3, preferably NaHCO.sub.3) and an organic solvent
(for example, CH.sub.2Cl.sub.2 or EtOAc, preferably
CH.sub.2Cl.sub.2). The two layers are stirred for about 15 minutes
then separated. The organic phase is concentrated under reduced
pressure. The resulting crude product can be purified by
trituration with an appropriate solvent (water, EtOH, toluene, or
EtOAc, preferably EtOH) or by chromatography, or 2). The reaction
mixture is directly concentrated under reduced pressure and
purified by chromatography, trituration, or crystallization.
Illustration of General Procedure O
Example #19a
N-Benzyl-(5-nitro-1H-indazol-3-yl)-amine
[0576] ##STR732##
[0577] To a suspension of 5-nitro-1H-indazol-3-ylamine (0.025 g,
0.140 mmol) and benzaldehyde (0.067 g, 0.60 mmol) in
CH.sub.2Cl.sub.2 (3.0 mL) was added acetic acid (0.024 mL, 0.42
mmol) followed by sodium triacetoxyborohydride (0.059 g, 0.28
mmol). The resulting solution was allowed to stir at room
temperature for about 19 hours. The reaction solution was diluted
with CH.sub.2Cl.sub.2 (5 mL) and treated with an aqueous solution
of NaOH (1N, 5 mL). The two phases were separated and the organic
solvent was removed under reduced pressure. The residue was further
purified by preparative HPLC (Thermo Hypersil-Keystone
250.times.21.2 mm 8 Hypersil.RTM. HS C18 column; 5%
acetonitrile/0.1 M aqueous ammonium acetate-100% acetonitrile over
20 min, 100% acetonitrile hold 5 minutes, 21 mL/min) to give
benzyl-(5-nitro-1H-indazol-3-yl)-amine (0.012 g, 0.046 mmol) as an
orange solid. RP-HPLC (Table 1, Method e) R.sub.t 2.15 min.; m/z:
(M+H).sup.+ 269. TABLE-US-00037 TABLE O.1 Examples prepared from
using general procedure O from Example #F.1.9 ##STR733## Amine
Product Example # R.sub.t/min(method) m/z(ESI+) Dimethylamine
##STR734## O.1.1 1.36(e) 383.4 (M - H).sup.-
[0578] TABLE-US-00038 TABLE O.2 Examples prepared using general
procedure O from Example #F.8.1 ##STR735## Aldehyde/Ketone Product
Example # R.sub.t/min(method) m/z(ESI+) 4-(Imidazolo[1,2-
a]pyridin-4-yl) benzaldehyde ##STR736## O.2.1 2.1(e) 472.4 (M +
H).sup.+
[0579] TABLE-US-00039 TABLE O.3 Examples prepared using general
procedure O from Example #F.5.4 ##STR737## Amine Precursor Product
Example # R.sub.t/min(method) m/z Piperidine ##STR738## O.3.1
1.24(g) 456.4 (M + H).sup.+ N,N-Dimethyl-1,2- ethanediamine
##STR739## O.3.2 1.06(g) 459.3 (M + H).sup.+ 2-Methoxyethyl amine
##STR740## O.3.3 1.12(g) 446.3 (M + H).sup.+ N-(2-
Aminoethyl)morph- oline ##STR741## O.3.4 1.12(g) 501.4 (M +
H).sup.+ Piperazine ##STR742## O.3.5 1.13(g) 457.3 (M + H).sup.+
1-Methylpiperazine ##STR743## O.3.6 1.14(g) 471.4 (M + H).sup.+
Morpholine ##STR744## O.3.7 1.13(g) 458.3 (M + H).sup.+
2-Propen-1-amine ##STR745## O.3.8 1.13(g) 428.4 (M + H).sup.+
[0580] TABLE-US-00040 TABLE O.4 Examples prepared using general
procedure O from Example #5 ##STR746## Amine Example R.sub.t/min
Precursor Product # (method) m/z 2-Propen-1-amine ##STR747## O.4.1
1.05 (g) 409.1 (M - H).sup.-
General Procedure P. Deprotection of a Methyl-Protected Alcohol
Using Boron Tribromide
[0581] To a suspension of a methyl-protected alcohol in an organic
solvent (1,2-dichloroethane or CH.sub.2Cl.sub.2, preferably
1,2-dichloroethane) is added a solution of BBr.sub.3 (8-20
equivalents, preferably 10 equivalents) in CH.sub.2Cl.sub.2. The
reaction mixture is stiffed at about -10 to 5.degree. C.
(preferably about 0.degree. C.) for about 0.5-3 hours (preferably
about 2 hours), then heated at about 30-100.degree. C. (preferably
about 80.degree. C.) for about 2-8 hours (preferably about 3
hours). The reaction mixture can be treated in two different ways:
1). The reaction mixture is allowed to cool to about -10-10.degree.
C. (preferably about 0.degree. C.) and quenched with an aqueous
solution (for example, saturated aqueous NaHCO.sub.3 or
Na.sub.2CO.sub.3, preferably NaHCO.sub.3) and extracted with an
organic solvent (EtOAc, Et.sub.2O, or CH.sub.2Cl.sub.2, preferably
CH.sub.2Cl.sub.2). The residue is partitioned between water and an
organic solvent. The organic layer is separated and the aqueous
layer further extracted with the organic solvent. The combined
organic extracts are dried over a desiccant and the solvent removed
under reduced pressure. 2). The reaction mixture can be cooled down
to room temperature and diluted with MeOH then the solvents are
removed under reduced pressure. The compound can be further
purified by chromatography or crystallization.
Illustration of General Procedure P.
Example #19b
7-[5-(2-Amino-pyrimidin-4-ylamino)-1H-indazol-3-yl]-naphthalen-2-ol
diacetate
[0582] ##STR748##
[0583] To a suspension of
4-[3-(7-methoxy-naphthalen-2-yl)-1H-indazol-5-ylamino]-pyrimidine-2-amine
(Preparation #28 followed by general procedure N and F, 20 mg, 0.05
mmol) in CH.sub.2Cl.sub.2 (1 mL) was added 1M BBr.sub.3 in THF (1
mL). The mixture was stirred for about 2 hours at room temperature
then methanol (1 mL) was added and the mixture concentrated under
reduced pressure. The residue was purified by preparative reverse
phase HPLC to give
7-[5-(2-amino-pyrimidin-4-ylamino)-1H-indazol-3-yl]-naphthalen-2-ol
diacetate (12 mg, 60%); (DMSO-d.sub.6, 400 MHz) .delta.9.08 (s,
1H), 8.35 (s, 1H), 8.30 (s, 1H), 8.03 (d, 1H), 7.89 (d, 1H), 7.80
(m, 2H), 7.72 (d, 1H), 7.53 (d, 1H), 7.16 (s, 1H), 7.11 (d, 1H),
6.06 (bs, 2H), 5.99 (d, 1H), 1.87 (s, 6H); RP-HPLC (Table 1, Method
e) R.sub.t 1.43 min; m/z: (M+H).sup.+ 369.2. TABLE-US-00041 TABLE
P.1 Examples synthesized using general procedure P Example
R.sub.t/min m/z Precursor Product # (method) (ESI+)
4-[3-(5-Methoxy- benzo[b]thiophen- 2-yl)-1H-indazol-5- ylamino]-
pyrimidine-2-amine (Preparation #28, N, F) ##STR749## P.1.1 1.19
(e) 375.3 (M + H).sup.+
General Procedure Q: Acid Catalyzed Cleavage of Esters, Amidines,
and Carbamates
[0584] An acid (HCl or TFA, preferably HCl) was added to an amine
protected with a carbamate or amidine moiety optionally dissolved
in an organic solvent (MeOH, CH.sub.2Cl.sub.2 or dioxane,
preferably MeOH) at about 0-100.degree. C., preferably 40.degree.
C. The reaction mixture is stirred for about 5 minutes to 24 hours
(preferably 16 h) until the reaction had proceeded to completion as
judged by TLC or HPLC analysis. Where necessary, additional acid is
added to achieve complete conversion. The solvents are then removed
under reduced pressure. The crude product can be treated in two
different ways. 1) The material is purified by chromatography,
trituration, or crystallization. 2) The material is treated with an
aqueous solution of an appropriate base (for example NaOH,
NaHCO.sub.3, or Na.sub.2CO.sub.3, preferably NaHCO.sub.3) and
either collected by filtration or extracted into an organic solvent
(for example, CH.sub.2Cl.sub.2, CH.sub.2Cl.sub.2/MeOH (9:1), or
EtOAc, preferably CH.sub.2Cl.sub.2). The resulting crude product
can be purified by chromatography, trituration, or
crystallization.
Illustration of General Procedure Q
Example 19c #48
7-Benzo[b]thiophen-2-yl-1H-indazole-5-carboxylic acid
[4-(1H-indol-2-yl)-phenyl]-amide
[0585] ##STR750##
[0586] TFA (0.078 g, 0.68 mmol) was added to a solution of
24-[(7-benzo[b]thiophen-2-yl-1H-indazole-5-carbonyl)-amino]-phenyl-indole-
-1-carboxylic acid tert-butyl ester (Preparation #7 then B, 0.100
g, 0.137 mmol) in CH.sub.2Cl.sub.2 (2.5 mL, 0.039 mol) at about
0.degree. C. The reaction mixture was stirred at about 0.degree. C.
for about 30 min then additional TFA (80 uL) was added. After about
30 min the reaction was allowed to warm to room temperature and
stirred for about 16 hours, prior to the addition of more TFA (150
uL). After 2 hours the mixture was concentrated under reduced
pressure and the crude product was purified by RP-HPLC to yield
7-benzo[b]thiophen-2-yl-1H-indazole-5-carboxylic acid
[4-(1H-indol-2-yl)-phenyl]-amide (13 mg, 20% yield): RP-HPLC (Table
1, Method e) R.sub.t=2.4 min MS m/z: (M-H).sup.- 483.2.
TABLE-US-00042 TABLE Q.1 Examples prepared using general procedure
Q Ester/Carbamate Example R.sub.t/min m/z Precursor Product #
(method) (ESI+) 4-{[(2-Amino- pyrimidin-4-yl)-(7-
benzo[b]thiophen-2-yl- 1H-indazol-5-yl)- amino]-methyl}-
piperidine-1-carbox ylic acid tert-butyl ester (Example #F.8.1, O,
N) ##STR751## Q.1.1 1.78 (e) 416 (M + H).sup.+ 7-(1-tert-
Butoxycarbonyl-1H- indazol-5-yl)-4- dimethylamino-2-
(dimethylamino- methyleneamino)- pyrrolo[3,2- d]pyrimidine-5-
carboxylic acid tert- butyl ester (J. Med. Chem., 2003, 46, 3060-
3071, F) ##STR752## Q.1.2 0.82 (e) 294.1 (M + H).sup.+ 4-(7-
Benzol[b]thiophen-2-yl- 1H-indazol-5-yl)- pyrazole-1-carboxylic
acid tert-butyl ester (Preparation #26, F) ##STR753## Q.1.3 2.00
(e) 315.1 (M + H).sup.+ (3-{5-[5-(2- Aminopyrimidin-4-
ylamino)-1H-indazol-7- yl]-indol-1-yl}-propyl)- carbamic acid
tert-butyl ester (Example #F.11.5, R) ##STR754## Q.1.4 1.15 (g)
399.3 (M + H).sup.+ (2-{5-[5-(2- Aminopyrimidin-4-
ylamino)-1H-indazol-7- yl]-indol-1-yl}-ethyl)- carbamic acid
tert-butyl ester (Example #F.11.5, R) ##STR755## Q.1.5 1.10 (g)
385.3 (M + H).sup.+ (3-{6-[5-(2- Aminopyrimidin-4-
ylamino)-1H-indazol-7- yl]-indol-1-yl}-propyl)- carbamic acid
tert-butyl ester (Example #F.5.2, R) ##STR756## Q.1.6 1.09 (g)
399.5 (M + H).sup.+
General Procedure R: Base-Promoted Amine Alkylation ##STR757##
[0587] A mixture of an amine substrate and a base (for example,
NaH, K.sub.2CO.sub.3, Cs.sub.2CO.sub.3, t-BuOK or Na.sub.2CO.sub.3,
preferably Na.sub.2CO.sub.3) (2-6 equivalents, preferably 2
equivalents) in an organic solvent (for example, THF, DME or DMF,
preferably DMF) is stirred at about -10-25.degree. C. (preferably
about 0.degree. C.), for about 0-60 minutes (preferably 40 minutes)
under an inert atmosphere. An organic halide (for example an
organic bromide or an organic chloride, preferably an organic
bromide) (2-6 equivalents, preferably 3 equivalents) is added and
the reaction is stirred for about 4-96 hours (preferably about 24
hours) at about 20-100.degree. C. (preferably about 60.degree. C.).
The solvent is removed under reduced pressure and the crude product
can be purified by chromatography, crystallization or used in the
next step without further purification.
Illustration of General Procedure R:
Example #20
3-[7-[7-Benzo[b]thiophen-2-yl-1-(2-trimethylsilanyl-ethoxymethyl)-1H-indaz-
ol-5-yl]-2-(dimethylamino-methyleneamino)-pyrrolo[3,2-d]pyrimidin-5-yl]-pr-
opionic acid methyl ester
[0588] ##STR758##
[0589] To a mixture of
{7-[7-benzo[b]thiophen-2-yl-1-(2-trimethylsilanyl-ethoxymethyl)-1H-indazo-
l-5-yl]-5H-pyrrolo[3,2-d]pyrimidin-2-yl}-N,N-dimethyl-formamidine
(Preparation #5, 240 mg, 0.42 mmol) in DMF (3 mL) at about
0.degree. C. and under an inert atmosphere was added
K.sub.2CO.sub.3 (140 mg, 1.02 mmol). The reaction mixture was
stirred at about 0.degree. C. for about 40 minutes, then
3-bromo-propionic acid methyl ester (0.12 mL, 1.02 mmol) was added.
The reaction mixture was stirred at about 60.degree. C. for about
24 hours, then the solvent was removed under reduced pressure and
the residual material was used in the next step without further
purification. LC/MS (Table1, Method h) R.sub.t 3.29 min; ESI-MS
[M+H].sup.+=654.4. General Procedure S: Formation of a Sulfonamide
from an Amine: ##STR759##
[0590] To a mixture of an amine and a base (for example, pyridine,
Et.sub.3N, or ethyl-diisopropyl-amine, preferably
ethyl-diisopropyl-amine) (1-5 equivalents, preferably 1.5
equivalents) in an organic solvent (for example, CH.sub.2Cl.sub.2,
DME, or DMF, preferably DMF) at about 0-50.degree. C. (preferably
about 20.degree. C.) and under an inert atmosphere is added a
sulfonylchloride (1-5 equivalents, preferably 1.05 equivalents).
The reaction mixture is stirred for about 1-6 hours (preferably 2
hours), then concentrated under reduced pressure and purified by
chromatography, crystallization or it can be used in the next step
without further purification.
Illustration of General Procedure S:
Example #21
3-Oxo-3,4-dihydro-2H-benzo[1,4]oxazine-6-sulfonic acid
(7-benzo[b]thiophen-2-yl-1H-indazol-5-yl)-amide
[0591] ##STR760##
[0592] To a mixture of 7-benzo[b]thiophen-2-yl-1H-indazol-5-ylamine
(Example #F.8.1, 32 mg, 0.12) and ethyl-diisopropylamine (0.032 mL,
0.18 mmol) in DMF (1 mL) at room temperature and under an inert
atmosphere was added
3-oxo-3,4-dihydro-2H-benzo[1,4]oxazine-6-sulfonyl chloride (33 mg,
0.13 mmol ). The reaction mixture was stirred at room temperature
for 2 hours then concentrated under reduced pressure. The crude
material was purified by preparative HPLC (20% to 80%
acetonitrile/0.05 M aqueous ammonium acetate, buffered to pH 4.5
over 30 min at 20 mL/min; Hyperprep C18, 300 .ANG., 8 .mu.m,
250.times.21.1 mm column) to afford
3-oxo-3,4-dihydro-2H-benzo[1,4]oxazine-6-sulfonic acid
(7-benzo[b]thiophen-2-yl-1H-indazol-5-yl)-amide as a white solid
(34 mg, 58%). LC/MS (Table 1, Method e) R.sub.t 1.75 min; ESI-MS
[M+H].sup.+=475.3. TABLE-US-00043 TABLE S.1 Examples synthesized
using general procedure S from Example #F.8.1 ##STR761## Example
HPLC R.sub.t m/z Precursor Product # (Method) (ESI+)
Benzo[1,2,5]thiadiazole- 4-sulfonyl chloride ##STR762## S.1.1 2.00
(e) 362.1 (M - H).sup.+ 5-Pyridin-2- yl-thiophene- 2-sulfonyl
chloride ##STR763## S.1.2 2.11 (e) 487.2 (M - H).sup.+ Thiophene-2-
sulfonyl chloride ##STR764## S.1.3 1.98 (e) 410.2 (M - H).sup.+
5-Chloro- 1,3-dimethyl- 1H-pyrazole- 4-sulfonyl chloride ##STR765##
S.1.4 1.89 (e) 456.2 (M - H).sup.+ 4-Methoxy- benzene- sulfonyl
chloride ##STR766## S.1.5 2.07 (e) 134.2 (M - H).sup.+ 1-Methyl-
1H- imidazole-4- sulfonyl chloride ##STR767## S.1.6 1.57 (e) 408.0
(M - H).sup.+ Benzo[1,2,5]oxadiazole- 4-sulfonyl chloride
##STR768## S.1.7 2.01 (e) 446.0 (M - H).sup.+
Benzo[1,2,5]thiadiazole- 5-sulfonyl chloride ##STR769## S.1.8 2.06
(e) 462.2 (M - H).sup.+ Quinoline-8- sulfonyl chloride ##STR770##
S.1.9 2.05 (e) 455.1 (M - H).sup.+ 4-Amino- benzene- sulfonyl
chloride ##STR771## S.1.10 1.80 (e) 419.2 (M - H).sup.+
Isoquinoline- 5-sulfonyl chloride ##STR772## S.1.11 1.89 (e) 455.2
(M - H).sup.+ 2-Amino-4- methyl- thiazole-5- sulfonyl chloride
##STR773## S.1.12 1.77 (e) 439.4 (M - H).sup.+ 3,5- Dimethyl-
isoxazole-4- sulfonyl chloride ##STR774## S.1.13 2.00 (e) 423.0 (M
- H).sup.+ 5-(2-Methyl- thiazol-4-yl)- thiophene- 2-sulfonyl
chloride ##STR775## S.1.14 2.13 (e) 507.2 (M - H).sup.+ 3-Oxo-3,4-
dihydro-2H- benzo[1,4]oxazine-6- sulfonyl chloride ##STR776##
S.1.15 1.75 (e) 475.3 (M - H).sup.+ 1,2- Dimethyl- 1H- imidazole-4-
sulfonyl chloride ##STR777## S.1.16 1.59 (e) 422.0 (M - H).sup.+ 4-
Acetylamino- benzene- sulfonyl chloride ##STR778## S.1.17 1.72 (e)
461.3 (M - H).sup.+ 2- Acetylamino- 4-methyl- thiazole-5- sulfonyl
chloride ##STR779## S.1.18 1.75 (e) 482.1 (M - H).sup.+
General Procedure T: Mitsunobu Coupling ##STR780##
[0593] To a mixture of an alcohol (1-5 equivalents, preferably 3
equivalents) and PPh.sub.3 (1-5 equivalents, preferably 2
equivalents) in an organic solvent (for example, THF, DME or
CH.sub.2Cl.sub.2, preferably THF) at about -10 to 20.degree. C.
(preferably about 0.degree. C.) under an inert atmosphere is added
a pyrrolo[3,2-d]pyrimidine (preferably 1 equivalent) followed by
slow addition of a Mitsunobu coupling reagent (for example,
diisopropyl azodicarboxylate, 1,1'-azobis(N,N-dimethylformamide) or
diethyl azodicarboxylate, preferably diisopropyl azodicarboxylate)
(2-4 equivalents, preferably 2 equivalents). The reaction mixture
is stirred at about 0 to 60.degree. C. (preferably at 20.degree.
C.) for about 1-6 hours (preferably 2 hours). The reaction mixture
is then concentrated under reduced pressure and the residual crude
product is purified by chromatography, crystallization or can be
used in the next step without further purification.
Illustration of General Procedure T:
Example #23
N'-{7-[7-Benzo[b]thiophen-2-yl-1-(2-trimethylsilanyl-ethoxymethyl)-1H-inda-
zol-5-yl]-5-isopropyl-5H-pyrrolo[3,2-d]pyrimidin-2-yl}-N,N-dimethylformami-
dine
[0594] ##STR781##
[0595] To a mixture of i-PrOH (0.023 uL, 0.3 mmol) and PPh.sub.3
(52.4 mg, 0.2 mmol) in THF at about 0.degree. C. under an inert
atmosphere was added
{7-[7-benzo[b]thiophen-2-yl-1-(2-trimethylsilanyl-ethoxymethyl)-1H--
indazol-5-yl]-5H-pyrrolo[3,2-d]pyrimidin-2-yl}-N,N-dimethylformamidine
(Preparation 5a, 50 mg, 0.1 mmol) followed by the slow addition of
diisopropyl azodicarboxylate (0.04 mL, 0.2 mmol). The reaction
mixture was stirred at about 20.degree. C. for about 4 hours. The
reaction mixture was then concentrated, and utilized in the next
step without further purification. LC/MS (Table1, Method e) R.sub.t
2.80 min; ESI-MS [M+H].sup.+=555.4. General Procedure U:
Sonogashira Coupling of a Halide with an Acetylene Compound
##STR782##
[0596] To a solution of a halide (preferably 1.0 equivalent) in an
organic solvent (for example, DMF or piperidine, preferably DMF) is
added a terminal acetylene (1.0-12.0 equivalents, preferably 1.2
equivalent), a palladium catalyst (for example,
dichlorobis(triphenylphosphine) palladium(II), tetrakis
(triphenylphosphine) palladium(0), preferably
dichlorobis(triphenylphosphine) palladium(II)) (0.02-0.05
equivalent, preferably 0.05 equivalent), a base (for example,
piperidine, triethylamine, preferably triethylamine) (0.03-0.06
equivalent, preferably 0.05 equivalent), and copper salt (for
example copper (I) bromide, copper (I) iodide, preferably copper
(I) iodide) (0.03-0.15 equivalent, preferably 0.10 equivalent). The
reaction mixture is heated in a microwave reactor at about
80-130.degree. C. (preferably about 120.degree. C.) for about 2-40
minutes (preferably about 5 minutes). The mixture is allowed to
cool to ambient temperature. The insoluble residue is removed by
filtration, and the filtrate is concentrated under reduced
pressure. The residual crude product is purified by chromatography
or crystallization.
Illustration of General Procedure U
Example #24
4-(7-Phenylethynyl-1H-indazol-5-ylamino)-pyrimidine-2-amine
[0597] ##STR783##
[0598] To a solution of
N'4'-(7-bromo-1H-indazol-5-yl)-pyrimidine-2,4-diamine (Example
#N.2.7, 0.060 g, 0.197 mmol) in DMF (1 mL) in a microwave tube was
added phenylacetylene (0.028 ml, 0.256 mmol), copper (I) iodide
(0.004 g, 0.020 mmol) and tetrakis (triphenylphosphine)
palladium(0) (0.011 g, 0.009 mmol). The tube was sealed and the
reaction mixture was heated in a microwave at about 120.degree. C.
for about 5 minutes. The mixture was allowed to cool to ambient
temperature. The insoluble residue was removed by filtration and
washed with DMF (2 mL). The filtrate was purified by preparative
RP-HPLC (Rainin C18, 8 mm, 300 .ANG., 35 cm; 5-100%
acetonitrile/0.1 M ammonium acetate over 20 min, 100% acetonitrile
hold 10 minutes, 21 mL/min) to obtain
4-(7-phenylethynyl-1H-indazol-5-ylamino)-pyrimidine-2-amine as a
white solid (0.015 g, 0.046 mmol); RP-HPLC (Table 1, Method e)
R.sub.t 1.70 min; m/z: (M+H).sup.+ 327.2. TABLE-US-00044 TABLE U.1
Examples prepared using General Procedure U using 3-iodo-5-(2-
aminopyrimidin-4-yl)amino-1H-indazole ##STR784## ##STR785##
3-Iodo-5-(2-aminopyrimidin-4-yl)amino-1H-indazole was prepared from
Preparation #28 via general procedure N using
2-amino-4-chloropyrimdine. Example HPLC Rt Acetylene Product #
(Method) m/z Ethynyl- benzene ##STR786## U.1.1 2.20 (a) 327 (M +
H).sub.+ 3,3- Dimethyl- but-1-yne ##STR787## U.1.2 2.10 (a) 307 (M
+ H).sup.+
[0599] TABLE-US-00045 TABLE U.2 Examples prepared using General
Procedure U from Example #N.2.7 ##STR788## Acetylene Example
R.sub.t/min m/z Precursor Product # (method) (ESI+)
Hex-5-ynenitrile ##STR789## U.2.1 1.27 (e) 318.2 (M + H).sup.+
Pent-4-yn-1-ol ##STR790## U.2.2 0.70 (e) 309.0 (M + H).sup.+
Dimethyl-prop-2- ynyl-amine ##STR791## U.2.3 1.05 (e) 308.0 (M +
H).sup.+ 2-Methyl-but- 3-yn-2-ol ##STR792## U.2.4 0.73 (e) 307.0 (M
+ H).sup.+ Prop-2-yn-1-ol ##STR793## U.2.5 0.53 (e) 278.9 (M +
H).sup.+ Ethynyl-benzene ##STR794## U.2.6 1.70 (e) 327.2 (M +
H).sup.+ Methyl-prop-2- ynyl-amine ##STR795## U.2.7 0.53 (e) 294.0
(M + H).sup.+ 3-Ethynyl-phenol ##STR796## U.2.8 1.20 (e) 343.0 (M +
H).sup.+
General Procedure V: Hydrolysis of an Ester to a Carboxylic Acid
##STR797##
[0600] To a solution of an ester in an organic solvent (for
example, THF, MeOH, or 1,4-dioxane, preferably 1,4-dioxane) at
about 10-50.degree. C. (preferably about 25.degree. C.) is added an
aqueous base solution (for example, Na.sub.2CO.sub.3, NaOH or KOH,
preferably Na.sub.2CO.sub.3) (3-20 equivalents, preferably 5
equivalents). The mixture is stirred at about 10-80.degree. C.
(preferably about 25.degree. C.) for about 0.5-2 hours (preferably
about 1 hour). The mixture is acidified with an acid (preferably 1M
HCl solution) to about pH 3. If a precipitation is formed it is
filtered off and washed with water. If no precipitation is formed
the solvent is removed under reduced pressure and the residue is
partitioned between an aqueous acidic solution (for example HCl)
and an organic solvent (for example EtOAc or CH.sub.2Cl.sub.2,
preferable CH.sub.2Cl.sub.2). The organic layer is separated and
the aqueous layer is further extracted with an organic solvent. The
combined organic extracts are dried over a desiccant. The solvents
are removed under reduced pressure to afford the product which can
be further purified by crystallization or chromatography.
Illustration of General Procedure V
Example #25
{[5-(2-Amino-pyrimidin-4-ylamino)-1H-indazole-3-carbonyl]-amino}-acetic
acid
[0601] ##STR798##
[0602] A solution of
{[5-(2-amino-pyrimidin-4-ylamino)-1H-indazole-3-carbonyl]-amino}acetic
acid methyl ester (was prepared from Example N.2.8, B, 0.014 g,
0.043 mmol) and 2M aqueous NaOH solution (1.0 mL, 2.0 mmol) in
1,4-dioxane (2 mL) was stirred at ambient temperature for about 30
minutes. The reaction mixture was acidified with 1M aqueous HCl
solution until pH 3. The white precipitation was filtered off,
washed with water (3 mL) and dried under reduced pressure to give
{[5-(2-amino-pyrimidin-4-ylamino)-1H-indazole-3-carbonyl]-amino}-acetic
acid (0.001 g, 0.003 mmol); RP HPLC (Table 1, Method a)
R.sub.t=0.42 min; m/z: (M+H).sup.+ 328.2. TABLE-US-00046 TABLE V.1
Examples prepared using general procedure V m/z (ESI+) or NMR (400
Example R.sub.t/min MHz) (d.sub.6- Ester Precursor Product #
(method) DMSO) 3-{[5-(2-Amino- pyrimidin-4-ylamino)- 1H-indazole-3-
carbonyl]-amino}- benzoic acid ethyl ester (Example #N.2.8, B)
##STR799## V.1.1 6.90 (j) 13.8 (br, 1H), 10.51 (s, 1H), 9.67 (m,
1H), 8.58 (s, 1H), 8.22 (m, 1H), 8.08 (d, 1H), 7.89 (d, 1H), 7.82
(d, 1H), 7.64 (m, 2H), #7.47 (t, 1H), 6.62 (m, 2H), 6.11 (d, 1H).
5-Bromo-1H-indazole- 7-carboxylic acid methyl ester ##STR800##
V.1.2 0.48 (e) 239/241 (M - H).sup.- 2-[5-(2-Amino-
pyrimidin-4-ylamino)- 1H-indazol-7-yl]-1H- indole-7-carboxylic acid
methyl ester (Example #F.5.11) ##STR801## V.1.3 0.8 (e) 383.9 (M -
H)- 2-Amino-6-(7- benzol[b]thiophen-2-yl- 1H-indazol-5-ylamino)-
pyrimidine-4- carboxylic acid methyl ester (Example #N.4.2)
##STR802## V.1.4 1.32 (e) 403 (M + H)+
General Procedure W: Amide Formation from an Acid Chloride and an
Amine ##STR803##
[0603] To a solution of an acid chloride and an amine (preferably 1
equivalent) in an organic solvent (for example, pyridine,
CH.sub.2Cl.sub.2 or 1,2-dichloroethane, preferably
CH.sub.2Cl.sub.2) is added a base (for example Et.sub.3N or
pyridine, preferably pyridine). The reaction mixture is stirred at
about 0-50.degree. C. (preferably about 25.degree. C.) for about
0.5-20 hours (preferably about 1 hour). The mixture is diluted with
an organic solvent (for example, EtOAc or CH.sub.2Cl.sub.2,
preferably CH.sub.2Cl.sub.2) and washed with water, then dried
under reduced pressure. The product can be further purified by
crystallization or chromatography.
Illustration of General Procedure W
Example #26
3-Dimethylamino-N-(5-nitro-1H-indazol-3-yl)-benzamide
[0604] ##STR804##
[0605] To a solution of 5-nitro-1H-indazol-3-ylamine in pyridine
(Ryan Scientific, 0.150 g, 0.838 mmol) cooled to about 0.degree. C.
in an ice bath, was added 3-dimethylamino-benzoyl chloride (0.154
g, 0.838 mmol). The reaction mixture was stirred as it warmed to
ambient temperature. After about 1 hour it was poured into crushed
ice, then extracted with EtOAc (10 mL). The organic solvent portion
was washed with a 1M aqueous HCl solution, then concentrated and
dried under reduced pressure. The residue was further purified via
preparative RP-HPLC (Rainin C18, 8 mm, 300 .ANG., 35 cm; 5-100%
acetonitrile/0.1 M ammonium acetate over 20 min, 100% acetonitrile
hold 10 minutes, 21 mL/min) to obtain
3-dimethylamino-N-(5-nitro-1H-indazol-3-yl)-benzamide as a white
solid (0.002 g, 0.006 mmol); RP-HPLC (Table 1, Method e) R.sub.t
1.95 min; m/z: (M+H).sup.+ 326.4. TABLE-US-00047 TABLE W.1 Examples
prepared from 5-nitro-1H-indazol-3-ylamine using General Procedure
W ##STR805## Acid chloride Example R.sub.t/min m/z Precursor
Product # (method) (ESI+) 3-Dimethylamino- benzoyl chloride
##STR806## W.1 1.95 (e) 326.4 (M + H).sup.+ Benzoyl chloride
##STR807## W.2 1.83 (e) 281 (M - H).sup.-
[0606] TABLE-US-00048 TABLE W.2 Examples prepared from Example
#F.2.16 using general procedure W ##STR808## Example R.sub.t/min
m/z Acid chloride Product # (method) (ESI+) Acetyl chloride
##STR809## W.2.1 0.92 (e) 360.6 (M + H).sup.+ Benzoyl chloride
##STR810## W.2.2 1.65 (e) 422.1 (M + H).sup.+ Cyclobutane carbonyl
chloride ##STR811## W.2.3 1.55 (e) 400.3 (M + H).sup.+
[0607] TABLE-US-00049 TABLE W.3 Preparation of oxalates from
Preparation #15 using general procedure W ##STR812## m/z or .sup.1H
NMR Example HPLC R.sub.t (d.sub.6-DMSO, Amine Product # (Method)
400 MHz) 2-Methoxy- ethylamine ##STR813## W.3.1 1.84 (e) 395 (M +
H).sup.+ N,N,N'-Trimethyl- ethane-1,2-diamine ##STR814## W.3.2 1.34
(a) 422 (M + H).sup.+ Pyridin-2-ylamine ##STR815## W.3.3 2.23 (a)
414 (M + H).sup.+ Aniline ##STR816## W.3.4 2.44 (a) 411 (M -
H).sup.- Ammonia ##STR817## W.3.5 1.66 (a) 337 (M + H).sup.+
Morpholine ##STR818## W.3.6 1.80 (a) 407 (M + H).sup.+ Methylamine
##STR819## W.3.7 1.86 (a) 351 (M + H).sup.+ Dimethyl-amine
##STR820## W.3.8 1.74 (a) 363 (M - H).sup.- 1-[2-(1-piperidine)-1-
oxo-ethyl]piperazine ##STR821## W.3.9 NMR (DMSO): 1.58-1.41 (m,
8H), 3.21 (s, 2H), 3.40- 3.55 (m, 10H), 7.44 (m, 2H), 7.91- 8.25
(m, 6H). Cyclohexylamine ##STR822## W.3.10 2.98 (k) 417 (M -
H).sup.- 1-(3-Amino-propyl)- pyrrolidin-2-one ##STR823## W.3.11
2.28 (k) 460 (M - H).sup.- Cyclopropyl- methylamine ##STR824##
W.3.12 2.65 (k) 389 (M - H).sup.- Tetrahydro-pyran-4- ylamine
##STR825## W.3.13 2.35 (k) 419 (M - H).sup.- [2,2']-Bithiophenyl-
5-yl-methylamine ##STR826## W.3.14 3.09 (k) 513 (M - H).sup.-
Pyridin-4-ylamine ##STR827## W.3.15 2.48 (k) 412 (M - H).sup.-
Pyridin-3-ylamine ##STR828## W.3.16 2.42 (k) 412 (M - H).sup.-
Naphthalen-2-yl- methylamine ##STR829## W.3.17 3.02 (k) 475 (M -
H).sup.- Pyrimidin-5-ylamine ##STR830## W.3.18 2.27 (k) 413 (M -
H).sup.- 2-Ethoxy-ethylamine ##STR831## W.3.19 1.93 (k) 407 (M -
H).sup.- 1-Pyrazin-2-yl- piperazine ##STR832## W.3.20 2.28 (k) 482
(M - H).sup.- 1-Isopropyl- piperazin-2-one ##STR833## W.3.21 2.22
(k) 460 (M - H).sup.- 4-Pyrimidin-2-yloxy- piperidine ##STR834##
W.3.22 2.62 (k) 497 (M - H).sup.- 3-Imidazol-1-yl- propylamine
##STR835## W.3.23 2.45 (k) 443 (M - H).sup.- (1-Methyl-1H-pyrrol-
2-yl)-methylamine ##STR836## W.3.24 2.63 (k) 428 (M - H).sup.-
1-Methyl-piperazine ##STR837## W.3.25 2.19 (k) 418 (M - H).sup.-
N-Methyl-(2-pyridin- 2-yl)ethylamine ##STR838## W.3.26 2.28 (k) 454
(M - H).sup.- N,N-Diethyl- piperidine-3- carboxamide ##STR839##
W.3.27 2.32 (k) 502 (M - H).sup.- 2-(2-Methyl- benzimidazol-1-yl)-
ethylamine ##STR840## W.3.28 2.35 (k) 493 (M - H).sup.-
5-Methyl-pyrazin-2- ylmethylamine ##STR841## W.3.29 2.27 (k) 441 (M
- H).sup.- Pyrazin-2-ylamine ##STR842## W.3.30 2.48 (k) 413 (M -
H).sup.- N,N-Dimethyl- ethane-1,2-diamine ##STR843## W.3.31 2.36
(k) 406 (M - H).sup.- 1-Morpholin-4-yl-2- piperazin-1-yl- ethanone
##STR844## W.3.32 2.09 (k) 531 (M - H).sup.- 2-(1-Methyl-1H-
pyrrol-2-yl)- ethylamine ##STR845## W.3.33 2.69 (k) 442 (M -
H).sup.- Pyridin-2-yl- methylamine ##STR846## W.3.34 2.37 (k) 426
(M - H).sup.- Pyridin-3-yl- methylamine ##STR847## W.3.35 2.28 (k)
426 (M - H).sup.- Benzo[1,3]dioxol-5- yl-methylamine ##STR848##
W.3.36 2.67 (k) 469 (M - H).sup.- Benzothiazol-6- ylamine
##STR849## W.3.37 2.70 (k) 468 (M - H).sup.- 2,5-Dimethyl-2H-
pyrazol-3-ylamine ##STR850## W.3.38 2.33 (k) 429 (M - H).sup.-
Pyridin-4-yl- methylamine ##STR851## W.3.39 2.28 (k) 426 (M -
H).sup.-
General Procedure X: Indazole Formation Using Hydrazine
##STR852##
[0608] A mixture of an ortho-halobenzonitrile (1 equivalent) in 30%
aqueous hydrazine (1-10 equivalents, preferably about 3
equivalents) is heated in a sealed tube to about 50-200.degree. C.
(preferably about 120.degree. C.) for about 30-120 minutes
(preferably about 45 minutes). The mixture is cooled to ambient
temperature and the precipitation is filtered off, washed with
water and dried under reduced pressure to yield the desired
indazole.
Illustration of General Procedure X
[0609] Preparation # 49. 7-Nitro-1H-indazol-3-ylamine
##STR853##
[0610] A mixture of 5-nitro-2-fluoro-benzonitrile (Aldrich, 1.00 g,
6.02 mmol) in 30% aqueous hydrazine (5.00 mL, 18.1 mmol) was heated
to about 120.degree. C. in a sealed tube for about 40 minutes. The
mixture was cooled to ambient temperature and the precipitate was
filtered off, washed with water (10 mL) and dried under reduced
pressure to yield 7-nitro-1H-indazol-3-ylamine (0.470 g, 26.4
mmol); (DMSO-d.sub.6, 400 MHz) .delta. 12.16 (br, 1H), 8.90 (m,
1H), 8.05 (dd 1H), 7.35 (d, 1H), 5.98 (br, 2H); RP-HPLC (Table 1,
Method j) R.sub.t 8.07 min. TABLE-US-00050 TABLE X.1. Examples
prepared using general procedure X ##STR854## m/z or .sup.1H NMR
(d.sub.6 Benzonitrile R.sub.t/min DMSO, Precursor Product Example #
(method) 400 MHz) 2-Fluoro-6- iodo- benzonitrile ##STR855## X.1.1
1.24(e) 260 (M + H).sup.+ 2-Fluoro-5- bromo- benzonitrile
##STR856## X.1.2 1.78(e) 210/212 (M - H).sup.- 2-Fluoro-6- bromo-
benzonitrile ##STR857## X.1.3 1.82(e) 210/212 (M - H).sup.-
General Procedure Y: Pd Mediated Coupling of an Aryl Halide with an
Amine Followed by Acid Deprotection
[0611] To a mixture of an amine (1-5 equivalents, preferably 1.25
equivalents), an aryl halide (for example, an aryl bromide, aryl
chloride or an aryl iodide, preferably an aryl iodide) (0.7-3
equivalents, preferably 1 equivalent) and an inorganic base (for
example, KF, Na.sub.2CO.sub.3 or Cs.sub.2CO.sub.3, preferably
Cs.sub.2CO.sub.3) (2-16 equivalents, preferably 2.5 equivalents) in
a degassed organic solvent (for example THF, DME, DMF, 1,4-dioxane,
toluene, preferably 1,4-dioxane) is added a palladium catalyst (for
example tris(benzylideneacetone)dipalladium (0) and XANTPHOS,
tetrakis(triphenylphosphine)palladium(0),
bis(acetato)triphenylphosphinepalladium(II) (.about.5% Pd)
polymer-bound FibreCat.TM. or
[1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II),
complex with dichloromethane, preferably
tris(benzylideneacetone)dipalladium (0) and XANTPHOS) (0.01-0.10
equivalents, preferably 0.05 equivalents). The reaction mixture is
heated at about 40-150.degree. C. (preferably about 95.degree. C.)
for about 0.5-24 hours (preferably about 2 hours) or at about
100-200.degree. C. (preferably 150.degree. C.) for about 5-60
minutes (preferably about 15 minutes) in a microwave under an inert
atmosphere. The reaction mixture is allowed to cool and the crude
product is treated with an acid (preferably trifluoroacetic acid)
(5-80 M solution, preferably 20M solution) optionally containing a
cation scavenger (preferably triisopropyl silane) (0.7-2.5
equivalents, preferably 1.2 equivalents) for about 10-150 minutes
(preferably about 15 minutes) at about 70-150.degree. C.
(preferably about 100.degree. C.) in a sealed tube, either by
conventional heating or by microwave heating. Solvents are removed
under reduced pressure to give the product that can be further
purified by crystallization or chromatography.
Illustration of General Procedure Y
Example #27
N-Phenyl-5-(pyridin-4-ylaniino)-1H-indazole-7-carboxamide
[0612] ##STR858##
[0613] A mixture of
5-bromo-2-(4-methoxy-benzyl)-2H-indazole-7-carboxylic acid,
phenylamide (prepared from preparation #12a using general
procedures V and B, 75.0 mg, 0.20 mmol), 4-aminopyridine(24.0 mg,
0.25 mmol), cesium carbonate (195 mg, 0.60 mmol), and XANTPHOS
(11.6 mg, 0.02 mmol) was suspended in 1,4-dioxane (2.5 mL) at
ambient temperature under an inert atmosphere.
Tris(dibenzylideneacetone)dipalladium(0) (9.2 mg, 0.01 mmol) was
added and nitrogen gas was bubbled through the resulting suspension
for about 5 minutes. The reaction mixture was heated at about
95.degree. C. for about 2 hours. The resulting mixture was allowed
to cool to ambient temperature and filtered through a celite pad
and the solvent was removed under reduced pressure. The residue was
dissolved in trifluoroacetic acid (4.0 mL) containing
triisopropylsilane (51.0 uL, 0.25 mmol) and the mixture was heated
at about 100.degree. C. in a microwave reactor for about 15
minutes. Solvents were removed under reduced pressure and the
residue was purified preparative RP-HPLC (Rainin C18, 8 mm, 300
.ANG., 35 cm; 5-100% acetonitrile/0.1 M ammonium acetate over 20
min, 100% acetonitrile hold 10 minutes, 21 mL/min) to afford
N-phenyl-5-(pyridin-4-ylamino)-1H-indazole-7-carboxamide (30 mg,
46%) as an off-white solid, RP HPLC (Table 1, Method e)
R.sub.t=1.32; MS m/z: (MH).sup.+ 330. TABLE-US-00051 TABLE Y.1.
Examples synthesized using general procedure Y m/z or .sup.1H NMR
Example HPLC R.sub.t (d.sub.6 DMSO, 400 Amine Product # (Method)
MHz) 5-Bromo-1-(4- methoxy- benzyl)-1H- indazole-7- carboxylic acid
phenylamide (preparation #11d, V and B) ##STR859## Y.1.1 1.37(e)
345 (MH).sup.+
[0614] TABLE-US-00052 TABLE Y.2. Examples prepared using general
procedure Y from Preparation #F.8.1 (4- methoxybenzylated using the
conditions used to prepare Prepn. 11d and 12a) ##STR860##
##STR861## m/z or .sup.1H NMR (d.sub.6 Heterocyclic HPLC R.sub.t
DMSO, 400 halide Product Example # (Method) MHz) 3-Chloro-5-
methyl-isoxazole ##STR862## Y.2.1 2.1 min (e) 347.2 (M +
H).sup.+
General Procedure Z: Acid Cleavage of a THP-Protecting Group
##STR863##
[0615] To a mixture of a THP protected alcohol in an organic
solvent (for example MeOH, EtOH, i-PrOH or dioxane, preferably
MeOH) is added an acid (for example aqueous HCl or PPTS, preferably
PPTS) (0.1-1.0 equivalents, preferably 0.5 equivalents). The
reaction mixture is stirred at about 10-85.degree. C. (preferably
about 25.degree. C.) for about 1-24 hours (preferably about 6
hours). The reaction mixture was diluted with an organic solvent
(for example EtOAc, Et.sub.2O, or CH.sub.2Cl.sub.2, preferably
EtOAc) and was washed with an aqueous basic solution (for example
aqueous Na.sub.2CO.sub.3 or NaOH, preferably Na.sub.2CO.sub.3). The
solvent is evaporated and the product can be further purified by
crystallization or chromatography.
Illustration of General Procedure Z
Example #28
(E)-4-[5-(2-Amino-pyrimidin-4-ylamino)-1H-indazol-7-yl]-but-3-en-1-ol
[0616] ##STR864##
[0617] PPTS (0.019 g, 0.075 mmol) was added to a mixture of
4-{7-[(E)-4-(tetrahydro-pyran-2-yloxy)-but-1-enyl]-1H-indazol-5-ylamino}--
pyrimidine-2-amine (prepared from Example #N.2.7 reacted with
trans-2-[3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)allyoxy]-tetrahyd-
ropyran using general procedure F, 0.037 g, 0.100 mmol) in MeOH
(3.0 mL). The reaction mixture was stirred at about 25.degree. C.
for about 5 hours. The reaction mixture was diluted with EtOAc (5
mL) and was washed with aqueous Na.sub.2CO.sub.3 solution (5 mL).
The organic portion was evaporated under reduced pressure to afford
(E)-4-[5-(2-amino-pyrimidin-4-ylamino)-1H-indazol-7-yl]-but-3-en-1-ol
(0.015 g, 0.051 mmol) as an off white solid; RP-HPLC (Table 1,
Method e) Rt 0.62 min; m/z: (M+H).sup.+ 297.0. General Procedure
AA: Deprotection of a Cbz-Protected Amino Group ##STR865##
[0618] A solution of a Cbz protected amine substrate and formic
acid (5-20 equivalents, preferably 10 equivalents) in an organic
solvent (for example methanol or ethanol, preferably methanol) is
added dropwise to a suspension of Palladium black (1-10
equivalents, preferably 2 equivalents) in an organic solvent (for
example methanol or ethanol, preferably methanol). The resulting
mixture is allowed to stir at room temperature for about 2-20 hours
(preferably 16 hours). The suspension is filtered though a plug of
celite and the solvent is removed under reduced pressure. The
resulting crude product can be purified by titration with an
appropriate solvent (water, ethanol, toluene or ethyl acetate,
preferably ethanol) or by chromatography.
Illustration of General Procedure AA
Example # 29
N.sup.4-(3-amino-propyl)-N.sup.4-(7-benzo[b]thiophen-2-yl-1H-indazol-5-yl)-
-pyrimidine-2,4-diamine
[0619] ##STR866##
[0620] A solution of
{3-[(2-amino-pyrimidin-4-yl)-(7-benzo[b]thiophen-2-yl-1H-indazol-5-yl)-am-
ino]-propyl}-carbamic acid benzyl ester (prepared from Example
#F.8.1 using general procedures O and N, 0.169 g, 0.308 mmol) and
formic acid (0.116 mL, 3.08 mmol) in methanol (2 mL) was added
dropwise to a suspension of Palladium black (0.080 g, 0.752 mmol)
in methanol (1.5 mL). The resulting mixture was allowed to stir at
ambient temperature for about 19 hours. The resulting suspension
was filtered though celite and the solvent was removed under
reduced pressure. The resulting crude product was purified by
reverse chromatography (Thermo Hypersil-Keystone 250.times.21.2 mm
8.mu. Hypersil.RTM. HS C18 column; 5% acetonitrile/0.1 M aqueous
ammonium acetate-100% acetonitrile over 20 min, 100% acetonitrile
hold 5 minutes, 21 mL/min) to afford
N.sup.4-(3-amino-propyl)-N.sup.4-(7-benzo[b]thiophen-2-yl-1H-indazol-5-yl-
)-pyrimidine-2,4-diamine (0.021 g, 17% yield) as a green solid.
RP-HPLC (Table 1, Method e) R.sub.t 1.62 min.; m/z: (M+H).sup.+
416.1.
Specific Examples and Intermediate Preparations
Example #1
2-Amino-4-(1H-indazol-5-ylamino)-thieno[2,3-d]pyrimidine-6-carboxylic
acid amide
[0621] ##STR867##
[0622] A mixture of
2-amino-4-(1H-indazol-5-ylamino)-thieno[2,3-d]pyrimidine-6-carboxylic
acid methyl ester (Example #N.7.1, 0.050 g, 0.15 mmol) and ammonia
(ca. 7N in methanol, 1.0 mL) was heated at about 60.degree. C. in a
sealed vessel for about 1.5 hours. The mixture was allowed to cool
to ambient temperature and additional ammonia (ca. 7N in methanol,
5.0 mL) was added. The reaction mixture was then heated at about
75.degree. C. for about 18 hours, cooled to ambient temperature,
additional ammonia (ca. 7N in methanol, 2.0 mL) was added, and
heating at about 75.degree. C. was continued for about another 3
days. The mixture was concentrated under reduced pressure and the
residue was purified by preparative HPLC (Thermo Hypersil-Keystone
250.times.21.2 mm 8.mu. Hypersil.RTM. HS C18 column; 5%
CH.sub.3CN/50 mM aqueous ammonium acetate hold for 5 min, 5-100%
CH.sub.3CN/50 mM aqueous ammonium acetate over 30 min, hold at 100%
CH.sub.3CN for 5 minutes, 21 mL/min) to give
2-amino-4-(1H-indazol-5-ylamino)-thieno[2,3-d]pyrimidine-6-carboxylic
acid amide (0.015 g, 31%) as a beige solid; RP-HPLC (Table 1,
Method a) R.sub.t 0.68 min, m/z (ESI+) 325.9 (M+H).sup.+.
Example #2
1-Benzyl-3-(3-iodo-1H-indazol-5-yl)-urea
[0623] ##STR868##
[0624] Benzyl isocyanate (0.25 mL, 2.0 mmol) was added to
3-iodo-1H-indazol-5-ylamine (Preparation #28, 0.50 g, 1.9 mmol) in
THF (10 mL). After stirring at ambient temperature for about 2.5
hours, the mixture was filtered and washed with Et.sub.2O to give
1-benzyl-3-(3-iodo-1H-imdazol-5-yl)-urea (0.41 g, 55%) as an ivory
solid; RP-HPLC (Table 1, Method e) R.sub.t 0.98 min, m/z
(ESI.sup.+) 393.0 (M+H).sup.+.
Example #3
2-Amino-4-(7-benzo[b]thiophen-2-yl-1H-indazol-5-ylamino)-7H-pyrrolo[2,3-d]-
pyrimidine-5-carboxamide
[0625] ##STR869##
[0626] Sodium percarbonate (0.040 g, 0.25 mmol) was added to a
mixture of
2-amino-4-(7-benzo[b]thiophen-2-yl-1H-indazol-5-ylamino)-7H-pyrrolo[2,3-d-
]pyrimidine-5-carbonitrile (prepared via General Procedure N from
the reaction of Example #F.8.1 with
6-amino-4-chloro-3-cyano-pyrrolo[2,3-d]pyrimidine [prepared by
chlorination of the 4-oxo derivative (J. Med. Chem., 2001, 44(12),
1993-2003) using POCl.sub.3 (Tet., 2004, 60, 943-959), 0.10 g, 0.24
mmol) in 1N KOH (2.4 mL) at ambient temperature. After about 21
hours, the reaction mixture was acidified with 5N HCl and filtered.
The resulting solid was purified by preparative HPLC (Thermo
Hypersil-Keystone 250.times.21.2 mm 8.mu. Hypersil.RTM. HS C18
column; 5% CH.sub.3CN/50 mM aqueous ammonium acetate hold for 5
min, 5-100% CH.sub.3CN/50 mM aqueous ammonium acetate over 30 min,
hold at 100% CH.sub.3CN for 5 minutes, 21 mL/min) to give an impure
solid that was triturated with heptane and filtered to give
2-amino-4-(7-benzo[b]thiophen-2-yl-1H-indazol-5-ylamino)-7H-pyrrolo[2,3-d-
]pyrimidine-5-carboxamide (6.9 mg, 7%); RP-HPLC (Table 1, Method e)
R.sub.t 1.64 min; m/z (ESI.sup.+): 441.0 (M+H).sup.+.
Example #4
3-(7-Benzo[b]thiophen-2-yl-1H-indazol-5-ylamino)-4-methoxy-cyclobut-3-ene--
1,2-dione
[0627] ##STR870##
[0628] A vial containing a solution of
7-benzo[b]thiophen-2-yl-1H-indazol-5-ylamine (Example #F.8.1, 0.020
g, 0.075 mmol), 3,4-dimethoxy-3-cyclobutene-1,2-dione (0.011 g,
0.077 mmol), N,N-diisopropylethylamine (14 .mu.L, 0.080 mmol) and
MeOH (1.5 mL) was shaken at ambient temperature for about 16 hours
then filtered to give
3-(7-benzo[b]thiophen-2-yl-1H-indazol-5-ylamino)-4-methoxy-cyclobut-3-ene-
-1,2-dione (0.022 g, 78%) as a tan solid; RP-HPLC (Table 1, Method
e) R.sub.t 1.80 min, m/z (ESI.sup.+) 375.9 (M+H).sup.+.
Example #5
5-[5-(2-Amino-pyrimidin-4-ylamino)-1H-indazol-7-yl]-1H-indole-3-carboxalde-
hyde diacetate
[0629] ##STR871##
[0630] Phosphoryl chloride (43 .mu.L, 0.46 mmol) was added dropwise
to DMF (0.17 mL) at about 0.degree. C. After about 20 min, a
solution of
5-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-1H-indole
(Aldrich, 0.10 g, 0.42 mmol) in DMF (0.70 mL) was added dropwise.
The reaction was allowed to warm slowly to ambient temperature.
After about 7.5 hours, the reaction mixture was concentrated under
reduced pressure to give a crude mixture containing
5-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-1H-indole-3-carboxaldehy-
de. The mixture was dissolved in DME (3.0 mL) and transferred to a
microwave vial.
N.sup.4-(7-bromo-1H-indazol-5-yl)-pyrimidine-2,4-diamine (Example
#N.2.7, 0.10 g, 0.34 mmol), Pd(PPh.sub.3).sub.4 (0.039 g, 0.034
mmol), and Na.sub.2CO.sub.3 (2.0 M in water, 2.1 mL, 4.2 mmol) were
added and the vial was heated in CEM microwave at about 150.degree.
C. for about 10 min. The reaction was diluted with water then
extracted with EtOAc (3.times.15 mL). The precipitate present at
the layer interface was kept with the organics. The combined
organic layers were washed with brine, dried over Na.sub.2SO.sub.4,
decanted, and concentrated. The crude product was triturated with
CH.sub.2Cl.sub.2 and filtered to give a solid which was dissolved
in DMSO and purified by preparative HPLC (Thermo Hypersil-Keystone
250.times.21.2 mm 8.mu. Hypersil.RTM. HS C18 column; 5%
CH.sub.3CN/50 mM aqueous ammonium acetate hold for 5 min; 5-50%
CH.sub.3CN/50 mM aqueous ammonium acetate over 15 min; 50-100%
CH.sub.3CN/50 mM aqueous ammonium acetate over 1 min; hold at 100%
CH.sub.3CN for 5 minutes, 21 mL/min). The combined fractions
containing impure product were concentrated under reduced pressure,
lyophilized, dissolved in DMSO, and further purified by preparative
HPLC (Thermo Hypersil-Keystone 250.times.21.2 mm 8.mu.
Hypersil.RTM. HS C18 column; 5% CH.sub.3CN/50 mM aqueous ammonium
acetate hold for 5 min; 5-50% CH.sub.3CN/50 mM aqueous ammonium
acetate over 20 min; 50-100% CH.sub.3CN/50 mM aqueous ammonium
acetate over 1 min; hold at 100% CH.sub.3CN for 5 minutes, 21
mL/min) to afford 5-[5-(2-amino-pyrimidin-4-ylamino)-1H-indazol-7-y
l]-1H-indole-3-carbaldehyde diacetate (12.3 mg, 6%); RP-HPLC (Table
1, Method e) R.sub.t 1.18 min, m/z (ESI.sup.+) 370.3
(M+H).sup.+.
Example #6
N.sup.4-(7-Piperidin-3-yl-1H-indazol-5-yl)pyrimidine-2,4-diamine
diacetate
[0631] ##STR872##
[0632] To a vial containing
N.sup.4-7-pyridin-3-yl-1H-indazol-5-yl)-pyrimidine-2,4-diamine
diacetate (Example #F.5.5, 0.040 g, 0.090 mmol) was added
L-Selectride.RTM. (1.0 M in THF, 0.45 mL, 0.45 mmol). Heated at
about 130.degree. C. for about 16 hours Cooled to room temperature
and added L-Selectride.RTM. (1.0 M in THF, 1.0 mL, 1.0 mmol).
Heating at about 130.degree. C. was resumed for about 24 hours.
Cooled to room temperature and added L-Selectride.RTM. (1.0 M in
THF, 0.5 mL, 0.5 mmol). Heating at about 130.degree. C. was resumed
for about another 24 hours. The reaction was then cooled to room
temperature, quenched with MeOH, and concentrated. The crude
product was dissolved in DMSO and purified by preparative HPLC
(Thermo Hypersil-Keystone 250.times.21.2 mm 8.mu. Hypersil.RTM. HS
C18 column; 5% CH.sub.3CN/50 mM aqueous ammonium acetate hold for 5
min; 5-50% CH.sub.3CN/50 mM aqueous ammonium acetate over 20 min;
50-100% CH.sub.3CN/50 mM aqueous ammonium acetate over 1 min; hold
at 100% CH.sub.3CN for 5 minutes, 21 mL/min) to give
N.sup.4-(7-Piperidin-3-yl-1H-indazol-5-yl)pyrimidine-2,4-diamine
diacetate (9.1 mg, 23%) as a white solid; RP-HPLC (Table 1, Method
g) R.sub.t 0.94 min, m/z (ESI.sup.+) 310.3 (M+H).sup.+.
Example #7
N.sup.4-{7-[5-(Aminomethyl)-1-benzothien-2-yl]-1H-indazol-5-yl}pyrimidine--
2,4-diamine acetate
[0633] ##STR873##
[0634] A microwave vial containing
N.sup.4-(7-5-[(allylamino)methyl]-1-benzothien-2-yl-1H-indazol-5-yl)pyrim-
idine-2,4-diamine triacetate (Example #O.3.8, 0.022 g, 0.036 mmol),
chlorotris(triphenylphosphine)-rhodium(I) (8.4 mg, 0.0090 mmol),
CH.sub.3CN (0.84 mL), and H.sub.2O (0.16 mL) was heated in a CEM
microwave at about 120.degree. C. for about 30 min. The reaction
was diluted with CH.sub.3CN (5 mL), filtered, and washed with
CH.sub.3CN and EtOAc, to give
N.sup.4-7-[5-(aminomethyl)-1-benzothien-2-yl]-1H-indazol-5-yl}pyrimidine--
2,4-diamine acetate (12.8 mg, 76%) as a tan solid; RP-HPLC (Table
1, Method g) R.sub.t 1.05 min, m/z (ESI.sup.+) 388.3 (M+H).sup.+.
Preparation #1: 4-Chloro-2-methanesulfonyl-pyrimidine
##STR874##
[0635] A solution of 4-chloro-2-methylsulfanyl-pyrimidine (Aldrich,
41.37 g, 0.252 mol) in DCM (800 mL) at about 0.degree. C. was
treated with 3-chloroperbenzoic acid (75% by weight, 127.76 g,
0.555 mol) in small portions. The reaction mixture was warmed up to
ambient temperature and stirred for about 2.5 hours. The insoluble
residue was collected by filtration and washed with dichloromethane
(100 mL). The filtrate and washings were washed with saturated
aqueous sodium bicarbonate solution (3.times.150 mL) and saturated
aqueous sodium chloride solution (200 mL), dried over anhydrous
magnesium sulfate, and concentrated to dryness to give
4-chloro-2-methanesulfonyl-pyrimidine (41.83 g, 86%): .sup.1H NMR
(DMSO-d.sub.6, 400 MHz) .delta.9.08 (d, 1H), 8.10 (d, 1H), 3.44 (s,
3H); LC/MS (Table 1, Method a) R.sub.t 0.70 min.; m/z: (M+H).sup.+
193. Preparation #2: 4-Chloro-pyrimidin-2-ylamine ##STR875##
[0636] A suspension of 4-chloro-2-methanesulfonyl-pyrimidine
(Preparation #1, 41.83 g, 0.217 mol) in ethanol (30 mL) was treated
with a solution of saturated ammonia gas in ethanol (300 mL). It
was stirred at ambient temperature for about 2 hours, and the white
precipitate was collected, washed with methanol (100 mL), and dried
under reduced pressure to give 4-chloro-pyrimidin-2-ylamine (15.99
g, 57%): .sup.1H NMR (DMSO-d.sub.6, 400 MHz), .delta.8.18 (d, 1H),
7.13 (br, 2H), 6.65 (d, 1H); LC/MS (Table 1, Method a) R.sub.t 1.18
min. Preparation # 3: 4-Chloro-7H-pyrrolo[2,3-d]pyrimidin-2-ylamine
##STR876##
[0637] A mixture of 2-amino-7H-pyrrolo[2,3-d]pyrimidin-4-ol (Sigma,
150 mg, 1.0 mmol) in phosphorus oxychloride (1.5 mL) was heated at
about 110.degree. C. for about 30 minutes. Phosphorus oxychloride
was carefully removed under reduced pressure and the reaction
mixture was quenched by slow addition of ice water (10 mL). The
resulting mixture was neutralized with saturated aqueous sodium
carbonate (about 5 mL) to pH 7. The crude product was extracted
into dichloromethane (20 mL) and washed with water (15 mL). The
organic layer was separated and the aqueous phase was further
extracted with dichloromethane (3.times.30 mL). The combined
organic extracts were dried over anhydrous sodium sulfate and
concentrated to give 4-chloro-7H-pyrrolo[2,3-d]pyrimidin-2-ylamine
(0.036 g, 0.21 mmol) as a light yellow solid; LC/MS (Table 1,
Method a) R.sub.t 1.17 min; MS m/z: (M+H).sup.+ 169. Preparation
#4:
tert-Butyl-1,2-(dimethylaminomethyleneamino)-7-iodo-pyrrolo[3,2-d]pyrimid-
ine-5-methanoate ##STR877## Step 1. Preparation # 4a.
N'-(7-iodo-5H-pyrrolo[3,2-d]pyrimidin-2-yl)-N,N-dimethyl-formamidine
[0638] N-Iodosuccinimide (3.2 g, 14.2 mmol) was added portionwise
to an ice-cold stirred suspension of
N,N-dimethyl-N'-(5H-pyrrolo[3,2-d]pyrimidin-2-yl)-formamidine
(Journal of Medicinal Chemistry, 2003, 46(14), 3060-3071, 2.68 g,
14.2 mmol) in DMF (50 mL). After stirring at ambient temperature
overnight, the reaction was concentrated, dissolved in DCM (40 mL)
and the product was precipitated using EtOAc (250 mL). After
filtration, the pale yellow powder was collected, washed with EtOAc
(2.times.20 mL) and dried under a vacuum overnight to afford
N'-(7-iodo-5H-pyrrolo[3,2-d]pyrimidin-2-yl)-N,N-dimethyl-formamidine
(3.8 g, 85%) as a yellow powder; .sup.1H NMR (DMSO-d.sub.6, 400
MHz) .delta. 12.38 (s, 1 H), 8.74 (s, 1 H), 8.04 (s, 1 H), 7.93 (s,
1 H), 3.29 (s, 3 H), 3.19 (s, 3 H); ESI-MS [M+H].sup.+=316.1.
Step 2.
Preparation #4:
tert-Butyl-1,2-(dimethylaminomethyleneamino)-7-iodo-pyrrolo[3,2-d]pyrimid-
ine-5-methanoate
[0639] Na.sub.2CO.sub.3 (1.27 g, 12 mmol) was added to a stirred
suspension of
N'-(7-iodo-5H-pyrrolo[3,2-d]pyrimidin-2-yl)-N,N-dimethyl-formamidine
(Preparation #4a, 1 g, 3.17 mmol) in anhydrous THF (20 mL).
Di-tert-butyl dicarbonate (2.76 g, 12 mmol) was added portionwise
at ambient temperature and the mixture was stirred at ambient
temperature for about 16 hours prior to diluting with DCM (150 mL),
filtering and concentrating the filtrate to dryness. The product
precipitated from the residue using EtOAc/heptane (50:50, 100 mL).
The precipitate was filtered and dried to afford
tert-butyl-1,2-(dimethylamino-methyleneamino)-7-iodo-pyrrolo[3,2-d-
]pyrimidine-5-methanoate (0.95 g, 72%) as a pale yellow solid;
.sup.1H NMR (DMSO-d.sub.6, 400 MHz) .delta. 9.10 (s, 1 H), 8.74 (s,
1 H), 7.96 (s, 1 H), 3.23 (s, 3 H), 3.18 (s, 3 H), 1.68 (s, 9 H);
ESI-MS [M+H].sup.+=416.2. Preparation #5:
N'-{7-[7-Benzo[b]thiophen-2-yl-1-(2-trimethylsilanyl-ethoxymethyl)-1H-ind-
azol-5-yl]-5H-pyrrolo[3,2-d]pyrimidin-2-yl}-N,N-dimethyl-formamidine
##STR878## Step 1. Preparation #5a.
7-[7-benzo[b]thiophen-2-yl-1-(2-trimethylsilanyl-ethoxymethyl)-1H-indazol-
-5-yl]-5H-pyrrolo[3,2-d]pyrimidin-2-ylamine
[0640]
2-(Dimethylamino-methyleneamino)-7-iodo-pyrrolo[3,2-d]pyrimidine-5-
-carboxylic acid tert-butyl ester (Preparation #4, 0.415 g, 1.0
mmoles) was added to a mixture of cesium carbonate (977 mg, 3.0
mmoles), Pd(PPh.sub.3).sub.4 (0.12 g, 0.1 mmoles) and
7-(1H-inden-2-yl)-5-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-1-(2-t-
rimethylsilanyl-ethoxymethyl)-1H-indazole (Preparation #23 then E,
0.7 g, 1.1 mmoles) in DME (10 mL) and water (0.9 mL) at ambient
temperature. The reaction was heated at about 65.degree. C. for
about 16 hours then the solvent was evaporated under reduced
pressure. EtOH (4 mL) and 30% aqueous NaOH (4 mL) were added and
the mixture was heated to about 85.degree. C. for about 1 hour
before the EtOH was removed under reduced pressure. The mixture was
diluted with EtOAc (150 mL) and washed with water (50 mL) and brine
(50 mL), dried over sodium sulfate, filtered, and concentrated
under reduced pressure. The crude product was purified by flash
column chromatography (0-5% MeOH in CH.sub.2Cl.sub.2) to afford
7-[7-benzo[b]thiophen-2-yl-1-(2-trimethylsilanyl-ethoxymethyl)-1H-indazol-
-5-yl]-5H-pyrrolo[3,2-d]pyrimidin-2-ylamine (0.3 g, 60%) as a pale
brown solid; LC/MS (Table 1, Method e) R.sub.t 2.66 min; ESI-MS
[M+H].sup.+=511.3.
Step 2.
Preparation #5:
N'-{7-[7-Benzo[b]thiophen-2-yl-1-(2-trimethylsilanyl-ethoxymethyl)-1H-ind-
azol-5-yl]-5H-pyrrolo[3,2-d]pyrimidin-2-yl}-N,N-dimethyl-formamidine
[0641]
7-[7-Benzo[b]thiophen-2-yl-1-(2-trimethylsilanyl-ethoxymethyl)-1H--
indazol-5-yl]-5H-pyrrolo[3,2-d]pyrimidin-2-ylamine (Preparation
#5a, 490 mg, 0.96 mmol) was added to a solution of
N,N-dimethylformamide dimethyl acetal (1.27 mL, 9.6 mmol) in
CH.sub.2Cl.sub.2/CHCl.sub.3 (3:2, 5 mL) at ambient temperature. The
mixture was heated to about 45.degree. C. for about 16 hours. After
concentration, the crude product was purified by flash column
chromatography (5-10% MeOH in CH.sub.2Cl.sub.2) to afford
7'-{7-[7-benzo[b]thiophen-2-yl-1-(2-trimethylsilanyl-ethoxymethyl)-1H-ind-
azol-5-yl]-5H-pyrrolo[3,2-d]pyrimidin-2-yl}-N,N-dimethyl-formamidine
(0.4 g, 73%) as a pale brown solid; LC/MS (Table1, Method h)
R.sub.t 2.97 min; ESI-MS [M+H].sup.+=568.4. Preparation #6:
7-Bromo-1H-indazol-5-ylamine ##STR879## Step 1. Preparation #6a.
2-Bromo-4-nitro-6-methyl-aniline
[0642] Bromine (34.0 mL, 662 mmol) was added dropwise from an
addition funnel to a suspension of 2-methyl-4-nitroaniline (100 g,
657 mmol) in glacial HOAc (1 L) at ambient temperature over about
40 min. The reaction mixture was stirred for about an additional 30
min at ambient temperature then diluted with H.sub.2O (1 L). The
resulting solid was filtered, washed with additional H.sub.2O (1
L), and then dried in a vacuum oven overnight (at about
50-60.degree. C.) to give the first crop of material (138.5 g,
91%). Additional precipitate, formed in the filtrate, was
collected, washed with H.sub.2O (300 mL) then dried in a vacuum
oven overnight (at about 50-60.degree. C.) to give an additional
batch of 2-bromo-6-methyl-4-nitroaniline (11.4 g, 7%); .sup.1H NMR
(DMSO-d.sub.6, 400 MHz) .delta.8.14 (d, J=2.4 Hz, 1H), 7.92 (d,
J=2.4 Hz, 1H), 6.49 (br s, 2H), 2.23 (s, 3H); LC/MS (Table 1,
Method e) R.sub.t 2.02 min; m/z (ESI.sup.-) 230.7.
Step 2.
Preparation #6b. 7-Bromo-5-nitro-1H-indazole
[0643] NaNO.sub.2 (65.00 g, 942.0 mmol) in H.sub.2O (140 mL) was
added via addition funnel to a 5L 3-neck round bottom flask,
equipped with a mechanical stirrer and a thermometer, containing a
mixture of crude 2-bromo-6-methyl-4-nitroaniline (145.0 g, 627.6
mmol) and glacial HOAc (2.5 L). During the addition, the reaction
mixture was cooled with an ice bath to to maintain the internal
reaction temperature below 25.degree. C. About 1 hour after the
addition was complete, additional NaNO.sub.2 (21.65 g, 313.8 mmol)
in H.sub.2O (50 mL) was added to the reaction mixture relatively
rapidly (<5 min) with no evidence of an exotherm. After an
additional 1 hour, the reaction mixture was concentrated under
reduced pressure. The resulting solid was triturated with
MeOH/H.sub.2O (1:1, 1 L) then filtered, washed with additional
MeOH/H.sub.2O (1:1, 500 mL), and dried in a vacuum oven at about
50-60.degree. C. for about 16 hours to give
7-bromo-5-nitro-1H-indazole (109.4 g, 72%, 90% pure by HPLC);
.sup.1H NMR (DMSO-d.sub.6, 400 MHz) .delta.14.28 (br s, 1H), 8.87
(d, J=1.9 Hz, 1H), 8.57 (s, 1H), 8.40 (d, J=1.9 Hz, 1H); LC/MS
(Table 1, Method e) R.sub.t 1.75 min; m/z (ESI.sup.-) 241.7.
Step 3.
Preparation #6: 7-Bromo-1H-indazol-5-ylamine
[0644] A mixture of iron (Aldrich 99.99+%, 13.85 g, 248.0 mmol) and
crude 7-bromo-5-nitro-1H-indazole (20.00 g, 82.63 mmol) in glacial
acetic acid (100 mL) was heated at about 80.degree. C. in a 2-neck
round bottom flask equipped with a mechanical stirrer and a
nitrogen line with a bubbler. After about 2.5 hours, MeOH (100 mL)
was added, warmed, and filtered hot through Celite.RTM.. The
Celite.RTM. pad was washed with additional MeOH (4.times.100 mL)
and the combined organic layers were concentrated under reduced
pressure. The residues were basified to pH .about.7 using aqueous
Na.sub.2CO.sub.3 (2M) and the product was extracted into EtOAc (1
L) over about 16 hours. The layers were separated and the aqueous
layer was further extracted with additional EtOAc (3.times.500 mL).
The combined organic extracts were washed with brine, dried over
anhydrous Na.sub.2SO.sub.4, decanted, and concentrated. The
resulting solid was pre-adsorbed onto silica and purified by silica
gel chromatography using heptane/EtOAc (1:1) as the eluent to
afford 7-bromo-1H-indazol-5-ylamine (6.92 g, 40%); .sup.1H NMR
(DMSO-d.sub.6, 400 MHz) .delta.12.92 (br s, 1H), 7.87 (s, 1H), 7.03
(d, J=1.6 Hz, 1H), 6.77 (d, J=1.2 Hz, 1H) 4.96 (br s, 2H); LC-MS
(Table 1, Method e) R.sub.t 0.83. Preparation #7.
7-Benzo[b]thiophen-2-yl-1H-indazole-5-carboxylic acid ##STR880##
Step 1. Preparation #7a. Methyl
7-benzo[b]thiophen-2-yl-1H-indazol-5-yl carboxylate
[0645] A solution of 7-benzo[b]thiophen-2-yl-5-bromo-1H-indazole
(Preparation #26, 4.5 g, 13.7 mmol) in N,N-dimethylformamide (100
mL) was degassed and purged with carbon monoxide. Triethylamine
(4.1 g, 41 mmol), methanol (13.1 g, 410 mmol) and
dichloro[bis(triphenylphosphine)]palladium (II) (1.45 g, 2.05 mmol)
were added and the mixture was heated to about 90.degree. C. for
about 15 hours. The mixture was cooled and the solvent was removed
under reduced pressure. The residue was triturated with ethyl
acetate (75 mL) and water (35 mL) then further purified by flash
chromatography over silica gel using dichloromethane/ethyl acetate
(95:5) as the eluent to give
methyl-7-benzo[b]thiophen-2-yl-1H-indazole-5-methanoate (3.37 g,
80%).
Step 2.
Preparation #7b. 7-Benzo[b]thiophen-2-yl-1H-indazole-5-carboxylic
acid
[0646] Lithium hydroxide monohydrate (2.25 g, 53.5 mmol) was added
to a suspension of
methyl-7-benzo[b]thiophen-2-yl-1H-indazole-5-methanoate (3.37 g,
10.71 mmol) in a mixture of 1,4-dioxane (65 mL) and water (9 mL).
The mixture was heated to about 65.degree. C. for about 18 hours
then cooled to about 40.degree. C. and filtered. The filtrate was
acidified with aqueous hydrochloric acid (1N, 54 mL) and the
resulting precipitate was collected by filtration and dried under
reduced pressure to give
7-benzo[b]thiophen-2-yl-1H-indazole-5-carboxylic acid (3.16 g,
100%); .sup.1H NMR (DMSO-d.sub.6, 400 MHz) .delta. 13.56 (bs, 1H),
8.51 (d, 1H), 8.47 (s, 1H), 8.14 (d, 1H), 8.04 (d, 1H), 7.94 (d,
1H), 7.45 (d, 2H); RP-HPLC (Table 1, Method e) R.sub.t=1.06, m/z:
(M-H).sup.- 292.8.
Preparation #8.
(7-Benzo[b]thiophen-2-yl-1H-indazol-5-yl)-(2-methanesulfonyl-pyrimidin-4--
yl)-amine
[0647] Preparation #9.
4-(7-Benzo[b]thiophen-2-yl-1H-indazol-5-ylamino)-pyrimidin-2-ol
##STR881##
[0648] To a mixture of 4-chloro-2-methanesulfonyl-pyrimidine
(Preparation #1, 2.54 g, 13.2 mmol) in DME (20 mL) was added
7-benzo[b]thiophen-2-yl-1H-indazol-5-ylamine (Example #F.8.1, 1.95
g, 7.35 mmol) and triethylamine (1.43 mL, 10.3 mmol) in DME (160
mL). After about 16 hours, the mixture was filtered, and the
filtrate evaporated and purified by flash column chromatography
over alumina using dichloromethane/methanol (99:1) as the eluent to
yield product (190 mg, 6% yield). Additional product was obtained
by washing the alumina with dichloromethane/methanol (8:2) and
concentrating the solution to yield
(7-benzo[b]thiophen-2-yl-1H-indazol-5-yl)-(2-methanesulfonyl-pyrimidin-4--
yl)-amine (900 mg, 30% yield); LC/MS (Method e) R.sub.t 1.8 min;
m/z (ESI-): (M-H).sup.+ 419.9.
[0649] In an alternate work up, the crude reaction mixture was
filtered and the solid was purified by RP-HPLC to yield
4-(7-benzo[b]thiophen-2-yl-1H-indazol-5-ylamino)-pyrimidin-2-ol (2
mg, 0.006 mmol, 0.1% yield): LC/MS R.sub.t (Table 1, Method e)
R.sub.t 1.3 min; m/z (ESI-): (M-H).sup.+ 358.3. Preparation #10.
N'-(1-Benzenesulfonyl-3-bromo-1H-pyrrolo[2,3-c]pyridin-5-yl)-N,N-dimethyl-
-formamidine ##STR882## Step 1. Preparation #10a.
N'-[4-((E)-2-Dimethylamino-vinyl)-5-nitro-pyridin-2-yl]-N,N-dimethylforma-
midine ##STR883##
[0650] 4-Methyl-5-nitro-pyridin-2-ylamine (Aldrich, 4.80 g, 31.4
mmol) was suspended in dimethoxymethyl-dimethylamine (50 mL) and
the mixture was heated at about 120.degree. C. in a sealed vessel
with stirring for about 4 days. The reaction was cooled and
concentrated to afford
N'-[4-((E)-2-Dimethylamino-vinyl)-5-nitro-pyridin-2-yl]-N,N-dimethyl-fonn-
amidine (8.36 g, 101%) as a dark solid, RP HPLC (Table 1, Method e)
R.sub.t=1.62, m/z: (MH).sup.+ 264. The crude product was then used
in the next step without further purification.
Step 2.
[0651] Preparation #10b.
N,N-Dimethyl-N'-(1H-pyrrolo[2,3-c]pyridin-5-yl)-formamidine
##STR884##
[0652] A suspension of
N'-[4-((E)-2-dimethylamino-vinyl)-5-nitro-pyridin-2-yl]-N,N-dimethyl-form-
amidine (Preparation #10a, 8.36 g, 31.4 mmol) and 10% Pd on carbon
(800 mg) in ethanol (120 mL) was shaken in a hydrogenation vessel
under an atmosphere of 10-55 psi H.sub.2 for about 24 hours. The
reaction was filtered through Celite.RTM. and concentrated to yield
N,N-dimethyl-N'-(1H-pyrrolo[2,3-c]pyridin-5-yl)-formamidine (6.19
g, 105%) as a dark solid. RP HPLC (Table 1, Method e) R.sub.t=0.84,
m/z: (MH).sup.+ 189. The crude product was used in the next step
without further purification.
Step 3.
[0653] Preparation #10.
N'-(1-Benzenesulfonyl-3-bromo-1H-pyrrolo[2,3-c]pyridin-5-yl)-N,N-dimethyl-
-formamidine ##STR885##
[0654] 1-Bromo-pyrrolidine-2,5-dione (5.34 g, 30 mmol) was added to
a stirred solution of
N,N-dimethyl-N'-(1H-pyrrolo[2,3-c]pyridin-5-yl)-formamidine
(Preparation #10b, 6.00 g, 31.9 mmol) in DMF (200 mL) at about
0.degree. C. The reaction was allowed to warm to ambient
temperature then stirred for about 1 hour. Benzenesulfonyl chloride
(3.83 mL, 30.0 mmol) and Na.sub.2CO.sub.3 (6.36 g, 60.0 mmol) were
added and the mixture was warmed at about 60.degree. C. for about 1
hour. The reaction mixture was concentrated under reduced pressure
and the dark solids were triturated with EtOAc (2.times.100 mL) and
filtered. The combined EtOAc layers were passed through a 6 inch
silica gel column, eluting with EtOAc. The product fractions were
combined and concentrated to yield
N'-(1-benzenesulfonyl-3-bromo-1H-pyrrolo[2,3-c]pyridin-5-yl)-N,N-dimethyl-
formamidine (4.29 g, 35%) as a tan solid. RP HPLC (Table 1, Method
e) R.sub.t=2.18, m/z: (MH).sup.+ 407/409.
Preparation #11. Methyl
1-(4-Methoxy-benzyl)-5-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-1H--
indazole-7-carboxylate
[0655] Preparation #12. Methyl
2-(4-Methoxy-benzyl)-5-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-2H--
indazole-7-carboxylate ##STR886## Step 1. Preparation #11a. Methyl
2-amino-5-bromo-3-iodo-benzoate ##STR887##
[0656] 1-Iodo-pyrrolidine-2,5-dione (10.35 g, 46.0 mmol) was added
in one portion to a solution of methyl 2-amino-5-bromo-benzoate
(10.35 g, 45.0 mmol) in trifluoroacetic acid (90 mL) at ambient
temperature. The reaction was stirred for about 1 hour at ambient
temperature then concentrated under reduced pressure. The residue
was dissolved in CH.sub.2Cl.sub.2 (150 mL), washed with saturated
Na.sub.2CO.sub.3 solution (2.times.150 mL) and a 10% aqueous
solution of Na.sub.2S.sub.2O.sub.4 (2.times.100 mL), dried over
anhydrous MgSO.sub.4, filtered and concentrated to yield methyl
2-amino-5-bromo-3-iodo-benzoate (15.5 g, 97%) as a yellow solid; RP
HPLC (Table 1, Method e) R.sub.t=2.45, .sup.1H NMR (DMSO-d.sub.6,
400 MHz) .delta. 3.83 (s, 3H), 7.74 (broad s), 2H), 7.86-7.88 (d,
2H), 8.00-8.02 (d, 1H).
Step 2.
[0657] Preparation #11b. Methyl 2-amino-5-bromo-3-methylbenzoate
##STR888##
[0658] 2,4,6-Trimethyl-cyclotriboroxane (6.99 ml, 50.0 mmol) was
added to a stirred suspension of methyl
2-amino-5-bromo-3-iodo-benzoate (Preparation #11a, 15.5 g, 43.6
mmol), [1,1'-bis(diphenylphosphino)-ferrocene)dichloropalladium(II)
1:1 complexed with dichloromethane (1.67 g, 2.05 mmol) and cesium
carbonate (42.9 g, 132 mmol) in 1,4-dioxane (200 mL) under N.sub.2.
After about 4 hours at about 90.degree. C. additional
2,4,6-trimethyl-cyclotriboroxane (1.00 ml, 7.15 mmol) was added and
the reaction was continued with heating for about 2 more hours. The
reaction was cooled, filtered through a short pad of silica gel and
concentrated to afford an oil. The crude product was purified by
flash chromatography over silica gel using heptane:EtOAc (92:8) as
the eluent to yield methyl 2-amino-5-bromo-3-methyl-benzoate (5.9
g, 55%) as a pale yellow solid; RP HPLC (Table 1, Method e)
R.sub.t=2.72, m/z: (MH).sup.+ 244/246.
Step 3.
[0659] Preparation #11c. Methyl 5-bromo-1H-indazole-7-carboxylate
##STR889##
[0660] 3-Methyl-1-nitrosooxy-butane (3.39 ml, 25.2 mmol) was added
to a solution of 2-methyl amino-5-bromo-3-methyl-benzoate (5.38 g,
22.0 mmol) in glacial acetic acid (300 mL) cooled to about
17.degree. C. The reaction was stirred for about 10 minutes at
about 17.degree. C. then transferred over about 1 hour to a mixture
of acetic acid (60 mL) and potassium acetate (20.0 g, 0.20 mol)
held at 60.degree. C. with stirring. The mixture was stirred about
1 hour then cooled to ambient temperature and concentrated under
reduced pressure. The residue was dissolved in EtOAc (about 350 mL)
and washed with water (3.times.150 mL) and saturated aqueous NaCl
solution (100 mL), then dried over anhydrous MgSO.sub.4. The
residues were triturated with ether (50 mL), filtered, washed with
additional ether (2.times.10 mL), and dried to yield
5-bromo-1H-indazole-7-carboxylic acid methyl ester (4.42 g, 79%) as
a tan solid, RP HPLC (Table 1, Method e) R.sub.t=2.43, m/z:
(MH).sup.+ 255/257.
Step 4.
Preparation #11d. Methyl
1-(4-methoxy-benzyl)-5-bromo-1H-indazole-7-carboxylate, and,
[0661] Preparation #12a. Methyl
2-(4-methoxy-benzyl)-5-bromo-2H-indazole-7- ##STR890##
[0662] A mixture of methyl 5-bromo-1H-indazole-7-carboxylate
(Preparation #11c, 2.60 g, 10.2 mmol), potassium carbonate 3.31 g,
24.0 mmol) and 4-methoxy-benzyl chloride (1.62 ml, 12.0 mmol) in
N,N-dimethylformamide (40 mL) was warmed at about 60.degree. C. for
about 4 hours. The reaction was filtered, concentrated under
reduced pressure and the residue was partitioned between EtOAc (100
mL) and water (50 mL). The layers were separated and the organic
layer was washed with water (2.times.50 mL), dried over anhydrous
MgSO.sub.4, filtered and concentrated to yield a mixture of methyl
1-(4-methoxy-benzyl)-5-bromo-1H-indazole-7-carboxylate and methyl
2-(4-methoxy-benzyl)-5-2H-indazole-7-carboxylate as an oil (4.07 g,
106%). RP HPLC (Table 1, Method e) R.sub.t=2.17, m/z: (MH).sup.+
244/246, and R.sub.t=2.46, m/z: (MH).sup.+ 244/246. The crude
product was used without further purification.
Step 5.
Preparation #11. Methyl
1-(4-methoxy-benzyl)-5-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-1H--
indazole-7-carboxylate
[0663] Preparation #12. Methyl
2-(4-methoxy-benzyl)-5-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-2H--
indazole-7-carboxylate ##STR891##
[0664] [1,1'-Bis(diphenylphosphino)-ferrocene)dichloropalladium(II)
1:1 complex with dichloromethane (408 mg, 0.50 mmol) was added to a
mixture of methyl
1-(4-methoxy-benzyl)-5-bromo-1H-indazole-7-carboxylate and methyl
2-(4-methoxy-benzyl)-5-2H-indazole-7-carboxylate (Preparations #11d
and 12a, 3.70 g, 9.87 mmol),
4,4,5,5,4',4',5',5'-octamethyl-[2,2']bi[[1,3,2]dioxaborolanyl]
(7.62 g, 30.0 mmol) and potassium acetate (5.88 g, 60.0 mmol) in
dimethylformamide (50 mL) under a nitrogen atmosphere. The mixture
was sealed and heated at about 80.degree. C. for about 1 hour then
cooled to ambient temperature, filtered, and concentrated. The
mixture was purified on a silica gel column using CH.sub.2Cl.sub.2
as the eluent to elute fractions containing the first isomer. These
combined fractions were triturated with heptane (about 15 mL),
filtered and dried to yield isomer A (2.06 g, 94% purity, 46%
yield), RP HPLC (Table 1, Method e) R.sub.t=2.50, m/z: (MH).sup.+
423. The second isomer was eluted using EtOAc and again the
fractions were combined, concentrated, and dried to yield isomer B
(2.31 g, 55%), RP HPLC (Table 1, Method e) R.sub.t=2.24, m/z:
(MH).sup.+ 423. Preparation #13.
5-(5-Amino-1H-pyrrolo[2,3-c]pyridin-3-yl)-1H-indazole-7-carboxylic
acid monohydrochloride ##STR892##
[0665] [1,1'-Bis(diphenylphosphino)-ferrocene)dichloropalladium(II)
1:1 complex with dichloromethane (408 mg, 0.50 mmol) was added to a
mixture of methyl
5-bromo-1-(4-methoxy-benzyl)-1H-indazole-7-carboxylate ester and
methyl 5-bromo-2-(4-methoxy-benzyl)-2H-indazole-7-carboxylate
(Preparations #11 and 12, 1:1, 3.99 g, 9.45 mmol), cesium carbonate
(9.75 g, 30.0 mmol) and
N'-(1-benzenesulfonyl-3-bromo-1H-pyrrolo[2,3-c]pyridin-5-yl)-N,N-dimethyl-
-formamidine (Preparation #10, 3.85 g, 9.45 mmol) in
1,2-dimethoxyethane (100 mL) and water (25 mL) under an atmosphere
of N.sub.2. The reaction mixture was heated at about 90.degree. C.
for about 4 hours. The reaction was cooled to ambient temperature
and the layers separated. The organic layer was filtered through a
silica gel pad, eluting with 5% MeOH/EtOAc and the filtrate was
concentrated under reduced pressure. The residue was dissolved in
trifluoroacetic acid (50 mL) containing triisopropylsilane (2.05
ml, 10.0 mmol) and the mixture was heated in a sealed tube at about
100.degree. C. for about 30 minutes then cooled to ambient
temperature and concentrate under reduced pressure. The residue was
triturated with ether (100 mL) and the resulting solid was
collected by filtration. The solid was then dissolved in methanol
(75 mL), treated with aqueous sodium hydroxide (2N, 50 ml, 100
mmol) and heated at reflux for about 6 hours. The reaction was
filtered hot, then cooled and acidified with acetic acid to about
pH 5.5. The product was filtered off, washed with water (2.times.10
mL) and dried to yield
5-(5-amino-1H-pyrrolo[2,3-c]pyridin-3-yl)-1H-indazole-7-carboxylic
acid (2.60 g, 78%) as the acetate salt. The acetate salt was
dissolved in methanol (300 mL) and aqueous HCl (2N, 25 mL) was
added. The mixture was concentrated and dried to yield
5-(5-amino-1H-pyrrolo[2,3-c]pyridin-3-yl)-1H-indazole-7-carboxylic
acid monohydrochloride (2.35 g, 75%) as a pale yellow solid. RP
HPLC (Table 1, Method e) R.sub.t=1.31, m/z: (MH).sup.+ 294.
Preparation #14:
(7-Benzo[b]thiophen-2-yl-1H-indazol-5-yl)-thiocarbamic acid
S-methyl ester ##STR893##
[0666] To a solution of
7-benzo[b]thiophen-2-yl-1H-indazol-5-ylamine (Example #F.8.1, 530
mg, 2.0 mmol) and methyl chlorothioformate (0.25 mL, 2.8 mmol) in
ethanol (10 mL) was added triethylamine (0.56 mL, 4.0 mmol). The
reaction mixture was stirred at ambient temperature for about 16
hours and the resulting solid was collected by filtration, washed
with water (3.times.50 mL), and dried to yield
(7-benzo[b]thiophen-2-yl-1H-indazol-5-yl)-thiocarbamic acid
S-methyl ester (448 mg, 66%); LC/MS (Table1, Method e) R.sub.t 2.14
min; m/z: [M-H].sup.- 338. Preparation #15:
2-(7-Benzo[b]thiophen-2-yl-1H-indazol-5-ylamino)-2-oxalyl chloride
##STR894## Step 1. Preparation #15a.
Ethyl-N-(7-benzo[b]thiophen-2-yl-1H-indazol-5-yl)-oxamate
[0667] To a suspension of
7-benzo[b]thiophen-2-yl-1H-indazol-5-ylamine (Example #F.8.1, 151
mg, 0.57 mmol) in dichloromethane (6 mL) was added triethylamine
(0.088 mL, 0.63 mmol). The reaction mixture was stirred at about
-5.degree. C. for about 10 minutes and ethyl oxalyl chloride (0.064
mL, 0.57 mmol) was added dropwise. The reaction mixture was stirred
at about -5.degree. C. for about 90 minutes prior to quenching the
reaction with water (about 10 mL). The suspension was extracted
with EtOAc (3.times.50 mL), washed with brine solution (100 mL),
and dried over anhydrous magnesium sulfate. The solvent was removed
in vacuo and the crude product was purified by flash chromatography
over silica gel using heptane:EtOAc (30:70) as the eluent to yield
ethyl-N-(7-benzo[b]thiophen-2-yl-1H-indazol-5-yl)-oxamate (169 mg,
81%) as a pale yellow solid, RP HPLC (Table 1, Method e)
R.sub.t=2.03, m/z: (M-H).sup.- 364.
Step 2.
Preparation #15b.
N-(7-benzo[b]thiophen-2-yl-1H-indazol-5-yl)-oxamate
[0668] Sodium hydroxide solution (2% aqueous solution, 2 mL) was
added to a suspension of
ethyl-N-(7-benzo[b]thiophen-2-yl-1H-indazol-5-yl)-oxamate
(Preparation #15a, 83 mg, 0.23 mmol) in methanol (3 mL) and the
reaction mixture was refluxed at 100.degree. C. for about 1 hour.
The solvent was removed in vacuo, and water was added to the
residue. The aqueous layer was acidified using aqueous hydrochloric
acid solution (1 N) and the resulting solid was collected by
filtration, washed with water (3.times.5 mL), and dried to yield
the N-(7-benzo[b]thiophen-2-yl-1H-indazol-5-yl)-oxamate (76 mg,
99%); LC/MS (Table 1, Method e) R.sub.t 0.89 min; m/z: [M-H].sup.-
336.
Step 3.
Preparation #15:
2-(7-Benzo[b]thiophen-2-yl-1H-indazol-5-ylamino)-2-oxalyl
chloride
[0669] A mixture of
N-(7-benzo[b]thiophen-2-yl-1H-indazol-5-yl)-oxamate (Preparation
#15b, 30 mg, 0.089 mmol) and thionyl chloride (0.5 mL, 6.7 mmol)
was stirred at about 80.degree. C. for about 1 hour. The excess
thionyl chloride was removed in vacuo and the
2-(7-benzo[b]thiophen-2-yl-1H-indazol-5-ylamino)-2-oxalyl chloride
(31 mg, 98%) was used without further purification. Preparation
#16. 5-Pyridin-3-yl-3-(1H-pyrrol-2-yl)-1H-indazole ##STR895## Step
1. Preparation #16a. 5-Bromo-2-fluoro-N,N-dimethylbenzamide
##STR896##
[0670] Thionyl chloride (19.8 mL, 228 mmol) was added to a mixture
of 5-bromo-2-fluoro-benzoic acid (Aldrich, 5.0 g, 22.8 mmol) in
toluene (45 mL). The resulting mixture was heated at reflux for
about 3 hours, cooled to ambient temperature and the solvents were
removed under reduced pressure. The residue was stirred in THF (40
mL) at about 0.degree. C. and then the reaction was treated with
gaseous dimethylamine. The mixture was stirred for about 15 min,
concentrated, dissolved in EtOAc (100 mL), washed with 2N HCl
solution (2.times.50 mL), 2N NaOH solution (2.times.50 mL), and
finally with saturated NaCl solution (50 mL). The organic layer was
dried over anhydrous MgSO.sub.4, filtered, concentrated, and dried
to yield 5-bromo-2-fluoro-N,N-dimethyl-benzamide (4.82 g, 86%) of
as an oil, RP HPLC (Table 1, Method e) R.sub.t=2.33, m/z:
(MH).sup.+ 246/248
Step 2.
[0671] Preparation #16b.
(5-Bromo-2-fluoro-phenyl)-(1H-pyrrol-2-yl)-methanone ##STR897##
[0672] 5-Bromo-2-fluoro-N,N-dimethyl-benzamide (Preparation #16a,
4.75 g, 19.3 mmol) and phosphorus oxychloride (5.46 ml, 40.5 mmol)
were combined and warmed at about 35.degree. C. for about 28 hours.
The mixture was cooled to ambient temperature and a mixture of
pyrrole (1.38 mL, 20.0 mmol) in CH.sub.2Cl.sub.2 (40 mL) was added
and the reaction was stirred for about 3 hours at ambient
temperature. The reaction was quenched by cautious addition of
aqueous Na.sub.2CO.sub.3 solution (10% w/v, .about.150 mL) and the
resulting mixture was heated at reflux for about 2 hours. The
product was extracted with CH.sub.2Cl.sub.2 (3.times.50 mL), dried
over anhydrous MgSO.sub.4, filtered and concentrated. The crude
product was further purified on silica gel using EtOAc:heptane
(1:1) as the eluent to yield
5-bromo-2-fluoro-N,N-dimethyl-benzamide (2.57 g, 50%) as an oil
which solidifies on standing. RP HPLC (Table 1, Method e)
R.sub.t=2.57; m/z: (M-H).sup.- 266/268
Step 3.
[0673] Preparation #16c. 5-Bromo-3-(1H-pyrrol-2-yl)-1H-indazole
##STR898##
[0674] A slurry containing
(5-bromo-2-fluoro-phenyl)-(1H-pyrrol-2-yl)-methanone (Preparation
#16b, 2.40 g, 8.96 mmol) and hydrazine hydrate (35 mL) was sealed
and heated by microwave iat about 150.degree. C. for about 1 hour.
The reaction was cooled to ambient temperature and diluted with
water (150 mL). The product was extracted with EtOAc (150 mL),
washed with 2N HCl solution (50 mL), saturated NaHCO.sub.3 solution
(50 mL) and finally a saturated NaCl solution. The EtOAc layer was
dried over anhydrous MgSO.sub.4, filtered and concentrated under
reduced pressure to yield 5-bromo-3-(1H-pyrrol-2-yl)-1H-indazole
(2.38 g, 99%) as an oil. RP HPLC (Table 1, Method e) R.sub.t=2.95;
m/z: (MH).sup.+ 262/264
Step 4.
[0675] Preparation #16.
5-Pyridin-3-yl-3-(1H-pyrrol-2-yl)-1H-indazole ##STR899##
[0676] [1,1'-Bis(diphenylphosphino)-ferrocene)dichloropalladium(II)
1:1 complex with dichloromethane (40.8 mg, 0.05 mmol) was added to
a mixture containing 5-bromo-3-(1H-pyrrol-2-yl)-1H-indazole
(Preparation #16c, 105 mg, 0.40 mmol), aqueous pyridine-3-boronic
acid (1M, 1.0 mL), and Cs.sub.2CO.sub.3 (391 mg, 1.20 mmol) in DMF
(2.0 mL) under a nitrogen atmosphere was added and the mixture was
purged with N.sub.2 again, then heated at reflux for about 3 days.
The reaction was cooled to ambient temperature and the organic
layer was filtered through silica gel and concentrated under
reduced pressure. The residue was further purified by preparative
HPLC (Thermo Hypersil-Keystone 250.times.21.2 mm 8.mu.
Hypersil.RTM. HS C18 column; 5% CH.sub.3CN/50 mM aqueous ammonium
acetate hold for 5 min; 5-50% CH.sub.3CN/50 mM aqueous ammonium
acetate over 20 min; 50-100% CH.sub.3CN/50 mM aqueous ammonium
acetate over 1 min; hold at 100% CH.sub.3CN for 5 minutes, 21
mL/min). Product fractions were combined and concentrated to remove
organic solvents and the lyophilized to yield
5-pyridin-3-yl-3-(1H-pyrrol-2-yl)-1H-indazole (44 mg, 42%) as an
off-white powder. RP HPLC (Table 1, Method e) R.sub.t=2.23; m/z:
(MH).sup.+ 261. Preparation #17. 5-Pyridin-3-yl-1H-indazole
##STR900## Step 1. Preparation #17a. 5-Iodo-1H-indazole
##STR901##
[0677] A solution of NaNO.sub.2 (6.24 g, 90.0 mmol) in water (36
mL) was added dropwise to a mixture of 1H-indazol-5-ylamine
(Aldrich, 12.0 g, 90.1 mmol), water (36 mL), acetonitrile (12 mL)
and concentrated HCl (14.4 mL) that was pre-cooled to about
-10.degree. C., maintaining the reaction temperature below about
-5.degree. C. during the addition. The mixture was stirred for
about 10 minutes at about -5.degree. C. after the addition was
complete then a solution of KI (15.0 g, 90.0 mmol) in cold water
(30 mL) was added, followed by cold acetonitrile (50 mL). The cold
bath was removed and the reaction was allowed to warm to ambient
temperature with stirring overnight. The organic solvent was
removed under reduced pressure and the solid product was filtered
off, then re-dissolved in acetonitrile (125 mL) and stirred in the
presence of charcoal (about 5 g) for about 30 min. The mixture was
filtered and concentrated to yield 5-iodo-1H-indazole (13.1 g, 60%)
as a light brown solid. RP HPLC (Table 1, Method e) R.sub.t=2.38;
m/z: (MH).sup.+ 245.
Step 2.
[0678] Preparation #17b.
5-Iodo-1-(2-trimethylsilanyl-ethoxymethyl)-1H-indazole
##STR902##
[0679] 1H-Indazol-5-ylamine (Preparation #17a, 12.9 g, 52.9 mmol)
was dissolved in CHCl.sub.3 (66 mL), cooled to about 0.degree. C.
and treated with a solution of KOH (66.0 g, 1.18 mol) in water (66
mL) and tetrabutylammonium bromide (175 mg, 0.54 mmol).
(2-chloromethoxy-ethyl)-trimethyl-silane (10.5 ml, 59.3 mmol) was
added over about 5 minutes at about 0.degree. C. with vigorous
stirring. The reaction was then stirred for about 30 minutes at
about 0.degree. C., diluted with water (100 mL) and extracted with
CHCl.sub.3 (3.times.100 mL). The CHCl.sub.3 layer was dried over
anhydrous MgSO.sub.4, filtered, and concentrated to give an oil.
The crude product was further purified over silica gel using
EtOAc:heptane (95:5) as the eluent to yield
5-iodo-1-(2-trimethylsilanyl-ethoxymethyl)-1H-indazole (11.2 g,
56%) as an oil. RP HPLC (Table 1, Method e) R.sub.t=3.04; NMR
(d.sub.6-DMSO, 400 MHz) .delta. -0.12 (s, 9H), 0.77-0.80 (t, 2H),
3.47-3.51 (t, 2H), 5.74 (s, 2H), 7.60-7.63 (d, 1H), 7.67-7.70 (d,d
1H), 8.09-8.10 (d, 1H), 8.21-8.22 (m, 1H).
Step 3.
[0680] Preparation #17c.
5-Pyridin-3-yl-1-(2-trimethylsilanyl-ethoxymethyl)-1H-indazole
##STR903##
[0681] [1,1'-Bis(diphenylphosphino)-ferrocene)dichloropalladium(II)
1:1 complex with dichloromethane (204 mg, 0.25 mmol) was added to a
mixture of 5-iodo-1-(2-trimethylsilanyl-ethoxymethyl)-1H-indazole
(Preparation #17a, 1.87 g, 5.00 nmnol), pyridine-3-boronic acid
(737 mg, 6.00 mmol), and Cs.sub.2CO.sub.3 (4.89 g, 15.0 mmol) in
1,2-dimethoxy-ethane (16 mL) and water (3.2 mL) under a nitrogen
atmosphere. The reaction was heated at about 100.degree. C.
overnight, cooled, concentrated and extracted with CH.sub.2Cl.sub.2
(about 30 mL). The extracts were adsorbed onto silica and purified
over a silica gel column eluting first with heptane:EtOAc (85:15)
and then with heptane:EtOAc (3:2) to yield
5-pyridin-3-yl-1-(2-trimethylsilanyl-ethoxymethyl)-1H-indazole (857
mg, 53%) as an oil. RP HPLC (Table 1, Method e) R.sub.t=3.04, m/z:
(MH).sup.+ 326.
Step 4.
[0682] Preparation #17. 5-Pyridin-3-yl-1H-indazole ##STR904##
[0683]
5-Pyridin-3-yl-1-(2-trimethylsilanyl-ethoxymethyl)-1H-indazole
(Preparation #17c, 100 mg, 0.31 mmol) and ethylenediamine (133
.mu.L, 2.00 mmol) were dissolved in 1M tetrabutylammonium fluoride
in THF (4.0 mL) and the mixture was heated at reflux for about 2
hours. The reactions was cooled to ambient temperature and
concentrated under reduced pressure. The residue was dissolved in
EtOAc (25 mL), washed with water (2.times.10 mL) and concentrated
under reduced pressure. The crude product was further purified by
reverse phase preparative HPLC (Thermo Hypersil-Keystone
250.times.21.2 mm 8.mu. Hypersil.RTM. HS C18 column; 5%
CH.sub.3CN/50 mM aqueous ammonium acetate hold for 5 min; 5-50%
CH.sub.3CN/50 mM aqueous ammonium acetate over 20 min; 50-100%
CH.sub.3CN/50 mM aqueous ammonium acetate over 1 min; hold at 100%
CH.sub.3CN for 5 minutes, 21 mL/min) to yield
5-pyridin-3-yl-1H-indazole (61 mg, 64%) as an off-white solid. RP
HPLC (Table 1, Method e) R.sub.t=1.65, m/z: (MH).sup.+ 196.
Preparation #18. Indole-1,4-dicarboxylic acid 1-tert-butyl ester
4-methyl ester ##STR905##
[0684] Di-tert-butyldicarbonate (0.068 g, 0.31 mmol) was added to a
solution of 1H-indole-4-carboxylic acid methyl ester (Aldrich,
0.050 g, 28 mmol) and 4-dimethylaminopyridine (0.7 mg, 0.006 mmol)
in methylene chloride (1.0 mL, 0.016 mol). After 45 minutes, the
mixture was quenched and acidified with 1N HCl to about a pH 4.
Methylene chloride was added and the layers were separated. The
aqueous layer was further extracted with methylene chloride and the
combined organics were dried over anhydrous MgSO.sub.4 and
concentrated to yield indole-1,4-dicarboxylic acid 1-tert-butyl
ester 4-methyl ester (0.072 g, 92% yield); (DMSO-d.sub.6, 400 MHz)
.delta. 8.37 (d, 1H), 7.91 (d, 1H), 7.86 (d, 1H), 7.46 (t, 1H),
7.21 (d, 1H), 3.92 (s, 3H), 1.65 (s, 10H); RP-HPLC (Table 1, Method
e) R.sub.t=2.7, m/z: (M+H).sup.+ 276.3. Preparation #19.
Indole-1,7-dicarboxylic acid 1-tert-butyl ester 7-methyl ester
##STR906##
[0685] Di-tert-butyldicarbonate (16 g, 0.071 mol) was added to a
solution of 1H-indole-7-carboxylic acid methyl ester (Acros
chemicals, 5.0 g, 0.028 mol) and 4-dimethylaminopyridine (0.3 g,
0.003 mol) in methylene chloride (100 mL). The mixture was heated
at about 45.degree. C. for about 16 hours. The mixture was quenched
and acidified with 1N HCl to about a pH 4. Methylene chloride was
added and the layers were separated. The aqueous layer was further
extracted with methylene chloride and the combined organics were
dried over anhydrous MgSO.sub.4 and concentrated to yield
indole-1,7-dicarboxylic acid 1-tert-butyl ester 7-methyl ester (9.5
g, 97% yield); RP-HPLC (Table 1, Method e) R.sub.t=2.5, m/z:
(M+H).sup.+ 276.2. Preparation #20.
Indole-2-boronic-1,7-dicarboxylic acid 1-tert-butyl ester 7-methyl
ester ##STR907##
[0686] To a mixture of indole-1,7-dicarboxylic acid 1-tert-butyl
ester 7-methyl ester (Preparation #19, 9.5 g, 0.028 mol) in
tetrahydrofuran (39 mL, 0.48 mol) was added triisopropyl borate
(9.5 mL, 0.041 mol). The heterogeneous mixture was cooled to about
0-5.degree. C. and lithium diisopropylamide in tetrahydrofuran
(2.0M, 25 mL) was added slowly. After about 2 hours the mixture was
quenched with 1N HCl and the layers were separated. The aqueous
layer was washed with DCM and the combined organics were dried over
anhydrous MgSO.sub.4 and concentrated. Trituration in ether/heptane
gave 3 crops of indole-2-boronic-1,7-dicarboxylic acid 1-tert-butyl
ester 7-methyl ester (4.10 g, 1.6 g and 3.0 g respectively) as a
yellow solid; RP-HPLC (Table 1, Method e) R.sub.t 1.7 min; m/z
(M+H).sup.+ 378.4. Preparation #21.
Indole-2-boronic-1,4-dicarboxylic acid 1-tert-butyl ester 4-methyl
ester ##STR908##
[0687] To a solution of indole-1,4-dicarboxylic acid 1-tert-butyl
ester 4-methyl ester (Preparation #18, 0.207 g, 0.752 mmol) in THF
(1.1 mL) was added triisopropyl borate (260 .mu.L, 0.0011 mol). The
solution was cooled to about 0-5.degree. C. and lithium
diisopropylamide in tetrahydrofuran (2.0M, 600 .mu.L) was added
slowly over about 1 hour. After about 30 minutes, the mixture was
quenched with 1N HCl, and the layers were separated. The aqueous
layer was washed with DCM and the combined organics were dried over
anhydrous MgSO.sub.4 and concentrated. The mixture was triturated
in heptane (50 mL) and ether (5 mL) and filtered to yield
indole-2-boronic-1,4-dicarboxylic acid 1-tert-butyl ester 4-methyl
ester (175 mg, 51% yield): RP-HPLC (Table 1, Method e) R.sub.t 1.84
min; m/z 377.9(M-H).sup.-. Preparation #22.
4-Diisopropylcarbamoyl-indole-2-boronic-1-carboxylic acid
1-tert-butyl ester ##STR909##
[0688] Triisopropyl borate (870 .mu.L, 0.0038 mol) was added to a
solution of indole-1,4-dicarboxylic acid 1-tert-butyl ester
4-methyl ester (Preparation #18, 0.70 g, 0.0025 mol) in THF (36
mL). The solution was cooled to about 0-5.degree. C. and lithium
diisopropylamide in tetrahydrofuran (2 M, 2.8 mL) was added slowly
over about 1 hour. After about another 1.5 hours, the mixture was
quenched with 1N HCl, and the layers were separated. The aqueous
layer was extracted with DCM, and the combined organics were dried,
concentrated, triturated in heptane (50 mL) and ether (5 mL) and
filtered. The material was further purified by flash column
chromatography using DCM/MeOH (98:2) as the eluent to afford
4-diisopropylcarbamoyl-indole-2-boronic-1-carboxylic acid
1-tert-butyl ester (20 mg, 2% yield): RP-HPLC (Table 1, Method e)
R.sub.t 2.0 min; m/z 389.4 (M+H).sup.+.
Example #8
4-(7-Benzo[b]thiophen-2-yl-1H-indazol-5-ylamino)-pyrimidin-2-ol
[0689] ##STR910##
[0690] To a mixture of 4-chloro-2-methanesulfonyl-pyrimidine
(Preparation #1, 1.35 g, 7.0 mmol) in DME (10 mL) was added a
mixture of 7-benzo[b]thiophen-2-yl-1H-indazol-5-ylamine (Example
#F.8.1, 1.03 g, 3.9 mmol) and triethylamine (0.76 mL, 5.4 mmol) in
DME (70 mL). After about 16 hours at ambient temperature the
mixture was filtered, and the solid was purified by reverse phase
preparative HPLC (Thermo Hypersil-Keystone 250.times.21.2 mm 8.mu.
Hypersil.RTM. HS C18 column; 5% CH.sub.3CN/50 mM aqueous ammonium
acetate hold for 5 min; 5-50% CH.sub.3CN/50 mM aqueous ammonium
acetate over 20 min; 50-100% CH.sub.3CN/50 mM aqueous ammonium
acetate over 1 min; hold at 100% CH.sub.3CN for 5 minutes, 21
mL/min) to yield 4-(7-Benzo[b]thiophen-2-yl-1H
-indazol-5-ylamino)-pyrimidin-2-ol (2 mg, 0.006 mmol, 0.1% yield):
LC/MS R.sub.t (Method e) 1.3 min; m/z (M-H).sup.- 358.3.
Example #9
{2-[5-(2-Amino-pyrimidin-4-ylamino)-1H-indazol-7-yl]-1H-indol-7-yl}-methan-
ol
[0691] ##STR911##
[0692]
2-[5-(2-Amino-pyrimidin-4-ylamino)-1H-indazol-7-yl]-1H-indole-7-ca-
rboxylic acid methyl ester (Preparation #F.8.1, 0.100 g, 0.000250
mol) was added to a solution of lithium aluminum hydride in
tetrahydrofuran (1.0M, 1.0 mL) at about 0.degree. C. in 3 portions.
Additional THF (1.0 mL) was added after about 10 min., and after
about 40 min, the mixture was allowed to warm to ambient
temperature. After about a further 60 min, lithium aluminum hydride
in THF (1.0M, 1 mL) was added. About 16 hours later, the mixture
was quenched with water and neutralized with a saturated aqueous
solution of ammonium chloride. The mixture was diluted with EtOAc,
and the layers were separated. The aqueous layer was further
extracted with EtOAc, and the combined organics were dried over
anhydrous MgSO.sub.4 and concentrated to yield
{2-[5-(2-amino-pyrimidin-4-ylamino)-1H-indazol-7-yl]-1H-indol-7-yl}-metha-
nol (28 mg, 30% yield); LC/MS R.sub.t (Method e) 0.8 min; m/z
(M-H).sup.- 370.5.
Example #10
2-[5-(2-Amino-pyrimidin-4-ylamino)-1H-indazol-7-yl]-1H-indole-7-carboxylic
acid amide
[0693] ##STR912##
[0694] A solution of
2-[5-(2-amino-pyrimidin-4-ylamino)-1H-indazol-7-yl]-1H-indole-7-carboxyli-
c acid (Example #F.5.11, 0.100 g, 0.000259 mol) and
N,N-carbonyldiimidazole (0.0842 g, 0.000519 mol) in
N,N-dimethylformamide (2.5 mL, 0.032 mol) was heated at about
55.degree. C. for about 45 min. The mixture was cooled with an ice
bath and treated with ammonia gas for about 15 min at about
0.degree. C. The mixture was sealed and allowed to warm to ambient
temperature. After about 1 hour the mixture was opened to
atmosphere, and a 1.2 mL portion of the mixture was purified by
reverse phase preparative HPLC (Thermo Hypersil-Keystone
250.times.21.2 mm 8.mu. Hypersil.RTM. HS C18 column; 5%
CH.sub.3CN/50 mM aqueous ammonium acetate hold for 5 min; 5-50%
CH.sub.3CN/50 mM aqueous ammonium acetate over 20 min; 50-100%
CH.sub.3CN/50 mM aqueous ammonium acetate over 1 min; hold at 100%
CH.sub.3CN for 5 minutes, 21 mL/min) then filtered to remove the
remaining acid. The filtrate was then lyophilized to yield
2-[5-(2-amino-pyrimidin-4-ylamino)-1H-indazol-7-yl]-1H-indole-7-carboxyli-
c acid amide (2 mg, 2% yield): LC/MS R.sub.t (Method e) 0.7 min;
m/z (M+H).sup.+ 385.4. Preparation #22a. 5-Bromo-7-iodo-1H-indazole
##STR913##
[0695] A 1 L round bottom flask equipped with a stir bar was
charged with 4-bromo-2-methylaniline (Aldrich, 24.3 g, 0.130 mmol)
and dichloromethane (250 mL).
bis(pyridine)iodonium(I)tetrafluoroborate (50.0 g, 0.13 mmol) was
added in four portions over approximately 10 minutes. The mixture
was stirred for about 30 min at ambient temperature then two
additional portions of the
bis(pyridine)iodonium(I)tetrafluoroborate (2.5 g each) were added
and the reaction was continued for about 1 h. Water (150 mL) was
added and after stirring for about 10 minutes the mixture was
transferred to a separatory funnel and the layers separated. The
organic solution was then washed with saturated aqueous
Na.sub.2S.sub.2O.sub.3 (100 mL) then water (50 mL). The organic
solution was dried over anhydrous magnesium sulfate then filtered
and evaporated to give an oil (51.4 g) which was applied to a
silica gel column (400 g) and eluted with
heptane/dichloromethane/ethyl acetate (12:7:1) to give
4-bromo-2-iodo-6-methyl-phenylamine (31.08 g, 76.6%) as a dark
solid.
[0696] 4-bromo-2-iodo-6-methyl-phenylamine (31.08 g, 99.6 mmol) was
dissolved in glacial acetic acid (400 mL) in a 1 L round bottom
flask equipped with a stir bar. The flask was then charged in one
portion with sodium nitrite (7.56 g, 109.6 mmol) dissolved in water
(18.7 mL). The mixture was stirred for about 15 minutes then the
solvents were removed by evaporation on a rotovap at a bath
temperature of about 35.degree. C. The residue was stirred with
water (200 mL) for 15 minutes and the resulting solid was collected
by filtration and dried to yield 5-bromo-7-iodo-1H-indazole (30.6
g, 95%) as a brownish-tan solid; (DMSO-d.sub.6, 400 MHz) .delta.
13.6 (bs, 1H), 8.24 (s, 1H), 8.04 (d, J=1.54 Hz, 1H), and 7.88 (d,
J=1.54 Hz, 1H); RP-HPLC (Table 1, Method e) R.sub.t=3.63 min; m/z:
(M-H).sup.- 322.8. Preparation #22b:
N,N-Dimethyl-1-[5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indol--
3-yl]methanamine ##STR914##
[0697] To a suspension of Eschenmoser's salt (0.91 g, 4.9 mmol) in
CH.sub.3CN (3 mL) and HOAc (1.5 mL) at rt was added a solution of
5-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-1H-indole (1.0 g,
4.1 mmol) in CH.sub.3CN (3 mL) dropwise over about 10 min. After
about 2 hours, the reaction was quenched with saturated aqueous
NaHCO.sub.3 and extracted with CH.sub.2Cl.sub.2 (3.times.15 mL).
The combined organic layers were washed with brine, dried over
Na.sub.2SO.sub.4, decanted, and concentrated to give crude
N,N-Dimethyl-1-[5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indol--
3-yl]methanamine (0.60 g, 50%); RP-HPLC (Table 1, Method g) R.sub.t
1.39 min; .sup.1H NMR (d.sub.6-DMSO, 400 MHz) .delta.11.26 (br s,
1H), 8.07 (s, 1H), 7.44 (d, J=8.2 Hz, 1H), 7.37 (m, 2H), 3.92 (s,
2H), 2.40 (s, 6H), 1.31 (s, 12H). Preparation #22c:
Thieno[2,3-b]pyridin-2-ylboronic acid. ##STR915##
[0698] To a solution of thieno[2,3-b]pyridine (0.50 g, 3.7 mmol) in
THF (25 mL) at about -78.degree. C. was added n-BuLi (1.6 M in
hexane, 2.5 mL, 4.1 mmol) dropwise over about 10 min. After about
45 min, added triisopropyl borate (0.93 mL, 4.1 mol). Stirred for
about 1 hour at about -78.degree. C. then at about 0.degree. C. for
about 30 min. 10% aqueous HCl (10 mL) was added and the ice bath
was removed. After about 30 min, EtOAc (30 mL) was added. The
reaction mixture was filtered to remove a precipitate that was
washed with additional water and EtOAc. The combined layers were
separated and the aqueous layer was extracted with additional EtOAc
(2.times.30 mL). The combined organic layers were washed with
brine, dried over anhydrous Na.sub.2SO.sub.4, decanted, and
concentrated to get a solid that was triturated with EtOAc and
heptane then filtered to give thieno[2,3-b]pyridin-2-ylboronic acid
(0.043 g, 6%); RP-HPLC (Table 1, Method g) R.sub.t 1.67 min, m/z
(ESI+) 180.1 (M+H).sup.+. Preparation #22d:
2-Amino-4-chloro-thieno[2,3-d]pyrimidine-6-carboxylic acid methyl
ester ##STR916## Step 1. Preparation #22e.
(2-amino-6-chloro-5-formyl-pyrimidin-4-ylsulfanyl)-acetic acid
methyl ester
[0699] To a mixture of
2-amino-4,6-dichloro-5-pyrimidinecarbaldehyde (Apin, 2.00 g, 10.4
mmol) in dioxane (20 mL) was added triethylamine (1.60 mL, 11.5
mmol) and methyl thioglycolate (1.90 mL, 21.2 mmol). After about 3
hours, the reaction mixture was diluted with water (30 mL) and then
filtered, washed with additional water to give
(2-amino-6-chloro-5-formyl-pyrimidin-4-ylsulfanyl)-acetic acid
methyl ester (1.801 g, 66%) as a yellow solid; RP-HPLC (Table 1,
Method a) R.sub.t 1.85 min, m/z (ESI+) 262.0 (M+H).sup.+.
Step 2.
Preparation #22d:
2-Amino-4-chloro-thieno[2,3-d]pyrimidine-6-carboxylic acid methyl
ester
[0700] To a mixture of
(2-amino-6-chloro-5-formyl-pyrimidin-4-ylsulfanyl)-acetic acid
methyl ester (Preparation #22e, 0.20 g, 0.76 mmol) in dioxane (7.6
mL) was added K.sub.2CO.sub.3 (0.21 g, 1.5 mmol). The resulting
mixture was heated at about 100.degree. C. overnight, cooled to
room temperature and water (1 mL) added to dissolve base. The
remaining solid was filtered and washed with MeOH to give
2-amino-4-chloro-thieno[2,3-d]pyrimidine-6-carboxylic acid methyl
ester (0.16 g, 84%) as a pale yellow solid; RP-HPLC (Table 1,
Method a) R.sub.t 2.38 min; .sup.1H NMR (d.sub.6-DMSO, 400 MHz)
.delta.7.82 (s, 1H), 7.72 (br s, 2H), 3.86 (s, 3H). Preparation
#50. 7-Benzo[b]thiophen-2-yl-5-nitro-1H-indazol-3-ol ##STR917##
[0701] A mixture of
3-Benzo[b]thiophen-2-yl-2-chloro-5-nitro-benzoic acid (0.11 g, 0.33
mmol), hydrazine (0.35 mL) and isopropyl alcohol (3 mL) was heated
to about 90.degree. C. for about 1 hour. The mixture was cooled
then the solvents were evaporated under reduced pressure. The
residue was treated with 6N aqueous hydrochloric acid (5 mL) the
mixture was extracted with ethyl acetate (3.times.30 mL). The
organic extracts were combined then concentrated to give
7-Benzo[b]thiophen-2-yl-5-nitro-1H-indazol-3-ol RP-HPLC (Table 1,
Method e) Rt 1.41 min; m/z: (M-H).sup.- 310.24.
Example #51
2-(7-Bromo-1H-indazol-5-ylamino)-2-methyl-propan-1-ol
[0702] ##STR918##
[0703] To a solution of 2,2-dimethyl-oxazine (0.100 mL, 1.13 mmol)
in THF (5.0 mL) was added 7-bromo-1H-indazol-5-ylamine (Preparation
#6, 0.100 g, 0.472 mmol) and samarium chloride (0.012 g, 0.047
mmol). The reaction mixture was stirred at ambient temperature for
about 20 hours followed by removal of THF in vacuo. The crude
reaction mixture was purified by reverse phase chromatography
(RP-HPLC (Rainin C18, 8 mm, 300 .ANG., 35 cm; 5-100%
acetonitrile/0.1 M ammonium acetate over 20 min, 100% acetonitrile
hold 10 minutes, 21 mL/min) to afford
2-(7-bromo-1H-indazol-5-ylamino)-2-methyl-propan-1-ol (0.033 g,
0.116 mmol). RP-HPLC (Table 1, Method e) R.sub.t 1.18 min; m/z:
(M+H).sup.+ 286.1. Preparation #52.
(7-Benzo[b]thiophen-2-yl-1H-indazol-5-yl)-phenyl-methanone
##STR919##
[0704] A mixture of 7-benzo[b]thiophen-2-yl-5-bromo-1H-indazole
(Preparation #26, 0.25 g, 0.76 mol), tributylphenyltin (0.56 g,
1.52 mmol), triethylamine (0.23 g, 2.28 mmol) and
trans-dichloro[bis(triphenylphosphine)]palladium (II) (0.08 g,
0.114 mmol) in N,N-dimethylformamide (4 mL) was purged with carbon
monoxide then stirred under an atmosphere of carbon monoxide at
about 90.degree. C. in an oil bath for about 2 hours. The solvent
was removed in vacuo and the residue was applied to a silica gel
column then eluted with dichloromethane/methanol (95:5). The
fractions that contained product were combined and triturated with
heptane then the solids were collected by filtration and purified
by preparative reverse phase HPLC to give
(7-Benzo[b]thiophen-2-yl-1H-indazol-5-yl)-phenyl-methanone(23 mg,
8.5%); (DMSO-d.sub.6, 400 MHz) .delta. 13.85 (bs, 1H), 8.49 (bs,
1H), 8.27 (s, 1H), 8.18 (bs, 1H), 8.06 (m, 2H), 7.93 (m, 1H), 7.81
(m, 2H), 7.71 (m, 1H), 7.61 (m, 2H), 7.45 (m, 2H); RP-HPLC (Table
1, Method e) Rt 2.50 min; m/z: (M+H).sup.+ 353.0. Preparation #53.
(7-Benzo[b]thiophen-2-yl-1H-indazol-3-yl)-pyridin-2-yl-methanone
##STR920##
[0705] A mixture of
7-benzo[b]thiophen-2-yl-5-bromo-2-(2-trimethylsilanyl-ethoxymethyl)-2H-in-
dazole (Preparation #23, 0.15 g, 0.326 mmol) in tetrahydrofuran (2
mL) was cooled to about -65.degree. C. then a solution of
n-butyllithium (1.6 M, 0.36 mL, 0.36 mmol) was added dropwise.
After about 30 minutes, 2-pyridinecarboxaldehyde (0.042 g, 0.39
mmol) was added. The mixture was quenched with methanol (1 mL) then
warmed to room temperature. The solvent was removed in vacuo and
the residue was purified by preparative reverse phase HPLC
chromatography (RP-HPLC (Rainin C18, 8 mm, 300 .ANG., 35 cm; 5-100%
acetonitrile/0.1 M ammonium acetate over 20 min, 100% acetonitrile
hold 10 minutes, 21 mL/min) to give the intermediate
[7-benzo[b]thiophen-2-yl-2-(2-trimethylsilanyl-ethoxymethyl)-2H-indazol-3-
-yl -pyridin-2-yl-methanol (50 mg) which was suspended in a mixture
of 1,4-dioxane (2 mL) and manganese dioxide (90 mg, 31%). The
mixture was heated to about 90.degree. C. for 15 minutes then
filtered and evaporated. The residue was purified by reverse phase
HPLC (RP-HPLC (Rainin C18, 8 mm, 300 .ANG., 35 cm; 5-100%
acetonitrile/0.1 M ammonium acetate over 20 min, 100% acetonitrile
hold 10 minutes, 21 mL/min) to give
(7-Benzo[b]thiophen-2-yl-1H-indazol-3-yl)-pyridin-2-yl-methanone
(22 mg, 44%); (DMSO-d.sub.6, 400 MHz) .delta. 8.8 (bs, 1H), 8.31
(d, 1H), 8.09 (m, 4H), 7.93 (d, 1H), 7.78 (bs, 1H), 6.96 (bs, 1H),
7.51 (t, 1H), 7.43 (m, 2H); RP-HPLC (Table 1, Method e) Rt 2.60
min; m/z: (M-H).sup.- 353.8. Preparation #54.
(7-Benzo[b]thiophen-2-yl-1H-indazol-5-yl)-pyridin-2-yl-methanone
##STR921##
[0706] Starting with
7-benzo[b]thiophen-2-yl-5-bromo-1-(2-trimethylsilanyl-ethoxymethyl)-1H-in-
dazole (Preparation #23, 0.2 g, 0.435 mmol) and using the procedure
for the preparation of
(7-benzo[b]thiophen-2-yl-1H-indazol-3-yl)-pyridin-2-yl-methanone
(Preparation #52 above) provided
(7-benzo[b]thiophen-2-yl-1H-indazol-5-yl)-pyridin-2-yl-methanone
(17 mg, 11%); (DMSO-d.sub.6, 400 MHz) .delta. 8.79 (d, 1H), 8.65(s,
1H), 8.54 (s, 1H), 8.27 (s, 1H), 8.24 (s, 1H), 8.11 (m, 1H), 8.05
(m, 2H), 7.95 (m, 1H), 7.72 (m, 1H), 7.45 (m, 2H); RP-HPLC (Table
1, Method e) Rt 2.28 min; m/z: (M-H).sup.- 354.1. ##STR922##
##STR923## Preparation #55.
7-(7-Benzo[b]thiophen-2-yl-3-methyl-1H-indazol-5-yl)-5H-pyrrolo[3,2-d]pyr-
imidin-2-ylamine ##STR924## ##STR925##
[0707] A mixture of
7-benzo[b]thiopen-2-yl-5-bromo-2-(2-trimethylsilanyl-ethoxymethyl)-2H-ind-
azole (Preparation #24, 1.0 g, 2.18 mmol) in tetrahydrofuran (15
mL) was cooled to about -65.degree. C. then a solution of
n-butyllithium (1.6 M, 1.5 mL, 2.4 mmol) was added dropwise. After
about 5 minutes methyliodide (0.37 g, 2.6 mmol) was added then the
solution was warmed to about -20.degree. C. Saturated ammonium
chloride (1 mL) was added then the mixture was diluted with ethyl
acetate (25 mL) and water (10 mL). The layers were separated then
the organic layer was dried over magnesium sulfate, filtered and
evaporated to give the crude
7-benzo[b]thiophen-2-yl-5-bromo-3-methyl-2-(2-trimethylsilanyl-ethoxymeth-
yl)-2H-indazole which was converted to
7-benzo[b]thiophen-2-yl-3-methyl-5-(4,4,5,5-tetramethyl-[1,3,2]dioxaborol-
an-2-yl)-2-(2-trimethylsilanyl-ethoxymethyl)-2H-indazole (0.29 g,
25% over 2 steps) using general procedure E. The boronate (200 mg,
0.385 mmol) was coupled with
2-(dimethylamino-methyleneamino)-7-iodo-pyrrolo[3,2-d]pyrimidine-5-carbox-
ylic acid tert-butyl ester (0.135 g, 0.32 mmol) using general
procedure F and the resulting product deprotected using general
procedure G to give
7-(7-benzo[b]thiophen-2-yl-3-methyl-1H-indazol-5-yl)-5H-pyrrolo[3,2-d]pyr-
imidin-2-ylamine (24 mg, 19%); (DMSO-d.sub.6, 400 MHz) .delta.
12.48 (bs, 1H), 11.44 (s, 1H), 8.50 (m, 3H), 8.18(d, 1H), 8.07 (bs,
1H), 8.02 (d, 1H), 7.90 (d, 1H), 7.43 (m, 2H), 5.94 (bs, 2H), 2.61
(s, 3H); RP-HPLC (Table 1, Method e) Rt 1.76 min; m/z: (M-H).sup.-
394.9.
* * * * *